Prostaglandins as biochemical markers of radiation injury to the salivary glands after iodine-131 therapy?

International Nuclear Information System (INIS)

Rodrigues, M.; Havlik, E.; Sinzinger, H.; Peskar, B.

1998-01-01

Because salivary glands, as well as thyroid tissue, are able to concentrate radioiodine, the treatment of thyroid diseases with iodine-131 may have secondary effects on salivary gland function which seriously impair the quality of life. Such effects include sialoadenitis and xerostomia. Salivary secretion is stimulated by prostaglandins (PGs). In this study we evaluate whether 131 I therapy influences the levels of PGs in saliva. Patients who had previously received 131 I for treatment of hyperthyroidism or differentiated thyroid cancer and healthy volunters were studied. Levels of PGs [6-oxo-PGF 1α , bicyclo-PGEm, thromboxane B 2 (TXB 2 ), PGF 2α ], in unstimulated saliva were measured using enzyme immunoassay. Significantly lower levels of 6-oxo-PGF 1 α , bicyclo-PGEm and PGF 2α and higher levels of TXB 2 were found in the group of patients in comparison with the controls. Differences between patients and controls were more pronounced in smokers. This study demonstrates that salivary gland uptake of 131 I significantly affects PG levels in saliva. (orig.)

Radiation protection measures for reduction of incorporations of iodine-131 by the staff of a radionuclide therapy ward

International Nuclear Information System (INIS)

Petzold, J.; Meyer, K.; Lincke, T.; Sabri, O.; Alborzi, H.; Lorenz, J.; Schoenmuth, T.; Keller, A.

2009-01-01

The air in patient's rooms with thyroid therapies is loaded with iodine 131, which is to be seen as a cause for the incorporation of iodine 131 by the staff. The patients exhale a part of the iodine applied for their intended radionuclide therapy. The activity is concentrated in the saliva and, thereby, the breath air is moistened and iodine reaches the exhaled and compartment air. The detection of iodine in the form of contaminations and/or incorporations with the staff succeeds only after a longer stay in the patient's room. With this, a clear relation between the particular type of work performed in the room and therapy of malignant thyroid disease with high amounts of radioactivity can be found. The measured values of incorporations, obtained with an whole-body counter, are in the range of up to 400Bq. The activity concentration in the compartment air some hours after application of the therapeutic activity reaches a maximum and then decreases with a half-life of about 15 hours. As a protection measure we asked the patients wearing a mask up to 30 hours after application to (orig.)

Immunothyropathy with hyperthyroidism following /sup 131/iodine treatment for toxic thyroid nodule

Energy Technology Data Exchange (ETDEWEB)

Mueller, H.W.; Schneider, C.; Schroeder, S.

1985-06-01

The rare case of a diffuse immunothyropathy with hyperthyroidism 3 weeks after /sup 131/Iodine treatment for a toxic thyroid nodule is presented. Diagnosis of 'toxic thyroid nodule' has been established by /sup 131/Iodine scintiscan and suppression test. The diagnosis 'immunothyropathy' is based on thyroid-antibody-determinations (TAK, MAK), ultrasound, histology, and clinical course. Corresponding to the knowledge of pathogenesis in immunothyropathies (Graves' disease, Hashimoto's disease) /sup 131/Iodine therapy is considered as inducing factor of the recorded immunothyropathy.

The exposure of relatives to patients of a nuclear medical ward after radio iodine therapy by inhalation of 131I in their home

International Nuclear Information System (INIS)

Wellner, U.; Eschner, W.; Hillger, H.W.; Schicha, H.

1998-01-01

From a model of iodine metabolism exhalation coefficients shall become derived to calculate 131 I exhalation by patients after a radioiodine treatment. The validity of these exhalation coefficients shall be reviewed by whole body activity measurements of relatives of patients, who inhaled the radioiodine exhaled by the patients in their homes. The exposure of relatives to patients of a nuclear medical ward after release by exhalation of iodine-131 is investigated. Methods: Iodine 131 I-activity of 17 relatives to patients who had to undergo a radioiodine therapy became measured in a whole body counter only a few days after release of the patient form the nuclear medical ward. The results of the measurements have been compared with the results of calculations according to the model of iodine metabolism. Results: The calculated values of incorporated radioiodine in the relatives of the patient at time of measurement (A model ) correlate with the measured whole body activity (A GK ) according to the regression: A model = A GK -47.3 (r 2 =0.959). This relation holds if 2.1 μg of iodine become exhaled per day of the 60 μg of iodine which are the daily intake of iodine by food. The exposure of all relatives did never exceed 100 μSv eff . Using the same model parameters the effective dose equivalent of the relatives to our patients rises up to 6.5 mSv under ambulant radio therapy conditions. Conclusion: the daily exhalation of 131 I is able to be calculated by a mathematical model of iodine metabolism. After staying of patients at least 3 days in a nuclearmedical ward the exposure of relatives to patients in their home does not exceed the value of 100 μSv eff by inhalation of iodine-131. This are 10% of the limit of 1 mSv eff according to the Recommendations of the Commission on Radiological Protection (ICRP 60). Radioiodine therapy outside of a hospital and 'iodine therapy tourisme' of German patients to other countries cannot be accepted. (orig.) [de

Treatment of hyperthyroidism by 131-iodine; Traitement des hyperthyroidies par l'iode 131: dose calculee versus dose fixe

Energy Technology Data Exchange (ETDEWEB)

Fieffe, S.; Cuif-Joba, A.; Testard, A.; Fortuna, I.; Pocharta, J.M.; Papathanassioua, D.; Schvartz, C. [Service d' endocrinologie et medecine nucleaires, institut Jean-Godinot, 1, rue du General Koeing, 51056 Reims, (France)

2009-05-15

In a first time, we chose to modify the dose to be administered, on using always the Marinelli formula but on increasing the absorbed dose. In a second time, we wanted to simplify the determination of the dose to be administered by modulating it only in function of the thyroid volume. Two groups of patients were managed for hyperthyroidism recurrence. In a first group the iodine dose ({sup 131}I) was determined with the help of the simplified Marinelli formula: chosen absorbed dose was 150 Gy, gland volume determined by echography, measurement of the fixation at the sixth hour. In the second group, the thyroid volume was determined by echography. The patients with a thyroid from 5 to 30 g received 185 MBq, from 30 to 50 g 370 MBq and superior to 50 g 555 MBq of iodine 131. The two groups of patients have the same characteristics. the results of treatment by iodine 131, evaluated on the dosages of T4L and TSH at three and six months, show the preservation of euthyroidism or the passage in hypothyroidism among 94% of patients in the group 1 and 80% of patients in the group 2. These results are not significantly different. The easiness of the realisation of the treatment in the group 2 lead us to continue this simplified therapy scheme that allows equally to improve the radiation protection of medical personnel by avoiding the use of iodine 131. (N.C.)

Thyroid γ ray measurement after iodine-131 therapy for Graves' disease

International Nuclear Information System (INIS)

Liu Jianfeng; Guo Qingling; Ye Genyao; Li Xin; Wang Anyu; Wang Ying; Zhu Hui; He Ling; Yuan Chao

2004-01-01

Objective: To study the thyroid 131 I uptake within 24 hours following 131 I therapy for Graves' disease. Methods: Eighteen hyperthyroidism patients were divided into two groups according to thyroid weight and radiotherapy dosage. Low-dose group and high-dose group received the mean dose 162.8 MBq (4.4 mCi) and 255.3 MBq (6.9 mCi), respectively. The γ ray dose rates from thyroids were measured in all patients at 1, 2, 4, 8,12 and 24 h after 131 I therapy. Results: γ ray dose rates were elevated rapidly at 1 hour and continued at high level between 2-12 h and slowly fell in 24 h after 131 I therapy. γ Rat curve of low-dose group was lower than that of high-dose group. Conclusion: There was a rapid absorption and concentration period in 1 h and slow metabolism and release period after 12 h in thyroid following radioiodine therapy of Graves' disease. The thyroids of hyperthyroidism patients displayed different γ ray curves. (author)

Model of iodine metabolism in a T3-thyrotoxic patient undergoing I-131 therapy

International Nuclear Information System (INIS)

Ahuja, S.; Price, R.; Brill, A.B.; Dobyns, B.M.; Berman, M.

Data on radioactivity in the thyroid, urine, serum, butanol-extractable iodine (BEI) and chromatographic fractionations of BEI, obtained during four I-131 therapeutic treatments of a T 3 -thyrotoxic patient, have been analyzed and simulated with the help of a 7-compartment model. Good fits to most of the data can be obtained with both the dose-independent and dose-dependent models. A model with 3 or 4 compartments, which provides adequate fits to iodine kinetic data in most euthyroid and hyperthyroid patients is not satisfactory in the case of this patient. Thus, to represent iodine metabolism during T 3 -thyrotoxicosis therapy, we find that it is necessary to provide for separate biochemical pathways for the BEI components as well as the butanol-insoluble compounds released by the thyroid gland

No impact of dietary iodine restriction in short term development of hypothyroidism following fixed dose radioactive iodine therapy for Graves' disease.

Science.gov (United States)

Jacob, Jubbin Jagan; Stephen, Charles; Paul, Thomas V; Thomas, Nihal; Oommen, Regi; Seshadri, Mandalam S

2015-01-01

The increased incidence of autoimmune thyroid disease with increasing dietary iodine intake has been demonstrated both epidemiologically and experimentally. The hypothyroidism that occurs in the first year following radioactive iodine therapy is probably related to the destructive effects of the radiation and underlying ongoing autoimmunity. To study the outcomes at the end of six months after fixed dose I, (131)therapy for Graves' disease followed by an iodine restricted diet for a period of six months. Consecutive adult patients with Graves' disease planned for I(131) therapy were randomized either to receive instructions regarding dietary iodine restriction or no advice prior to fixed dose (5mCi) I(131) administration. Thyroid functions and urinary iodine indices were evaluated at 3(rd) and 6(th) month subsequently. Forty seven patients (13M and 34F) were assessed, 2 were excluded, 45 were randomized (Cases 24 and Controls 21) and 39 patients completed the study. Baseline data was comparable. Median urinary iodine concentration was 115 and 273 μg/gm creat (p = 0.00) among cases and controls respectively. Outcomes at the 3(rd) month were as follows (cases and controls); Euthyroid (10 and 6: P = 0.24), Hypothyroid (3 and 5: P = 0.38) and Hyperthyroid (7 and 8: P = 0.64). Outcomes at the end of six months were as follows (cases and controls); Euthyroid (10 and 5: P = 0.12), Hypothyroid (3 and 5: P = 0.38) and Hyperthyroid (7 and 9: P = 0.43). Of the hypothyroid patients 5 (cases 1 and controls 4: P = 0.13) required thyroxine replacement. There was no statistical significant difference in the outcome of patients with dietary iodine restriction following I(131) therapy for Graves' disease.

Source of Iodine-131 in Europe Identified

International Nuclear Information System (INIS)

2011-01-01

Full text: The IAEA has received information from the Hungarian Atomic Energy Authority (HAEA) that the source of the iodine-131 (I-131) detected in Europe was most probably a release to the atmosphere from the Institute of Isotopes Ltd., Budapest. The Institute of Isotopes Ltd. produces radioisotopes for healthcare, research and industrial applications. According to the HAEA, the release occurred from September 8 to November 16, 2011. The cause of the release is under investigation. As previously mentioned, the levels of I-131 that have been detected in Europe are extremely low. There is no health concern to the population. If any member of the public were to breathe iodine for a whole year at the levels measured in European countries, then they would receive a dose in the range of 0.01 microsieverts for the year. To put this into perspective, the average annual background is 2 400 microsieverts per year. The IAEA was first notified of the presence of trace levels of I-131 by authorities from the Czech Republic on 11 November. Since this notification, the IAEA contacted several member states throughout the region to determine the cause and origin. The IAEA also worked with the World Meteorological Organization (WMO) to conduct air dispersion modelling, as part of efforts to determine the source. (IAEA)

Treatment of hyperthyroidism with fixed dose form Iodine 131

International Nuclear Information System (INIS)

Pacheco Torres, P.; Cerquera, A.M.; Acosta, F.; Sierra, M.

2007-01-01

Full text: Objective: Evaluation of the response to therapy with fixed dose of Iodine-131 in patients with hyperthyroidism. One hundred seventeen patients with hyperthyroidism were tested and sent for treatment with Iodine-131. The dose of the therapy was calculated according to the pathology (Diffuser goiter (DG): Multinodular goiter (MNG) and Single toxic nodule (NST). Values of TSH confirmed hyperthyroidism by laboratory methods. The thyroid-blocking agents were discontinued: methimazole for five days and propylthiouracil two days prior to therapy. The pregnancy tests were routinely conducted in females of reproductive age group. Patients reported fasting for therapy. The doses were administered in capsule form after obtaining informed consent from the patients. The patients were normally instructed to eat only after two hours after administration of iodine to promote gastric absorption of the radionuclide. Normally a post therapy thyroid scan is performed four days after treatment. Patients are usually followed up by the endocrinologists. A three- month post therapy evaluation is done by the nuclear medicine physician by telephone. The demographic data of our patients treated are as follows: Total number of patients: 117 Female: 88 (75.21%) Male: 29 (24.79%) Age average: 45 years. Diffuse Goiter= 94 (80.34%), Multinodular Goiter= 17 (14.52%) and Toxic Adenoma (NST) = 6 (5.12%). The average administered dose was 22.5 mCi to DG, 41.8 mCi to MNG and 37.5 mCi to NST. 102 (87.14%) patients at the control at 2 years after treatment presented stable response to therapy, 15 (12.86%) required a second therapy, 11 (11.70%) with BD and 4 (23.52%) with BMN; and any patient with NST required a second therapy. 83 (88.29%) of the patients with BD; 13 (76.48%) with BMN and 6 (100%) with NST the therapy was successful. Conclusion: Fixed dose of I-131 in hyperthyroidism is useful in patients with DG (11.70%). In patients with MNG whom a fixed dose is supplied, 23.52% require a

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

International Nuclear Information System (INIS)

Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Urquizo Baldomero, R. M.; Vega Ramírez, J. L.

2016-01-01

The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

Energy Technology Data Exchange (ETDEWEB)

Apaza Veliz, D. G., E-mail: dgav02@gmail.com [Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa, Perú, Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru); Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Urquizo Baldomero, R. M. [Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa (Peru); Vega Ramírez, J. L. [Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru)

2016-07-07

The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

Science.gov (United States)

Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Vega Ramírez, J. L.; Urquizo Baldomero, R. M.

2016-07-01

The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

Influence of surgical or propylthiouracil pretreatment on the efficacy of iodine-131 therapy in hyperthyroidism

International Nuclear Information System (INIS)

Shi Genming; Xu Qin; Yang Yili; Ye Anfang; Zhu Chengyi

2006-01-01

Objective: To investigate the influence of surgical or propylthiouracil(PTU) pretreatment on the efficacy of radioactive iodine therapy in hyperthyroidism. Methods: A group (group 1) of 41 hyperthyroidism patients relapsed after surgery were treated with 131 I in our department from 2003 through 2004. During that period, another group (group 2) of 41 cases were selected randomly from patients untreated either surgically or chemically before oral administration of 131 I, and a third group (group 3) of 41 cases were selected randomly from those pretreated only with PTU. We analysed the results of these three groups of patients after followed-up for 3 and 6 months separately after 131 I therapy. Results: Approximately 90.24% (37/41 cases) and 92.68% (38/ 41 cases) of patients in group 2 without any pretreatment were cured 3 months and 6 months after 131 I treatment, respectively, and 9.76% (4/41 cases) and 7.32% (3/41 cases) of them did not respond to 131 I treatment. About 43.90% (18/41 cases) and 53.66 % (22/41 cases) of patients pretreated with PTU (group 3) were cured at 3 and 6 months, respectively, and approximately 56.10% (23/41 cases) and 46.34% (19/41 cases) of this group patients did not respond to 131 I treatment at 3 and 6 months, respectively (P 131 I treatment, respectively, and 31.71% (13/41) and 29.27% (12/ 41) of them did not respond to 131 I treatment (P 131 I treatment can affect the efficacy of 131 I therapy, resulting in reduction of the cure rate. (authors)

Optimizing a single fixed dose of Iodine-131 in Graves' Disease (An Experience)

International Nuclear Information System (INIS)

Khan, S.H.

2007-01-01

Full text: Kashmir is a Himalayan mountain state of India enclosed by high snow capped ridges of Pir Panjal Mountains at an average height of 4000-5000 meters above the sea level. For most of the 4 million inhabitants in this land locked valley, agriculture horticulture and handcrafts are the main source of income. Due to long and severe winters the terraced farming on the mountain slopes yield just a single crop of rice which is barely sufficient to meet the local needs of this staple diet. People are relatively poor with low annual per capita income. Goiter is endemic in the Valley of Kashmir. In a published report the overall prevalence of goiter among the school going children in Kashmir between the ages of 5 years is 45.2% (+ SEM) with urinary iodine excretion of 49 + 3.55 μg per gram of creatinine. The extremely shy people of Kashmir are casual towards the aesthetic aspects of their goiters but nevertheless seek medical advice when associated with physical symptoms. In a published study of 203 patients of thyrotoxicosis from Kashmir, Graves' disease was the commonest cause, accounting for 63% of patients. One hundred and twentyone patients of Graves' disease were prospectively studied for their response to a single fixed dose of I-131. Patients were randomly treated with two different fixed doses of I- 131. Sixty four patients belonging to Group-I received a fixed dose of 185 MBq (Low Dose) and 57 patients belonging to Group -2 received 370 MBq (High Dose) of I- 131. Following therapy all patients were evaluated at 3 months. Patients with normal or reduced thyroid hormone levels were termed as responders and those with persistently elevated levels of thyroid hormone were termed as non responders. The response rates among the two groups were analyzed for their statistical significance. Patients treated with the high fixed dose of 370 MBq revealed good response to therapy achieving a rate of 91.22%, while the response rate in the group of patients treated with

Labeling of DOTATATE with 131-iodine for therapy application

International Nuclear Information System (INIS)

Araujo, E.B.; Nagamati, L.T.; Caldeira Filho, J.S.; Colturato, M.T.; Silva, C.P.G. da

2004-01-01

Full text: Peptide receptor radiotherapy (PRRT) and peptide receptor imaging (PRI) of malignant neoplasms have become a primary focus of interest in nuclear medicine. [111In]-DTPA-D-Phe1-octreotide is routinely used as diagnostic tool and promising therapeutic results have been reported with [90Y] DOTA-Tyr3-octreotide in patients with somatostatin (sst) receptor-positive advanced tumours. The radio-iodinated analogue, [123I] Tyr3-octreotide was the first sst-directed radiotracer to be clinically evaluated. The diagnostic and therapeutic usefulness of radio-iodinated sst ligands has been limited by their unfavourable biokinetics, in vivo deiodination and resulting dosimetry. The radio-iodination of sst derivatives is often time-consuming multi step procedure and needs final product purification. However, comparative studies with the radioiodinated sst analogues Tyr3-octreotide and Tyr3-Thr8-octreotide (octreotate) showed that the substitution of Thr(ol)8 by Thr8 reduces the lipophilicity and also dramatically improves the biodistribution in nude mice bearing AR42J rat pancreatic tumour xenografts. Favourable pharmacokinetic of DOTA-Tyr3-octreotate labeled with 90Y and 177Lu was observed, including rapid renal clearance and high focal uptake in sst receptor positive tumors. This work studied the labelling of DOTA-Tyr3-octreotate (Pichem) with 131-iodine (Nordion/CNEN - 2.9 x 1016 Bq/mol), quality control and purification procedures to evaluate the production viability of 131I-labeled sst analogue in radiotherapeutic amounts. 131I radiolabeling of DOTA-Tyr3-octreotate was performed using the Chloramine T method. A solution of 1.5-10 mg of peptide in 40 ml of PBS (0.1M phosphate buffered saline pH 7.5) was transferred to an Eppendorf. After the addition of 5 ml of Chloramine T solution (5 mg/PBS) and 5-10 ml of radioiodine solution (37-740 MBq, molar peptide to radionuclide ratios varying from 0.8 to 45), the cap was carefully vortexed and the labelling reaction was

Cancer risk after iodine-131 therapy for hyperthyroidism

International Nuclear Information System (INIS)

Holm, L.E.; Hall, P.; Wiklund, K.; Lundell, G.; Berg, G.; Bjelkengren, G.; Cederquist, E.; Ericsson, U.B.; Hallquist, A.; Larsson, L.G.

1991-01-01

Cancer incidence was studied in 10,552 patients (mean age, 57 years) who received 131I therapy (mean dose, 506 MBq) for hyperthyroidism between 1950 and 1975. Follow-up on these patients was continued for an average of 15 years. Record linkage with the Swedish Cancer Register for the period 1958-1985 identified 1543 cancers occurring 1 year or more after 131I treatment, and the standardized incidence ratio (SIR) was 1.06 (95% confidence interval = 1.01-1.11). Significantly increased SIRs were observed for cancers of the lung (SIR = 1.32; n = 105) and kidney (SIR = 1.39; n = 66). Among 10-year survivors, significantly elevated risks were seen for cancers of the stomach (SIR = 1.33; n = 58), kidney (SIR = 1.51; n = 37), and brain (SIR = 1.63; n = 30). Only the risk for stomach cancer, however, increased over time (P less than .05) and with increasing activity administered (P = not significant). The risk for malignant lymphoma was significantly below expectation (SIR = 0.53; n = 11). Overall cancer risk did not increase with administered 131I dose or with time since exposure. The absence of any increase in leukemia adds further support to the view that a radiation dose delivered gradually over time is less carcinogenic than the same total dose received over a short time. Only for stomach cancer was a possible radiogenic excess suggested

Iodine-131 treatment strategy in papillary and follicular thyroid cancers at Centre Antoine Lacassagne (Nice)

International Nuclear Information System (INIS)

Bussiere, F.

2003-01-01

We report on iodine-131 treatment strategy in 1207 papillary and 250 follicular thyroid cancers admitted at our institution between 1976 and 2001. At the time of diagnosis, 51 patients (3.5%) had already metastases. The rest were 155 (11 %) pT4, 619 (44.6 %) pT1 588 (42,6 %) pT2, 26 pT3, 5 pT0 and 4 pTx. All patients underwent quasi-total thyroidectomy. Lymph node dissection was performed in most patients except in 49.7 %n of pT1 and 33% of pT2. Lastly, multifocal thyroid lesions were found in 28.5% of pT1 and 27,6 % of pT2. 80 patients did not receive radio-iodine (among them 60 were pT1 pN0 or pNx). 1114 patients received one therapeutic dose of 3.7 GBq of 131-iodine 6 to 8 weeks post surgery. 181 patients were treated twice (89 for remnants and 92 for disease progression). 82 patients received at least 3 doses and 5 up to 7 doses. 116 deaths were recorded, 59 (4 %) were related to thyroid cancer. The relatively poor prognosis of the follicular form is confirmed with 15.2 % deaths. This study needs to be further analysed focusing oil the follow-up of pT1 patients in order to redefine the indications of iodine therapy in that group. (author)

Model of iodine metabolism in a T₃-thyrotoxic patient undergoing I-131 therapy

Energy Technology Data Exchange (ETDEWEB)

Ahuja, S.; Price, R.; Brill, A. B.; Dobyns, B. M.; Berman, M.

1975-06-01

Data on radioactivity in the thyroid, urine, serum, butanol-extractable iodine (BEI) and chromatographic fractionations of BEI, obtained during four I-131 therapeutic treatments of a T₃-thyrotoxic patient, have been analyzed and simulated with the help of a 7-compartment model. Good fits to most of the data can be obtained with both the dose-independent and dose-dependent models. A model with 3 or 4 compartments, which provides adequate fits to iodine kinetic data in most euthyroid and hyperthyroid patients is not satisfactory in the case of this patient. Thus, to represent iodine metabolism during T₃-thyrotoxicosis therapy, we find that it is necessary to provide for separate biochemical pathways for the BEI components as well as the butanol-insoluble compounds released by the thyroid gland. (auth)

Radiation safety considerations for post-iodine-131 hyperthyroid therapy

International Nuclear Information System (INIS)

Culver, C.M.; Dworkin, H.J.

1991-01-01

The purpose of this study was to develop guidelines based on patient measurements as to when iodine-131- (131I) treated hyperthyroid patients may resume close personal contact. External exposure rates were measured on 59 patients using an ionization survey meter in the upright position. The initial measurement was recorded within 20 min post-dose administration at one meter. Exposure rates were measured 2-11 days post-dose administration at 1, 0.6, and 0.3 meters from the patient's thyroid. In the administered dose range of 3 to less than 12 mCi of 131I, all 40 patients measured less than or equal to 2.0 mR/hr at one meter on Day 0, and 25 patients (25/29) were less than or equal to 2.0 mR/hr at 0.6 meter on Days 2-4. Guidelines can be prepared based on the administered dose that are rational and in conformity with existing radiologic health standards

Hyperthyroidism treatment by iodine 131: about a study on 270 patients; Traitement de l'hyperthyroidie par l'iode 131: a propos d'une etude sur 270 patients

Energy Technology Data Exchange (ETDEWEB)

Leroux, M.A

2005-07-01

This study constitutes a starting point for a thought about the use of iodine 131 in the treatment of hyperthyroidism. The therapies are different depending on the teams, for the iodine 131 activities to deliver and their calculation modes; The use of synthesis anti-thyroid drugs before therapy is discussed. The radiation protection is an important factor in the decision of a metabolic radiotherapy. The indications of the treatment by radioactive iodine are different in Europe and in Usa. (N.C.)

The radio-iodine therapy of the functional autonomy. Indications, findings, risks

International Nuclear Information System (INIS)

Reiners, C.

1990-01-01

The functional autonomy of the thyroid is a disorder, which appears in connection with iodine deficit and befalls the complete organ. An absolute indication for a radio-iodine-therapy is given in case of hyperthyreoidism (these are 25 % of all at the functional autonomy). Contrary to the operation method the advantage of the I-131-therapy is, that all of the functional autonome-cells can be reached. The risk at the I-131-therapy is low. (Botek)

Chromosomal damage after Iodine-131 treatment for differentiated thyroid cancer: in vivo dose-effect relationship

International Nuclear Information System (INIS)

Nguyen, V.K.; Nguyen, X.P.; Truong, Q.X.

2007-01-01

Full text: Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in- vivo dose-effect relationship in patients receiving Iodine-131 treatment and the results of previous studies are controversial. In this study, the dicentric chromosomal aberrations (DCA) analysis method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 58 differentiated thyroid cancer patients who received dose 1,1 GBq of Iodine-131 (group A), and 34 patients who received dose 3,7 GBq of Iodine- 131 (group B). The mean 100 metaphase spreads were scored for each subject. The DCA frequencies in cultured peripheral lymphocytes were determined before treatment to assess basal DCA frequencies, on the 3rd day to assess acute DCA frequencies and 6 months later to assess late DCA frequencies. The basal, acute and late DCA frequencies were divided into two groups: 0,18%, 2,14% and 0,53% (group A) and 0,18%, 2,12 % and 0,89% (group B), respectively, and these values differed significantly at various time after treatment (p 2 = 0,987), and group B as Y= 32,71 + 0,189 X. (r = 0,9381, R 2 = 0,880). However, there was an interesting difference in comparison with in- vitro studies, in that we found the coefficient β to have a negative value, suggesting the disappearance of damaged lymphocytes from peripheral circulation in a dose- dependent manner following Iodine-131 treatment. Further studies are therefore needed to clarify the effect of the negative β value on biological dosimetry approach in continuous internal low LET radiation, as in the case of Iodine-131 treatment. (author)

[Metabolic therapy with iodine 131 in patients with chronic renal failure. Clinical case].

Science.gov (United States)

Vázquez-Rodríguez Barbero, Inmaculada; Espadas-Maeso, María José; Muñoz-Morales, Ana; Flores-Gómez, Pilar; Serrano-Carretero, María Belén; Castedo-Sal, Juan José; Sánchez Rey-Castro, Elena; Zamorano-Córdoba, Antonio

2015-01-01

62 year-old male with CKD stage 5 in dialysis program since 2012 who underwent surgery for papillary thyroid carcinoma with lymph node metastasis. Subsequently, the patient was admitted to the Unit of Metabolic Therapy at his reference hospital, where he is administered 80 millicuries of iodine-131 as a treatment associated with the surgery, unable to have his conventional dialysis, nursing interventions required in various stages of implementation of the continuous extrarenal clearance techniques (TCDE) were performed. The following care values were addressed targeted to patients undergoing treatment with I(131): specific equipment, personal protective measures and major diagnoses and nursing interventions. TCDE, despite being attributed to very critical patients, they can be extrapolated to other patients in a given time. TCDE allowed these patients to undergo dialysis in a safe environment for staff, ensuring proper disposal of contaminated liquids. TCDE were an effective treatment for the removal of I131, a single ssesion being necessary to normalize the levels of radioactivity. Coordination between services allewed ensure proper and effective treatment for the patient. Copyright © 2015 Elsevier España, S.L.U. All rights reserved.

Radiation exposure in I-131 iodine therapy

International Nuclear Information System (INIS)

Friedrich, W.

1985-01-01

In the past five years, the applied I-131 radioactivity quantity has doubled with a constant number of beds. In 1984, it was 925 GBq (25 Ci). Despite this development, no changes in the professional radiation exposure were made out. The evaluation shows a dose smaller than 0.04 man Sv/TBq (0.16 man rem/Ci) of I-131 applied. This value is below the traceability limit of the film badges. The incorporation load of the personnel (27 members) was determined by monthly body counter measurements. Only in one measurement thyroid gland activity of 5 kBq (140 nCi) was detected. Most measurements did not show any incorporation; and the few positive results were below 0.74 kBq (20 nCi). The environmental load due to unfiltered release from patients' rooms was determined at the fence of the nuclear research plant. The maximum was 0.24 mSv/a thyroid gland dose of a small child in 1982 taking into account the measured 90% partion of organic compound iodine. The waste water is decayed following chemical treatment in storage tanks. (orig./HP) [de

Retrospective reconstruction of Iodine-131 distribution through the analysis of Iodine-129

Science.gov (United States)

Matsuzaki, Hiroyuki; Muramatsu, Yasuyuki; Ohno, Takeshi; Mao, Wei

2017-09-01

Iodine-131 distribution released from the Fukushima Dai-ichi Nuclear Power Plant accident was reconstructed through the iodine-129 measurements. From nearly 1,000 surface soil samples iodine was extracted by the pyro hydrolysis method. Extracted iodine was then mixed with carrier, purified and finally collected as silver iodide. Silver iodide sample was pressed into the cathode holder and set at the ion source of the MALT facility, The University of Tokyo. The isotopic ratio 129I/127I was measured by means of Accelerator Mass Spectrometry. From 129I data obtained, 131I deposition map was constructed. There observed various fine structures in the map which could not estimated neither by the simulation nor 137Cs distribution.

Experience in the patients management which received treatments with radioactive iodine (131I). Measurements and dosimetry pertaining to the personnel related

International Nuclear Information System (INIS)

Ruiz J, A.

1999-01-01

In the INNSZ there are administering ablative doses of radioactive iodine to patients with problems of the thyroid gland from 40 years ago. Starting from 1992 was initiated the restlessness to inform to the patients verbally and in writing over the measurements of radiological safety that must be followed for the protection of their families. In this work it is commented, the benefits obtained with the patients and the teachings to give to the personnel what attend the patients which receive treatments with iodine-131 and must be hospitalized. It is commented too over the standardization standing of the patients discharged whom received radioactive material and lastly, it was make a dosimetric study of the nurses, radiotherapeutic and control area. (Author)

Radiation exposure and radiation protection of the physician in iodine-131 Lipiodol therapy of liver tumours

International Nuclear Information System (INIS)

Risse, J.H.; Ponath, C.; Palmedo, H.; Biersack, H.J.; Menzel, C.; Gruenwald, F.

2001-01-01

Intra-arterial iodine-131 labelled Lipiodol therapy for liver cancer has been investigated for safety and efficacy over a number of years, but data on radiation exposure of personnel have remained unavailable to date. The aim of this study was to assess the radiation exposure of the physician during intra-arterial 131 I-Lipiodol therapy for liver malignancies and to develop appropriate radiation protection measures and equipment. During 20 intra-arterial administrations of 131 I-Lipiodol (1110-1924 MBq), radiation dose equivalents (RDE) to the whole body, fingers and eyes of the physician were determined for (a) conventional manual administration through a shielded syringe, (b) administration with an automatic injector and (c) administration with a lead container developed in-house. Administration by syringe resulted in a finger RDE of 19.5 mSv, an eye RDE of 130-140 μSv, and a whole-body RDE of 108-119 μSv. The injector reduced the finger RDE to 5 mSv. With both technique (a) and technique (b), contamination of angiography materials was observed. The container allowed safe transport and administration of the radiopharmaceutical from 4 m distance and reduced the finger RDE to 131 I-Lipiodol was administered by syringe or injector, but was significantly reduced with the lead container. (orig.)

Chapter 5: Measurements of iodine-131 in milk supplies

International Nuclear Information System (INIS)

Duggleby, J.C.; Kotler, L.H.; Wilks, M.J.; Wise, K.N.

1974-01-01

As with previous series of French nuclear tests in Polynesia, a program was instituted to monitor major milk supplies for iodine-131. This program extended from 25 July to 23 October 1973, and was terminated only after there was no further possibility of iodine-131 reaching the milk supplies. The program covered the nine major population centres and effectively monitored the milk consumed by 80 per cent of the entire Australian population. The method employed for iodine-131 assay of milk supplies is described, and the final results obtained are presented. (author)

Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer

International Nuclear Information System (INIS)

Gutierrez, S.; Carbonell, E.; Creus, A.; Marcos, R.

1999-01-01

To detect the incidence and persistence of potential chromosome damage induced by iodine-131 therapy, we applied the cytokinesis-block micronucleus assay to peripheral blood lymphocytes from hyperthyroidism and thyroid cancer patients treated with 131 I. Two groups of patients were evaluated in a longitudinal study; one group was composed of 47 hyperthyroid patients and the other of 39 thyroid cancer patients. In the hyperthyroidism group, the micronuclei frequency was determined before 131 I therapy and 1 week, 1 month and 3 months after it. Furthermore, an additional sample was taken from a subgroup of 17 hyperthyroidism patients 6 months after treatment. In the thyroid cancer group, the analysis was also conducted over time, and four samples were studied: before treatment and 1 week, 6 months and 1 year later. Simultaneously, a cross-sectional study was performed with 70 control subjects and 54 thyroid cancer patients who had received the last therapeutic dose 1-6 years before the present study. In the hyperthyroidism group a significant increase in the micronuclei average was found over time. In the sample obtained 6 months after therapy, the micronuclei mean frequency was practically the same as in the sample taken 3 months before. In the thyroid cancer group a twofold increase in the frequency of micronuclei was seen 1 week after therapy. Although this value decreased across time, the micronuclei frequency obtained 1 year after 131 I therapy remained higher than the value found before it. Concerning the data from the cross-sectional study, a significant increase in the frequency of micronuclei was detected in the subgroup of thyroid cancer patients treated between 1 and 3 years before the current study. These results indicate that exposure to 131 I therapy induces chromosome damage in peripheral lymphocytes and that the cytokinesis-block micronucleus assay is sensitive enough to detect the genetic damage by exposure to sufficiently high levels of radiation

Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer

Energy Technology Data Exchange (ETDEWEB)

Gutierrez, S.; Carbonell, E.; Creus, A.; Marcos, R. [Universitat Autonoma de Barcelona (Spain). Dept. de Genetica i de Microbiologia; Galofre, P. [Servei de Medicina Nuclear, Ciutat Sanitaria i Universitaria Vall d' Hebron, Barcelona (Spain)

1999-12-01

To detect the incidence and persistence of potential chromosome damage induced by iodine-131 therapy, we applied the cytokinesis-block micronucleus assay to peripheral blood lymphocytes from hyperthyroidism and thyroid cancer patients treated with {sup 131}I. Two groups of patients were evaluated in a longitudinal study; one group was composed of 47 hyperthyroid patients and the other of 39 thyroid cancer patients. In the hyperthyroidism group, the micronuclei frequency was determined before {sup 131}I therapy and 1 week, 1 month and 3 months after it. Furthermore, an additional sample was taken from a subgroup of 17 hyperthyroidism patients 6 months after treatment. In the thyroid cancer group, the analysis was also conducted over time, and four samples were studied: before treatment and 1 week, 6 months and 1 year later. Simultaneously, a cross-sectional study was performed with 70 control subjects and 54 thyroid cancer patients who had received the last therapeutic dose 1-6 years before the present study. In the hyperthyroidism group a significant increase in the micronuclei average was found over time. In the sample obtained 6 months after therapy, the micronuclei mean frequency was practically the same as in the sample taken 3 months before. In the thyroid cancer group a twofold increase in the frequency of micronuclei was seen 1 week after therapy. Although this value decreased across time, the micronuclei frequency obtained 1 year after {sup 131}I therapy remained higher than the value found before it. Concerning the data from the cross-sectional study, a significant increase in the frequency of micronuclei was detected in the subgroup of thyroid cancer patients treated between 1 and 3 years before the current study. These results indicate that exposure to {sup 131}I therapy induces chromosome damage in peripheral lymphocytes and that the cytokinesis-block micronucleus assay is sensitive enough to detect the genetic damage by exposure to sufficiently high

Iodine-131 monitoring in sewage plant outflow

International Nuclear Information System (INIS)

McGowan, D R; Crawley, M T; Pratt, B E; Hinton, P J; Peet, D J

2014-01-01

Three different hospital sites (Oxford, Sutton and Guildford) have performed sampling of their local sewage plant outflow to determine levels of radioactivity resulting from iodine-131 patients undergoing radionuclide therapies. It was found that a maximum of 20% of activity discharged from the hospitals was present in the sewage plant final effluent channel. This is significantly below the level predicted by mathematical models in current use. The results further show that abatement systems to reduce public exposure are unlikely to be warranted at hospital sites. (paper)

Additional effective dose by patients undergoing NAI-131 capsules therapy

Energy Technology Data Exchange (ETDEWEB)

Orlic, M.; Jovanovic, M.; Spasic Jokic, V.; Cuknic, O.; Ilic, Z.; Vranjes Djuric, S. [VINCA - Institute of Nuclear Sciences, Belgrade, Serbia and Montenegro (Yugoslavia)

2006-07-01

Capsules or solutions containing Na{sup 131}I are indicated for the therapy of some thyroid carcinomas such as functioning metastatic papillary or follicular carcinoma of the thyroid; and for the treatment of hyperthyroidism (diffuse toxic goiter and single or multiple toxic nodular goiter). The recommended dosage ranges of Na{sup 131}I capsules or solution for the therapy of the average patient (70 kg) are: (3.7-5.55) GBq for ablation of normal thyroid tissue; (3.7-7.4) GBq for subsequent treatments; a (148-370) MBq for hyperthyroidism. The purpose of this paper is to calculate effective dose as a result of iodine-131 capsules remaining in stomach before absorption starts. This result can determine the disadvantage of capsule versus solution containing sodium iodine-131 (Na{sup 131}I) in radionuclide therapy application from radiation protection point of view. The Monte Carlo code MCNP4b was used to model transport of gamma and beta particles emitted by radionuclide {sup 131}I treated as a point source at the bottom of stomach. Absorbed energy per unit transformation in stomach and surrounding organs has been calculated. (authors)

Radioiodine 131 therapy in hyperthyroidism evaluation of French nuclear medicine practices

International Nuclear Information System (INIS)

Bernard, D.; Boin, C.; Desruet, M.; Roux, J.; Wolf, M.; Fagret, D.; Allenet, B.; Foroni, L.

2015-01-01

Full text of publication follows. Aim Radioiodine 131 I (RAI) is currently used routinely in the treatment of hyperthyroidism including Graves disease (GD), toxic multi-nodular goitre (TMNG) and toxic solitary nodule (TSN). It has proved to be safe, efficient and relatively inexpensive therapy. But after more than 60 years, many protocols are coexisting and no consensus exists on the most appropriate way to prescribe RAI dose: fixed dose regime or calculated doses based on gland size or turnover of RAI. This is the first nationwide French survey assessing the current practices about radioiodine treatment in thyrotoxicosis. Methods: we sent a questionnaire to French nuclear medicine hospital units and cancer treatment centres (n=69) about their practices in 2012. Questions were asked about RAI treatment: objectives, way to prescribe the therapeutic dose and its factors, radioisotope use to explore thyroid function and method of gland size measurement. Results: we received 40 responses. Euthyroidism was a successful treatment outcome for 33% of French respondents whereas hypothyroidism was the aim for 26%. Antithyroid drugs were stopped 7 days on average (range 3-21 days) before therapy. 68% of physicians used ultrasound for thyroid volume measurement. Calculated doses were used by 40% of clinicians (Marinelli's formula: 80%). Factors influencing prescription were thyroid uptake (100%) based on radiotracer iodine-131 (33%) or iodine-123 (67%), thyroid volume (93%) and disease (80%). Fixed activities represented 60% of the prescribed doses (72,5% for TMNG and TSN). The administered dose was chosen between 1 to 3 levels of standard doses, according to the patient characteristics. Factors influencing this choice were disease, with respectively a median of 370 MBq (range:185-740), 555 MBq (185-740), 555 MBq (296-925) for GD, TSN and TMNG, thyroid volume (59%) and thyroid uptake (52%) with the radiotracer iodine-123 (30%) or technetium-99m (70%). Even physicians

Guidelines on the management of patients treated with iodine-131

International Nuclear Information System (INIS)

1993-03-01

The purpose of these guidelines is to assist health care institutions establish protocols for the management of patients treated with iodine-131. These guidelines are written primarily for the use of Na 131 I in the treatment of benign and malignant thyroid disease. The principles have some application for the use of complex 131 I-labelled radiopharmaceuticals in that the treated patient will become a temporary radiation source and since contamination with body fluids of treated patients must be guarded against. The document outlines radiation protection and logistical concerns associated with the management of 131 I patients before, during and after therapy. These concerns include the safety of health care personnel, visitors, and any other persons who are at risk; and protection of the environment. (L.L.) 23 refs., 2 tabs

Resveratrol Sensitizes Selectively Thyroid Cancer Cell to 131-Iodine Toxicity

Directory of Open Access Journals (Sweden)

Seyed Jalal Hosseinimehr

2014-01-01

Full Text Available Background. In this study, the radiosensitizing effect of resveratrol as a natural product was investigated on cell toxicity induced by 131I in thyroid cancer cell. Methods. Human thyroid cancer cell and human nonmalignant fibroblast cell (HFFF2 were treated with 131I and/or resveratrol at different concentrations for 48 h. The cell proliferation was measured by determination of the percent of the survival cells using 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT assay. Results. Findings of this study show that resveratrol enhanced the cell death induced by 131I on thyroid cancer cell. Also, resveratrol exhibited a protective effect on normal cells against 131I toxicity. Conclusion. This result indicates a promising effect of resveratrol on improvement of cellular toxicity during iodine therapy.

Conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation 1948--1951

International Nuclear Information System (INIS)

Denham, D.H.; Mart, E.I.; Thiede, M.E.

1993-09-01

This report is a part of the Hanford Environmental Dose Reconstruction (HEDR) Project, whose goal is to estimate the radiation dose that individuals could have received from emissions since 1944 at the US Department of Energy's (DOE) Hanford Site near Richland, Washington. The key radionuclide emitted that would affect the radiation dose was iodine-131 (Napier 1992). Because the early methods of measuring iodine-131 were not comparable to later techniques, conversion and correction factors are needed to convert the historical measurement data into concentration values that would be determined using today's knowledge and technologies. This report describes the conversion and correction factors developed for reconstructing historical measurements of iodine-131 in Hanford-area vegetation, which was collected from 1948 through the end of December 1951

Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan. Current issues with historical review and future perspective

International Nuclear Information System (INIS)

Higashi, Tatsuya; Kudo, Takashi; Kinuya, Seigo

2012-01-01

Radioactive iodine (RAI, 131 I) has been used as a therapeutic agent for differentiated thyroid cancer (DTC) with over 50 years of history. Recently, it is now attracting attention in medical fields as one of the molecular targeting therapies, which is known as targeted radionuclide therapy. Radioactive iodine therapy (RIT) for DTC, however, is now at stake in Japan, because Japan is confronting several problems, including the recent occurrence of the Great East Japan Disaster (GEJD) in March 2011. RIT for DTC is strictly limited in Japan and requires hospitalization. Because of strict regulations, severe lack of medical facilities for RIT has become one of the most important medical problems, which results in prolonged waiting time for Japanese patients with DTC, including those with distant metastasis, who wish to receive RIT immediately. This situation is also due to various other factors, such as prolonged economic recession, super-aging society, and subsequent rapidly changing medical environment. In addition, due to the experience of atomic bombings in Hiroshima and Nagasaki, Japanese people have strong feeling of ''radiophobia ''. There is fear that GEJD and related radiation contamination may worsen this feeling, which might be reflected in more severe regulation of RIT. To overcome these difficulties, it is essential to collect and disclose all information about the circumstances around this therapy in Japan. In this review, we would like to look at this therapy through several lenses, including historical, cultural, medical, and socio-economic points of view. We believe that clarifying the problems is sure to lead to the resolution of this complicated situation. We have also included several recommendations for future improvements. (author)

Dose {sup 131}I radioactivity interfere with thyroglobulin measurement in patients undergoing radioactive iodine therapy with recombinant human TSH?

Energy Technology Data Exchange (ETDEWEB)

Park, So Hyun; Bang, Ji In; Lee, Ho Young; Kim, Sang Eun [Dept. of Nuclear Medicine, Seoul National University College of Medicine, Seoul (Korea, Republic of)

2015-06-15

Recombinant human thyroid-stimulating hormone (rhTSH) is widely used in radioactive iodine therapy (RIT) to avoid side effects caused by hypothyroidism during the therapy. Owing to RIT with rhTSH, serum thyroglobulin (Tg) is measured with high 131I concentrations. It is of concern that the relatively high energy of 131I could interfere with Tg measurement using the immunoradiometric assay (IRMA). We investigated the effect of 131I administration on Tg measurement with IRMA after RIT. A total of 67 patients with thyroid cancer were analysed retrospectively. All patients had undergone rhTSH stimulation for RIT. The patients’ sera were sampled 2 days after 131I administration and divided into two portions: for Tg measurements on days 2 and 32 after 131I administration. The count per minute (CPM) of whole serum (200 μl) was also measured at each time point. Student’s paired t-test and Pearson’s correlation analyses were performed for statistical analysis. Serum Tg levels were significantly concordant between days 2 and 32, irrespective of the serum CPM. Subgroup analysis was performed by classification based on the 131I dose. No difference was noted between the results of the two groups. IRMA using 125I did not show interference from 131I in the serum of patients stimulated by rhTSH.

Occupational and public radiation protection in the treatment with iodine 131

International Nuclear Information System (INIS)

Di Trano, Jose L.; Rojo, Ana M.; Kunst, Juan J.

2004-01-01

A common radionuclide therapy carried out by nuclear medicine departments is the administration of 131 I for thyroid ablation and for hyperthyroid treatment. The administration of 140 a 600 MBq for hyperthyroid treatment and 3700 a 7400 MBq for carcinoma diseases is made after surgery to ablate thyroid tissues and metastasis. The revision of radiological protection was done on the occupational exposure of workers, members of the public and relatives of patients treated with 131 I. This paper presents the results of area and individual dosimetry to external exposure, surface activity and air concentration of 131 I carried out during the practice in the nuclear medicine department. An area survey in the isolation room allowed to determine exposure rate from surface activity and air concentration of 131 I. The patient clothes activity was determined as well as the activity excreted in urine and sweat. On the basis of this analysis, can be concluded that the annual effective dose for workers due to external and internal exposure, considering 40 iodine practice per year, reach values from 4 up to 30 mSv per year. The patients with cancer therapy treatment must be hospitalized during the first 48 hrs after iodine administration, in an isolated room taking into account the radioprotection of the staff, others patients and public during the isolation. The patients with hyperthyroid treatment do not need hospitalization but they must to follow the instructions given by the physician, which will take into account socioeconomic conditions. (author)

Alteration of radioactive iodine uptake after treatment of hyperthyroidism with iodine 131

International Nuclear Information System (INIS)

Heath, R.C.; Gossain, V.V.; Rovner, D.R.

1988-01-01

To determine whether a therapeutic dose of iodine 131 affects the results of 24-hour radioactive iodine uptake (RAIU) testing, we reviewed records of hyperthyroid patients previously treated with 131 I at Michigan State University and its affiliated hospitals. We identified 26 patients who had had clinical evaluation and determination of the serum thyroxine (T4) level, triiodothyronine resin uptake (T3RU), and RAIU (using 131 I) within two weeks before and several months after the therapeutic dose of 131 I. Before treatment, all patients had clinical hyperthyroidism, with an elevated T4 level and increased T3RU and RAIU. After treatment with 131 I, eight patients (31%) had an RAIU that was discordant with their clinical and biochemical (T4 and T3RU) assessment. In six patients (23%) of the RAIU was inappropriately high, and in two patients (8%) it was inappropriately low. Since we did not identify any other factors known to interfere with the results of RAIU testing, we conclude that a therapeutic dose of 131 I, may by itself increase or decrease a subsequent RAIU determination; therefore, after treatment with 131 I, RAIU is not a good diagnostic index of thyroid activity

Hyperthyroidism and radioactive iodine

International Nuclear Information System (INIS)

Corstens, F.H.M.

1980-01-01

The study details the results of treatment of patients with hyperthyroidism using a combination of fractionated low doses radioactive iodine and anthithyroid drug therapy. The patients studied were treated according to this regimen after August 1968 and all reached euthyroidism before March 1979. None of the patients had been treated with radioactive iodine prior to the start of the protocol. A subgroup of the patients had received an unsuccessfull course with antithyroid drug therapy and, or, surgical therapy before the start of the protocol. Patients who had never been treated for hyperthyroidism were given antithyroid drug therapy for at least 6 months in an attempt to reach euthryroidism without the use of 131 I therapy. Therefore, all patients had experienced a course of unsuccessfull therapy prior to the start of the treatment protocol using combined fractionated low doses of 131 I and antithyroid drug therapy. (Auth.)

Internal contamination of nurses as a result of the therapeutic use of iodine-131

Energy Technology Data Exchange (ETDEWEB)

Termorshuizen, W; Gerritsen, A J.M.

1988-02-01

The internal contamination of nurses with sodium iodide-131 is studied in two different housing situations. Before moving, the therapy unit was an unventilated double room with a lock. In the new building, the unit consists of three single rooms and one double room with a lock and air conditioning. Also the concentration of iodine-131 in the air is measured. 2 figs.; 1 table.

Status of urinary iodine and I-131 uptake after universal iodination of common salt

International Nuclear Information System (INIS)

Alam, F.; Begum, F.; Haque, M.; Karim, M.A.; Faruque, O.; Ali, L.; Khan, A.K.A.

2002-01-01

This work was carried out in the Institute of Institute of Nuclear Medicine (INM), Bangabandhu Sheikh Mujib Medical University and Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka. Here we have tried to explore present status of urinary iodine and uptake status in Bangabandhu. Period study was from 1998 to 2000. Total study population was 300, of them 84 was male and 216 was female. Populations of all social and economic strata have been studied, starting from bottoms to top-level income groups as well as urban, rural and suburban populations are included randomly. We studied I-131 uptake and urinary iodine. I-131 given orally in liquid form and the quantity accumulated by the thyroid gland at 24 hours intervals of time is measured using a gamma scintillation counter. Gamma-ray emission of 364 keV energy by I-131 is detected gamma scintillation counter. Urinary iodine is estimated by CIS-BIO kit. Urine is digested with chloric acid under mild conditions and determined manually by its catalytic role in the reduction of ceric ammonium sulfate in the presence of arsenious acid. The uptake was grouped into four categories according to their uptake percentage. Group-A; (lowest uptake group) 99 subject, have uptake between 0 to 4.9%, Group-B; 100 subjects, (relatively low uptake) who have uptake between 4.91-9.9%, group-C; 73 subjects, who have uptake between 10-30% and in-group D, there was 28 subjects their uptake was above 30%. We have also found in group-A median uptake is 3.0% and urinary iodine level is 43.31 μg/dl, in group-B median uptake is 7.0% and urinary iodine level is 33.95 μg/dl, in group-C median uptake is 23.0% and urinary iodine level is 12.97 μg/dl, in group-D median uptake is 34.0% and urinary iodine level is 9.35 μg/dl. We have found 1.04% have severe type low urinary iodine, 3.48% moderate type of low urinary iodine, 3.48%, 16.72% mild type of low urinary iodine and 78.74% have normal

Determination of radiation dose rates and urinary activity of patients received Sodium Iodide-131 for treatment of differentiated thyroid carcinoma

International Nuclear Information System (INIS)

Beiki, D.; Shahhosseini, S.; Dadashzadeh, S.; Eftekhari, M.; Tayebi, H.; Moosazadeh-Rashti, G.

2004-01-01

Sodium Iodide-131 is administrated for treatment of hyperthyroidism and thyroid cancer. Iodine-131 has multiple routs of excretion (urine, saliva, sweat, milk, feces, exhalation) from the body. Patients receiving Sodium Iodide-131 therapy exposes other persons and the environment to unwanted radiation and contamination. The major sources of radiation dose from administration of Iodine-131 is external radiation , also there is a potential for exposure via contamination.Precautions are necessary to limit the radiation dose to family members, nursing staff and members of public and waste treatment workers to less than 1mSv. Patients received Sodium Iodide-131 may come into close contact with other persons. In order to derive appropriate recommendations, dose rates were measured from the anterior mid-trunk of 29 patients in the upright position with 15 minutes post-dose administration at 3 meters and just before they left the nuclear medicine department at 0.5, 1, and 3 meters. We have also measured urinary iodide excretion in 29 patients to estimate Sodium Iodide-131 urinary excretion pattern in iranian patients. Based on results, the maximum cumulative dose to nursing staff was on third day (leaving day) still less than recommended dose bye ICRP. The cumulative dose family members will be more but regarding the time and distance in close contact it will be also less than recommended dose by ICRP.Radiation dose rate was decreased significantly on third day. The urinary excretion patterns in all patients were similar. The urinary excretion rate-time curve in all patients showed multiple peaks due to retention and redistribution of Iodine-131 or enterohepatic cycle of radioiodinated thyroid hormones, which didn't allow calculation of urinary excretion rate constant. The results also showed that 67 hours post administration of Sodium Iodide-131 about 70% of radiopharmaceutical was excreted through urine, 28% physically decayed or eliminated through other biological

Long-term outcomes of {sup 131}Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders

Energy Technology Data Exchange (ETDEWEB)

Mulholland, Nicola; Chakravartty, Riddhika; Devlin, Lindsey; Kalogianni, Eleni; Corcoran, Ben; Vivian, Gillian [King' s College Hospital, Department of Nuclear Medicine, London (United Kingdom)

2015-12-15

{sup 131}Iodine (I131)-metaiodobenzylguanidine (mIBG) is a radionuclide-based treatment option for metastatic gastrointestinal-pancreatic neuroendocrine tumours (GEP NET). This study aimed at identifying prognostic indicators of long-term outcome based on initial evaluation following a first mIBG treatment (7400 MBq) in a patient cohort with such tumours, with a secondary aim of evaluating progression-free survival (PFS) and overall survival (OS) following mIBG therapy. Retrospective review of the hospital records was performed to identify a cohort of 38 adult patients who underwent {sup 131}Iodine-mIBG therapy over a 9-year period for metastatic GEP NETs and neuroendocrine tumours with an unknown primary. Treatment response was evaluated based on radiological criteria (RECIST1.1), biochemical markers [serum Chromogranin A (CgA)/urinary 5HIAA] and symptomatic response at clinical follow-up, all evaluated at 3-6 months from first mIBG treatment. Progression-free survival (PFS) and overall survival (OS) from the first mIBG treatment were recorded. At 3-6 months following a single mIBG therapy, 75 %, 67 %, and 63 % of patients showed either a partial response (PR) or stable disease (SD) on radiological, biochemical, and symptomatic criteria, respectively. Complete response (CR) was not seen in any patient. OS from the date of diagnosis and from the first therapy was 8 years +/-1.1 (95 % CI 5.7 to 10.2 years) and 4 years+/-0.69 (95 % CI 2.6-5.3 years), respectively. Twenty-nine percent of patients were alive at 10 years. Significant survival advantage was seen in patients with SD/PR as compared to those who had progressive disease (PD) for each of these three criteria. Biochemical, radiological (RECIST 1.1) and symptomatic assessment of disease status at 3 to 6 months after first I131-mIBG therapy stratifies patients with a poor prognosis. This can be used to identify patients who may benefit from alternative strategies of treatment. (orig.)

Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease.

Science.gov (United States)

Rohrs, Henry J; Silverstein, Janet H; Weinstein, David A; Amdur, Robert J; Haller, Michael J

2014-01-01

Female, 11 FINAL DIAGNOSIS: Thyroid storm Symptoms: Diarrhea • tachycardia • tachypnea • tremor • wheezing - Clinical Procedure: - Specialty: - Rare disease. A growing number of pediatric endocrinologists treat Graves disease with radioactive iodine (RAI) therapy due to the typically definitive nature of I-131 therapy. Given the published benefits and perceived low risks of RAI when compared to surgery or long-term anti-thyroid medication, the trend towards therapy with RAI is likely to continue. Nevertheless, RAI is not without significant risk. An 11-year-old girl with newly diagnosed Graves disease received RAI for definitive treatment of her hyperthyroidism. Within 24 hours of receiving I-131, she developed increasing sleepiness and eventually became unresponsive. Upon arrival at the emergency department she had a tonic-clonic seizure and was diagnosed with thyroid storm. Despite best efforts to manage her hyperthyroidism, she suffered a stroke of the left cerebral hemisphere that left her with persistent neurological deficits. Although thyroid storm after thyroid ablation is rare, the significant morbidity and potential mortality of pediatric thyroid storm warrant further studies to determine if children with markedly elevated thyroid hormone concentrations at diagnosis should receive prolonged pretreatment with anti-thyroid drugs. While such an approach may reduce the efficacy of I-131 ablation, it can also reduce and hopefully eliminate the risk of post-ablative thyroid storm.

Transient hypothyroidism in iodine-131 treated thyrotoxicosis - a review of cases from 1970-1984 at JRRMMC

International Nuclear Information System (INIS)

Reyes, E.B.; de la Cruz, C.; Gonzales, V.L.

1988-01-01

This review was conducted to determine the minimum dose of radioactive iodine necessary to show signs and symptoms of thyrotoxicosis among Filipinos, to determine the incidence of hypothyroidism secondary to radioactive treatment and to determine if some cases of hypothyroidism following radioactive iodine treatment are only transient and replacement therapy could be withheld or not. A total of 212 patients who had I-131 therapy was evaluated (177 female and 35 male). Of this number 19 or 8.9% developed hypothyroidism. After three years, 14 or 74% of the hypothyroids were noted. Easy fatigability ranked first of the patients complaints, followed by dry skin, sleepiness, numbness of extremities, and joint pains. Results of this study indicate that there is a definite, although low incidence of hypothyroidism following I-131 therapy (8.9%). (ELC). 6 refs.; 6 tabs

Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan

International Nuclear Information System (INIS)

Castagnoli, A.; Biti, G.; De Cristofaro, M.T.R.; Papi, M.G.; Ferri, P.; Magrini, S.M.; Bianchi, S.

1992-01-01

Two cases of Merkel cell carcinoma, a neuroendocrine neoplasia of the skin, investigated with iodine, 131 metaiodobenzylguanidine ( 131 I-mIBG) scintigraphy, are reported. Uptake in the tumor was evident only in 1 case. The possible diagnostic and therapeutic role of 131 I-mIBG in patients with this rare neoplasm is discussed. (orig.)

Iodine 131 and 133 as Fission Indicators

Energy Technology Data Exchange (ETDEWEB)

Broda, E.

1944-07-01

This report was written by E. Broda at the Cavendish Laboratory (Cambridge) in September 1944 and is about the possible use of Iodine 131 and 133 as fission indicators. Additionally, the description of the chemical procedure for I 131 and I 133 and the corresponding results can be found in this report. (nowak)

Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism

International Nuclear Information System (INIS)

Holm, L.E.; Lundell, G.; Israelsson, A.; Dahlgvist, I.

1982-01-01

We have studied the long-term incidence of hypothyroidism in 4,473 formerly hyperthyroid patients given I-131 therapy between 1951 and 1975. The mean age at the first I-131 treatment was 56 yr. Six percent developed hypothyroidism within one year of therapy, and 72% within 26 yr. Prior antithyroid medication did not affect the incidence of hypothyroidism. Patients cured with one dose of I-131 had a lower cumulative long-term incidence of hypothyroidism than those requiring more than one dose

Genetic effects of iodine 131 incorporation in mammals

International Nuclear Information System (INIS)

Bajrakova, A.

1988-01-01

The translocation yield after single treatment of male mice with iodine 131 (55,5 - 222,0 kBq/g b.w.) was investigated. The results of the cytogenetic analysis of the gonad cells revealed the effectiveness only of the highest activity, distroying the thyroid gland. The so-called direct method was also used for determination of the risk coefficients for the expected new carriers of balanced and unbalanced translocations in the first generation - the genetic effects which could be expected from the use of iodine-131-diagnostics in a hypothetic population

Radiosensitizers action on Iodine 131 therapeutical effect

International Nuclear Information System (INIS)

Agote, Marcos; Kreimann, Erica L.; Bocanera, Laura V.; Dagrosa, Maria A.; Juvenal, Guillermo J.; Pisarev, Mario A.

1999-01-01

Present studies were aimed to research the possible application of a radiosensitizer, nicotinamide, to increase the therapeutical effect of radioiodine. There were used goitrous and normal rats with growing dose of Iodine 131, with and without simultaneous treatment with nicotinamide. The obtained results show that the nicotinamide treatment importantly increases the thyroid radio destructive effect induced by radioiodine. Under these experimental conditions, nicotinamide induces to a significant increase of thyroid vascularisation, without changes in the proteins ADP-ribosylation activity. These results show, for the first time, the radiosensitizer effect of nicotinamide in front of Iodine 131 and give the possibility of using it in the treatment of hyperthyroid or thyroid difference cancer patients. (author)

Iodine-131 therapy for the treatment of multinodular goitre

International Nuclear Information System (INIS)

Akerman, R.L.; Howarth, D.M.

1997-01-01

Full text: The purpose of this study was to investigate the effectiveness of 131 l therapy for toxic and non-toxic multinodular goitre (MNG)in the patients treated with the standard dose of 4 x 555 MBq (total 2.2 Bq) and therefore give some indication as to the adequacy of this therapy. This was a retrospective study using information from patients' notes. All patients with large multinodular goitres who had radioiodine therapy for treatment of MNG since 1991 were selected. Data obtained included age, gender, pre, peri and post therapy symptoms and serial biochemical thyroid function results. Each patient was followed for a minimum of six months. The subjects were 35 patients (32 female, three male) with an age range of 37 - 87 years. 26 patients had non-toxic MNG, nine patients had toxic MNG, 24 patients had retrosternal or obstructive symptoms and five patients had had previous thyroid therapy. The patients with retrosternal or obstructive symptoms experienced a reduction in those symptoms. 8.6 per cent of the patients experienced no change at all in symptoms. 2.8 per cent of the patients experienced non-transient side effects (sore throat). 32.8 per cent of the patients experienced transient hyperthyroidism during 131 I therapy. In the toxic group, 77.8 per cent became euthyroid. 11.1 per cent became hypothyroid and 11.1 per cent remained hyperthyroid and required additional treatment. In the non-toxic group, 42.3 per cent became hypothyroid and 57.7 per cent remained euthyroid. The overall incidence of hypothyoidism was 34.4 per cent. The results of this study suggests 131 l therapy in the form of 4 x 555 MBq oral doses (one dose per month for four months) is effective, efficient, relatively risk-free, easy and generally well-tolerated treatment for toxic and non-toxic multinodular goitre

Iodine-131 therapy for the treatment of multinodular goitre

Energy Technology Data Exchange (ETDEWEB)

Akerman, R.L.; Howarth, D.M. [John Hunter Hospital, Newcastle, NSW, (Australia). Department of Nuclear Medicine

1997-09-01

Full text: The purpose of this study was to investigate the effectiveness of {sup 131}l therapy for toxic and non-toxic multinodular goitre (MNG)in the patients treated with the standard dose of 4 x 555 MBq (total 2.2 Bq) and therefore give some indication as to the adequacy of this therapy. This was a retrospective study using information from patients` notes. All patients with large multinodular goitres who had radioiodine therapy for treatment of MNG since 1991 were selected. Data obtained included age, gender, pre, peri and post therapy symptoms and serial biochemical thyroid function results. Each patient was followed for a minimum of six months. The subjects were 35 patients (32 female, three male) with an age range of 37 - 87 years. 26 patients had non-toxic MNG, nine patients had toxic MNG, 24 patients had retrosternal or obstructive symptoms and five patients had had previous thyroid therapy. The patients with retrosternal or obstructive symptoms experienced a reduction in those symptoms. 8.6 per cent of the patients experienced no change at all in symptoms. 2.8 per cent of the patients experienced non-transient side effects (sore throat). 32.8 per cent of the patients experienced transient hyperthyroidism during {sup 131}I therapy. In the toxic group, 77.8 per cent became euthyroid. 11.1 per cent became hypothyroid and 11.1 per cent remained hyperthyroid and required additional treatment. In the non-toxic group, 42.3 per cent became hypothyroid and 57.7 per cent remained euthyroid. The overall incidence of hypothyoidism was 34.4 per cent. The results of this study suggests {sup 131}l therapy in the form of 4 x 555 MBq oral doses (one dose per month for four months) is effective, efficient, relatively risk-free, easy and generally well-tolerated treatment for toxic and non-toxic multinodular goitre.

Production of 131 Iodine in research reactors from elementary tellurium

International Nuclear Information System (INIS)

Silva, Constancia Pagano Goncalves da

1970-01-01

Presents the history of the production of iodine-131 in the Institute of Atomic Energy (IEA), SP, Brazil), the preliminary works for the development of the method, which were done in small scale and it was not necessary protection for the operators, the evolution of these operations until the final assembling of the equipment in shielded cells, the efficiency of operations and product purity. The problems linked to the presence of iodate in the preparations and the changes made for elimination of that ion, harmful to many types and use of iodine-131 are examined. The quality of the product delivered today, an average of 140 departures per month, and the number of departures, per year since the beginning of iodine-131 production were indicated

Low dose iodine-131 therapy in solitary toxic thyroid nodules

International Nuclear Information System (INIS)

Prakash, Rajeev

1999-01-01

Forty patients with solitary hyperfunctioning thyroid nodules were treated with relatively low dose radioiodine therapy, 131 I doses were calculated taking into account thyroid mass and radioiodine kinetics to deliver 100 μCi/g of estimated nodule weight corrected for uptake. Patients remaining persistently hyperthyroid at four months after the initial therapy were retreated with a similarly calculated dose. Cure of the hyperthyroid state was achieved in all patients, total administered dose in individual cases ranging from 3-17 mCi. 28 of the 40 patients required a single therapy dose. 36 patients were euthyroid after a 4.5 year mean follow-up period. Four cases developed post therapy hypothyroidism requiring replacement therapy. Nodules regressed completely in nine cases following 131 I treatment, with partial regression in size in 19 patients. Control of hyperthyroid state in cases of solitary toxic thyroid nodules can be satisfactorily achieved using relatively low dose radioiodine therapy with low incidence of post therapy hypothyroidism. (author)

Scoping calculation for components of the cow-milk dose pathway for evaluating the dose contribution from iodine-131

International Nuclear Information System (INIS)

Ikenberry, T.A.; Napier, B.A.

1992-12-01

A series of scoping calculations have been undertaken to evaluate The absolute and relative contribution of different exposure pathways to doses that may have been received by individuals living in the vicinity of the Hanford site. This scoping calculation (Calculation 001) examined the contributions of the various exposure pathways associated with environmental transport and accumulation of iodine-131 in the pasture-cow-milk pathway. Addressed in this calculation were the contributions to thyroid dose of infants and adult from (1) the ingestion by dairy cattle of various feedstuffs (pasturage, silage, alfalfa hay, and grass hay) in four different feeding regimes; (2) ingestion of soil by dairy cattle; (3) ingestion of stared feed on which airborne iodine-131 had been deposited; and (4) inhalation of airborne iodine-131 by dairy cows

Destruction of post-surgery thyroid remnants by 19 mCi (703 MBq) of iodine 131

International Nuclear Information System (INIS)

Tassy, D.; Lonchampt, M.F.; Minebois, A.; Antigny, J.F.

1997-01-01

The adjuvant treatment by iodine 131 in good prognostic forms of differentiated thyroid cancers (DTC) makes not the object of a general consensus. There is no study demonstrating the benefit from such a treatment. Administration of an elevated iodine 131 activity and the constraint of a supplementary hospitalization are in these conditions questionable. In 6 patients, presenting the criteria of good prognostic and in post-operation, ambulatory conditions, administration of 19 mCi (703 MBc) of iodine 131 was done without previous administration of tracing dosage, followed after 72 hours by a whole-body scintigraphy, in the usual pause conditions. This administration was repeated 6 to 12 months later and followed by a new scintigraphic examination. The cervical fixation of iodine 131 was established qualitatively and quantitatively (as compared with a control zone). Five/six patients presented initially a cervical intense fixation with the star-like usual image and 1/6 patient a moderated fixation. Beginning with the second administration no cervical fixation was noted in 4/6 patients and a very low fixation in 2/6 patients. The concomitantly measured thyroglobulin, under simulation by TSH endogenous, was 131 I after quasi-total thyroidectomy in good-prognostic forms of DTC, without administration of previous tracing dosage to avoid possible phenomena of thyroid tissue blocking, allows probably, in overwhelming majority of cases, both a full or quasi-full destruction of the thyroid remnants and a severe reduction in the thyroglobulin rate measured in the conditions of pause of hormone-therapy

Radiolabeling and Preclinical Evaluation of 131I-anti-CD20 for Non-Hodgkin's Lymphomas Therapy

International Nuclear Information System (INIS)

Kullaprawittaya, Usa; Khongpetch, Pranom; Ngamprayad, Tippanan; Nuanchuen, Suphatphong

2007-08-01

Full text: In this study, a monoclonal anti-CD20 was developed for radioimmunotherapy of non-Hodgkin's B-cell lymphoma by reacting anti-CD20 with iodine-131 using iodogen procedure. It was found that radiochemical yield was > 95 % independently of incubation time and the antibody could be conjugated with iodine-131 up to 10 mCi/mg. The radiolabeled antibody exhibited excellent retention of immunoreactivity with radio incorporations >95% for 6 hr at 4 o C. In vitro stability tests showed minimal loss of iodine-131 from the conjugate in the presence of cysteine and in human serum at 37 o C. Biodistribution study in normal ICR mice showed higher uptake by the liver, kidney and intestines but lower thyroid uptake compared to 131 I -MIBG. Biodistribution studies confirmed the in vitro stability of 131 I -anti-CD20. In particular, excellent in vivo retention of iodine-131 was demonstrated by lower thyroid accumulation over 48 hr. A favorable biological distribution of 131 I -anti-CD20 suggests this radiopharmaceutical may be effectively used in the therapy of non-Hodgkin's lymphoma

Iodine neutron capture therapy

Science.gov (United States)

Ahmed, Kazi Fariduddin

A new technique, Iodine Neutron Capture Therapy (INCT) is proposed to treat hyperthyroidism in people. Present thyroid therapies, surgical removal and 131I treatment, result in hypothyroidism and, for 131I, involve protracted treatment times and excessive whole-body radiation doses. The new technique involves using a low energy neutron beam to convert a fraction of the natural iodine stored in the thyroid to radioactive 128I, which has a 24-minute half-life and decays by emitting 2.12-MeV beta particles. The beta particles are absorbed in and damage some thyroid tissue cells and consequently reduce the production and release of thyroid hormones to the blood stream. Treatment times and whole-body radiation doses are thus reduced substantially. This dissertation addresses the first of the several steps needed to obtain medical profession acceptance and regulatory approval to implement this therapy. As with other such programs, initial feasibility is established by performing experiments on suitable small mammals. Laboratory rats were used and their thyroids were exposed to the beta particles coming from small encapsulated amounts of 128I. Masses of 89.0 mg reagent-grade elemental iodine crystals have been activated in the ISU AGN-201 reactor to provide 0.033 mBq of 128I. This activity delivers 0.2 Gy to the thyroid gland of 300-g male rats having fresh thyroid tissue masses of ˜20 mg. Larger iodine masses are used to provide greater doses. The activated iodine is encapsulated to form a thin (0.16 cm 2/mg) patch that is then applied directly to the surgically exposed thyroid of an anesthetized rat. Direct neutron irradiation of a rat's thyroid was not possible due to its small size. Direct in-vivo exposure of the thyroid of the rat to the emitted radiation from 128I is allowed to continue for 2.5 hours (6 half-lives). Pre- and post-exposure blood samples are taken to quantify thyroid hormone levels. The serum T4 concentration is measured by radioimmunoassay at

Proposal of a methodology for individualized iodine-131 therapy for Graves' disease in patients with hyperthyroidism

International Nuclear Information System (INIS)

Araujo, Francisco de; Melo, Rossana Corbo de; Rebelo, Ana Maria de Oliveira; Dantas, Bernardo Maranhao; Dantas, Ana Leticia A.; Lucena, Eder Augusto de

2007-01-01

Objective: Several methods are utilized for determining the radioiodine activity in the treatment of Graves' disease (hyperthyroidism). Some of this methods do not take into consideration the thyroid absorbed dose or the necessary parameters for this estimation. The association between absorbed dose and administered activity depends on effective half-life, iodine uptake and thyroid mass of each patient. The present study was aimed at developing a methodology for individualized 131 I therapy for Graves' disease in patients with hyperthyroidism of the Graves' disease. Materials and methods: A neck-thyroid phantom developed at Instituto de Radioprotecao e Dosimetria, containing a standard solution of 131 I, was utilized for calibrating the scintillation gamma camera and uptake probe installed in the Department of Nuclear Medicine of the Hospital Universitario Clementino Fraga Filho da Universidade Federal do Rio de Janeiro. Results: The view angle of the collimator/detector assembly presented values compatible with the thyroid gland size for distances of 25 cm (uptake probe) and 45.8 cm (scintillation gamma camera). Calibration factors were 39.3 ± 0.78 and 4.3 ± 0.17 cpm/kBq, respectively. The 14-30-hour interval in the retention curve allows the estimation of activity between two points for determining the effective iodine half-life in the thyroid. Conclusion: The utilization of equipment usually available in nuclear medicine clinics is feasible, so this is a simple, effective and low cost methodology. (author)

Some methods of detection of atmospheric contamination by iodine 131

International Nuclear Information System (INIS)

Billard, Francois; Chevalier, Gerard; Gaillard, Pierre; Pradel, Jacques

1964-01-01

Due to the extensive use of iodine, risks of contamination by iodine 131 are increasing. Moreover, the increase of reactor power requires venting installations equipped with efficient safety filters which must be tested. The authors thus report the study of iodine trapping in filters, and its atmospheric detection and measurement. They report studies and achievements in the field of measurement of atmospheric pollution, and tests performed on iodine trapping by activated coals. After having outlined key qualities of an apparatus for atmospheric control, the authors indicate the various sampling methods. They discuss the method and calibration for the measurement of radioactivity of filters and coal which have trapped iodine 131. They discuss measurement sensitivity. They report how the efficiency of coals has been checked. They describe the experimental installation, and report the tests of some detectors of atmospheric contamination: sampling cartridges full of activated coal, gas mask cartridge, continuous control apparatus ('coffee machine' type), and detector of gaseous iodine. Appendices indicate the calculation of error on a cartridge counting rate, iodine generation methods (discontinuous method, continuous method) [fr

Conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation, 1945--1947

International Nuclear Information System (INIS)

Mart, E.I.; Denham, D.H.; Thiede, M.E.

1993-12-01

This report is a result of the Hanford Environmental Dose Reconstruction (HEDR) Project whose goal is to estimate the radiation dose that individuals could have received from emissions since 1944 at the U.S. Department of Energy's (DOE) Hanford Site near Richland, Washington. The HEDR Project is conducted by Battelle, Pacific Northwest Laboratories (BNW). One of the radionuclides emitted that would affect the radiation dose was iodine-131. This report describes in detail the reconstructed conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation which was collected from the beginning of October 1945 through the end of December 1947

Iodine-125 and Iodine-131 in the Thames Valley and other areas

International Nuclear Information System (INIS)

Howe, J.R.; Lloyd, M.K.; Bowlt, C.

1985-01-01

Part of the Iodine-125 and Iodine-131 waste from hospitals and research centres is discarded down drains and passes through sewage and water reclamation works into the river system. Relatively high concentration of radioiodine occur in outfalls that discharge into the river Thames, lower levels are found in the mainstream river and less still in the reservoirs and tap water supplies abstracted from the river. The pathway from waste to drinking water could account for the low levels of Iodine-125 found in the thyroid glands of some farm animals and human beings in the Thames valley

Thyroid disorders and radio iodine therapy: dental perspectives

International Nuclear Information System (INIS)

Batra, Arika; Krishnan, Manu; Tiwari, Brijesh; Singh, Sanjana; Sharma, Anu

2014-01-01

Thyroid disorders; hyper/hypothyroidism/thyroiditis/neoplasms are widely prevalent endocrine disorders. Oral manifestations of hyperthyroidism are increased susceptibility to caries, periodontal disease, maxillary/mandibular osteoporosis, premature shedding of deciduous teeth and early eruption of permanent teeth, sjogren and burning mouth syndromes. Undiagnosed/untreated hyperthyroidism often precipitates as 'Thyroid storm' during a stressful episode of surgical intervention/trauma. Hypothyroidism shows macroglossia, micrognathia, dysgeusia, thick lips, delayed eruption of teeth, poor periodontal health, enamel hypoplasia, anterior open bite, delayed wound healing and subnormal growth of jaws. Its congenital variant has underdeveloped mandible/overdeveloped maxilla, shortening of skull base and flaring of nostrils. Stomatodynia predominates in subacute thyroiditis. Radioactive iodine ( 131 I) is a common mode of therapy for thyrotoxicosis and carcinomas; where its beta radiations cause destruction of thyroid follicles. Since all forms of iodine are actively taken up by the salivary glands, salivary dysfunction is a consequent of 131 I therapy. It usually presents as xerostomia, mucositis, stomatitis, glossitis and dysguesia. Though reversible and dose-dependent to some extent, damage to bone marrow and gonads are also reported. It follows that thyroid disorders and its therapy with radio iodine show wide ranging side effects: both dental and general. In this context, this paper explains a novel method to evaluate these changes through salivary biochemistry, dental indices and periodontal markers. (author)

[Thyroid cancer after Chernobyl: is iodine 131 the only culprit ? Impact on clinical practice].

Science.gov (United States)

Guiraud-Vitaux, Françoise; Elbast, Mouhamad; Colas-Linhart, Nicole; Hindie, Elif

2008-02-01

The large increase in the incidence of thyroid cancer among children who were mainly less than five years old at the time of the Chernobyl accident is still a major preoccupation for endocrinologists and nuclear physicians. Epidemiological studies have focused solely on iodine 131. However, past knowledge on thyroid irradiation (medical use of iodine 131, radioactive fallout on Marshall islands and the Nevada, and Hanford site releases) as well as number of recent works (about low-dose irradiation), raise question on the role of other factors. It is here shown that post-Chernobyl thyroid irradiation is complex and that all factors (iodine 131, but also short lived isotopes of iodine and external irradiation) should be considered. Finally, one need to think about some of the present medical uses of iodine 131, and especially to the treatment of hyperthyroidism in young subjects.

Thyroid cancer following 131I therapy for hyperthyroidism

International Nuclear Information System (INIS)

Watanabe, Iwao

1980-01-01

A women aged 37 who had thyroid cancer after 131 I therapy for hyperthyroidism was reported. She had received various conservative therapies and surgical treatments for hyperthyroidism for 10 years before 131 I therapy. Similar cases were picked out from many reports, and their clinical characteristics were discussed. The incidence of thyroid cancer after 131 I therapy, age and sex of patients, dosage of 131 I, histological changes after the irradiation of 131 I, sites of thyroid cancer, and the relationship between 131 I therapy and the occurrence time of thyroid cancer were also considered. (Tsunoda, M.)

Reduced radioiodine uptake at increased iodine intake and {sup 131}I-induced release of ''cold'' iodine stored in the thyroid

Energy Technology Data Exchange (ETDEWEB)

Meller, B.; Haase, A.; Richter, E.; Baehre, M. [Dept. of Radiotherapy and Nuclear Medicine, Univ. of Luebeck (Germany); Seyfarth, M. [Inst. of Clinical Chemistry, Univ. of Luebeck (Germany); Wenzel, B.E. [Clinic of Internal Medicine I, Univ. of Luebeck (Germany)

2005-07-01

Aim: the extent of urinary iodine excretion (UIE) provides information about iodine supply and release. In the present study we investigated correlations between UIE and radioiodine uptake (RIU) as well as effects of radioiodine therapy on UIE in patients with autonomous goitre. Patients, methods: In 197 consecutive patients with thyroid autonomy, UIE was measured twice during radioiodine test (RITe) and correlated with RIU. In 98 of these patients, thyroglobulin and thyroid volume (V) were determined prior to therapy. Individual changes in urinary iodine excretion ({delta}UIE) and TG ({delta}TG) could be investigated four weeks (4W) and six months (6M) after radioiodine therapy. Additionally, {delta}V was determined 6M after therapy. {delta}UIE, {delta}TG and {delta}V were correlated with target dose and target volume. Results: patients with higher iodine excretion exhibited significantly lower thyroidal radioiodine uptake values. Twofold increased UIE prior to therapy decreased radioiodine uptake by 25%. Compared with pretherapeutic values, UIE and TG were significantly increased four weeks after radioiodine therapy (p < 0.001). Median values of both parameters were found to be doubled. The product of target dose and target volume was not only correlated with a decrease of thyroid volume 6M after therapy, but also with an increase of UIE and TG in the early phase after therapy. Conclusions: it was confirmed that UIE during RITe is a measure for iodine intake and can be used to investigate the competition between stable iodine and radioiodine. The increase of UIE and TG four weeks after therapeutic administration of radioiodine can be explained by disintegrated thyroid follicles. The therapy-induced iodine release may be one important cause for the development of hyperthyroidism in some patients during the first weeks after radioiodine therapy. It may contribute to the known decrease of radioiodine uptake after preapplications of {sup 131}I in various thyroid

Proposal of a methodology for individualized iodine-131 therapy for Graves' disease in patients with hyperthyroidism

Energy Technology Data Exchange (ETDEWEB)

Araujo, Francisco de [Instituto de Radioprotecao e Dosimetria (IRD), Rio de Janeiro, RJ (Brazil)]. E-mail: faraujo@ird.gov.br; Melo, Rossana Corbo de [Universidade Federal do Rio de Janeiro (UFRJ), RJ (Brazil); Rebelo, Ana Maria de Oliveira [Universidade Federal, Rio de Janeiro, RJ (Brazil). Coordenacao dos Programas de Pos-graduacao de Engenharia (COPPE); Dantas, Bernardo Maranhao; Dantas, Ana Leticia A.; Lucena, Eder Augusto de [Universidade do Estado do Rio de Janeiro (UERJ), RJ (Brazil)

2007-11-15

Objective: Several methods are utilized for determining the radioiodine activity in the treatment of Graves' disease (hyperthyroidism). Some of this methods do not take into consideration the thyroid absorbed dose or the necessary parameters for this estimation. The association between absorbed dose and administered activity depends on effective half-life, iodine uptake and thyroid mass of each patient. The present study was aimed at developing a methodology for individualized {sup 131}I therapy for Graves' disease in patients with hyperthyroidism of the Graves' disease. Materials and methods: A neck-thyroid phantom developed at Instituto de Radioprotecao e Dosimetria, containing a standard solution of {sup 131}I, was utilized for calibrating the scintillation gamma camera and uptake probe installed in the Department of Nuclear Medicine of the Hospital Universitario Clementino Fraga Filho da Universidade Federal do Rio de Janeiro. Results: The view angle of the collimator/detector assembly presented values compatible with the thyroid gland size for distances of 25 cm (uptake probe) and 45.8 cm (scintillation gamma camera). Calibration factors were 39.3 {+-} 0.78 and 4.3 {+-} 0.17 cpm/kBq, respectively. The 14-30-hour interval in the retention curve allows the estimation of activity between two points for determining the effective iodine half-life in the thyroid. Conclusion: The utilization of equipment usually available in nuclear medicine clinics is feasible, so this is a simple, effective and low cost methodology. (author)

Determination of intake and internal radiation dose for occupationally exposed workers to iodine 131

International Nuclear Information System (INIS)

Kharita, M. H.; Maghrabi, M.; Sadyya, A.

2004-12-01

Workers who prepare and inject radioactive Iodine I 131 doses at the medical centers in Syria are potentially exposed to the radioactive intake by ingestion or inhalation during preparation or injection processes. The received amount of the radioactive intake differs according to the amount of the I 131 that released during the preparation or injection processes, and to the work conditions and the applying ways of the radiation protection principles. Because of this radioactive intake, the thyroid gland may expose to amounts of I 131 which may negatively affect the health of the workers, so it is necessary to make routine monitoring for all workers who receive an intake of more than 10% of the annual intake limit which is (2*10 6 Bq/y) for I 131 . To make this monitoring process, it is necessary to use either the thyroid gland counter in order to know the concentrated amount of the radioactivity in the gland, or the analysis of a 24 hours urine sample of the exposed workers to determine the eliminated amount of the radioactivity using gamma spectrometry, also the two processes can be applied at the same time. Since the thyroid gland counter is not available, the analysis of urine sample was done to determine the concentrated amount of the radioactivity in urine, then to estimate the radioactive intake and the internal radioactive dose. The results of applying this method dictated that some workers work in safe conditions according to the radiation protection and there is no need for them to make routine monitoring . But the other workers receive a radioactive intake of about 10% yearly of the annual intake limit and that requires a routine periodical monitoring for those workers in addition to the necessity of applying the principles of the radiation protection during the work with I 131 . These principles and systems should indicate the basic requirement of radiation protection that must be available in the laboratory that deal with I 131 either for therapy or for

Treatment of Graves' disease with I131: Case Report

International Nuclear Information System (INIS)

Sanchez Povis, J.E.; Sandoval Okuma, J.C.; Contreras Carreno, S.E.; Cabello Morales, E.

2006-01-01

Objective: To describe the response and complications in children and teenagers suffering Graves' disease who received radioactive iodine therapy. Material and Methods: The clinical records of the patients attended at Paediatric Endocrinology Unit of Hospital Nacional Cayetano Heredia who received therapy with I 131 were reviewed. Demographic characteristics, thyroid weight, radioactive iodine uptake, I 131 dose and clinical and thyroid function evolution were registered. Results: We include thirteen patients: 1 male and 12 females. The mean thyroid weight obtained was 47.56 ± 10.70 gr. Initial calculated dose was 3.92 ± 0.95 mCi, with a total dose of 4.47 ± 1.66 mCi, and mean following period of 2.76 years. Ten patients received only one dose, 2 patients received two doses and one patient received three doses; all cases remitted. Patients who received only 1 dose showed disease remission at 13.13 weeks and mean remission period of the population was 24.62 weeks. Hypothyroidism prevalence up to six months from initiating treatment was 66.66%, and up to 257 weeks 83.33%. Conclusions: We conclude that I 131 was 100% effective in the treatment of children and adolescents suffering Graves' disease in this small series. (author)

Detriments of radioactive Iodine 131 in managing thyroid carcinoma - a retrospective study with review of the current scenario

International Nuclear Information System (INIS)

Mohan, Shaweta; Agnihotri, Gaurav

2016-01-01

Radioactive iodine (RAI) ablation following thyroidectomy is recommended for most patients diagnosed with papillary and follicular thyroid carcinoma. We performed a literature search on MEDLlNE and EMBASE, using keywords, such as, differentiated thyroid carcinoma, radioiodine therapy, "1"3"1I complications, adverse effects and side effects, and chose the most relevant studies till date to prepare this work on the side effects of RAIT (Radioactive Iodine Therapy) for thyroid cancer. We contacted authors of published studies where appropriate for further information. Also, the percentage incidence of the hazards was determined for North Indian population accessing data from Govt. Medical Colleges of Punjab, Haryana, and Postgraduate Institute of Medical Education and Research, Chandigarh. The most prominent side effect came out to be xerostomia with an incidence of 47%, followed by local neck pain and swelling (39%). The incidence of gastritis was also common (34%). Radioactive iodine therapy complications have been divided into early and late effects. Early complications include gastrointestinal symptoms, radiation thyroiditis, sialadenitis/xerostomia, bone marrow suppression, gonadal damage, dry eye, and nasolacrimal duct obstruction. Late complications include secondary cancers, pulmonary fibrosis, permanent bone marrow suppression, and genetic effects. As "1"3"1I is an efficacious form of treatment that can significantly decrease the rate of mortality, recurrence and metastasis, and as the side effects are often minor and well-tolerated, radio iodine therapy remains the principal mode of treatment for patients. (author)

Evaluation of the effect of various parameters on the amount of radiation dose received by family members after 131-I therapy

International Nuclear Information System (INIS)

Sarkar, S.; Dehghanpour, M.; Saghari, M.; Ghiasinezhad, M.

2001-01-01

The main concern with respect to discharge of patients from hospital after 131-I therapy is contamination of their surroundings and exposure of people who are in close contact with them. In this study, we evaluated absorbed dose received by home mates of these patients within one week of discharge from hospital. This study was based on 100 patients (23 patients with thyroid cancer together with 70 members of their families and 2 hyperthyroid patients plus 5 of their family members). Measurements were performed by TLD. Patients were discharged from hospital if the dose rate from a meter distance of their thyroid was below 20 μSv/hr (ICRP-60). The hospitalization period for those patients with thyroid cancer varied between 2-3 days (depending on the amount of radioactivity received). Hyperthyroid patients were treated as outpatients. Our data indicate that although hyperthyroid patients received much less activity in comparison to those with thyroid cancer, but due to the slow iodine discharge rate from their bodies, they radiated more to their surroundings. For patients with thyroid cancer, when the given activity increased from 100 mCi to 150 mCi, the average dose absorbed by their family members increased by a factor of 3. The duration of hospitalization as well as the amount of activity given to the patients have a significant effect on the amount of radiation dose received by the family members. In a group of patients who received 100 mCi of 131-I, the average radiation dose received by the family members of those patients who were hospitalized for 2 days were 1.5 times more than of those patients who were hospitalized for 3 days, whereas following therapy with 150 mCi of 131-Iodine, the average radiation dose received by the family members of those patients who were hospitalized for 2 days were about 6.5 times more than that of those who were hospitalized for 3 days. The size of the patient's house and the time that family spends with the patient at house are

Skin eruptions following treatment with Iodine-131 for hyperthyroidism. A rare and un-reported early/intermediate side effect

International Nuclear Information System (INIS)

Paul, A. K.; AL-Nahhas, A.; Ansari, S. M.; Islam, N.

2005-01-01

Iodine-131 ( 131I ) is a well-established method for the treatment of hyperthyroidism. Following such therapy, patients may experience symptoms relating to early or delayed side effects that can be prevented or minimized if necessary measures are taken. We have noticed an unusual side effect of 131I therapy in the form of a skin eruption (iododerma) and aimed at assessing the frequency and severity of this side effect. Retrospective review of 141 patients treated with 131I between January 1994 to December 2000 (86 F, 55 M; mean age 41.35±11.02 years) was performed. The dose of 131I ranged from 250.500 MBq. Post therapy clinical and biochemical evaluation of thyroid function was done at 6 weeks, 3, 6, and 9 months then annually. Of the 141 treated patients, 3 patients (2.1%) presented with iododerma 4.6 weeks after 131I therapy administration. Lesions were observed at both ankles and lower legs in all 3 cases. All lesions disappeared within 6 months with no residual effect. No other skin lesions were seen thereafter during the follow-up period. Iododerma is a rare complication of 131I therapy that has not been reported before. It appears within 4.6 weeks after therapy and is a self-limiting condition. (author)

Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma

International Nuclear Information System (INIS)

Boucher, Eveline; Garin, Etienne; Guylligomarc'h, Anne; Olivie, Damien; Boudjema, Karim; Raoul, Jean-Luc

2007-01-01

Background/Aim: The therapeutic effect of intra-arterial injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma in palliative or adjuvant settings has been promising. We report, the results of an open study of this therapy in cirrhotic patients with small hepatocellular carcinoma. Patients and method: Forty patients with hepatocellular carcinoma were given intra-arterial injections of 131-iodine-labeled lipiodol. These injections were repeated if necessary every 3 months. Tumor response (WHO criteria) was determined on CT scans performed after each treatment and every 3 months during the follow-up. Side effects and the cause of death were recorded. Therapeutic response and survival were analyzed. Results: The median number of treatment was 2 (1-4). There was one complete response, 18 partial responses (47.5% response rate); 19 had stable disease and 2 progressions. Overall survival rates (±CI 95%) at 1, 2 and 3 years were: 90 ± 4.7%, 60.3 ± 8%, and 39 ± 8.3%, respectively. Median survival was 27 months; 25 patients have died (4-56 months), 8 of tumor progression with a multifocal spread in the liver. Tolerance was good except for 2 patients who develop a fatal drug-related pulmonary insufficiency. Conclusion: These data suggest that intra-arterial therapeutic injection of 131-iodine-labeled lipiodol for treatment of hepatocellular carcinoma can provide high rate response and long survival for individuals not eligible for surgery or local treatment

Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship.

Science.gov (United States)

Erselcan, Taner; Sungu, Selma; Ozdemir, Semra; Turgut, Bulent; Dogan, Derya; Ozdemir, Ozturk

2004-05-01

Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in vivo dose-effect relationship in patients receiving iodine-131 treatment, and the results of previous studies are controversial. In this study, the sister chromatid exchange (SCE) method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 15 patients who received various doses of (131)I (259-3,700 MBq), either for thyrotoxicosis (TTX) or for ablation treatment in differentiated thyroid cancer (DTC). The SCE frequencies in cultured peripheral lymphocytes were determined before treatment (to assess basal SCE frequencies), on the 3rd day (to assess acute SCE frequencies) and 6 months later (to assess late SCE frequencies). The basal, acute and late SCE frequencies (mean+/-SD) were 3.19+/-0.93, 10.83+/-1.72 and 5.75+/-2.06, respectively, in the whole group, and these values differed significantly from each other ( Pdisappearance of damaged lymphocytes from the peripheral circulation in a dose-dependent manner following (131)I treatment. Further studies are therefore needed to clarify the effect of the negative beta value on the biological dosimetry approach in continuous internal low LET radiation, as in the case of (131)I treatment.

Influence of radioiodine therapy on urinary iodine excretion

International Nuclear Information System (INIS)

Meller, B.; Lauer, I.; Baehre, M.; Richter, E.

1998-01-01

In 214 patients with benign thyroid diseases the time-course of urinary iodine excretion (UIE) was investigated in order to identify changes after radioiodine therapy (RITh). Method: UIE was measured photometrically (cerium-arsenite method) and related to urinary creatinine on the first and last day of the radioiodine test and the three days, seven days, four weeks, and six months after 131 I administration. Results: As compared with the level found immediately before radioiodine therapy, median UIE had almost doubled four weeks after therapy and was still significantly elevated six months after therapy. This increase correlated significantly with the target volume as measured by scintigraphy and sonography. Conclusions: The persistent elevation of UIE for months after RITh is a measure of treatment-induced damage to thyrocytes. Therefore, in view of the unfavourable kinetics of iodine that follow it, RITh should if possible be given via a single-dose regime. (orig.) [de

I-131 Therapy in patients with hyperthyroidism 11- year follow-up

International Nuclear Information System (INIS)

Radeva, M.

2007-01-01

Full text: Radioiodine therapy is a well-established method for the treatment of patients with various forms of hyperthyroidism and is preferred in many countries as the first line therapy. Traditionally, it has been applied in Bulgaria in low doses, mainly in elderly patients with contraindications for surgery or after long-term antithyroid drug therapy. No systematic follow up of these patients has ever been done in the country. Materials and Methods: 571 subjects aged 34 to 79 years (mean 64, 7), 108 males with mean age of 68.61 years (54 to 76 yrs) and 463 females with mean age of 68.89 years (34 to 84 yrs). Mean disease duration was 73±5 months. The study included 296 patients with toxic nodular goiter, 220 patients with Graves- Basedow disease and Hashitoxicosis and 55 patients with adenoma toxicum. 256 females and 40 males with toxic nodular goiter, 158 females and 62 males with Graves- Basedow disease and Hashitoxicosis, 49 females and 6 males with adenoma toxicum. The disease duration is 48.19 months in females and 22.5 months in males. Methods: 131-iodine scan and uptake before the treatment and on follow-up visits at months 6,12,18 and 24 with a dose of 1.48 MBq 131-I for the both tests, given orally as a water solution. Uptake was measured at hours 2, 4 and 24; thyroid scan -at hour 24, thyroid ultrasound, FNB cytology if suspicious of malignancy, thyroid hormones -TSH (normal range 0.3-4.0 mU/l), FT4 (normal range 8-17 pmol/l) Results: 131-iodine therapy was administered to subjects with 131-I uptake over 25% at hour 24. Doses between 148- 370MBq were given depending on diagnosis and thyroid volume. A single radioiodine dose, mean value 189.07 MBq is applied in 246 (87, 85%) patients, second dose, mean value 183, 5 MBq is required in 30 (10, 72%) and third dose, mean value 148 MBq received 4 (1, 43%) patients. Effect of 131-iodine therapy-the change in radioiodine uptake is a marker for complex assessment of the result of the 131-iodine therapy. In

Radiation doses by therapeutical practices with iodine 131

International Nuclear Information System (INIS)

Di Trano, J.L.; Rojo, A.M.; Gomez Parada, I.M.; Grassi, E.; Gatica, N.; Kunst, J.J.; Gonzalez, M.

1998-01-01

The aim of this document is to estimate the doses to workers and public due to therapeutical practices with iodine 131. Environmental and personal doses by external irradiation were determined using thermoluminescent dosimeters (TLD). The environmental dosimetry resulted in an equivalent dose H * (10) of approximately 0,1 mSv. The calculated personal equivalent dose Hp (10) was of the order of 0,1 mSv. The exposition rate was measured, being the values obtained in the range of 0,20 and 0,35 mSv/h. (1m from the abdominal wall). Concentrations of iodine 131 were determinate in the air of the room, during the first day in the hospital. Values obtained were between 0,04 Bq/l and 0,20 Bq/l. Surface samples were taken in the service, obtaining levels of contamination in the range of 0,001 and 0,4 Bq/cm 2 . The surface samples obtained in the hospital room were about 0,15 Bq/cm 2 . Urine samples were collected resulting in an eliminated activity of iodine 131, during the first 24 hours, of about 60 % of the administered activity. Samples of sweat of different cutaneous regions were obtained, the maximum values of the activity measured reached 200 Bq/cm 2 . According to the obtained results it is important to elaborate guides to be given to patients as an instrument to reduce the external exposure and to avoid internal contamination. (author)

Putting to point the production process of iodine-131 by dry distillation (Preoperational tests)

International Nuclear Information System (INIS)

Alanis M, J.

2002-12-01

With the purpose of putting to point the process of production of 131 I, one of the objectives of carrying out the realization of operational tests of the production process of iodine-131, it was of verifying the operation of each one of the following components: heating systems, vacuum system, mechanical system and peripheral equipment that are part of the production process of iodine-131, another of the objectives, was settling down the optimal parameters that were applied in each process during the obtaining of iodine-131, it is necessary to point out that this objective is very important, since the components of the equipment are new and its behavior during the process is different to the equipment where its were carried out the experimental studies. (Author)

Uptake of Iodine-131 in mussel (Mytilus smaragdinns) and algae (caulerpa racemosa)

International Nuclear Information System (INIS)

Sombrito, E.Z.; Banzon, R.B.; de la Mines, A.S.; Bautista, E.Rb.

1982-01-01

The behavior of radionuclides in the environment has been the subject of research. Iodine-131, a beta emitter as one of the radionuclides has been studied. This study describes Iodine-131 uptake in mussel and algae. The bioaccumulation factor C was determined which gave the relationship between the concentration of radioactivity in biota relative to the water environment. Results of the experiments showed that the mussels steadily accumulated I-131 from radioactive medium. Much higher bioaccumulation factor was obtained in algae than in mussel. No attempt was made to measure activity in the soft parts. (ELC)

Radiation protection data sheets for the use of iodine 131 in unsealed sources

International Nuclear Information System (INIS)

Anon.

1993-01-01

This radiation protection data sheet is intended for supervisors and staff in the different medical, hospital, pharmaceutical, university and industrial laboratories and departments where Iodine 131 is handled, and also for all those involved in risk prevention in this field. It provides essential data on radiation protection measures during the use of Iodine 131 in unsealed sources: physical characteristics, risk assessment, administrative procedures, recommendations, regulations and bibliography

Treatment by iodine 131 and thyroid pathologies 14 Nfs iatrogenic 'Around France of that particular medical treatment'

International Nuclear Information System (INIS)

Baldet, L.

2000-01-01

In the case of hyperthyroidism bound to amiodarone, the iodine 131 prescription appears able to cure this disease in 84% of cases; the use of iodine 131 before amiodarone to prevent a hyperthyroidism, in case of goiter or thyroid nodules is little used (17% of practitioners) when it is more used in case of past history of induced hyperthyroidism (34% of physicians). This prescription is nevertheless efficient in the both cases. The use of iodine 131 is little used in the case of hyperthyroidism appeared during the use of cytokines (22% of physicians). The induction of hypothyroidism by iodine 131 in the case of severe cardiopathies is becoming little frequent (9% of physicians). (N.C.)

Standardization of 131I therapy for Graves disease

International Nuclear Information System (INIS)

Tang Jianlin; Li Yuying; Gao Liuyan; Tang Xiuping; Hu Hongyong

2011-01-01

Objective: To establish the normative and standard measures, to ensure medical safety and quality of care of the patients with Graves disease treated by 131 I therapy. Methods: Formulating and strictly implementing the medical organizational and technical measures of 131 I therapy for Graves disease and regular follow-up. Results: Receiving 131 I treatment of 104 patients, follow-up 6-36 months, no adverse events, the cure rate of 59.6%, the efficient rate is 99.9%. Conclusion: It is important guarantee for the medical quality and safety to standardize the 131 I therapy of Graves disease. (authors)

POSTOPERATIVE TREATMENT OF THYROID CANCER WITH RADIOACTIVE IODINE

Energy Technology Data Exchange (ETDEWEB)

Blahd, William H.; Koplowitz, Jerry M.

1963-06-15

Experiences in the postoperative treatment of thyroid cancer with radioactive iodine since 1949 are reviewed. Forty-five patients received therapeutic amounts of I/sup 131/ and were followed for more than one year. Cancer metastases were localized by means of the mechanical scintiscanner after patients had received large tracer doses of I/sup 131/ preceded by injections of thyrotropic hormone. A consistent therapeutic regimen was followed involving four basic modalities of therapy: surgical thyroidectomy, thyrotropic hormone stimulation, cancerocidal doses of I/sup 131/ and thyroid extract administration. Twenty-nine patients in the series had proved metastatic lesions; 11 died, 18 are living, and 41% have lived 5 or more years. All patients who were free of metastases after initial thyroid surgery are alive. No complications from I/sup 131/ therapy were observed. This is attributed to the conservative dosage regimen employed. The results of the use of I/sup 131/ in the postoperative treatment of thyroid cancer in other reported series are also reviewed. (P.C.H.)

The present status of I-131 therapy for Graves' hyperthyroidism in Japan. Survey by questionnaire

International Nuclear Information System (INIS)

Ikekubo, Katsuji; Kusakabe, Kiyoko; Kanaya, Shinichi; Nakada, Kunihiro; Mori, Yutaka

2003-01-01

A survey on the I-131 therapy of Graves' hyperthyroidism was undertaken by questionnaire in 1,246 hospitals of Japan. One thousand and ninety seven of them (88.0%) responded to the questionnaire. In this paper, we report the results and analysis of the replies to the questionnaire. In the 121 hospitals (11.03%) of the respondents, I-131 therapy is being performed for Graves' hyperthyroidism. A gradual increase was observed in the annual number of I-131 treated Graves' disease patients during the period of 1998-2001, from 1,740 to 2,484. I-131 treatment was selected mainly for the cases with side effects from antithyroid drug (ATD) therapy, followed by the cases with complication of heart or hepatic diseases, recurrences of hyperthyroidism after surgery, radioiodine treatment, and long-term ATD treatment. The 41% of respondents used I-131 in order to restore euthyroidism, 34% aimed for hyperthyroidism and 41% used the dose properly between the two according to the patients. Administration dosage of I-131 was estimated mainly on the basis of thyroid uptake and volume in 93% of the respondents and 48% calculated the radiation dose by also determining the effective half-life in the thyroid gland. Thyroid size was estimated by scintigram (51%), ultrasonography (US) (33%), CT (22%) and palpation (12%). ATD treatment was used before I-131 administration by 70% of the respondents and 34% after radioiodine therapy. A low-iodine diet was given to the patients for a week (46%) or two weeks (47%) before I-131 administration. However, after treatment only 46% of the respondents continued low-iodine diet for a week. (author)

Effect of decicurie doses of radioactive iodine 131 on parathyroid function

International Nuclear Information System (INIS)

Glazebrook, G.A.

1987-01-01

Although parathyroid deficiency has been reported after administration of relatively small doses of iodine 131, reports of such deficiency after the much larger doses given in the management of thyroid cancer are notable by their absence in the literature. We observed one such patient, then instituted a prospective study. We observed a 58 percent incidence of apparently diminished parathyroid reserve among 53 patients given high doses of I 131. Susceptibility does not appear to be related to age, sex, extent of thyroid operation, operative technique, the amount of thyroidal I 131 uptake, the use of external radiation to the neck, or to the presence of parathyroid glands or of Hashimoto's disease in the operative specimen; however, susceptibility may be related to the anatomic location of the parathyroid glands in relation to the thyroid gland. The administered dose of I 131 almost reached significant levels (p = 0.1) in the present study. The initial pretreatment serum calcium levels were consistently lower among affected patients (p = 0.01), suggesting the presence of a preexisting latent impairment of parathyroid reserve which was subsequently unmasked after the administration of I 131. Thyroid cancer is compatible with very long-term survival, and therefore, there is a considerable risk of delayed chronic hypocalcemia among patients who have received large doses of I 131, particularly female patients in the premenopausal age group. These patients deserve special management surveillance

Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure.

Science.gov (United States)

Yeyin, Nami; Cavdar, Iffet; Uslu, Lebriz; Abuqbeitah, Mohammad; Demir, Mustafa

2016-03-01

Radioiodine therapy could be challenging in chronic renal failure patients requiring hemodialysis. The aim of this study was to establish the effects of hemodialysis on elimination of radioiodine from the body in thyroid carcinoma patients with end-stage chronic renal failure and to determine its effects on environmental radiation dose. Three end-stage chronic renal failure patients (four cases) diagnosed with differentiated thyroid carcinoma requiring radioiodine therapy were included in our study. Each patient was given 50-75 mCi (1850-2775 MBq) iodine-131 with 50% dose reduction. Dose rate measurement was performed at the 2nd, 24th, and 48th hour (immediately before and after hemodialysis) after radioiodine administration. The Geiger-Müller probe was held at 1 m distance at the level of the midpoint of the thorax for the dose rate measurement. The effective half-life of iodine-131 for three patients was found to be 44 h. In conclusion, the amount of radioiodine excreted per hemodialysis session was calculated to be 51.25%.

Study on the damage effect of 131I-iodinated oil internal radiation in SMMC-7721 hepatoma model in rat

International Nuclear Information System (INIS)

Wu Shuyan; Zhang Xuguang; Wang Xiangying; Li Su'an; Mao Dihua

2004-01-01

Objective: To investigate the damage effect of 131 I-iodinated oil internal radiation in hepatoma. Methods: SMMC-7721 rat hepatoma model was used to evaluate the damage of 131 I-iodinated oil internal radiation in carcinoma. 131 I-iodinated oil was injected sector-shapely into tumor model of SMMC-7721 hepatoma with arc-needle, matched with routine straight-needle injection. Tumor damage induced by 131 I-iodinated oil intralesion radiation in the carcinoma models are recorded through survival time, weight of rat, local carcinoma, pathology, electron microscopy. Results: Arc-needle injection 131 I-iodinated oil in SMMC-7721 hepatoma at subcutis could increase rat's survival time, the body weight kept less descent, the lumps necrosed wholly. Pathology and ultrastructure detection revealed cell necrosis and collapse, sever nuclear damage was observed in the death cells. The early characteristics of necrosis such as margination of heterochromatin was also found in some tumor cells. Besides, well differentiated tumor cells, degenerative tumor cells and some lymphocytes were seen. Conclusion: Arc-needle injection 131 I-iodinated oil step-by step sector-shapely into tumor is a better method and necrosis is the major effect of 131 I-iodinated oil internal radiation in carcinoma at the level of treated dosage

Experimental results concerning the metabolism of ingested iodine-131 in adult sheep under lactation

International Nuclear Information System (INIS)

Daburon, F.; Capelle, A.; Tricaud, Y.; Nizza, P.

1967-01-01

The authors give the results of a series of experiments on metabolism of ingested iodine-131 in adult sheep under lactation; the measurement were carried out over a number of years from 1961 to 1966. The work was concerned initially with the fixation of iodine 131 in the thyroid gland, with the calculation of radiation doses absorbed and with ways of showing up any possible radiation damage in the gland. The modes of absorption of iodine 131 and its elimination through milk, urine and the faeces were then considered. Finally, a last chapter is devoted to changes in the radioactivity of the blood and of the milk, to variations of the PBI level of the blood serum as to different methods for measuring this level. (authors) [fr

The effect of eating salt with iodine on the normal values of thyroid 131I uptake rate

International Nuclear Information System (INIS)

Zhang Chunyan; Wang Huawen; Li Guirong; Chen Chunmei; Zhang Lixia; Yu Yuehua

2002-01-01

131 I uptake rates of control group, which stop eating salt with iodine for over six weeks, eating salt with iodine group, the hyperthyroidism group are determined in 2 h, 6 h and 24 h respectively. The results show 131 I uptake rate of eating salt with iodine group are (7.7 +- 4.2)% in 2 h, (13.8 +- 5.3)% in 6 h and (21.9 +- 7.7)% in 24 h. There are no difference between sex. There is significance of difference (P 131 I uptake rates between the hyperthyroidism group of eating salt with iodine and control group is 5.0%, and eating salt with iodine group is 22.5%. To determine the thyroid iodine uptake rate in the patients who did not stop eating salt with iodine, the ranges of normal values must be defined. This result could be as a standard to diagnose the patients of hyperthyroidism of eating salt with iodine

Vasoactive intestinal peptide (VIP) labelling with iodine-131 by direct method

International Nuclear Information System (INIS)

Colturato, M.T.; Silva, C.P.G. da; Araujo, E.B.

2002-01-01

The Vasoactive Intestinal Peptide (VIP) is a 28-amino acid polypeptide with a great numbers of receptors in tumoral cells, including adenocarcinomas and pancreatic and colon carcinomas. The VIP molecule contains two tyrosine residues, in positions 10 and 22, that are theoretically equally susceptible to iodination, The VIP was labeled with 131-iodine by direct method using Iodogen as oxidant agent: 15.03 mmol VIP + 0.10 nmol KI + [ 131 I]NaI + 13.9 mmol Iodogen; the final volume was adjust to 100 μL using 0.2 M phosphate buffer, pH 7.5 and the reaction proceed with stirring for 30 minutes at room temperature. The radiochemical purity was determined by electrophoresis (Whatman 1MM paper; 0.05 M barbital buffer; pH 8.6; 150 V; 40 minutes) that indicates low percent of free 131-iodine. The high performance liquid chromatography (HPLC) system using RPC 18 , 10 μm, 4 x 250mm column, was able to separate the different radiochemical species, only when an isocratic mixture of acetonitrile: 0.1% trifluoroacetic acid (27:73) was used, with 0.5 mL/min. flux. (author)

The influential factors of 131I treatment for hyperthyroidism

International Nuclear Information System (INIS)

Tan Benxu

2003-01-01

Many factors such as iodine-131 uptake, effective half-life, thyroid volume, and antithyroid drugs affect the iodine-131 dose for every hyperthyroid patient. The outcome of radioiodine therapy in hyperthyroidism is decided by all of these factors

Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours

International Nuclear Information System (INIS)

Wafelman, A.R.; Hoefnagel, C.A.; Maessen, H.J.M.; Maes, R.A.A.; Beijnen, J.H.

1997-01-01

Iodine-131 labelled meta-iodobenzylguanidine ([ 131 I[MIBG) is used for diagnostic scintigraphy and radionuclide therapy of neural crest-derived tumours. After administration of therapeutic doses of [ 131 I[MIBG (3.1-7.5 GBq) to 17 patients (n=32 courses), aged 2-73 years, 56%±10%, 73%±11%, 80%±10% and 83%±10% of the dose was cumulatively excreted as total radioactivity in urine at t=24 h, 48 h, 72 h and 96 h, respectively. Except for two adult patients, who showed excretion of 14%-18% of [ 131 I[meta-iodohippuric acid ([ 131 I[MIHA), the cumulatively excreted radioactivity consisted of >85% [ 131 I[MIBG, with 6% of the dose excreted as free [ 131 I[iodide, 4% as [ 131 I[MIHA and 2.5% as an unknown iodine-131 labelled metabolite. Cumulative renal excretion rates of total radioactivity and of [ 131 I[MIBG appeared to be higher in neuroblastoma and phaeochromocytoma patients than in carcinoid patients. Based on the excretion of small amounts of [ 131 I[meta-iodobenzoic acid in two patients, a possible metabolic pathway for [ 131 I[MIBG is suggested. The degree of metabolism was not related to the extent of liver uptake of radioactivity. (orig.). With 2 figs., 5 tabs

Incidence of thyroid carcinoma in patients who had diagnostic iodine-131 tests during childhood and adolescence

International Nuclear Information System (INIS)

Hahn, K.; Schnell-Inderst, P.; Haenseler, G.J.; Kandziora, C.; Meyer, G.

1999-01-01

To determine the carcinogenic effects of diagnostic amounts of radioactive iodine-131 on the infantile thyroid gland a multi-center retrospective cohort study was conducted which included data of 4973 subjects who had either been referred to diagnostic iodine-131 uptake tests (2262 subjects) or had had a diagnostic procedure of the thyroid without 131-iodine (2711 subjects) until the age of 18 years. Follow-up examinations of 35 percent of the subjects in the iodine-131 group and 41 percent of the subjects in the control group took place after a mean time period of 20 years after the first examination. Dosimetry of the thyroid burden of iodine-131 was carried out according to ICRP 53. The median of the thyroid organ dose was 1012 mGy. The report compares prevalences or incidences of thyroid disorders resp. occurring in both groups and gives a stratified analysis of primary diagnosis, age at exposure, and organ dose. A total number of five carcinomas of the thyroid was found. In the radioiodine group two carcinomas were assessed in a period of 16500 person-years. The control group yielded three carcinomas over 21000 person-years (Relative rate: 0,89, 95% confidence interval: 0,14-5,13). (orig.) [de

Iodine-131 in milk 1961-62 and in thyroid glands of cattle and sheep 1962

International Nuclear Information System (INIS)

Hvinden, T.; Lillegraven, A.

1976-03-01

Cases of late effects from radioactive iodine uptake in children have renewed interest in this contaminant. I-131 data collected in Norway during periods following the nuclear weapons test series in 1961 and 1962 have been re-examined and collated with more recent data on natural iodine in the milk and thyroid glands from domestic animals. Some of the measured values may be interpreted as indications of an inverse relationship between the level of natural iodine and the uptake of I-131, but the material is too small and inconsistent to draw any conclusions. Obviously the uptake and concentration of I-131 in animal milk and thyroid glands are influenced by many factors besides the fallout amounts; at present it is not possible to determine their relative importance and set up a satisfactory model for the I-131 uptake. (Auth.)

RETROSPECTIVE RECONSTRUCTION OF INTEGRAL IODINE-131 FALLOUT FOR THE SETTLEMENTS OF THE BRYANSK REGION OF RUSSIA ON THE BASIS OF RESULTS OF IODINE-129 CONTENT IN THE SOIL DETERMINATION IN 2008

Directory of Open Access Journals (Sweden)

Yu. I. Gavrilin

2009-01-01

Full Text Available The article briefly describes the procedure of reconstruction of integral iodine-131 fallouts using fragmentary data on iodine-131 fallouts in May-June 1986, as well as results of determination (in the late period after the accident of iodine-129 concentration in the soil and values of integral fallouts of cesium-137 in the settlements of the Bryansk region of Russia. Results of estimation of integral iodine-131 fallouts (in the area of 32 soil sampling points are presented in the table form. Regularities of ratio (131I/137CsII change in the integral radionuclide fallouts are being determined and values of integral iodine-131 fallouts are being estimatedfor the other settlements of the region with the known values of integral cesium-137 fallouts. It is shown that variability of the average for settlements values of integral iodine-131 fallouts is 70 times less then variability of corresponding integral cesium-137 fallouts.

RADIOACTIVE IODINE THERAPY WITHOUT RECENT ANTITHYROID DRUG PRETREATMENT FOR HYPERTHYROIDISM COMPLICATED BY SEVERE HYPERBILIRUBINEMIA DUE TO HEPATIC DYSFUNCTION: EXPERIENCE OF A CHINESE MEDICAL CENTER.

Science.gov (United States)

Ding, Yong; Xing, Jialiu; Qiu, Zewu; Wang, Yong; Zhang, Youren; Fang, Yi; Peng, Xiaobo; Long, Yahong; Deng, Pei

2016-02-01

The objective of this work is to report our experience with (131)I therapy without recent antithyroid drug (ATD) pretreatment for refractory severe hyperthyroidism complicated by hyperbilirubinemia due to hepatic dysfunction. Five patients with refractory severe hyperthyroidism were treated with (131)I at 90 to 120 μCi/g-thyroid (total activity, 6.2 to 10.1 mCi). The patients previously had received ATD treatment from 2 months to 12 years and discontinued ATDs from 2 months to 4 years before (131)I treatment due to treatment failure or severe jaundice. Prior to (131)I therapy, the patients were asked to take a low-iodine diet and were treated with bisoprolol fumarate, digoxin, furosemide, S-adenosylmethionine, polyene phosphatidylcholine, and plasma exchange as supportive treatment for related clinical conditions. Four of the patients also received lithium carbonate in conjunction with their (131)I treatment. The patients were followed for 4 to 9 years after (131)I therapy. After (131)I treatment, jaundice disappeared completely within 3 to 4 months in all patients, and liver function tests returned to normal. Concurrent atrial fibrillation and heart failure, leukopenia and thrombocytopenia, or thrombocytopenia and left cardiac enlargement improved remarkably in 3 patients during the follow-up period. Three to 45 months after (131)I treatment, hypothyroidism was noted in the patients and they were treated with L-thyroxine replacement therapy. (131)I therapy without recent ATD pretreatment for refractory severe hyperthyroidism complicated by serious jaundice appears to be safe and effective, with good long-term results. It may be the preferred therapy for such patients and should be used as early as possible.

Conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation, 1945--1947. Hanford Environmental Dose Reconstruction Project

Energy Technology Data Exchange (ETDEWEB)

Mart, E.I.; Denham, D.H.; Thiede, M.E.

1993-12-01

This report is a result of the Hanford Environmental Dose Reconstruction (HEDR) Project whose goal is to estimate the radiation dose that individuals could have received from emissions since 1944 at the U.S. Department of Energy`s (DOE) Hanford Site near Richland, Washington. The HEDR Project is conducted by Battelle, Pacific Northwest Laboratories (BNW). One of the radionuclides emitted that would affect the radiation dose was iodine-131. This report describes in detail the reconstructed conversion and correction factors for historical measurements of iodine-131 in Hanford-area vegetation which was collected from the beginning of October 1945 through the end of December 1947.

Using ion-selective electrode for determining iodine-131 preparation specific activity

International Nuclear Information System (INIS)

Melnik, M.I.; Nazirova, T.E.

2002-01-01

A pilot facility was developed in 2000 for the production of iodine-131. The parameters of the preparation are as follows: chemical form: sodium iodide solution (NaI-131) in a carbonate-bicarbonate buffer (or in 0.001M NaOH); specific activity: carrier free (> 5 Ci/mg); solution pH: 7-10; radionuclide purity: > 99.9%; radiochemical purity: > 97%; bulk activity: 0.15 Ci/ml. The experimental results of investigation aimed at the determination of the specific activity of the I-131 preparation using a iodine-selective electrode are described. The method enables the analytical concentration of iodide ions in the carbonate-bicarbonate buffer (pH = 8-11) and NaOH solution (0.01 mol/l, pH = 8-11) to be determined. A micro-cell has been developed for the analysis of the I-131 solution allowing the sample volume to be reduced to below 0.3 ml. The relative error of determination of the analytical concentration of iodide (10 -6 to 10 -1 mol/l) does not exceed 1%

Experience in the patients management which received treatments with radioactive iodine ({sup 131}I). Measurements and dosimetry pertaining to the personnel related; Experiencia en el manejo de pacientes que recibieron tratamientos con yodo radiactivo ({sup 131}I). Mediciones reglamentarias y dosimetria del personal relacionado

Energy Technology Data Exchange (ETDEWEB)

Ruiz J, A [Instituto Nacional de la Nutricion Salvador Zubiran, Departamento de Medicina Nuclear, Tlalpan, 14000 Mexico D.F. (Mexico)

1999-07-01

In the INNSZ there are administering ablative doses of radioactive iodine to patients with problems of the thyroid gland from 40 years ago. Starting from 1992 was initiated the restlessness to inform to the patients verbally and in writing over the measurements of radiological safety that must be followed for the protection of their families. In this work it is commented, the benefits obtained with the patients and the teachings to give to the personnel what attend the patients which receive treatments with iodine-131 and must be hospitalized. It is commented too over the standardization standing of the patients discharged whom received radioactive material and lastly, it was make a dosimetric study of the nurses, radiotherapeutic and control area. (Author)

Iodine-131 releases from the Hanford Site, 1944--1947

International Nuclear Information System (INIS)

Heeb, C.M.

1992-10-01

Detailed results of the Hanford Environmental Dose Reconstruction (HEDR) iodine-131 release reconstruction are presented in this volume. Included are daily data on B, D, and F Plant, reactor operations from the P-Department Daily Reports (General Electric Company 1947). Tables of B and T Plant material processed from the three principal sources on separations plant operations: The Jaech report (Jaech undated), the 200 Area Report (Acken and Bird 1945; Bird and Donihee 1945), and the Metal History Reports (General Electric Company 1946). A transcription of the Jaech report is also provided because it is computer-generated and is not readily readable in its original format. The iodine-131 release data are from the STRM model. Cut-by-cut release estimates are provided, along with daily, monthly, and yearly summations. These summations are based on the hourly release estimates. The hourly data are contained in a 28 megabyte electronic file. Interested individuals may request a copy

I131-meta-iodobenzylguanidine in the diagnosis and treatment of neural crest tumours

International Nuclear Information System (INIS)

Hoefnagel, C.A.; Hartog Jager, F.C.A. den; Taal, B.G.; Engelsman, E.; Kraker, J. de; Voute, P.A.

1988-01-01

Iodine-131-meta-iodobenzylguanidine (I-131-MIBG) was used for scintigraphic detection and therapy of neural crest tumours. The methodology of both techniques is described. Based upon experience with I-131-MIBG-scintigraphy in 170 patients with neural crest tumours, of whom 46 received multiple therapeutic doses of I-131-MIBG, and upon the cumulative reports in the literature, the role of I-131-MIBG in diagnosis and treatment of each of these diseases is indicated. I-131-MIBG-scintigraphy is one of the most sensitive and specific techniques for the diagnosis, staging and follow-up of phaeochromocytoma and neuroblastoma and I-131-MIBG-therapy may induce remission in a number of these patients. In carcinoid and medullary thyroid carcinoma the diagnostic sensitivity is less; however, once the diagnosis has been made, it is useful to establish that the tumour concentrates I-131-MIBG, to see if the patients at some point in time may be amenable to I-131-MIBG-therapy

Analysis of changes in the percentage of B (CD19) and T (CD3) lymphocytes, nk cells, subsets CD4, CD8 in differentiated thyroid cancer patients treated with iodine-131

International Nuclear Information System (INIS)

Luo Quanyong; Yu Yongli; Chen Libo; Lu Hankui; Zhu Ruisen

2004-01-01

Objective: To evaluate the changes in the percentage of B (CD19) and T (CD3) lymphocytes, NK cells, subsets CD4, CD8 in patients with differentiated thyroid carcinoma (DTC) who received iodine-131 for therapeutic purposes. Methods: In this study, 102 DTC patients were divided into three groups. Group A, 8 cases received 1850 MBq of iodine-131 for the remnant thyroid ablation. Group B, 43 cases received 3700 MBq of iodine-131 for the treatment of cervical lymph node metastasis. Group C, 51 cases received 7400 MBq of iodine-131 for remote metastasis. All patients were in a hypothyroid state at the time of administration of iodine-131 and resumed L-thyroxine (2μg/Kg/day) 5 days after iodine-131 administration. The percentage of B and T lymphocytes, NK cells, subsets CD4, CD8 in peripheral blood were serially analyzed at baseline and at days 7, 30 and 90 after iodine-131 administration using a Coulter EPICS XL cytometer. Ten healthy individuals were used as a control group for lymphocyte subset values. Results: Comparing the basal lymphocyte subset levels in groups A, B and C with the control group, only NK cells showed significantly higher levels in patients than in controls (P=0.043). In group A, only the percentage of NK cells (P=0.031) and B cells (P =0.024) were reduced at day 7. In group B, a decrease in the percentage of NK cells at days 7(P=0.005), 30 (P=0.021) was observed, while a significant decrease in the percentage of B cells was only observed at day 7(P=0.006). Among T cells, only CD4+ was obviously affected, resulting in a reduction in the CD4+/CD8+ ratio at day 30 (P=0.034). In group C, patients showed a decrease in the percentage of NK cells at days 7 (P=0.023), 30 (P=0.006). A decrease in the percentage of both B and T lymphocytes was observed at days 7(P=0.020, 0.018 respectively), 30(P=0.041, 0.025 respectively). Among T cells, a decrease in the percentage of CD4+ and an increase in the percentage of CD8+ were observed, resulting in a marked

Quality of life assessment in radionuclide therapy: a feasibility study of the EORTC QLQ-C30 questionnaire in palliative 131I-lipiodol therapy

International Nuclear Information System (INIS)

Brans, B.; Lambert, B.; De Beule, E.; De Winter, F.; Dierckx, R.A.; Van Belle, S.; Van Vlierberghe, H.; De Hemptinne, B.

2002-01-01

The good tolerance of radionuclide therapy has frequently been proposed as a major advantage. This study explored the feasibility of using the EORTC QLQ-C30 questionnaire in palliative iodine-131 lipiodol therapy for hepatocellular carcinoma. Questionnaires were completed during interviews in which all symptoms, co-morbidity and medication were assessed at baseline within 1 week before 131 I-lipiodol therapy, and subsequently after 1 and 3 months, in 20 patients treated with locoregional, intra-arterial 131 I-lipiodol therapy with or without cisplatin. Principal observations were that (1) a number of important scales, i.e. overall quality of life, physical functioning and pain, worsened between 0 and 3 months after 131 I-lipiodol therapy, irrespective of tumour response, and (2) the occurrence of clinical side-effects was associated with a negative impact on quality of life and physical functioning 1 and 3 months after 131 I-lipiodol. The QLQ-C30 can be regarded as a feasible method for quality of life assessment in 131 I-lipiodol therapy for hepatocellular carcinoma and possibly in other radionuclide therapies. These observations should be related to the impact of other treatment modalities on quality of life. (orig.)

Do the benefits of iodine-131 lipiodol therapy for HCC outweigh the radiation safety issues?

International Nuclear Information System (INIS)

Kitchener, M.I.; Barnden, L.R.

2005-01-01

Introduction: lodine-131 Lipiodol is a well recognised palliative treatment option for Hepatocellular carcinoma (HCC) unsuitable for surgical resection/transplantation. However, the biological and physical half-life of lodine-131 Lipiodol in this situation has significant implications for radiation protection. Methods: A retrospective study was performed to evaluate the practical radiation issues and treatment efficacy. 22 patients were referred for assessment and 12 received Lipiodol therapy, 5 having multiple doses. Administered doses ranged from 1.0-2.2 GBq. Results: Patients were hospitalised between 4 and 8 days, with discharge rates ranging between 16 and 61uSv/hr at 1 metre. The shorter hospital stays and highest discharge rates related to 2 patients (multiple doses) who had difficulty tolerating the in-hospital isolation. Only 4 patients had discharge rates < 25uSv/hr at 1 metre. 2 with reduced doses. Special exemption was required from the State Radiation Protection Branch (RPB) to allow early discharge. Patients were given a radiation precaution sheet on discharge (as per the FMC program) and asked to observe the restrictions including not returning to work for 14-24 days and avoiding close contact with young children for 25-44 days post-discharge. The measured radiation dose for a patient's spouse/carer was < lOOuSv on 2 occasions. The mean exposure for nurses per patient admission was 9.1 uSv. The TLD readings for the Interventional Radiologist and treating Nuclear Physician remained well within acceptable levels. 4 of the 12 patients have died at a mean of 16.25 months (range 13-20 months) after their first dose of lodine-131 Lipiodol. Of the other 7, 3 now have progressive disease but are alive 18, 36 and 41 months following their first dose. 4 are less than 12 months post-therapy. With the co-operation of the State RPB. the issues relating to radiation protection are manageable and these patients do receive a therapeutic benefit

Internal Contamination by 131I in nuclear medicine department

International Nuclear Information System (INIS)

Chahed, N.; Mtimet, S.; Hammami, H.; Mhiri, A.

1998-01-01

Therapeutic applications in nuclear medicine use high activities of 131 I in sodium iodine liquid from which is volatile at ambient temperature. Besides external exposure there is, for the nuclear medicine personnel, an internal exposure risk induced by 131 iodine inhalation. So we tried to assess this risk among the personnel in a nuclear medicine department. We used direct method for measuring 131 radioactivity in vivo by external counting. Gamma ray detector with a Nal ( TI ) probe positioned near the thyroid gland allows investigation of 131 radioactivity. We realised 34 measurements among the personnel, two times at an interval of one month. The results indicate that an 131 iodine internal contamination is found. Estimated thyroid activities were ranging from 35 to 132 Bq. The highest activities has been found in the thyroid of the technicians involved in the administration of 131 iodine therapy. Therefore this values are lower than norms. This study must lead to the implementation control of the 131 iodine internal contamination in order to optimise the personnel protection in nuclear medicine departments (author)

Impact of iodine 131 release from an anti cancerous center on the activity present in the channel of waste water treatment

International Nuclear Information System (INIS)

Desjardins, E.; Laugle, S.; Houy, J.C.

2002-01-01

Iodine 131 has been detected in the incineration waste. This iodine 131 would come from the muds of the water treatment by plant of Beaurade. This plant treats the waste water of Rennes. This radioactivity is caused by iodine 131 used in the medical medium for the diagnosis and the treatment of liver and thyroid neoplasms. The urines are stocked in tanks until a decrease of activity to 7 Bq/l and the waste waters used to wash the clothes are at delayed evacuation. The iodine comes from the patients feces. This study consists in defining the activity levels of iodine 131 in the channel of waste water treatment, from the purification station of Beaurade to the incinerator of Villejean. (N.C.)

Investigations on the retention of 131I by an iodine filter of a pressurized water reactor

International Nuclear Information System (INIS)

Deuber, H.; Gerlach, K.

1983-09-01

The retention of 131 I by an equipment room exhaust filter of a German pressurized water reactor was determined by various methods to particularly obtain reliable results. Moreover, investigations were performed to clarify the reason for aging of the carbon contained in the iodine filter mentioned. The actual retention of the organic 131 I, corresponding to a value of 99.9%, was limited by 131 I in the form of penetrating iodine compounds. It was lower than the retention of CH 3 131 I under layout conditions by more than one order of magnitude. The aging was essentially caused by the adsorption of low-volatile organic compounds. (orig.) [de

Investigations on the retention of I-131 by an iodine filter of a pressurized water reactor

International Nuclear Information System (INIS)

Deuber, H.; Gerlach, K.

1984-01-01

The retention of I-131 by an equipment room exhaust filter of a German pressurized water reactor was determined by various methods to particularly obtain reliable results. Moreover, investigations were performed to clarify the reason for aging of the carbon contained in the iodine filter mentioned. The actual retention of the organic I-131, corresponding to a value of 99.9%, was limited by I-131 in the form of penetrating iodine compounds. It was lower than the retention of CH 3 I-131 under layout conditions by more than one order of magnitude. The aging was essentially caused by the adsorption of low-volatile organic compounds. (orig.) [de

Evaluation of the Basedow disease treatment by a iodine 131 fixed dose; Evaluation du traitement de la maladie de Basedow par une dose fixe d'iode 131

Energy Technology Data Exchange (ETDEWEB)

El Ajmi, W.; Slim, I; Rmadi, S.; Yeddes, I.; Krimi, S.; Ltaief, B.; Mhiri, A.; Ben Slimene, M.F. [Service de medecine nucleaire, institut Salah Azeiz, Tunis, (Tunisia)

2009-05-15

The treatment of the basedow disease by iodine 131 is more and more used. however, the doses used stay variable. In order to reduce the treatment failure, we chose a protocol with strong fix doses of iodine 131. We give our preliminary results for 63 patients. The treatment by strong fix dose of iodine 131 is simple, safe and efficient for the control of hyperthyroidism in the Basedow disease. This protocol has for advantage to be simpler comparatively to these ones using adjusted doses according the weight of the thyroid and its fixation rate. (N.C.)

Immunotoxic effects of iodine-131 in prenatally exposed rats

International Nuclear Information System (INIS)

Cole, D.A.; Stevens, R.H.; Lindholm, P.A.; Cheng, H.F.

1985-01-01

Present results suggest that offspring exposed in utero to radioactive iodine-131 develop a measureable cell-mediated immune (CMI) response. Regnant Fischer F344 inbred rats were exposed to 370 kBg to 3.7 MBg (10 to 100 μCi) Na 131I on 16 to 18 days of gestation and evaluated for CMI responsiveness 2 to 3 months post exposure using an 125I radiolabeled membrane release assay. Current data suggest that not only the F1, but also the F2 pups develop a measureable CMI response. In order to determine whether other immune functions are altered studies have been initiated to evaluate the immunotoxic effect of prenatal exposure to 131I. These studies include the evaluation of the delayed hypersensitivity response and the blastogenic responses to phytoheemagglutinin, concanavalin A, and lipopolysaccharide

Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship

International Nuclear Information System (INIS)

Erselcan, Taner; Ozdemir, Semra; Turgut, Bulent; Dogan, Derya; Sungu, Selma; Ozdemir, Ozturk

2004-01-01

Although it is well known that radiation induces chromosomal aberrations, there is a lack of information on the in vivo dose-effect relationship in patients receiving iodine-131 treatment, and the results of previous studies are controversial. In this study, the sister chromatid exchange (SCE) method was employed to investigate acute and late chromosomal damage (CD) in the peripheral lymphocytes of 15 patients who received various doses of 131 I (259-3,700 MBq), either for thyrotoxicosis (TTX) or for ablation treatment in differentiated thyroid cancer (DTC). The SCE frequencies in cultured peripheral lymphocytes were determined before treatment (to assess basal SCE frequencies), on the 3rd day (to assess acute SCE frequencies) and 6 months later (to assess late SCE frequencies). The basal, acute and late SCE frequencies (mean±SD) were 3.19±0.93, 10.83±1.72 and 5.75±2.06, respectively, in the whole group, and these values differed significantly from each other (P 131 I dose in the whole group, but a negative correlation was found between the 131 I dose and the RR at the 6th month (r=-0.60, P=0.04). The best fit for this relationship was obtained by a linear-quadratic model, as y=104.89x-28.4x 2 +38.1 (R 2 =0.51, P=0.04). On the other hand, comparative analysis with the results of previous studies with comparable sampling times revealed that the best fit for the relationships between the administered dose of 131 I and DR and RR were obtained with a linear-quadratic model (Y=αD+βD 2 ) rather than a linear one. However, there was an interesting difference in comparison with in vitro studies, in that we found the coefficient β to have a negative value, suggesting the disappearance of damaged lymphocytes from the peripheral circulation in a dose-dependent manner following 131 I treatment. Further studies are therefore needed to clarify the effect of the negative β value on the biological dosimetry approach in continuous internal low LET radiation, as in the case

Effect of 131I therapy on outcomes of Graves' ophthalmopathy

International Nuclear Information System (INIS)

Wang Renfei; Tan Jian; Zhang Guizhi; Yin Liang

2011-01-01

Objective: To analyze the correlation between the therapeutic effect of Graves' hyperthyroidism and the outcomes of Graves' ophthalmopathy after 131 I therapy, and to explore the effect of 131 I treatment on turnout of Graves' ophthalmopathy. Methods: Six hundreds and fifty-two patients of Graves' disease accompanied with Graves' ophthalmopathy, received one-time 131 I treatment according to routine procedure. We recorded exophthalmometer readings, the signs and symptoms of eyes before therapy. Regular follow-up and appraisal of curative effect were carried out. Results: At least six months after 131 I therapy, the effective rate of Graves' hyperthyroidism and Graves' ophthalmopathy were 94.3% and 73.3% respectively. The total effective rate of hyperthyroidism with ophthalmopathy was 71.2%. There was a significant correlation between the prognosis of Graves' ophthalmopathy and therapeutic efficacy of hyperthyroidism (r=0.302, P 131 I therapy (χ 2 =0.296, P>0.05). Conclusions: The key to treat Graves' ophthalmopathy is the cure of Graves' hyperthyroidism through 131 I therapy. The timely diagnosis and replacement treatment of hypothyroidism can effectively avoid the aggravation of Graves' ophthalmopathy after 131 I therapy. (authors)

Iodine-131 distribution on the territory of the Republic of Belarus during the first period of the Chernobyl NPP catastrophe

International Nuclear Information System (INIS)

Germenchuk, M.G.; Zhukova, O.M.; Shagalova, E.D.; Matveenko, I.I.

1998-01-01

To reconstruct space distribution of iodine-131 on the territory of Belarus we used the following data: (i) contents of iodine-131 in soil measured by gamma spectrometry method in May-July, 1986; (ii) contents of iodine-131 in samples of radioactive atmospheric fall-outs measured by gamma spectrometry method in May, 1986; (iii) daily measurements of exposure dose power levels on the territory of Belarus obtained in April-July, 1986; (iv) results of aerial gamma radiation mapping, obtained in May, 1986; (v) daily measurements of radioactive contamination of milk on the territory of Belarus obtained in May-July, 1986; (vi) measurements of iodine-131 content in links of biological chain 'soil-grass-milk' sampled from 15 reference farms; (vii) maps of specific activity of natural hayfields grass on the territory of Belarus (for every district) obtained on June 2 and 5, on July 3, 1986. Dose commitments on thyroid gland caused by iodine isotopes were formed mainly during the first 2.5 months after the accident. Local irradiation of this organ was stipulated by high accumulation factor of iodine isotopes in thyroid gland that caused increasing of malignant thyroid tumors incidences, including children, on all over the territory of Belarus. Comparison of iodine-131 distribution map and malignant thyroid gland tumor incidences among children on the territory of Belarus map shows that the more level of iodine contamination the more malignant thyroid gland tumor incidence

Protective effect of Ocimum sanctum L after high-dose {sup 131}Iodine exposure in mice: an in vivo study

Energy Technology Data Exchange (ETDEWEB)

Bhartiya, Uma S; Raut, Yogita S; Joseph, Lebana J [Laboratory Nuclear Medicine Section, Radiochemistry and Isotope Group, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel, Mumbai (India); Rao, Badanidiyoor S [Radiological Physics and Advisory Division, Bhabha Atomic Research Centre, Mumbai (India)

2006-08-15

Radioprotective effect of aqueous extract of Ocimum sanctum (40 mg/kg body weight, for 15 days) in mice exposed to high-doses (3.7 MBq) of oral {sup 131}Iodine was investigated by studying the organ weights, lipid peroxidation and antioxidant defense enzymes in various target organs like liver, kidneys, salivary glands and stomach at 24 hr after exposure in adult Swiss mice. The mean weight of the salivary glands showed significant increase after {sup 131}Iodine administration. {sup 131}Iodine exposure significantly increased lipid peroxidation in kidneys and salivary glands in comparison to control animals. Pretreatment with O. sanctum in radioiodine exposed group showed significant reduction in lipid peroxidation in both kidneys and salivary glands. In liver, reduced glutathione (GSH) levels showed significant reduction after radioiodine exposure while pretreatment with O. sanctum exhibited less depletion in GSH level even after {sup 131}Iodine exposure. However, no such changes were observed in stomach. The results indicate the possibility of using aqueous extract of O. sanctum for ameliorating {sup 131}lodine induced damage to the salivary glands. (author)

Contribution of radio-iodine 131 in the treatment of Grave's Basedow disease in the department of nuclear medicine of Ibn Sina Hospital in Rabat

International Nuclear Information System (INIS)

Mbodj, M.; Amjad, I.; Guerrouj, H.; Ben Rais, N.A.

2009-01-01

One hundred and twenty-nine Grave's Basedow diseases in any gender and variable age patients, coming from several cities of Morocco, were randomized in a study of radio-iodine treatment who took place at the nuclear medicine department of Ibn Sina Hospital (Rabat, Morocco) during the period (from January 2001 to December 2008). The radio-iodine treatment was a first, second or third option and radio-iodine activities delivered varied (from 222 to 555 MBq 6 to 15 mCi) according to the age, the thyroid volume, the degree of hyperthyroidism and socio-economical situation. The high amounts of 131 I were reserved especially to the patients who live far and whose socio-economic level is low with an aim of quickly obtaining an easily controllable state of hypothyroidism by a substitute treatment. The results showed that: (1) 57.36% of patients reverted to euthyroidism (n = 74) with a patient having received two 131 I cures. The second cure was justified by recurrence of hyperthyroidism after the first cure; (2) 34.88% passed in hypothyroidism (n = 45) with three patients having received two cures of 131 I, the second cure was justified by recurrence of hyperthyroidism after the first cure in two patients and by the persistence of the hyperthyroidism after the first cure for the third patient. The average time of passage in hypothyroidism was 4.5 months; (3) 7.76% had remained in hyperthyroidism after the radioactive iodine treatment. Finally, 92.24% of our patients treated by radioactive iodine had passed in euthyroidism or hypothyroidism against 7.76% whose hyperthyroidism had persisted or occurred. (authors)

The Success Rate of Initial {sup 131I} Ablation in Differentiated Thyroid Cancer: Comparison Between Less strict and Very Strict Low Iodine Diets

Energy Technology Data Exchange (ETDEWEB)

Yoo, Ik Dong; Kim, Sung Hoon; Seo, Ye Young; Oh, Jin Kyoung; O, Joo Hyun; Chung, Soo Kyo [The Catholic Univ. of Korea, Seoul (Korea, Republic of)

2012-03-15

To decrease the risk of recurrence or metastasis in differentiated thyroid cancer (DTC), selected patients receive radioactive iodine ablation of remnant thyroid tissue or tumor. A low iodine diet can enhance uptake of radioactive iodine. We compared the success rates of radioactive iodine ablation therapy in patients who followed two different low iodine diets (LIDs). The success rates of postsurgical radioactive iodine ablation in DTC patients receiving empiric doses of 150 mCi were retrospectively reviewed. First-time radioactive iodine ablation therapy was done in 71 patients following less strict LID. Less strict LID restricted seafood, iodized salt, egg yolk, dairy products, processed meat, instant prepared meals, and multivitamins. Very strict LID additionally restricted rice, freshwater fish, spinach, and soybean products. Radioactive iodine ablation therapy was considered successful when follow up {sup 123I} whole body scan was negative and stimulated serum thyroglobulin level was less than 2.0 ng/mL. The success rate of patients following less strict LID was 80.3% and for very strict LID 75.6%. There was no statistically significant difference in the success rates between the two LID groups (P=0.48). Very strict LID may not contribute to improving the success rate of initial radioactive iodine ablation therapy at the cost of great inconvenience to the patient.

[131I therapy in hyperthyroidism. Results of treatment from 1960-1974].

Science.gov (United States)

Heinze, H G; Schenk, F

1977-02-01

488 PATIENTS WITH Graves' disease were treated by 131Iodine between 1960 and 1974. 427 (87,5%) of these patients were reexamined several times (clinically, 131I-uptake, PB127I, T4 (CPB-A), T3-uptake, and since 1973 TRH-test). The 131I was given as an individually calculated single dose treatment, using 7 000 -- 10 000 rd before 1965 and 6 000 rd thereafter. Two thirds of the patients became euthyroid after a single 131I-dose. In 20% the treatment had to be repeated. These patients show evidently a different biological behaviour of their disease, since multiple treatments revealed a higher rate of failure (33--35%). There is no principal difference between the out-come after 131I-therapy and surgery concerning the rate of failure, respectively relapse (3--4%) and hypothyroidism. Early incidence of hypothyrodism is dose--dependent, as could be shown in patients treated with higher doses before 1965. The reduction of the irradiation dose to 6 000 rd was followed by a drop of hypothyroidism from 18% to 7%. The reasons of late incidence of hypothyroidism are discussed. The incidence of hypothroidism was calculated by three different methods (over-all incidence, incidence within the observed interval after therapy, life-table method). All three methods revealed different results. This has to be taken into account comparing results after radioiodine as well as after surgery. Radioiodine therapy for hyperthyroidism offers a true alternative to surgery.

Radioactive iodine therapy in cats with hyperthyroidism

International Nuclear Information System (INIS)

Turrel, J.M.; Feldman, E.C.; Hays, M.; Hornof, W.J.

1984-01-01

Eleven cats with hyperthyroidism were treated with radioactive iodine ( 131 I). Previous unsuccessful treatments for hyperthyroidism included hemithyroidectomy (2 cats) and an antithyroid drug (7 cats). Two cats had no prior treatment. Thyroid scans, using technetium 99m, showed enlargement and increased radionuclide accumulation in 1 thyroid lobe in 5 cats and in both lobes in 6 cats. Serum thyroxine concentrations were high and ranged from 4.7 to 18 micrograms/dl. Radioactive iodine tracer studies were used to determine peak radioactive iodine uptake (RAIU) and effective and biological half-lives. Activity of 131 I administered was calculated from peak RAIU, effective half-life, and estimated thyroid gland weight. Activity of 131 I administered ranged from 1.0 to 5.9 mCi. The treatment goal was to deliver 20,000 rad to hyperactive thyroid tissue. However, retrospective calculations based on peak RAIU and effective half-life obtained during the treatment period showed that radiation doses actually ranged from 7,100 to 64,900 rad. Complete ablation of the hyperfunctioning thyroid tissue and a return to euthyroidism were seen in 7 cats. Partial responses were seen in 2 cats, and 2 cats became hypothyroid. It was concluded that 131 I ablation of thyroid tumors was a reasonable alternative in the treatment of hyperthyroidism in cats. The optimal method of dosimetry remains to be determined

Putting to point the production process of iodine-131 by dry distillation (Preoperational tests); Puesta a punto el proceso de produccion de yodo-131 por destilacion seca (Pruebas preoperacionales)

Energy Technology Data Exchange (ETDEWEB)

Alanis M, J. [ININ, Departamento de Materiales Radiactivos, 52045 Ocoyoacac, Estado de Mexico (Mexico)

2002-12-15

With the purpose of putting to point the process of production of {sup 131}I, one of the objectives of carrying out the realization of operational tests of the production process of iodine-131, it was of verifying the operation of each one of the following components: heating systems, vacuum system, mechanical system and peripheral equipment that are part of the production process of iodine-131, another of the objectives, was settling down the optimal parameters that were applied in each process during the obtaining of iodine-131, it is necessary to point out that this objective is very important, since the components of the equipment are new and its behavior during the process is different to the equipment where its were carried out the experimental studies. (Author)

Therapeutical uses of 131I

International Nuclear Information System (INIS)

Lago, Graciela.

1994-01-01

Physiology of thyroid gland, pathology of thyroid , papillary, follicular cancer is considered together as differentiated thyroid cancer with very good results under therapy with iodine, invitro determination of calcitonin, search of metastasis, anaplastic carcinoma, as indifferentiated carcinoma with similar results as medullary carcinoma. This work gives a protocol for therapeutical use of 131I , in hyperthyroidism due to Graves-Basedow disease, thyrotoxic adenoma or Plummer disease, toxic multi nodular goiter, subacute thyroiditis. Is studied too the treatment with pharmaceuticals, surgery and radioactive iodine. A recommended use of each and protocol for iodine administration, fixed dose technique, dose estimation,absorbed dose, recommendations about when to use and not use 131I are included in this work

Hypothyroidism following 131I therapy for hyperthyroidism

International Nuclear Information System (INIS)

Kubo, Atsushi; Kondo, Makoto; Kinoshita, Fumio; Maekawa, Akira; Okamoto, Jiro.

1977-01-01

Of 890 patients who received 131 I therapy for hyperthyroidism, the results of therapy were examined on 584 who could be followed up. Of these 502 (86%), were sured including 3 patients who had been completely healed after recurrence, 9 patients are still under medical treatment, and 10 died. The incidence of hypothyroidism following 131 I therapy was 1.6% after 1 year, 2.3% after 2 years, 4.7% after 5 years, 15.0% after 10-12 years, 22.1% after 13-15 years and 27.5% after 16-20 years. The incidence increased constantly with the passage of time. Factors influencing the response to treatment have been investigated. As a consequence, the number of rads delivered to the thyroid gland, the gland size, and previous surgery correlated with the incidence of hypothyroidism. The number of doses of 131 I, uptake and half-life of 131 I in the thyroid, previous antithyroid medication, time between the onset of hyperthyroid symptoms and 131 I therapy, and the age or sex of the patients appeared unrelated. The times taken to become euthyroid following a single dose of 131 I were 5.6 months with 2000-4000 rads, 4.4 months with 4001-7000 rads, 4.2 months with 7001-10000 rads and 3.5 months with more than 10001 rads. The time was prolonged with decrease of rads delivered to the thyroid gland. It was found that the patients who passed through a transient hypothyroid phase in the period of three to four months after administration of 131 I had a high incidence of late permanent hypothyroidism. (Evans, J.)

Prediction of iodine-131 biokinetics and radiation doses from therapy on the basis of tracer studies: an important question for therapy planning in nuclear medicine.

Science.gov (United States)

Willegaignon, José; Pelissoni, Rogério A; Lima, Beatriz C G D; Sapienza, Marcelo T; Coura-Filho, George B; Buchpiguel, Carlos A

2016-05-01

This study aimed to present a comparison of iodine-131 (I) biokinetics and radiation doses to red-marrow (rm) and whole-body (wb), following the administration of tracer and therapeutic activities, as a means of confirming whether I clearance and radiation doses for therapy procedures can be predicted by tracer activities. Eleven differentiated thyroid cancer patients were followed after receiving tracer and therapeutic I activity. Whole-body I clearance was estimated using radiation detectors and OLINDA/EXM software was used to calculate radiation doses to rm and wb. Tracer I activity of 86 (±14) MBq and therapeutic activity of 8.04 (±1.18) GBq were administered to patients, thereby producing an average wb I effective half-time and residence time of, respectively, 13.51 (±4.05) and 23.13 (±5.98) h for tracer activities and 13.32 (±3.38) and 19.63 (±4.77) h for therapy. Radiation doses to rm and wb were, respectively, 0.0467 (±0.0208) and 0.0589 (±0.0207) mGy/MBq in tracer studies and 0.0396 (±0.0169) and 0.0500 (±0.0163) mGy/MBq in therapy. Although the differences were not considered statistically significant between averages, those between the values of effective half-times (P=0.906), residence times (P=0.145), and radiation doses to rm (P=0.393) and to wb (P=0.272), from tracer and therapy procedures, large differences of up to 80% in wb I clearance, and up to 50% in radiation doses were observed when patients were analyzed individually, thus impacting on the total amount of I activity calculated to be safe for application in individual therapy. I biokinetics and radiation doses to rm and wb in therapy procedures are well predicted by diagnostic activities when average values of a group of patients are compared. Nonetheless, when patients are analyzed individually, significant differences may be encountered, thus implying that nuclear medicine therapy-planning requires due consideration of changes in individual patient-body status from

Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

International Nuclear Information System (INIS)

1992-01-01

This booklet contains information about procedures to protect hospital staff and visitors and families of patients treated with iodine 131 from exposure to radiation from I-131. It also includes a basic guide to the principles of the production of ionizing radiation and to methods of radiation protection and dosimetry

Altering iodine metabolism in the calf by feeding iodine-binding agents

International Nuclear Information System (INIS)

Miller, J.K.; Swanson, E.W.; Lyke, W.A.; Byrne, W.F.

1975-01-01

Effects of feeding cottonseed meal and anion-exchange resin on iodine absorption and excretion by calves were investigated. Each additional amount of resin fed from 0.3 to 3.5 g/kg body weight further increased fecal excretion from single oral iodine-131 and intravenous iodine-125 doses. By feeding 3 to 10 g cottonseed meal/kg body weight, excretion of oral iodine-131 given daily was increased 7 to 94 percent in feces and reduced as much as 35 percent in urine, but plasma iodine-131 was not changed. Introducing 1 g resin/kg body weight daily into the diet increased fecal iodine-131 excretion three to five times that with cottonseed meal alone and reduced both plasma and urinary iodine-131. The same amount of resin fed daily had similar effects on excretion of iodine-131 injected subcutaneously each day. Although iodine depletion by a highly efficient iodine binder (resin) in the gastrointestinal tract is probable, iodine binding by a natural feed constituent (cottonseed meal) was relatively inefficient. (U.S.)

Altering iodine metabolism in the calf by feeding iodine-binding agents

International Nuclear Information System (INIS)

Miller, J.K.; Swanson, E.W.; Lyke, W.A.; Byrne, W.F.

1975-01-01

Effects of feeding cottonseed meal and anion-exchange resin on iodine absorption and excretion by calves were investigated. Each additional amount of resin fed from 0.3 to 3.5 g/kg body weight further increased fecal excretion from single oral iodine-131 and intravenous iodine-125 doses. By feeding 3 to 10 g cottonseed meal/kg body weight, excretion of oral iodine-131 given daily was increased 7 to 94 percent in feces and reduced as much as 35 percent in urine, but plasma iodine-131 was not changed. Introducing 1 g resin/kg body weight daily into the diet increased fecal iodine-131 excretion three to five times that with cottonseed meal alone and reduced both plasma and urinary iodine-131. The same amount of resin fed daily had similar effects on excretion of iodine-131 injected subcutaneously each day. Although iodine depletion by a highly efficient iodine binder (resin) in the gastrointestinal tract is probable, iodine binding by a natural feed constituent (cottonseed meal) was relatively inefficient. (auth)

Labeling of Salmonella typhimurium with iodine-131 to study phagocytic function in rats

International Nuclear Information System (INIS)

Sato, M.K.; Rodrigues Junior, A.J.; Camargo, E.E.

1989-01-01

The present study descibes a method for labeling Salmonella tyhymurium with iodine-131 to evaluate both the morphological and the functional characteristics of the reticulo-endothelial system. A suspension containing 2 x 10 9 bacteria per ml was labeled with carrier-free Na 131 I without reductor, with a labeling yield of 46.5 +- 3% and 3.5 +- 1.3% of free Iodine-131. The biodistribution of the labeled bacteria in rats was studied with a large-field-of-view scintillation camera equiped with a pinhole collimator. Whole body images were obtained 15 and 30 minutes after intravenous injection of the labeled microorganisms. Images showed accumulation of bacteria in the liver and both normal and transplanted spleens of the animals. Autoradiographs of liver and spleen demonstrated labeled bacteria within the cells of the reticulo-endothelial system. The method described is easy to perform, has a good labeling yield and allows the function of the reticulo-monophagocytic system, including transplanted spleens. (author) [pt

[sup 131]I-metaiodobenzylguanidine therapy for malignant pheochromocytoma

Energy Technology Data Exchange (ETDEWEB)

Sakahara, Harumi; Saga, Tsuneo; Hosono, Makoto; Kobayashi, Hisataka; Konishi, Junji (Kyoto Univ. (Japan). Faculty of Medicine); Endo, Keigo

1994-05-01

[sup 131]I-metaiodobenzylguanidine (MIBG) therapy was given to five patients with malignant pheochromocytoma. The patients received 1-3 doses of 3.33-4.625 GBq (total dose: 3.7 to 10.73 GBq). Partial tumor regression was observed in two patients, the tumor was unchanged in two patients, and slow progression was noted in one patient. Marked improvement in clinical symptoms was achieved in four patients. The other patients had no symptoms before [sup 131]I-MIBG treatment, but the serum epinephrine and dopamine decreased. There were no severe untoward responses in four patients. However, one patient developed transient but severe orthostatic hypotension, hypertension, and hyperglycemia from 1 week to 1 month after [sup 131]I-MIBG administration. Although complete remission was not obtained, all the patients achieved some benefit from [sup 131]I-MIBG therapy. Thus, [sup 131]I-MIBG appears to be useful for the palliation of malignant pheochromocytoma. (author).

Iodine-131 MIBG scintigraphy of the extremities in metastatic pheochromocytoma and neuroblastoma

International Nuclear Information System (INIS)

Shulkin, B.L.; Shen, S.W.; Sisson, J.C.; Shapiro, B.

1987-01-01

Iodine-131 MIBG scintigraphy may be used to determine the presence or absence of metastases to the appendicular skeleton in malignant pheochromocytoma and neuroblastoma. Normal bones show no uptake of [ 131 I]MIBG and the joints are seen as photon-deficient areas surrounded by background muscle activity. Discrete concentrations of radioactivity in bone are often seen in patients with malignant pheochromocytoma and neuroblastoma. Bone marrow involvement in neuroblastoma may be indicated by diffuse uptake of [ 131 I]MIBG or focal accumulation at the metaphyses. Uncommonly, bone involvement may not be displayed by the [ 131 I]MIBG images. Since conventional bone scanning agents may also fail to detect these tumors, skeletal scintigraphy with both [ 131 I]MIBG and [/sup 99m/Tc]MDP is necessary to reliably stage malignant pheochromocytoma and neuroblastoma

Comparison of in-vivo kinetics of an antibody cocktail containing 131-iodine anti-CA-19/9 and 131-iodine anti-CEA with 111-indium labelled monoclonal anti-CA-19/9 using a tumor model in mice

International Nuclear Information System (INIS)

Koenig, S.; Orth, M.; Henze, E.

1993-01-01

In this study the potential diagnostic value of an 111-In-labelled CA-19/9-F (ab)-fragment was compared to that of an antibody cocktail of 131-iodine-labelled CA-19/9 and 131-iodine-labelled anti-CEA for identification of pancreas cancer by a nude mice model. 111-In-labelled CA-19/9 and the 131-iodine antibody cocktail were injected into 35 nude mice xenotransplantated with human pancreas cancer. Scintigrams were obtained and the relative distribution of activity in tumor and in several organs were determined by ROI-technique. These values were compared with the in vitro results of organ measurement after dissection of nude mice. Blood pool of 131-iodine-labelled antibodies showed only a nuclide accumulation in the thyroid because of very high rate of dejodination and missing blockade of thyroid. Other organs were not detectabel in scintigraphy because of high nucleotide accumulation of thyroid. The tumor-to-blood-ratio of organ-measurements was 18±4.3, kidneys-background-ratio 2.1±7.3, liver-background-ratio 5.8±2.0. These results are similar to those of 111-In-labelled fragments. Thus it is established that antibody cocktail had no essential advantage over singular antibody in mouse model. It gives a good tumor contrast with tumor-background-quotient of 15±7.4 measured by scintigraphy and tumor background-quotient 18±4.3 in-vitro-organ-measurement. (orig.) [de

Sequelae and survivorship in patients treated with (131)I-MIBG therapy.

Science.gov (United States)

Sze, W C C; Grossman, A B; Goddard, I; Amendra, D; Shieh, S C C; Plowman, P N; Drake, W M; Akker, S A; Druce, M R

2013-08-06

(131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. Newer treatment modalities are emerging for neuroendocrine tumours (NETs) and chromaffin cell tumours (CCTs), but many of these do not yet have adequate long-term follow-up to determine their longer term efficacy and sequelae. Fifty-eight patients with metastatic NETs and CCTs who had received (131)I-MIBG therapy between 2000 and 2011 were analysed. Survival and any long-term haematological or renal sequelae were investigated. In the NET group, the overall median survival and median survival following the diagnosis of metastatic disease was 124 months. The median survival following the commencement of (131)I-MIBG was 66 months. For the CCT group, median survival had not been reached. The 5-year survival from diagnosis and following the diagnosis of metastatic disease was 67% and 67.5% for NETs and CCTs, respectively. The 5-year survival following the commencement of (131)I-MIBG therapy was 68%. Thirty-two patients had long-term haematological sequelae: 5 of these 32 patients developed haematological malignancies. Two patients developed a mild deterioration in renal function. Long follow up of (131)I-MIBG therapy reveals a noteable rate of bone marrow toxicities and malignancy and long term review of all patients receiving radionuclide therapies is recommended.

Factors Predicting Treatment Failure in Patients Treated with Iodine-131 for Graves’ Disease

International Nuclear Information System (INIS)

Manohar, Kuruva; Mittal, Bhagwant Rai; Bhoil, Amit; Bhattacharya, Anish; Dutta, Pinaki; Bhansali, Anil

2013-01-01

Treatment of Graves' disease with iodine-131 ( 131 I) is well-known; however, all patients do not respond to a single dose of 131 I and may require higher and repeated doses. This study was carried out to identify the factors, which can predict treatment failure to a single dose of 131 I treatment in these patients. Data of 150 patients with Graves' disease treated with 259-370 MBq of 131 I followed-up for at least 1-year were retrospectively analyzed. Logistic regression analysis was used to predict factors which can predict treatment failure, such as age, sex, duration of disease, grade of goiter, duration of treatment with anti-thyroid drugs, mean dosage of anti-thyroid drugs used, 99m Tc-pertechnetate ( 99m TcO 4 - ) uptake at 20 min, dose of 131 I administered, total triiodothyronine and thyroxine levels. Of the 150 patients, 25 patients required retreatment within 1 year of initial treatment with 131 I. Logistic regression analysis revealed that male sex and 99m TcO 4 - uptake were associated with treatment failure. On receiver operating characteristic (ROC) curve analysis, area under the curve (AUC) was significant for 99m TcO 4 - uptake predicting treatment failure (AUC = 0.623; P = 0.039). Optimum cutoff for 99m TcO 4 - uptake was 17.75 with a sensitivity of 68% and specificity of 66% to predict treatment failure. Patients with >17.75% 99m TcO 4 - uptake had odds ratio of 3.14 (P = 0.014) for treatment failure and male patients had odds ratio of 1.783 for treatment failure. Our results suggest that male patients and patients with high pre-treatment 99m TcO 4 - uptake are more likely to require repeated doses of 131 I to achieve complete remission

The use of lithium carbonate in the treatment of Graves' disease with 131I

International Nuclear Information System (INIS)

Kang Yuguo; Chen Miao; Kuang Anren

2004-01-01

Lithium carbonate involving radioactive iodine uptake, goiter volume, thyroid hormone and applying range is reviewed briefly. Lithium may elongate the T 1/2 of iodine in thyroid gland, decrease 131 I dosage and enhance curative effect. Lithium carbonate inhibit iodine uptake and thyroid hormone synthesize, blocks the release of iodine and thyroid hormone from the thyroid gland, which lead to reduce the 131 I dosage the patients need and to decrease the surge of serum FT 3 and FT 4 levels caused by 131 I therapy. so lithium carbonate can alleviate the symptoms caused by 131 I treatment. For lithium carbonate can increase leucocyte amount, there are some merits with lithium carbonate in treating Graves' disease by 131 I. (authors)

Vasoactive intestinal peptide (VIP) labelling with iodine-131 by direct method; Marcacao do peptideo intestinal vasoativo (VIP) com iodo-131 por metodo direto

Energy Technology Data Exchange (ETDEWEB)

Colturato, M.T.; Silva, C.P.G. da; Araujo, E.B. [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil). Centro de Radiofarmacia

2002-07-01

The Vasoactive Intestinal Peptide (VIP) is a 28-amino acid polypeptide with a great numbers of receptors in tumoral cells, including adenocarcinomas and pancreatic and colon carcinomas. The VIP molecule contains two tyrosine residues, in positions 10 and 22, that are theoretically equally susceptible to iodination, The VIP was labeled with 131-iodine by direct method using Iodogen as oxidant agent: 15.03 mmol VIP + 0.10 nmol KI + [{sup 131} I]NaI + 13.9 mmol Iodogen; the final volume was adjust to 100 {mu}L using 0.2 M phosphate buffer, pH 7.5 and the reaction proceed with stirring for 30 minutes at room temperature. The radiochemical purity was determined by electrophoresis (Whatman 1MM paper; 0.05 M barbital buffer; pH 8.6; 150 V; 40 minutes) that indicates low percent of free 131-iodine. The high performance liquid chromatography (HPLC) system using RPC{sup 18}, 10 {mu}m, 4 x 250mm column, was able to separate the different radiochemical species, only when an isocratic mixture of acetonitrile: 0.1% trifluoroacetic acid (27:73) was used, with 0.5 mL/min. flux. (author)

Identifying best practice in relation to Iodine-131 ablation discharges to sewers in Ireland

International Nuclear Information System (INIS)

Ryan, Thomas P.; Fennell, Stepehn; McGarry, Ann; Punt, Adrian

2008-01-01

Full text: In line with a commitment in Ireland's strategy on the implementation of the Oslo-Paris Convention (OSPAR) as well as recent developments in the provision of national oncology services, best practice in relation to Iodine-131 (I-131) ablation discharges to sewers in Ireland is under review. Preparatory to this review the Radiological Protection Institute of Ireland (RPII) commissioned a study of current practices in Ireland and associated doses as well as a review of international best practice and advice. Currently, there are three hospitals in Ireland at which thyroid ablation therapy procedures (large therapeutic administrations of I-131 for thyroid cancer treatment) are carried out. Only one facility has a limited capacity for delay and decay storage prior to discharge. Based on current administrations and discharges, the potentially most exposed workers comprises hospital plumbers dealing with specific incidents with estimated doses in the order of 50 to 70 μSv per incident. Doses to sewage workers and fishing communities are estimated at less than 4 μSv y -1 and 0.4 μSv y -1 respectively. Based on anticipated future service requirements in Ireland, a marginal increase in doses to some of these groups is estimated. Iodine-131 discharges to the environment and associated doses to workers and members of the public may be significantly reduced by the introduction of state-of-the-art delay and decay tanks using multi-tank vacuum systems. The justification for the introduction of a regulatory requirement to install such systems is examined taking account of: discharges to the environment, concentrations in the environment, doses to workers and members of the public, best available techniques (BAT), international best practice and advice as well as the financial implications for medical facilities. The case for retrofitting delay and decay tanks to existing medical facilities is also examined as well as the option of including such tanks in the

Radioiodine Therapy for Graves’ Disease

International Nuclear Information System (INIS)

Makhdomi, B.K.

2015-01-01

Treatment of grave diseases include Antithyroid medications, Iodine-131 therapy and Surgery. First patient treated with radioiodine (Iodine-130) in 1941, while Iodine-131 therapy was introduced in 1946. Factors affecting treatment include Iodine uptake; Size of goitre; Length of time I-131 is retained in the gland; Homogeneity of distribution within the gland; Radiosensitivity of thyroid cells and Drug interactions. Some side effects include Transient sore throat or mild dysphagia; Exacerbation of ophthalmopathy; Radiation thyroiditis and no increase in incidence of thyroid cancer and Leukemia or other malignancies. There no harmful effect upon Health of progeny; Fertility and Reproductive history

Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: Role of iodine 131 metaiodobenzylguanidine

International Nuclear Information System (INIS)

Khafagi, F.A.; Shapiro, B.; Fischer, M.; Sisson, J.C.; Beierwaltes, W.H.; Hutchinson, R.

1991-01-01

Phaeochromocytomas and functioning paragangliomas are rare tumours in childhood and adolescence. We review our experience of 43 cases (24 men, 19 women) who were first diagnosed at the age of ≤ 18 years. All patients were evaluated at some point in their illness, with iodine 131 metaiodobenzylguanidine ( 131 I-mIBG) scintigraphy. Eight patients (19%) had bilateral adrenal tumours, 12 (28%) had solitary extraadrenal tumours, and 8 (19%) had multiple tumours. In 10 patients (23%), the tumours were associated with a familial neurocristopathic syndrome. Thirteen of 24 (54%) unifocal tumours which were initially considered to be benign ultimately proved to be multi-focal and/or malignant. The final prevalence of malignancy was 60% - 26 patients, of whom only 15 (57%) had obviously malignant tumours at the time of diagnosis. Primary tumour size ≥ 5 cm was more commonly associated with a malignant course in adrenal but not extra-adrenal tumours. No other clinical, biochemical or morphological characteristic was significantly associated with malignancy. Although the high prevalence of malignancy in this series at least partly reflects referral bias, the need for lifelong follow-up of these patients is underscored. 131 I-mIBG scintigraphy was positive in 36 patients (84%), with a somewhat lower false-negative rate (12%) than X-ray computed tomography (20%). Eight patients with malignant tumours received therapeutic doses of 131 I-mIBG, with partial tumour responses in 3. Thus, 131 I-mIBG is an efficacious, non-invasive, localising agent and may be considered as a palliative therapeutic agent when alternatives have failed. (orig.)

Treatment's results of hyperthyroid patients with Iodine-131

International Nuclear Information System (INIS)

Bastan-Hagh, M.H.; Larijani, B.; Rahim-Tabrizi, P.; Khalili-Fard, A.R.; Baradar-Jalili, R.; Saghari, M.

2004-01-01

Introduction: radioiodine ( 131 I) is an effective and inexpensive alternative to surgery in the treatment of thyroid hyper function. The debate today concerns the maximum and minimum ablative doses, and factors leading to hypothyroidism. Patients and method: 1035 hyperthyroid patients treated with weight-adjusted ablative doses of 131 I were retrospectively assessed for treatment outcome or correlated with sex, age, underlying pathology, and administrated dose of 131 I . Results: Thyroid hyper function was more common in women. The greatest proportions of patients were in the 31-40 years age group and the smallest proportion over -70. The commonest underlying pathology was Grave's disease. Men had a lower response rate to 131 I therapy, with 2.4-fold greater probability of persistent hyperthyroidism (P 131 I hypothyroidism decreased with increasing age (P 131 I therapy was seen in patients with toxic adenoma, (P=0.0001). The incidence of hypothyroidism did not show a positive correction with increased administered dose of 131 I (P 131 I was effective in reducing thyroid nodule size. There were 18 cases of temporary hyperthyroidism, all of which recovered to euthyroid status within 12 months. Conclusion: one dose of radioiodine was effective in treatment of hyperthyroid patients in 91.2 % of cases. Age, sex and underlying pathology were determining factors. In most cases the average time to hypothyroidism was reasonably short, obviating the need for long time follow up in these patients

Effect of 131I in the treatment of hyperthyroidism at Hospital San Juan de Dios for the period from January 1, 2005 to December 31, 2007

International Nuclear Information System (INIS)

Badilla Barboza, Oscar Yuran

2011-01-01

Radioactive iodine 131 ( 131 I) is used for the treatment of hyperthyroidism at Hospital San Juan de Dios. The most common causes of hyperthyroidism have been Graves disease or diffuse goiter, toxic multinodular goiter and toxic nodular goiter, among others; but, the results are unknown and factors that have influenced the treatment with 131 I. The study has included only patients with these causes, and have been administered radioactive iodine 131 as treatment. 180 cases have been treated with radioactive iodine, 75.0% have presented diffuse goiter, 22.2% multinodular goiter and 2.8% nodular goiter, where were been 144 female patients (80%) and 36 male patients (20%). Women have had predominance in the three groups that were analyzed pathologies, according to medical literature, an approximate incidence of 0.4 cases has existed per thousand women to year. A proportional relationship between clinical size of goiter and failure of therapy with 131 I has been in diffuse goiter for the handling of hyperthyroidism. Likewise, male sex has been risk factor in the failure of such therapy. Multinodular goiter and nodular goiter have not had difference between the results according to sex and size of goiter. Most hyperthyroid patients with diffuse goiter, nodular and multinodular have received 131 I as treatment, and previously this, they have received propylthiouracil; treatment outcome was unaffected. Treatment with 131 I in hyperthyroid patients has managed to be effective for reduction in size of the thyroid gland in diffuse goiter, nodular goiter and multinodular [es

The curative effect analysis of 131I-therapy on patients with Graves' disease

International Nuclear Information System (INIS)

Cui Qin; Lu Shujun; Lu Tianhe

2002-01-01

To investigate the curative effect of 131 I-therapy on Graves' disease, the authors analyse conditions of patients who have received 131 I-therapy (n -674). These results showed that the incidence of fully recover, improve, Graves' disease and invalid is 80.11%, 7.28%, 11.87% and 0.74% respectively. Therefore, 131 I-therapy on Graves' disease is convenient. It has little side effect, low cost and better curative effect, it is one of the best therapeutic methods to treat hyperthyroidism

The influence of physical parameters on the adsorption of iodine 131 by activated charcoals

International Nuclear Information System (INIS)

Billard, F.; Chevalier, G.; Caron, J.; Van Der Meersch, J.

1966-01-01

Following an outline of the means of generating iodine 131 in the gas phase and a brief description of the apparatus used, the authors analyse the experimental results obtained on the trapping of iodine 131 by activated charcoal. The efficiency depends concurrently on the relative humidity and the iodine concentration of the air. While it is independent of this concentration in dry air, it does not exceed 50 in moist air, whatever the bed depth, when the concentration is less than 1 mCi/m 3 , then it increases with the concentrations to reach values close to those obtained in dry air for concentrations of around 1000 Ci/m 3 . At the same time the efficiency of a dust filter with respect to iodine remains very low in dry air whatever the iodine concentration; in moist air this efficiency, which is high at low concentrations, decreases when the latter increases. In addition if a charcoal bed is divided into several beds, separated by an amount corresponding to a passage time of about a second, it is found that the efficiency of the whole is appreciably higher than that of the initial bed. These results appear to establish the existence of at least two forms of iodine, one molecular form and one particulate form probably formed by clusters, the forms equilibrium being functions of the relative concentrations of iodine and water vapour in the air. The third form evidence, a gaseous form compound, remains hypothetical; the experimental curves can be explained either by the molecular and particular forms reversibility or by the increase of clusters size with the relative humidity of the air. (authors) [fr

Calibration of CDTN-whole body counter for in vivo measurements of I-131

International Nuclear Information System (INIS)

Oliveira, Cassio M.; Silva, Tania V. da; Alonso, Thessa C.; Squair, Peterson L.

2009-01-01

Iodine-131 is frequently used in nuclear medicine services for diagnosis and therapy of thyroid diseases. Furthermore, the Nuclear Technology Development Centre (CDTN/CNEN), in Belo Horizonte, uses Iodine-131 for radiobiology and radiopharmacy researches. The increasing use of this radionuclide for medical and research purposes as well as its high volatility creates a demand for feasible methodologies to perform occupational control of internal contamination. Therefore the objective this work is to develop methods of in vivo bioassay for evaluation Iodine-131 incorporation by using NaI(Tl) 6'' x 4'' scintillation detector of the CDTN-Whole Body Counter (WBC). Such detector was calibrated for in vivo measurements with a neck-thyroid phantom, simulating Iodine-131 incorporation. The chosen counting geometry was lying under monitoring bed of CDTNWBC. A methodology for bioassay data interpretation, based on standard ICRP 56 model was established with software AIDE (activity internal dose estimate) version 6.0. It was concluded that in vivo measurements have sufficient sensitivity for the monitoring of Iodine-131 through CDTN-Whole Body Counter. Therefore, the CDTN-Whole Body Counter equipment of Belo Horizonte are ready to attend suspicion intake cases of Iodine- 131 (author)

Calibration of CDTN-whole body counter for in vivo measurements of I-131

Energy Technology Data Exchange (ETDEWEB)

Oliveira, Cassio M.; Silva, Tania V. da; Alonso, Thessa C.; Squair, Peterson L. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN-CNEN/MG), Belo Horizonte, MG (Brazil)], e-mail: cmo@cdtn.br

2009-07-01

Iodine-131 is frequently used in nuclear medicine services for diagnosis and therapy of thyroid diseases. Furthermore, the Nuclear Technology Development Centre (CDTN/CNEN), in Belo Horizonte, uses Iodine-131 for radiobiology and radiopharmacy researches. The increasing use of this radionuclide for medical and research purposes as well as its high volatility creates a demand for feasible methodologies to perform occupational control of internal contamination. Therefore the objective this work is to develop methods of in vivo bioassay for evaluation Iodine-131 incorporation by using NaI(Tl) 6'' x 4'' scintillation detector of the CDTN-Whole Body Counter (WBC). Such detector was calibrated for in vivo measurements with a neck-thyroid phantom, simulating Iodine-131 incorporation. The chosen counting geometry was lying under monitoring bed of CDTNWBC. A methodology for bioassay data interpretation, based on standard ICRP 56 model was established with software AIDE (activity internal dose estimate) version 6.0. It was concluded that in vivo measurements have sufficient sensitivity for the monitoring of Iodine-131 through CDTN-Whole Body Counter. Therefore, the CDTN-Whole Body Counter equipment of Belo Horizonte are ready to attend suspicion intake cases of Iodine- 131 (author)

Radiation Sialadenitis Induced by High-dose Radioactive Iodine Therapy

International Nuclear Information System (INIS)

Jeong, Shin Young; Lee, Jaetae

2010-01-01

Radioactive iodine ( 131 I) is accumulated in the thyroid tissue and plays an important role in the treatment of differentiated papillary and follicular cancers after thyroidectomy. Simultaneously, 131 I is concentrated in the salivary glands and secreted into the saliva. Dose-related damage to the salivary parenchyma results from the 131 I irradiation. Salivary gland swelling and pain, usually involving the parotid, can be seen. The symptoms may develop immediately after a therapeutic dose of 131 I and/or months later and progress in intensity with time. In conjunction with the radiation sialadenitis, secondary complications reported include xerostomia, taste alterations, infection, increases in caries, facial nerve involvement, candidiasis, and neoplasia. Prevention of 131 I sialadenitis may involve the use of sialogogic agents to hasten the transit time of the radioactive iodine through the salivary glands. However, studies are not available to delineate the efficacy of this approach. Treatment of the varied complications that may develop encompass numerous approaches and include gland massage, sialogogic agents, duct probing, antibiotics, mouthwashes, good oral hygiene, and adequate hydration. Recently interventional sialoendoscopy has been introduced an effective tool for the management of patients with 131 I-induced sialadenitis that is unresponsive to medical treatment.

Influencing factors of radioiodine therapy in hyperthyroidism in adults

International Nuclear Information System (INIS)

Xu Jiehua; Zhang Zikang; Cheng Muhua; Wu Chunxing; Wang Ping; Shan Hong

2007-01-01

The study was to evaluate factors affecting outcome of 131 I therapy in hyperthyroidism for optimizing the method. Data from 213 patients who received 131 I treatment from July 2003 to July 2005 in our department were retrospectively analyzed. Factors possibly contributing to the outcome of the 1311 therapy were analyzed, including gender, age, history of antithyroid drag, thyroid volume, duration of disease and radioactive iodine uptake rate. Multivariate analysis was done. The rates of euthyroidism and hypothyroidism were 69% and 8.5%, respectively, after one time 131 I therapy. Multivariate analysis of the patients showed no statistically significant factors affecting the outcome of 131 I therapy. The study showed that 131 I dose can be directly calculated, and this simplifies the dose-determined method and individualizes the therapy. (authors)

Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations

International Nuclear Information System (INIS)

Casara, D.; Rubello, D.; Saladini, G.; Piotto, A.; Pelizzo, M.R.; Girelli, M.E.; Busnardo, B.

1993-01-01

Seventy female patients who had been treated with high doses of iodine-131 for differented thyroid cancer (DTC) and who had a subsequent pregnancy were evaluated. The global 131 I dose ranged from 1.85 to 16.55 GBq (mean±SD=4.39±25.20 GBq). Age at first therapy ranged from 15 to 36 years (mean±SD=24.3±5.0 years) and the interval from 131 I therapy to pregnancy varied from 2 to 10 years (mean±SD=5.3±2.8 years). The estimated radiation dose to the gonads ranged from 10 to 63 cGy (mean±SD=24.0±13.5 cGy). All patients were treated with L-thyroxine at doses capable of suppressing thyroid-stimulating hormone. Seventy-three children were followed-up and seven pregnancies are still in progress. One child was affected by Fallot's trilogy and three had a low birth weight though with subsequent regular growth; the others were healthy with subsequent regular growth. No newborn with clinical or biochemical thyroid dysfunctions was found. Two spontaneous abortions during the second month of pregnancy were recorded. One of two patients in question subsequently had two healthy children. On the basis of these data, previous administration of high 131 I doses does not appear to be a valid reason for dissuading young female DTC patients from considering pregnancy. However, patients should be advised to avoid pregnancy after 131 I administration for a period sufficient to ensure complete elimination of the radionuclide and to permit confirmation of complete disease remission, i.e. at least 1 year in our opinion. (orig.)

Serum thyroxine concentrations after radioactive iodine therapy in cats with hyperthyroidism

International Nuclear Information System (INIS)

Meric, S.M.; Hawkins, E.C.; Washabau, R.J.; Turrel, J.M.; Feldman, E.C.

1986-01-01

Thirty-one cats with hyperthyroidism were given one dose of radioactive iodine (131I) IV. Serum thyroxine (T4) concentrations were measured before treatment in all cats, at 12-hour intervals after treatment in 10 cats, and at 48-hour intervals after treatment in 21 cats. Serum T4 concentrations also were measured one month after 131 I therapy in 29 cats. Activity of 131I administered was 1.5 to 6.13 mCi, resulting in a dose of 20,000 rads to the thyroid. Serum T4 concentrations before 131 I administration were 5.3 to 51.0 micrograms/dl, with a median T4 concentration of 11.0 micrograms/dl. Serum T4 decreased most rapidly during the first 3 to 6 days after treatment. Sixteen cats (55%) had normal serum thyroxine concentrations by day 4 after 131I administration, and 23 cats (74%) were euthyroxinemic by day 8 after treatment. One month after administration of 131I, the 29 cats evaluated were clinically improved, and 24 (83%) of the 29 cats evaluated had normal serum T4 concentrations, 3 cats (10%) remained hyperthyroxinemic, and 2 cats (7%) were hypothyroxinemic. Therefore, administration of 131I was a safe and effective method to quickly decrease serum T4 concentrations in hyperthyroid cats

Iodine-131 in breast milk following therapy for thyroid carcinoma

International Nuclear Information System (INIS)

Robinson, P.S.; Barker, P.; Campbell, A.

1994-01-01

This study evaluates breast milk secretion of 131 I following therapeutic adminstration of 4000 MBq of 131 I-iodide during lactation. Breast milk 131 I activity concentration was measured over a 32-day period. Dosimetry calculations were undertaken to estimate the period for discontinuation of breast feeding and the equivalent dose to the breasts. To achieve an infant effective dose 131 I-iodide adminstration is not undertaken during lactation and that breast feeding is discontinued several days prior to administration. 26 refs., 2 figs., 2 tabs

E1B-attenuated onco lytic adenovirus enhances antitumor effect of radionuclide therapy by P53-independent way: cellular basic for radionuclide-viral therapy

Energy Technology Data Exchange (ETDEWEB)

Zhenwei, Zhang [Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (China); Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai (China); Hua, Wu; Xuemei, Zhang [Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (China); Xinyuan, Liu [Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai (China)

2004-07-01

Purpose: Chemotherapy or external radiation therapy can potentiate the therapeutic effect of E1 B-attenuated oncolytic adenovirus. In this study, the antitumor efficacy of oncolytic adenovirus combined with internal radionuclide therapy was evaluated. Methods: Firstly, viral replication was examined by plaque assay and Southern blotting, after oncolytic adenovirus, ZD55, was exposed to iodine-131. Cell viability was evaluated qualitatively by crystal violet staining and quantitatively by MTT assay. FACS analysis was performed to determine the synergic proapoptotic effect of iodine-131 combined with ZD55. Results: Irradiation of iodine-131 does not influence ZD55 viral DNA replication. In combination with ZD55, iodine-131 can efficiently kill tumor cells in a p53-independent model. ZD55 augments the proapoptotic effect of iodine-131. Conclusion: Radionuclide-viral therapy might be a novel tool for treatment of hepatocarcinoma. (authors)

Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease

International Nuclear Information System (INIS)

Baczyk, M.; Ziemnicka, K.; Sowinski, J.; Junik, R.

2005-01-01

Poland, a country with mild/moderate iodine deficiency introduced an obligatory iodination salt system in 1996. Aim: To compare the results of radioiodine ( 131 I) uptake after 5 h and 24 h with the activity of radioiodine used in the treatment of hyperthyroid patients with Graves' disease in the years 1995 and 2003. Patients, methods: The marker of iodine content in the diet was urinary iodine excretion. 1000 randomly chosen patients (average age: 46±12 years) were included in the study. Every patient had routinely estimated radioiodine uptake after 5 h and 24 h and the activity of 131 I was calculated using scintigraphy and ultrasonography of the thyroid gland. Urinary iodine excretion in samples from year 1995 and 2003 was also determined in some patients and healthy volunteers. Results: The iodine load in the diet increased from 66 μg (average) in the year 1995 to 115 μg in the year 2003. Thyroid radioiodine uptake was 40% lower in comparison with the results from 1995. The average activity of 131 I given in the year 2003 (10 mCi) was about 40% higher than in the year 1995 (7 mCi). Conclusion: There was significant negative correlation between higher iodine content in the diet and lower values of radioiodine uptake, which led to the application of the higher activity of 131 I during treatment. (orig.)

Scintigraphic disagreement in the study of thyroid nodules using technetium 99m and iodine 131

International Nuclear Information System (INIS)

Planchon, C.A.

1977-01-01

116 patients with thyroid nodules, iso or hyperfixing, heterogeneous or scintigraphically indistinct after administration of pertechnetate 99mTc, were systematically re-examined with iodine 131. The results of this study are as follows: 1) 99mTc, while its advantages justify its extensive application, is an imperfect tracer and cannot replace iodine 131 altogether. In fact in 12% of the cases the results were conflicting. 2) The technological conditions may sometimes be to blame but the hypothesis of a special metabolic behavior of the nodule examined seems plausible in certain cases of disagreement (blocking of hormone synthesis and escape of non-hormonal iodine). 3) These observations correspond to no particular anatomo-clinical factors. The legitimate conclusion therefore is that the exclusive use of 99mTc could result in failure to recognise a non-functional nodule (1 case in about 10), a possibility not to be neglected because of the risk of cancer [fr

Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)

International Nuclear Information System (INIS)

Dadachova, E.; Bouzahzah, B.; Zuckier, L.S.; Pestell, R.G.

2002-01-01

The sodium-iodide symporter (NIS), which transports iodine into the cell, is expressed in thyroid tissue and was recently found to be expressed in approximately 80% of human breast cancers but not in healthy breast tissue. These findings raised the possibility that therapeutics targeting uptake by NIS may be used for breast cancer treatment. To increase the efficacy of such therapy it would be ideal to identify a radioactive therapy with enhanced local emission. The feasibility of using the powerful beta-emitting radiometal 188 Re in the form of 188 Re-perrhenate was therefore compared with 131 I for treatment of NIS-expressing mammary tumors. In the current studies, using a xenografted breast cancer model induced by the ErbB2 oncogene in nude mice, 188 Re-perrhenate exhibited NIS-dependent uptake into the mammary tumor. Dosimetry calculations in the mammary tumor demonstrate that 188 Re-perrhenate is able to deliver a dose 4.5 times higher than 131 I suggesting it may provide enhanced therapeutic efficacy

Production of fusion radionuclides: Molybdenum-99/ Iodine - 131 and Xenon-133

International Nuclear Information System (INIS)

Barrachina, M.; Carrillo, D.

1982-01-01

This report presents a new radiochemical method for industrial production of the radionuclides: molybdenum-99, iodine-131 and xenon-133. The above mentioned method based on the alkaline metathesis reaction of irradiated uranium (IV) fluoride, presents the best characteristics for the proposed objective. The study deals with the analysis of that reaction and the separation and purification processes. (Author) 71 refs

Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.

Science.gov (United States)

Khan, Shahbaz Ahmad; Khan, Muhammad Saqib; Arif, Muhammad; Durr-e-Sabih; Rahim, Muhammad Kashif; Ahmad, Israr

2015-07-01

To determine the patterns of dose rate reduction in single and multiple radioiodine (I-131) therapies in cases of well differentiated thyroid cancer patients. Analytical series. Department of Nuclear Medicine and Radiation Physics, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Multan, Pakistan, from December 2006 to December 2013. Ninety three patients (167 therapies) with well differentiated thyroid cancer treated with different doses of I-131 as an in-patient were inducted. Fifty four patients were given only single I-131 therapy dose ranging from 70 mCi (2590 MBq) to 150 mCi (5550 MBq). Thirty nine patients were treated with multiple I-131 radioisotope therapy doses ranging from 80 mCi (2960 MBq) to 250 mCi (9250 MBq). T-test was applied on the sample data showed statistically significant difference between the two groups with p-value (p < 0.01) less than 0.05 taken as significant. There were 68 females and 25 males with an age range of 15 to 80 years. Mean age of the patients were 36 years. Among the 93 cases of first time Radio Active Iodine (RAI) therapy, 59 cases (63%) were discharged after 48 hours. Among 39 patients who received RAI therapy second time or more, most were discharged earlier after achieving acceptable discharge dose rate i.e 25 µSv/hour; 2 out of 39 (5%) were discharged after 48 hours. In 58% patients, given single I-131 therapy dose, majority of these were discharged after 48 hours without any major complications. For well differentiated thyroid cancer patients, rapid dose rate reduction is seen in patients receiving second or subsequent radioiodine (RAI) therapy, as compared to first time receiving RAI therapy.

Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review

Directory of Open Access Journals (Sweden)

Eric R. Braverman

2014-04-01

Full Text Available Chernobyl demonstrated that iodine-131 (131I released in a nuclear accident can cause malignant thyroid nodules to develop in children within a 300 mile radius of the incident. Timely potassium iodide (KI administration can prevent the development of thyroid cancer and the American Thyroid Association (ATA and a number of United States governmental agencies recommend KI prophylaxis. Current pre-distribution of KI by the United States government and other governments with nuclear reactors is probably ineffective. Thus we undertook a thorough scientific review, regarding emergency response to 131I exposures. We propose: (1 pre-distribution of KI to at risk populations; (2 prompt administration, within 2 hours of the incident; (3 utilization of a lowest effective KI dose; (4 distribution extension to at least 300 miles from the epicenter of a potential nuclear incident; (5 education of the public about dietary iodide sources; (6 continued post-hoc analysis of the long-term impact of nuclear accidents; and (7 support for global iodine sufficiency programs. Approximately two billion people are at risk for iodine deficiency disorder (IDD, the world’s leading cause of preventable brain damage. Iodide deficient individuals are at greater risk of developing thyroid cancer after 131I exposure. There are virtually no studies of KI prophylaxis in infants, children and adolescents, our target population. Because of their sensitivity to these side effects, we have suggested that we should extrapolate from the lowest effective adult dose, 15–30 mg or 1–2 mg per 10 pounds for children. We encourage global health agencies (private and governmental to consider these critical recommendations.

131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment

Science.gov (United States)

Xing, Jialiu; Fang, Yi; Wang, Yong; Zhang, Youren; Long, Yahong

2015-01-01

The aim of this study is to evaluate the safety and long-term results of 131I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with 131I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to 131I therapy, all patients were given low-iodine diet. The dose of 131I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total 131I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that 131I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective. PMID:26341470

131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment.

Science.gov (United States)

Ding, Yong; Xing, Jialiu; Fang, Yi; Wang, Yong; Zhang, Youren; Long, Yahong

2016-02-01

The aim of this study is to evaluate the safety and long-term results of (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with (131)I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to (131)I therapy, all patients were given low-iodine diet. The dose of (131)I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total (131)I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective. © 2015 by the Society for Experimental Biology and Medicine.

Decreased uptake after fractionated ablative doses of iodine-131

Energy Technology Data Exchange (ETDEWEB)

Wu, Hurng-Sheng [Show Chwan Memorial Hospital, Department of Surgery, Changhua, Taiwan (Taiwan); Hseu, Huey-Herng [Taichung Veterans General Hospital, Department of Medical Education and Research, Taichung (Taiwan); Lin, Wan-Yu; Wang, Shyh-Jen [Taichung Veterans General Hospital, Department of Nuclear Medicine, Taichung, Taiwan (Taiwan); Liu, Yao-Chi [Department of Surgery, General Surgery, National Defense Medical Center, Taipe (Taiwan)

2005-02-01

In an attempt to obviate the necessity for hospitalisation, the ablative dose of {sup 131}I in the treatment of thyroid cancer is divided into two or three fractions at weekly intervals in some hospitals with no special bed for {sup 131}I treatment. Thyroid stunning has been observed in patients receiving a {sup 131}I dose between 74 and 370 MBq (2-10 mCi). However, the influence of {sup 131}I uptake after administration of a higher dose, such as 1,110-1,850 MBq of {sup 131}I, has never been reported. In this study, we evaluated the degree of reduction in {sup 131}I uptake after patients received 1,480 MBq of {sup 131}I and evaluated the clinical value of fractionated ablative doses of {sup 131}I. Thirty-five patients with functional thyroid cancer received a total of 4,440 MBq (120 mCi) of {sup 131}I which was divided into three fractions administered at weekly intervals. In all patients two {sup 131}I whole-body scans were performed. The first scan was performed directly prior to the second dose of {sup 131}I (7 days after the first administration of {sup 131}I), and the second scan was performed 7 days after the second administration of {sup 131}I and directly prior to the third administration. Regions of interest including the neck and lungs were drawn to calculate the uptake of {sup 131}I in the thyroid remnant and possible cervical lymph node and lung metastases. The mean uptake of {sup 131}I was 2.73% 7 days after the first administration, and decreased significantly to 0.26% 7 days after the second administration. The mean decrease was as high as 80.7%. The decrease in {sup 131}I uptake was significant in all patients except the two with lung metastases. In the two patients with lung metastases, no definite evidence of decreased uptake was noted; the uptake of {sup 131}I in the lung metastases even increased on the second {sup 131}I image in one of these patients. After administration of 1,480 MBq of {sup 131}I, the decreased uptake was significant in all

Iodine-131 treatment of hyperthyroidism in the elderly. Results in 180 patients. Radioprotection and waste management in 131-iodine therapy; Traitement de l'hyperthyroidie du sujet age par l'iode 131. A propos de 180 patients. Problemes de radioprotection et de gestion des dechets lies au traitement par l'iode 131

Energy Technology Data Exchange (ETDEWEB)

Dejax, C.; Freitas, D. de; Leroux, M.A.; Aubert, B. [Centre Jean-Perrin, Medecine Nucleaire, 63 - Clermont-Ferrand (France); Vennat, J.C. [Centre Jean-Perrin, Radiopharmacie, 63 - Clermont-Ferrand (France); Kwiatkowski, F. [Centre Jean-Perrin, Biostatistiques, 63 - Clermont-Ferrand (France)

2005-09-15

A retrospective study has been performed in patients treated by iodine-131 for hyperthyroidism between April 1999 and February 2004..Among the 270 patients, 180 were more than 65 years old. After 65 years, hyperthyroidism is most often the consequence of a toxic adenoma or multi-nodular goiter while Graves' disease is most frequent in young patients. Iodine-131 is usually proposed as first line treatment in the elderly, at the opposite of young patients. With a mean follow-up of 12 months, return to euthyroidism is observed in 56.5% of the older patients and in 73.6% of the young patients. We explain this results by the lower incidence of Graves' disease in the elderly. Nuclear medicine physicians are legally obliged to provide patients with a proper information about radioprotection. Recommendations should nevertheless not induce overdue nor illegitimate fear. They should not only be written and standardized, but also given orally and adapted to each patient. Urinary incontinence is not specific to the old patients, but it is more frequent after 65. Collection and storage of contaminated waste is sometimes difficult and has often to be solved on a case by case basis. (author)

Analysis of 131I therapy in 71 patients with hyperthyroidism

International Nuclear Information System (INIS)

Wang Ping; Chen Zequan; Wang Yuanzhi; Ye Shiqing

2001-01-01

Objective: To evaluate the clinical significance of iodine-131 treatment in patients with hyperthyroidism. Methods: The dose of 131 I was determined according to thyroid absorption of 131 I at 24 hrs post administration and thyroid weight estimated in ECT examination. Results: One dose cure rate of 131 I treatment was 96% (68/71). Hypothyroidism occurred in 3 of 71 patients (4%) in one year after administration. No other serious complication was observed. Conclusion: The therapeutic effect of 131 I in treating hyperthyroidism was quite encouraging. The administration regime was also simple

Radiation Sialadenitis Induced by High-dose Radioactive Iodine Therapy

Energy Technology Data Exchange (ETDEWEB)

Jeong, Shin Young; Lee, Jaetae [Kyungpook National University Hospital, Daegu (Korea, Republic of)

2010-06-15

Radioactive iodine ({sup 131}I) is accumulated in the thyroid tissue and plays an important role in the treatment of differentiated papillary and follicular cancers after thyroidectomy. Simultaneously, {sup 131}I is concentrated in the salivary glands and secreted into the saliva. Dose-related damage to the salivary parenchyma results from the {sup 131}I irradiation. Salivary gland swelling and pain, usually involving the parotid, can be seen. The symptoms may develop immediately after a therapeutic dose of {sup 131}I and/or months later and progress in intensity with time. In conjunction with the radiation sialadenitis, secondary complications reported include xerostomia, taste alterations, infection, increases in caries, facial nerve involvement, candidiasis, and neoplasia. Prevention of {sup 131}I sialadenitis may involve the use of sialogogic agents to hasten the transit time of the radioactive iodine through the salivary glands. However, studies are not available to delineate the efficacy of this approach. Treatment of the varied complications that may develop encompass numerous approaches and include gland massage, sialogogic agents, duct probing, antibiotics, mouthwashes, good oral hygiene, and adequate hydration. Recently interventional sialoendoscopy has been introduced an effective tool for the management of patients with {sup 131}I-induced sialadenitis that is unresponsive to medical treatment.

Clinical application and observation of curative effect in the near future of iodine-131 therapy in juvenile patients with hyperthyroidism

International Nuclear Information System (INIS)

Chen Huilin; Liang Jun; Liang Fengyun

2004-01-01

Objective: To assess clinical application of 131 I therapy and observation of curative effect in the near future after treatment in juvenile patients with hyperthyroidism Methods: 44 juvenile patients with hyperthyroidism were divided two subgroups of that children and early youths .The dosage of 131 I were respectively 135.1±34.0(3.65±0.92), 200.2±64.0 MBq(5.41±1.73 mCi). The curative effect belonged in four kinds being to fully recovered, quite a lot, fail to respond to medical and hypothyroidism at six month slater or from then. Results: 46 times treatment were gave and therapy effect was same in every subgroups. The effective rate of total was 89.1% and rater on clinical hypothyroidism was 4.3%. Conclusions: It had an obvious effect that 131 I therapy for juvenile patients with hyperthyroidism. 131 I therapy was also a firmly good select because a well ratio effect/cost. (authors)

Observation of radioactive iodine ({sup 131}I, {sup 129}I) in cropland soil after the Fukushima nuclear accident

Energy Technology Data Exchange (ETDEWEB)

Fujiwara, Hideshi, E-mail: hfuji@affrc.go.jp

2016-10-01

During the early stages of the Fukushima nuclear accident, the temporal variations of {sup 131}I deposited on the ground and of {sup 131}I accumulated in cropland soil were monitored at a fixed location in Japan. Moreover, concentrations of long-lived radioactive iodine ({sup 129}I) in atmospheric deposits and soil were measured to examine the feasibility of retrospectively reconstructing {sup 131}I levels from the levels of accident-derived {sup 129}I. The exceptionally high levels of {sup 131}I in deposits and soil were attributed to rainfall-related deposition of radionuclides. In the crop field studied, the losses of deposited {sup 131}I and {sup 129}I due to volatilization were small. The atomic ratio {sup 129}I/{sup 131}I in the topsoil corresponded to the same ratio in deposits. The {sup 131}I concentrations measured in the topsoil were very consistent with the {sup 131}I concentrations reconstructed from the {sup 129}I concentrations in the soil. - Highlights: • A high level of {sup 131}I contamination occurs through rainfall-related deposition. • Only a small loss of deposited radioactive iodine occurs via volatilization. • The {sup 129}I/{sup 131}I ratio in soil corresponds to the ratio in atmospheric deposit. • The feasibility of retrospectively reconstructing {sup 131}I is confirmed.

Introduction of iodine 131 and bromine 82 in antibiotics of tetracycline group

International Nuclear Information System (INIS)

Mironov, V.P.; Kudryashov, V.P.; Grushevich, L.E.; Kuz'mina, T.S.

1983-01-01

Chloline- and oxytetracycline reactions with iodide-131-and bromide-82-ions in methanol and acetone are studied. It is established that labelled compounds reveal tetracycline (TC) properties in pharmacokinetic experiments on laboratory animals for 20-25 hours after synthesis; the yield of purposeful preparations for radioactive isotopes is 90-95%. Kinetic dependences of iodine-131 and bromine-82-TC yield on acidity and temperature of medium are presented. TC radiation resistance in solutions and in solid state at different temperatures in the range of absorbed doses of 1-10 Mrad is investigated. The possibility of TC radiation sterilization is shown

Long term follow-up observation of /sup 131/Iodine treatment of hyperthyroidism

Energy Technology Data Exchange (ETDEWEB)

Kao, Y.; Liu, Y.; Ch' en, C.

1977-07-20

This paper reports the 5 to 13 years follow-up conditions of 241 cases of hyperthyroidism treated with /sup 131/iodine, with emphasis on the side-effect of incidence of hypothyroidism. Of the group, 192 cases were cured; 25 cases were improved; there were 3 cases of recurrence and 5 cases remained the same as before the treatment. Hypothyroidism yroidism occurred to the remaining 16 cases. The rate of incidence of hypothyroidism at the end of one year after treatment was 3.3%; at the end of 9 years 9.5%, with an average yearly increase of 0.8%. In foreign countries, the reported yearly increase rate of hypothyroidism has been reported to be 1 to 6%, and the ten-year aggregate may be as high as 30.2 to 70%, much higher than the observed data here reported. There was no incidence of thyroid nodules, cancer, or leukemia among the group of 241 cases treated with /sup 131/iodine, and the reproductive capacity was not observed to be affected by the treatment.

Case of hyperthyroidism complicated with diabetic ketoacidosis following /sup 131/I therapy

Energy Technology Data Exchange (ETDEWEB)

Itoh, Mitsuyasu; Funauchi, Masanori; Fukuma, Naobumi; Abe, Yohsuke; Hirooka, Yoshibumi; Nihei, Noriyuki (Hamamatsu Univ. Shizuoka (Japan). School of Medicine)

1982-10-01

The coexistence of diabetes mellitus and hyperthyroidism has long been known and, in a few cases, diabetic acidosis complicated with thyroid storm has been reported. We describe a case who developed thyroid storm and diabetic ketoacidosis following /sup 131/I therapy for severe hyperthyroidism. A 50-yr-old man was diagnosed as having hyperthyroidism complicated with diabetes mellitus at the age of 47. After he had been unsuccessfully treated with methimazole and oral hypoglycemic agents, radioactive iodine was administered twice. However, no remarkable effect was observed. After a third treatment with /sup 131/I, the patient showed symptoms like thyroid storm and diabetic ketoacidosis. He was hospitalized on October 3, 1980. Adm of insulin and supportive therapy including correction of dehydration alleviated his symptoms after admission. Administration of methimazole normalized his thyroid function. A 75 g GTT and tolbutamide i.v. test revealed impaired secretion of endogenous insulin. The patient had a high level of serum T/sub 3/ and T/sub 4/ following /sup 131/I therapy, indicating that the released hormone caused a transient condition like thyroid storm, which led to deterioration of glucose metabolism as indicated in high levels of hemoglobin A1c. Diabetic acidosis is the precipitating factor for thyroid storm. Prompt treatment for diabetic ketoacidosis, therefore, might prevent the complications of life-threatening thyroid storm.

A case of hyperthyroidism complicated with diabetic ketoacidosis following 131I therapy

International Nuclear Information System (INIS)

Itoh, Mitsuyasu; Funauchi, Masanori; Fukuma, Naobumi; Abe, Yohsuke; Hirooka, Yoshibumi; Nihei, Noriyuki

1982-01-01

The coexistence of diabetes mellitus and hyperthyroidism has long been known and, in a few cases, diabetic acidosis complicated with thyroid storm has been reported. We describe a case who developed thyroid storm and diabetic ketoacidosis following 131 I therapy for severe hyperthyroidism. A 50-yr-old man was diagnosed as having hyperthyroidism complicated with diabetes mellitus at the age of 47. After he had been unsuccessfully treated with methimazole and oral hypoglycemic agents, radioactive iodine was administered twice. However, no remarkable effect was observed. After a third treatment with 131 I, the patient showed symptoms like thyroid storm and diabetic ketoacidosis. He was hospitalized on October 3, 1980. Administration of insulin and supportive therapy including correction of dehydration alleviated his symptoms after admission. Administration inistration of methimazole normalized his thyroid function. A 75 g GTT and tolbutamide i.v. test revealed impaired secretion of endogenous insulin. The patient had a high level of serum T 3 and T 4 following 131 I therapy, indicating that the released hormone caused a transient condition like thyroid storm, which led to deterioration of glucose metabolism as indicated in high levels of hemoglobin A1c. Diabetic acidosis is the precipitating factor for thyroid storm. Prompt treatment for diabetic ketoacidosis, therefore, might prevent the complications of life-threatening thyroid storm. (author)

Iodine Supplementation for Pediatric Patients Receiving Long-Term Parenteral Nutrition.

Science.gov (United States)

Santoro, Jonathan D; Nespor, Colleen; Poole, Robert L; Kerner, John A

2016-04-01

Patients dependent on parenteral nutrition (PN) are among a group at risk of developing iodine deficiency. Supplementation with iodine in this population has been debated in a number of studies, resulting in variable clinical practices. The Committee on Clinical Practice Issues of the American Society for Clinical Nutrition recommends a dose of 1 mcg/kg/d of parenteral iodine for patients receiving PN. At our institution, PN trace elements do not include iodine, although this is not the case internationally. Our study sought to assess iodine levels and thyroid function in a cohort of PN-dependent pediatric patients. A retrospective analysis studied 32 pediatric patients with a variety of medical diagnoses who received PN as a primary means of nutrition for 6 months or longer. Patients received variable proportions of their total caloric intake as PN, which ranged from 14%-100%. Iodine and thyroid function levels were obtained by serum sampling. No patient in our cohort of 32 demonstrated thyroid dysfunction or developed iodine deficiency. The length of time on PN and the percentage of total nutrition intake as PN were not associated with iodine levels (P Parenteral and Enteral Nutrition.

Iodinated bleomycin

International Nuclear Information System (INIS)

Lunghi, F.; Riva, P.; Assone, F.; Villa, M.; Plassic, G.

1978-01-01

Bleomycin was labelled with iodine-131 by the iodine monochloride method. Iodination did not alter the chemical and chromatographic features and ''in vitro'' stability studies on freeze-dried 131 I-Bleomycin having a specific activity of 1 mCi/mg, stored at different temperatures, showed no appreciable variation of the free-iodine content. Tissue distribution of 131 I-Bleomycin has been evaluated in tumor bearing rats. Patients have been injected with 0.5-1.0 mCi of 131 I-Bleomycin corresponding to a maximum of 1.5 mg. No adverse reactions have been observed. Total body scans have been performed at 2, 6, 24 and 48 hours after injection. The iodinated Bleomycin was rapidly distributed and cleared from the body and showed an early uptake in the neoplastic tissue. A diagnostic accuracy of 90% has been observed in malignant deseases, while no false positive results have been, at the moment, recorded. (author)

A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.

Science.gov (United States)

Pilli, Tania; Brianzoni, Ernesto; Capoccetti, Francesca; Castagna, Maria Grazia; Fattori, Sara; Poggiu, Angela; Rossi, Gloria; Ferretti, Francesca; Guarino, Elisa; Burroni, Luca; Vattimo, Angelo; Cipri, Claudia; Pacini, Furio

2007-09-01

Recently, a multicenter study in differentiated thyroid cancer (DTC) patients showed that 3700 MBq 131-iodine ((131)I) after recombinant human TSH (rhTSH) had a successful thyroid ablation rate similar to that obtained after thyroid hormone withdrawal. We investigated whether 1850 MBq (131)I had a similar successful rate to 3700 MBq in patients prepared with rhTSH. A total of 72 patients with DTC were randomly assigned to receive 1850 (group A, n = 36) or 3700 MBq (group B, n = 36) (131)I after rhTSH. One injection of 0.9 mg rhTSH was administered for 2 consecutive days; (131)I therapy was delivered 24 h after the last injection, followed by a posttherapy whole-body scan. Successful ablation was assessed 6-8 months later. Successful ablation (no visible uptake in the diagnostic whole-body scan after rhTSH stimulation) was achieved in 88.9% of group A and B patients. Basal and rhTSH-stimulated serum thyroglobulin was undetectable (<1 ng/ml) in 78.9% of group A and 66.6% of group B patients (P = 0.46). Similar rates of ablation were obtained in both groups also in patients with node metastases. Therapeutic (131)I activities of 1850 MBq are equally effective as 3700 MBq for thyroid ablation in DTC patients prepared with rhTSH, even in the presence of node metastases.

Medical evaluations of ionizing radiation effects during I131 therapy in patients after thyroid carcinoma surgery

International Nuclear Information System (INIS)

Hermida, J.C.

1996-01-01

This study shows the para-clinical studies on a 39 years old patient who was operated on of a thyroid carcinoma and who, under the beirwaltes medical record (in use in our country), received in the post surgical stage, a Iodine-131 dose of about 2960 MBq (80 mCi) for ablation, having been noted subsequently her pregnancy condition. (author). 6 refs

Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma

International Nuclear Information System (INIS)

Kosmin, Michael A.; Cork, Nicholas J.; Gaze, Mark N.; Bomanji, Jamshed B.; Shankar, Ananth

2012-01-01

Radiolabelled meta-iodobenzylguanidine (mIBG), used as targeted therapy for neuroblastoma, is known to have effects on blood pressure (BP). In this study we audited BP changes in patients receiving 131 I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors. Between 2003 and 2010, 50 patients with neuroblastoma received 110 131 I-mIBG administrations. BP measurements before and after administration were compared with age- and sex-matched centile values. AE were analysed, and possible predisposing factors identified. This population had a baseline BP distribution higher than that of their age- and sex-matched peers, with 16% of preadministration systolic BP values above the 95th centile. Changes in BP after administration showed an approximately normal distribution with similar numbers of reduced and increased values. Four AE, all related to hypertension, occurred with one patient having generalized seizures. One AE was immediate, others occurred between 20 and 25 h after administration. No significant association between AE and patient age or sex was demonstrated. However, a significant association between AE and high preadministration BP was shown, both above the 90th centile (p = 0.0022) and above the 95th centile (p = 0.0135). Clinically relevant hypertension following 131 I-mIBG therapy affected less than 5% of administrations, but was more common in those patients with preexisting hypertension. As hypertensive episodes may occur many hours after treatment, close monitoring of BP needs to be continued for at least 48 h after administration of 131 I-mIBG. (orig.)

Radioactive iodine therapy in a case of Graves' disease with allergy to antithyroid drugs (ATD) and propranolol

International Nuclear Information System (INIS)

Bahri, I.M.; San Luis, T.O.L.

2007-01-01

Full text: This is a case of V.C., 56 year old, female, from Las Pinas City, Philippines, diagnosed as a case of Graves' disease. During the course of therapy, the patient had allergy to antithyroid drugs (ATDs) and beta blocker (Propranolol). She developed rashes all over the body, sparing the face the day after taking her ATDs as well as Propranolol, thus all medications were discontinued. Other options, such as RAI therapy and surgery, with their respective advantages and disadvantages were fully explained to the patient who then opted to undergo RAI therapy. In our institution, we usually compute the dose based on the size of the gland and radioactive Iodine-131 uptake measurements (RAIU) rather than using fixed doses. Thyroid scintigraphy and RAIU were done which revealed poorly visualized thyroid gland and markedly diminished 24-hour uptake but normal 4-hour uptake [RAIU 4 hour uptake: 26% (NV= 15-25%); 24 hour uptake: 6% (NV25-45%)]. * Note: Variations in normal uptake values compared to US are due to iodine deficiency still existing in some regions. Because of the very low 24-hour uptake, we reviewed the probable causes which can result in low uptake values. All causes were ruled out and the patient was advised to undergo two weeks of strict low-iodine diet prior to repeat thyroid scintigraphy and RAIU. Thereafter, the result of repeat study showed diffuse thyromegaly with elevated uptake values indicating rapid trapping and organification processes [RAIU 4 hour uptake: 82% (NV= 15-25%); 24 hour uptake: 68% (NV25-45%)]. The day after the study, the patient was given 10 mCi I-131 based on the estimated weight of the gland, rapid thyroid iodine turnover ('small pool') and 24-hour uptake. This was considered to be the highest allowable dose of RAI to decrease the probability of relapse and the need for re-treatment. Approximately 4 weeks after the therapy, the patient is noted to have responded satisfactorily to therapy with resolution of symptoms. (author)

Iodine metabolism and thyroid functions in various species of domestic animals and poultry birds. II - Distribution of iodine-131 in developing ova in poultry birds

International Nuclear Information System (INIS)

Parshad, Omkar; Setia, M.S.; Rattan, P.J.S.; Sodhi, S.P.S.; Varman, P.N.

1974-01-01

To study the distribution of iodine in different stages of developing ova in relation to iodine metabolism, twentyfour healthy laying birds were randomly distributed into four groups of 6 birds each. Each bird was injected with 25.26 μCi. of carrier-free iodine-131. Afterwards, birds of group I, II, III and IV were sacrificed at 24, 48, 72 and 96 hours respectively. The results have revealed that : (i) the state of development of ovum may be an important factor in controlling the distribution of iodine in ova; (ii) the iodine may be found distributed in both the lipid as well as non-lipid fractions of the ova; (iii) most of the iodine in the ova may be present in the form of inorganic iodine whereas very minor amount of the iodine may be as butanol-extractable iodine and (iv) the changes in iodine content in different stages of development of ova observed during the present study may be considered to have a direct effect on the overall metabolism of iodine in the poultry birds. (author)

Micronucleus induction as a measure of I-131 exposure

Energy Technology Data Exchange (ETDEWEB)

Kasuba, V; Horvat, D [Inst. for Medical Recearch and Occupational Health, Zagreb (Croatia). Laboratory for Mutagenesis; Kusic, Z [Clinical Hospital Sestre Milosrdnice, Zagreb (Croatia). Dept. of Oncology and Nuclear Medicine; Vlatkovic, M [Clinical Hospital Centre, Zagreb (Croatia). Dept. of Nuclear Medicine and Radiation Protection

1994-10-01

The change of cell numbers in the peripheral blood following irradiation has been studied for many years, particularly in patients undergoing radiotherapy. Recently, attention is directed towards the use of cytogenetic-mutagenetic methods to estimate the biological effects of received radiation dose. The aim of our study was to identify the difference in number and distribution of micronucleus, depending of applied therapeutic dose of iodine-131. According to their diagnosis, six patients have received iodine-131 in range from 80 to 140 mCi, while in the other group of patients the dose values varied from 7 to 32 mCi. On in vitro peripheral blood lymphocyte cultures micronucleus test was applied. Micronucleus analyses were carried out before the treatment, 24, 48 and 96 hours after the oral application of radiopharmaceutical. The number of micronucleus is showing increase, depending on applied radioactivity of iodine-131 and duration of exposition. The clear dose response relationship was never found. These results illustrate the problem associated with the inhomogeneous distribution of dose which results from the concentration of incorporated radionuclide into thyroid or other tissues. (author).

Breast cancer following 131I therapy for hyperthyroidism

International Nuclear Information System (INIS)

Hoffman, D.A.; McConahey, W.M.

1983-01-01

A retrospective cohort study of women treated for hyperthyroidism at the Mayo Clinic between 1946 and 1964 was conducted to determine if 1,005 women treated with ( 131 I) were at increased risk of breast cancer compared with 2,141 women traced, and a response (death certificate or questionnaire) was received for 99% of the traced women. The average duration of follow-up was 15 years for the 131 I-treated women and 21 years for women treated surgically. No increased risk of breast cancer was observed in the 131 I-treated women (adjusted relative risk . 0.8). No patterns were found of increased breast cancer risk by age at first treatment, by time since treatment, or by total exposure to 131 I. Failure to detect an increased risk of breast cancer in the 131 I-treated women was attributed to the moderately low doses from 131 I therapy and the relatively small number of exposed women. The study also failed to find any increased risk of breast cancer associated with hyperthyroidism

Radiation Exposure to Relatives of Patients Treated with Iodine-131 for Thyroid Cancer at Siriraj Hospital

International Nuclear Information System (INIS)

Tonnonchiang, S.; Sritongkul, N.; Chaudakshetrin, P.; Tuntawiroon, M.

2012-01-01

Thyroid carcinoma patients treated with I-131 are potential source of high radiation exposure to relatives who are knowingly and willingly exposed to ionizing radiation as a result of providing support and comfort to patients undergoing radionuclide therapy. The purpose of this study is to present the results of measurements of radiation doses to relatives who designated to care fornon self-supporting patients treated with radioiodine at Radionuclide Therapy Ward, Siriraj Hospital. Twenty caregivers of 20 patients underwent radioiodine therapy for thyroid cancers with a standard protocol were given specific instructions with regard to radiation safety and provided with electronic digital dosimeter (PDM 112) to continuously measure radiation dose received on the daily basis, during three days in the hospital. On the day of patients' release, in vivo bioassays were performed on caregivers to determine the thyroid uptake estimates. The 3-day accumulative doses to caregivers to patients receiving 5.55 GBq (n=11) and 7.4 GBq (n=9) of I-131 ranged from 37 to 333 μSv and 176 to 1920 μSv respectively depending on the extent and level of supports required. The thyroid uptake estimates in all caregivers were undetectable. Electronic dosimeters indicated a maximum whole-body effective dose of 1920 μSv was more than the public dose limit of 1 mSv but within the general dose constraint of 5 mSv. Radiation dose to caregivers of a non self-supporting hospitalized patient undergoing radioiodine therapy were well below the limits recommended by the ICRP and the IAEA. The patients can be comforted with confidence that dose to caregivers will be below the 5- mSv limit. This study provides guidance for medical practitioners to obtain practical radiation safety concerns associated with hospitalized patients receiving I-131 therapy especially when patients are comforted in the hospital ward by caregivers. (author)

Is radioactive iodine-131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?

International Nuclear Information System (INIS)

Souza, Marcelo Cruzick de; Momesso, Denise P.; Vieira Neto, Leonardo; Vaisman, Mario; Vaisman, Fernanda; Corbo, Rossana; Martins, Rosangela Aparecida Gomes

2016-01-01

Objective: Much controversy relates to the risk of non-synchronous second primary malignancies (NSSPM) after radioactive iodine treatment (RAI-131) in differentiated thyroid cancer (DTC) patients. This study evaluated the relationship between RAI-131 and NSSPM in DTC survivors with long-term follow-up. Materials and methods: Retrospective analysis of 413 DTC cases was performed; 252 received RAI-131 and 161 were treated with thyroidectomy alone. Exclusion criteria were: prior or synchronous non-thyroidal malignancies (within the first year), familial syndromes associated to multiple neoplasms, ionizing radiation exposure or second tumors with unknown histopathology. Results: During a mean follow-up of 11.0 ± 7.5 years, 17 (4.1%) patients developed solid NSSPM. Patients with NSSPM were older than those without (p = 0.02). RAI-131 and I-131 cumulative activity were similar in patients with and without NSSPM (p = 0.18 and p = 0.78, respectively). Incidence of NSSPM was 5.2% in patients with RAI-131 treatment and 2.5% in those without RAI-131 (p = 0.18). Using multivariate analysis, RAI-131 was not significantly associated with NSSPM occurrence (p = 0.35); age was the only independent predictor (p = 0.04). Under log rank statistical analysis, after 10 years of follow-up, it was observed a tendency of lower NSSPM-free survival among patients that received RAI-131 treatment (0.96 vs. 0.87; p = 0.06), what was not affected by age at DTC diagnosis. Conclusion: In our cohort of DTC survivors, with a long-term follow-up period, RAI-131 treatment and I-131 cumulative dose were not significantly associated with NSSPM occurrence. A tendency of premature NSSPM occurrence among patients treated with RAI-131 was observed, suggesting an anticipating oncogenic effect by interaction with other risk factors. (author)

Sub-stoichiometric isotope dilution analysis method for the determination of iodine in common salts using iodine-131 tracer

International Nuclear Information System (INIS)

Singh, Vivek; Garg, A.N.

1994-01-01

A sub-stoichiometric isotope dilution analysis (SIDA) method was developed for the determination of iodine in different brands of common salts. An aqueous salt solution containing 131 I tracer and NaI as carrier is oxidized by tartaric acid and KIO 3 and the liberated iodine is extracted with CCl 4 . To the extract an aqueous solution of AgNO 3 is added in substoichiometric amount to obtain a colloidal solution of AgI. On adding sodium thiosulfate solution, the NaI so formed passes into aqueous solution, which is then counted. Several different brands of salt were analysed. The method is especially suitable for the determination of microgram amounts of iodide in the presence of excess of chloride. (Author)

ADDITIONAL VALUE OF POST-THERAPY 131 I SPECT/CT IN PATIENTS WITH DIFFERENTIATED THYROID CANCER

Directory of Open Access Journals (Sweden)

Satyawati Deswal

2017-03-01

Full Text Available BACKGROUND Generally, it is seen that SPECT/CT images are more useful than the planar images. We compared post-therapy 131 I imaging findings on planar and SPECT/CT scans to assess the clinical utility of SPECT/CT in management of patients with differentiated thyroid cancer. MATERIALS AND METHODS Post-therapy imaging was performed at 4-7 (when 5mR/hrs. exposure rate were observed by the survey meter days after 131 I administration and all patients underwent whole-body scintigraphy and SPECT/CT scanning on the same day. A generalised McNemar 1 was used to determine to establish the agreement between planar whole-body imaging and SPECT/CT for the assignment of benign, equivocal and malignant findings. RESULTS In 44 patients, 32 of the 44 patients underwent postsurgical 131 I ablation of residual thyroid tissue and 12 of 44 patients, 2 patients were treated twice. Hence, a total of 46 scans were analysed. SPECT/CT helped to localise focal iodine uptake and characterise it as either normal or abnormal thereby reducing the need for additional imaging studies. In post-thyroidectomy patients, SPECT/CT findings affected the ATA risk classification with implications for management by changing the interval for clinical followup and the need for additional imaging and laboratory tests. Our study found an 11% change in nodal status in the postsurgical group. Change in patient management was observed in 18%. CONCLUSION SPECT/CT enabled more accurate characterisation of focal iodine accumulation in patients.

Place of synthesis anti thyroids in the hyperthyroidism treatment by iodine 131; Place des antithyroidiens de synthese dans le traitement par iode 131 des hyperthyroidies

Energy Technology Data Exchange (ETDEWEB)

Clerc, J. [Hopital Necker, 75 - Paris (France)

2000-01-01

The prescription of synthesis anti thyroids allows to get a fast control of hyperthyroidism when the average time of curing after iodine 131 varies from 6 to 12 weeks, according to the level of radiation doses. It allows to treat the patients in euthyroidism and to avoid aggravation of thyrotoxicosis in the following of the iodine and is particularly useful for the old patients with a cardio vascular risk.

Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials

International Nuclear Information System (INIS)

Chen Zhinan; Mi Li; Xu Jing

2006-01-01

Purpose: HAb18G/CD147 is a hepatocellular carcinoma (HCC)-associated antigen. We developed iodine ( 131 I) metuximab injection (Licartin), a novel 131 I-labeled HAb18G/CD147-specific monoclonal antibody F(ab') 2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials. Methods and Materials: In a Phase I trial, 28 patients were randomly assigned to receive the injection in 9.25-, 18.5-, 27.75-, or 37-MBq/kg doses by hepatic artery infusion. In a multicenter Phase II trial, 106 patients received the injection (27.75 MBq/kg) on Day 1 of a 28-day cycle. Response rate and survival rate were the endpoints. Results: No life-threatening toxic effects were found. The safe dosage was 27.75 MBq/kg. The blood clearance fitted a biphasic model, and its half-life was 90.56-63.93 h. In the Phase II trial, the injection was found to be targeted and concentrated to tumor tissues. Of the 73 patients completing two cycles, 6 (8.22%) had a partial response, 14 (19.18%) minor response, and 43 (58.90%) stable disease. The 21-month survival rate was 44.54%. The survival rate of progression-free patients was significantly higher than that of patients with progressive disease after either one or two cycles (p 131 I) metuximab injection is safe and active for HCC patients

Comparison of thallium-201, Tc-99m MIBI and I-131 scan in the follow-up assessment after I-131 ablative therapy in differentiated thyroid cancer

International Nuclear Information System (INIS)

Kwon, Jae Sung; Lee, Sung Keun; Kim, Doe Min; Park, Sae Jong; Jang, Kyong Sun; Kim, Eun Sil; Kim, Chong Soon

1999-01-01

We conducted a comparative study to evaluate the diagnostic values of Tl-201, Tc-99m MIBI and I-131 scans in the follow-up assessment after ablative I-131 therapy in differentiated thyroid cancer. The study population consisted of 20 patients who underwent surgical removal of thyroid cancer and ablative radioactive iodine therapy, and followed by one or more times of I-131 retreatment (33 cases). In all patients, Tl-201, Tc-99m MIBI, diagnostic and therapeutic I-131 scans were performed and the results were analyzed retrospectively. Also serum thyroglobulin levels were measured in all patients. The final diagnosis of recurrent or metastatic thyroid cancer was determined by clinical, biochemical, radiologic and/or biopsy findings. Positive rates (PR) of Tc-99m MIBI, Tl-201, diagnostic and therapeutic I-131 scans in detecting malignant thyroid tissue lesions were 70% (19/27), 54% (15/28), 35% (17/48) and 63% (30/48), respectively. The PR in the group of 20 cases (28 lesions) who underwent concomitant Tl-201 and I-131 scans were in the order of therapeutic 131 scan 71%, Tl-201 scan 54% and diagnostic I-131 scan 36%. There was no statistically significant difference between Tl-201 and diagnostic I-131 scans (p>0.05). In the group of 20 cases (27 lesions) who underwent concomitant Tc-99m MIBI and I-131 scans, the PR were in the order of Tc-99m MIBI scan 70%, I-131 therapeutic scan 52% and I-131 diagnostic scan 33%. The PR of Tc-99m MIBI was significantly higher than that of diagnostic I-131 scan (p<0.05). Tc-99m MIBI scan is superior to diagnostic I-131 scan in detecting recurrent or metastatic thyroid cancer following ablation therapy in patients with differentiated thyroid cancer. Tl-201 scan did not showed significantly higher positive rate than diagnostic I-131 scan. Instead of diagnostic I-131 scan before the I-131 retreatment, Tc-99m MIBI scan without discontinuing thyroid hormone replacement would be a prudent and effective approach in the management of these

Experimental dosimetry and kinetics of radioactive tracers for human applications: example of therapeutic injection of Lipiodol labelled with Iodine 131

International Nuclear Information System (INIS)

Ahmed Mahidi, N.

1992-10-01

We have evaluated the radiation dose received by the liver and lungs for 10 patients with a hepatic carcinoma after surgical operation followed by a therapeutic dose of Lipiodol labelled with iodine 131. The cumulated activities have been obtained by using a calibrated gamma camera. Fixation and kinetics of the I 131 Lipiodol in normal and cancers livers have been measured with the determination of the effective and biological half-lives. The calculated doses are based on the MIRD method. Results confirm that Lipiodol fixation is important in the liver at J1 (about 74% of the injected activity). Its elimination is essentially urinary, pulmonary fixation remained low, the dose received by the healthy part of liver is acceptable. These values have been compared with those obtained by another method using a thermoluminescent dosimeter (LiF) installed on the skin over the liver. Comparison between results obtained by the 2 methods shows a good correlation

A review of best practice in relation to iodine-131 ablation discharges to sewer

International Nuclear Information System (INIS)

Punt, A.; Kruse, P.; Smith, K

2010-03-01

This report was produced by Enviros Consulting Ltd under contract to the RPII. It presents a review of best practice in relation to the management of iodine-131 ablation discharges to sewer and recommends a waste management strategy that could be adopted in the Republic of Ireland

Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of {sup 131}I used in the treatment of hyperthyroid patients with Graves' disease

Energy Technology Data Exchange (ETDEWEB)

Baczyk, M.; Ziemnicka, K.; Sowinski, J. [Karol Marcinkowski Univ. School of Medical Sciences, Poznan (Poland). Dept. of Endocrinology, Metabolism and Internal Diseases; Junik, R. [Nicolaus Copernicus Univ., Torun (Poland). Dept. of Endocrinology and Diabetology

2005-07-01

Poland, a country with mild/moderate iodine deficiency introduced an obligatory iodination salt system in 1996. Aim: To compare the results of radioiodine ({sup 131}I) uptake after 5 h and 24 h with the activity of radioiodine used in the treatment of hyperthyroid patients with Graves' disease in the years 1995 and 2003. Patients, methods: The marker of iodine content in the diet was urinary iodine excretion. 1000 randomly chosen patients (average age: 46{+-}12 years) were included in the study. Every patient had routinely estimated radioiodine uptake after 5 h and 24 h and the activity of {sup 131}I was calculated using scintigraphy and ultrasonography of the thyroid gland. Urinary iodine excretion in samples from year 1995 and 2003 was also determined in some patients and healthy volunteers. Results: The iodine load in the diet increased from 66 {mu}g (average) in the year 1995 to 115 {mu}g in the year 2003. Thyroid radioiodine uptake was 40% lower in comparison with the results from 1995. The average activity of {sup 131}I given in the year 2003 (10 mCi) was about 40% higher than in the year 1995 (7 mCi). Conclusion: There was significant negative correlation between higher iodine content in the diet and lower values of radioiodine uptake, which led to the application of the higher activity of {sup 131}I during treatment. (orig.)

Use of Iodine-131 to Tellurium-132 Ratios for Assessing the Relationships between Human Inhaled Radioactivity and Environmental Monitoring after the Accident in Fukushima

Directory of Open Access Journals (Sweden)

Koji Uchiyama

2018-03-01

Full Text Available Significant differences in findings were seen between the intake amounts of iodine-131 that were derived from direct measurements and the estimated intake from environmental monitoring data at the Fukushima accident. To clarify these discrepancies, we have investigated the iodine-131 and tellurium-132 body burdens of five human subjects, who after being exposed to a radioactive plume, underwent 21.5 h whole body counter measurements at Fukui Prefectural Hospital, so clear intake scenario and thyroid counter measurement data were available. To determine the iodine-131 and tellurium-132 body burdens, we introduced a new method of whole body counter calibration composed of a self-consistent approach with the time-dependent correction efficiency factors concept. The ratios of iodine-131 to tellurium-132, ranging from 0.96 ± 0.05 to 2.29 ± 0.38, were consistent with results of the environmental measurements. The 24 h iodine uptake values ranging from 12.1–16.0% were within euthyroid range in Japanese people. These results suggest, even if the relatively low thyroid iodine uptake in the Japanese population was taken into consideration, that there is no doubt about the consistency between direct measurements and environmental monitoring data. Adequate intake scenario is suggested to be principally important to estimate the inhaled radioactivity in areas in or around nuclear accidents.

The method of obtaining of sodium orthoiodohippurate labelled with iodine-131

International Nuclear Information System (INIS)

Aripov, D.; Abdukayumov, M.; Shukurov, A.Sh.

1994-01-01

The method of labelling of sodium orthoiodohippurate was elaborated with the purpose of increasing the preparation quality. Method includes the reaction of isotopic exchange between orthoiodhippur acid and sodium iodide solution labelled with iodine-131 with volume activity 150-200 mCu/mL and pH=6,5-7,0. Reaction occurs at temperature 120-130 C during 1,1-1,3 hours and the compound obtained is dissolved in 1% sodium bicarbonate solution. (author)

Radionuclide therapy of Sipple syndrome using iodine-131 metaiodobenzylguanidine

International Nuclear Information System (INIS)

Furusawa, Mitsuhiro; Shimomura, Osamu; Tomiguchi, Seiji; Hirota, Yoshihisa; Takahashi, Mutsumasa; Yamauchi, Jyoji; Iwaoka, Daisuke; Satoh, Tatsuo

1992-01-01

A 40-years-old female who had lung and liver metastases from malignant pheochromocytoma was treated with 3.7 GBq 131 I-MIBG (metaiodobenzylguanidine). After the treatment, 131 I-MIBG showed increased uptake in the metastatic lesions of the lung and liver. The size of tumor was no significant change on CT and MRI, but the intensity of liver metastases decreased gradually on MRI. Prior to the treatment, the levels of adrenaline and noradrenaline were high. One to three days after treatment, the level of these laboratory data further increased, but they gradually decreased in 1 to 3 months. These changes may be due to necrosis of tumor tissue. (author)

Experimental results concerning the metabolism of ingested iodine-131 in adult sheep under lactation; Resultats experimentaux relatifs au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation

Energy Technology Data Exchange (ETDEWEB)

Daburon, F; Capelle, A; Tricaud, Y; Nizza, P [Commissariat a l' Energie Atomique, 92 - Fontenay-aux-Roses (France). Centre d' Etudes Nucleaires. Departement de la Protection Sanitaire, Laboratoire-etable de Radiobiologie Appliquee

1967-07-01

The authors give the results of a series of experiments on metabolism of ingested iodine-131 in adult sheep under lactation; the measurement were carried out over a number of years from 1961 to 1966. The work was concerned initially with the fixation of iodine 131 in the thyroid gland, with the calculation of radiation doses absorbed and with ways of showing up any possible radiation damage in the gland. The modes of absorption of iodine 131 and its elimination through milk, urine and the faeces were then considered. Finally, a last chapter is devoted to changes in the radioactivity of the blood and of the milk, to variations of the PBI level of the blood serum as to different methods for measuring this level. (authors) [French] Les auteurs rapportent les resultats d'une serie d'experimentations relatives au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation, et qui se sont etalees sur plusieurs annees, de 1961 a 1966. Les etudes ont porte d'abord sur les aspects de la fixation de l'iode 131 dans la thyroide, avec le calcul des doses de rayonnements absorbees et les moyens de mettre en evidence les radiolesions eventuelles de la glande. Ensuite ont ete traitees les modalites de l'absorption de l'iode 131 et de son elimination par le lait, les urines et les feces. Enfin un dernier chapitre a ete consacre a l'evolution de la radioactivite du sang et du lait, aux variations ainsi qu'aux divers moyens d'evaluation du taux de PBI du serum sanguin. (auteurs)

The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation.

Science.gov (United States)

Watanabe, Ken; Uchiyama, Mayuki; Fukuda, Kunihiko

2017-09-01

This article examines the outcome of radioactive iodine ablation therapy for thyroid cancer in high-risk patients and investigates background factors influencing ablation failure. We included 91 patients in this retrospective analysis and evaluated the ablation success rate. Successful ablation was defined as the absence of visible iodine-131 (I-131) accumulation in the thyroid bed after whole-body scans and thyroglobulin levels sex, I-131 dose, pathology, resection stump findings, tumor T category and thyroglobulin levels, which could affect ablation outcome. Successful ablation was achieved in only 14 patients (15.4%). Pre-ablation serum thyroglobulin levels were significantly higher in the ablation failure group than in the success group (P 10 ng/ml were significantly related to ablation failure after multivariate analysis (odds ratio 27.2; 95% confidence interval 2.469-299.7; P = 0.007). The ablation success rate was very low because of high thyroglobulin levels, even with high-dose I-131. High-risk patients, especially those with high thyroglobulin levels (>10 ng/ml), are unlikely to reach levels low enough to meet successful ablation criteria.

Is radioactive iodine-{sup 131} treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?

Energy Technology Data Exchange (ETDEWEB)

Souza, Marcelo Cruzick de; Momesso, Denise P.; Vieira Neto, Leonardo; Vaisman, Mario, E-mail: dmomesso@terra.com.br [Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, (Brazil). Servico de Endocrinologia; Vaisman, Fernanda; Corbo, Rossana [Instituto Nacional do Cancer (INCA), Rio de Janeiro, RJ (Brazil). Servico de Endocrinologia; Martins, Rosangela Aparecida Gomes [Hospital Universitario Clementino Fraga Filho (HUCFF), Rio de Janeiro, RJ (Brazil). Divisao de Pesquisa

2016-02-15

Objective: Much controversy relates to the risk of non-synchronous second primary malignancies (NSSPM) after radioactive iodine treatment (RAI-131) in differentiated thyroid cancer (DTC) patients. This study evaluated the relationship between RAI-131 and NSSPM in DTC survivors with long-term follow-up. Materials and methods: Retrospective analysis of 413 DTC cases was performed; 252 received RAI-131 and 161 were treated with thyroidectomy alone. Exclusion criteria were: prior or synchronous non-thyroidal malignancies (within the first year), familial syndromes associated to multiple neoplasms, ionizing radiation exposure or second tumors with unknown histopathology. Results: During a mean follow-up of 11.0 ± 7.5 years, 17 (4.1%) patients developed solid NSSPM. Patients with NSSPM were older than those without (p = 0.02). RAI-131 and I-131 cumulative activity were similar in patients with and without NSSPM (p = 0.18 and p = 0.78, respectively). Incidence of NSSPM was 5.2% in patients with RAI-131 treatment and 2.5% in those without RAI-131 (p = 0.18). Using multivariate analysis, RAI-131 was not significantly associated with NSSPM occurrence (p = 0.35); age was the only independent predictor (p = 0.04). Under log rank statistical analysis, after 10 years of follow-up, it was observed a tendency of lower NSSPM-free survival among patients that received RAI-131 treatment (0.96 vs. 0.87; p = 0.06), what was not affected by age at DTC diagnosis. Conclusion: In our cohort of DTC survivors, with a long-term follow-up period, RAI-131 treatment and I-131 cumulative dose were not significantly associated with NSSPM occurrence. A tendency of premature NSSPM occurrence among patients treated with RAI-131 was observed, suggesting an anticipating oncogenic effect by interaction with other risk factors. (author)

Hypertension complicating {sup 131}I-meta-iodobenzylguanidine therapy for neuroblastoma

Energy Technology Data Exchange (ETDEWEB)

Kosmin, Michael A.; Cork, Nicholas J.; Gaze, Mark N. [University College London Hospitals NHS Foundation Trust, Department of Oncology, London (United Kingdom); Bomanji, Jamshed B. [University College London Hospitals NHS Foundation Trust, Department of Nuclear Medicine, London (United Kingdom); Shankar, Ananth [University College London Hospitals NHS Foundation Trust, Department of Paediatric Oncology, London (United Kingdom)

2012-04-15

Radiolabelled meta-iodobenzylguanidine (mIBG), used as targeted therapy for neuroblastoma, is known to have effects on blood pressure (BP). In this study we audited BP changes in patients receiving {sup 131}I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors. Between 2003 and 2010, 50 patients with neuroblastoma received 110 {sup 131}I-mIBG administrations. BP measurements before and after administration were compared with age- and sex-matched centile values. AE were analysed, and possible predisposing factors identified. This population had a baseline BP distribution higher than that of their age- and sex-matched peers, with 16% of preadministration systolic BP values above the 95th centile. Changes in BP after administration showed an approximately normal distribution with similar numbers of reduced and increased values. Four AE, all related to hypertension, occurred with one patient having generalized seizures. One AE was immediate, others occurred between 20 and 25 h after administration. No significant association between AE and patient age or sex was demonstrated. However, a significant association between AE and high preadministration BP was shown, both above the 90th centile (p = 0.0022) and above the 95th centile (p = 0.0135). Clinically relevant hypertension following {sup 131}I-mIBG therapy affected less than 5% of administrations, but was more common in those patients with preexisting hypertension. As hypertensive episodes may occur many hours after treatment, close monitoring of BP needs to be continued for at least 48 h after administration of {sup 131}I-mIBG. (orig.)

Iodine-131 induced hepatotoxicity in previously healthy patients with Grave's disease.

Science.gov (United States)

Jhummon, Navina Priya; Tohooloo, Bhavna; Qu, Shen

2013-01-01

To describe the association of the rare and serious complication of liver toxicity in previously healthy Grave's disease (GD) patients after the treatment with radioactive iodine (131)I (RAI). We report the clinical, laboratory and pathologic findings of 2 cases of severe liver toxicity associated with the treatment with RAI in previously healthy patients with GD. Clinical examination and laboratory investigations excluded viral hepatitis, autoimmune hepatitis, granulomatous disease, primary biliary disease, extrahepatic biliary obstruction, and heart failure. Case 1: A previously healthy 52-years old man reportedly having a typical GD but following RAI treatment, concomitantly developed severe liver toxicity that required 1 week of treatment in hospital. Case 2: A previously healthy 34-years old woman is reported as having a typical GD but developed jaundice following RAI treatment that required several weeks of in hospital treatment in the hepato-biliary department. In both cases, the liver dysfunction resolved after intensive treatment with hepato-protective agents. In this report the therapeutic considerations as well as the pathogenetic possibilities are reviewed. To the best of our knowledge, this is the first description of the association observed, which is rare but may be severe and should be considered in any case of thyrotoxicosis where a liver dysfunction develops after the treatment with radioactive iodine (131)I.

Thyroid uptake and imaging with iodine-123 at 4-5 hours: replacement of the 24-hour iodine-131 standard

International Nuclear Information System (INIS)

Floyd, J.L.; Rosen, P.R.; Borchert, R.D.; Jackson, D.E.; Weiland, F.L.

1985-01-01

A study was carried out to determine the suitability of utilizing a 4 to 5 hr interval from administration of Iodine-123 to imaging and uptake measurement as a replacement for the 24-hr standard originally established with Iodine-131. In 55 patients who underwent scintigraphy at 4 and 24 hr, there was no discrepancy between paired images. In 55 patients who had uptake measured at 4 and 24 hr and in 191 patients who had uptake measured at 5 and 24 hr, the early measurements proved equal or better discriminants of euthyroid from hyperthyroid patients. In our institutions, these findings and the logistical advantages of completing the exam in 4-5 hr led us to abandon the 24-hr study in the majority of patients

Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities; Radioiodoterapia do carcinoma diferenciado da tireoide: impacto radiologico da liberacao hospitalar de pacientes com atividades entre 100 e 150 mCi de iodo-131

Energy Technology Data Exchange (ETDEWEB)

Sapienza, Marcelo Tatit; Willegaignon, Jose; Ono, Carla Rachel; Watanabe, Tomoco; Guimaraes, Maria Ines Calil Cury; Buchpiguel, Carlos Alberto [Universidade de Sao Paulo (USP), SP (Brazil). Faculdade de Medicina. Servico de Medicina Nuclear; Gutterres, Ricardo Fraga; Marechal, Maria Helena da Hora [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)

2009-07-01

Purpose: To evaluate exposure and dosimetry to family members and environment due to outpatient radioiodine therapy of differentiated thyroid carcinoma. Methods: Twenty patients were treated with 100-150 mCi of iodine-131 on an out-patient basis. Family members dosimetry (n = 27) and potential doses inside the house were measured with thermoluminescent dosimeters. Surface contamination and radioactive wastes were also monitored. Results: Less than 1.0 mSv doses were found in 26 co-habitants and 2.8 mSv in a single case (inferior to the acceptable value of 5.0 mSv/procedure). Potential doses in the houses were inferior to 0.25 mSv, excluding the patients bedroom (mean value = 0.69 mSv). Surface contamination (mean = 4.2 Bq.cm{sup -2}) were below clearance levels. Radioactive wastes generated had a volume of 2.5 liters and a total activity estimated in 90 {mu}Ci, with a calculated exposure close to the background radiation levels. Conclusions: No radiological impact was detected after iodine therapy with 100-150 mCi on an out-patient basis followed by experienced professionals. (author)

The treatment of hyperthyroidism in adolescents and children with 131I

International Nuclear Information System (INIS)

Feng Fei; Zhao Deshan

2009-01-01

Hyperthyroidism in adolescents and children is a common endocrinium disorder, which disturbs the development of diverse body systems, especially of skeletal and central nervous systems. The patients with hyperthyroidism have a lower long-term, spontaneous remission of the disease. The majority of adolescents and children patients with hyperthyroidism have to receive an effective, safe therapy. Currently, there are three methods for treating hyperthyroidism. They include in antithyroid drugs (ATD), surgery and radioactive iodine ( 131 I) therapy. ATD always is the first line way to these patients with hyperthyroidism for endocrinologist yet. But the remission rate of hyperthyroidism for ATD is lower, the remission of hyperthyroidism also need spend longer time, and side effects of ATD are more common in adolescents and children than in adult. The success ratio and complications of surgery are mainly depended on the technic of surgeons, 131 I has been used as the treatment of hyperthyroidism for more than six decades. So far, there are still no enough evidences to show that the incidence of thyroid cancer and other malignant diseases, the patients fertility rate, rate of abortion and malformation of descendants in hyperthyroidism patients following 131 I were marked difference with that in other people. The remission rate of hyperthyroidism following 131 I was higher and its side effects were less. 131 I therapy can be the first choice to adolescents and children with hyperthyroidism who are no suitable to ATD therapy. Hypothyroidism is most often one outcome of pediatric patients with hyperthyroidism after 131 I therapy. Hence, the patients with hypothyroidism have to receive the replacement treatment of thyroxine. Since the development of adolescents and children are more dependent on thyroxine and adolescents and children are more sensitive to the radioactive rays than adults, it is more suitable to get ideal control with a relative lower dosage of mi to

The effects of antithyroid drug treatment on thyroid hormone levels after 131I ablation for Graves' disease: a prospective randomized study

International Nuclear Information System (INIS)

Magalhaes, Patricia; Maciel, Lea

2005-01-01

Full text: The efficacy, safety and low cost of radioactive iodine ( 131 I) have made it the preferred definitive treatment in most patients with Graves' disease. The purposes of this study were: 1) Evaluate the acute changes in thyroid hormones (TH) levels before and after 131 I therapy in patients randomized to receive either antithyroid drug (ATD) pretreatment or no pretreatment, 2) Evaluate the effect of ATD pretreatment on the efficacy of 131 I therapy. 42 patients with clinical diagnosis of hyperthyroid Graves' disease were schedule to receive ablation therapy with 131 I: 24 were pretreated with methimazole (Group I) and 18 were not (Group II). ATD was stopped 5 days before 131 I therapy. Patients were monitorized clinically and biochemically with measurement of FT 3 , FT 4 and TSH on days -5, 0, 2, 6, 14, 30, 60, 120, 180, 360. Before 131 I treatment, comparing with baseline measurements, FT 4 levels after discontinuation of ATD have shown a mean increase of 61.8% (1.2 ± 0.6 to 1.8 ± 1.1 ng/dl, p=0.0006), while FT 3 levels increased 63.7% (3.2 ± 0.6 to 5.2 ± 2.2 pg/ml, p=0.0002). In this group, 131 I therapy resulted in a further increase in FT 4 levels on day 2 (p=0.0005) but not in T 3 levels. Conversely, the Group II patients experienced no further elevations in TH after 131 I therapy, which kept stable until day 30 th. After 60 days of treatment there was an important decrease in FT 4 concentrations for Group II patients, reaching similar values of the Group I levels but above the normal range. On the 120 th day, the TH levels were similar and at normal range in both groups. In the Group II, 12 patients (66.7%), 1 patient (5.6%) and 3 (16.7%) became hypothyroid, euthyroid or hyperthyroid, respectively. On the other hand, in the Group I, 7 patients (29.2%), 6 patients (25%) and 6 patients (25%) became hypothyroid, euthyroid or hyperthyroid, respectively. Conclusion: Pretreatment with methimazole before radioactive iodine therapy seems to interfere

Three-dimensional noninvasive monitoring iodine-131 uptake in the thyroid using a modified Cerenkov luminescence tomography approach.

Science.gov (United States)

Hu, Zhenhua; Ma, Xiaowei; Qu, Xiaochao; Yang, Weidong; Liang, Jimin; Wang, Jing; Tian, Jie

2012-01-01

Cerenkov luminescence tomography (CLT) provides the three-dimensional (3D) radiopharmaceutical biodistribution in small living animals, which is vital to biomedical imaging. However, existing single-spectral and multispectral methods are not very efficient and effective at reconstructing the distribution of the radionuclide tracer. In this paper, we present a semi-quantitative Cerenkov radiation spectral characteristic-based source reconstruction method named the hybrid spectral CLT, to efficiently reconstruct the radionuclide tracer with both encouraging reconstruction results and less acquisition and image reconstruction time. We constructed the implantation mouse model implanted with a 400 µCi Na(131)I radioactive source and the physiological mouse model received an intravenous tail injection of 400 µCi radiopharmaceutical Iodine-131 (I-131) to validate the performance of the hybrid spectral CLT and compared the reconstruction results, acquisition, and image reconstruction time with that of single-spectral and multispectral CLT. Furthermore, we performed 3D noninvasive monitoring of I-131 uptake in the thyroid and quantified I-131 uptake in vivo using hybrid spectral CLT. Results showed that the reconstruction based on the hybrid spectral CLT was more accurate in localization and quantification than using single-spectral CLT, and was more efficient in the in vivo experiment compared with multispectral CLT. Additionally, 3D visualization of longitudinal observations suggested that the reconstructed energy of I-131 uptake in the thyroid increased with acquisition time and there was a robust correlation between the reconstructed energy versus the gamma ray counts of I-131 (r(2) = 0.8240). The ex vivo biodistribution experiment further confirmed the I-131 uptake in the thyroid for hybrid spectral CLT. Results indicated that hybrid spectral CLT could be potentially used for thyroid imaging to evaluate its function and monitor its treatment for thyroid cancer.

[Iodine 131 joint radio frequency ablation treatment for child with hyperthyroidism goiter: one case report].

Science.gov (United States)

Chen, Yonghua; Liang, Li; Fang, Yanlan; Wang, Chunlin; Li, Linfa; Jiang, Tian'an

2017-01-25

A 12-year-old girl presented with a history of cervical mass, and one week of throat discomfort and dyspnea. Five years ago, the patient was diagnosed as Hashimoto's thyroiditis and hyperthyroidism; she received antithyroid drug treatment, but the result was not satisfactory. B-ultrasonic showed that the size of thyroid gland was 8.1 cm×3.2 cm in the left and 8.2 cm×4.8 cm in the right. After iodine 131 combined with radiofrequency ablation (RFA) treatment, throat discomfort and recumbent breathing difficulties disappeared, and B-ultrasonic showed that the size of thyroid reduced to 2.3 cm×1.7 cm (left) and 2.8 cm×2.0 cm (right). No recurrence was observed during the two and a half years of follow-up.

Hyperparathyroidism after radioactive iodine therapy for Graves' disease

International Nuclear Information System (INIS)

Kawamura, Juichi; Tobisu, Kenichi; Sanada, Shingo

1983-01-01

Herein we report a 36-year-old man with hyperparathyroidism and a past history of internal irradiation to the thyroid. Twelve years previously at age 24 years he had received 8 mCi of radioactive iodine for Graves' disease. An additional dose of 4 mCi was required 3 years later. A right lower parathyroid adenoma (28 x 23 x 20 mm, 5.7 g) was found at neck exploration. Although the association of external ionizing radiation to the head and neck and the subsequent development of hyperfunctioning parathyroid glands has been described in recent years, there are only 4 cases in the literature of parathyroid surgery for hyperparathyroidism secondary to earlier treatment with radioactive iodine for Graves' disease. In a long-term follow-up of 180 patients treated with radioactive iodine for Graves' disease, neither hypercalcemia nor hypophosphatemia was found. Whether internal radiation therapy can be a causative factor in the development of hyperparathyroidism should be elucidated in future. However, it seems reasonable to suggest that patients whose hyper-thyroidism has been treated with radioactive iodine should have their scrum calcium levels examined at 5-year intervals. (author)

The therapeutic threesome, Iodine 131, Lutetium-111 and Rhenium-188 Radionuclide Trifecta

International Nuclear Information System (INIS)

Turner, J.H.

2007-01-01

Full text: Affordable, available, cost-effective, safe, efficacious therapeutic radiopharmaceuticals are required for clinical application throughout the world. In-house preparation of non-proprietary therapeutic radiopharmaceuticals at tertiary referral hospitals in all countries following appropriate technology transfer and training at key research and development centres can potentially supply this need. Illustrative examples of novel therapeutic radiopharmaceuticals currently under development in physician sponsored phase II clinical trials and candidates for contemplation of translation to developing countries include: (1) I-131 Rituximab radioimmunotherapy of relapsed/refractory and first-line treatment of non- Hodgkin's lymphoma; (2) Lu-177 octreotate radiopeptide therapy of neuroendocrine malignancy with capecitabine tumour radiosensitization; (3) Re-188 lipiodol intrahepatic arterial therapy of hepatocellular carcinoma. In addition to presentation of preliminary clinical results, the logistics and techniques of preparation, quality control and administration of each of these therapeutic radiopharmaceuticals will be described and the calculation of individual patient dosimetry and issues of radiation safety will also be addressed. 1. Iodine-131 rituximab: I-131 rituximab may be prepared in a hospital department of nuclear medicine equipped with a shielded fume cupboard, using commercially available single-use sterile pyrogen-free labelling kits (Go Medical Industries Pty Ltd, Subiaco, Australia) (1). Individualized prospective dosimetry is performed on each patient by quantitative whole body gamma imaging, to determine the therapeutic administered activity, to provide a maximum safe whole body radiation absorbed dose of 0.75 Gy, which equates to less than 2 Gy to red marrow (2). More than 200 patients with relapsed/refractory non-Hodgkin's lymphoma have been treated at Fremantle Hospital without infection or haemorrhagic incident. Myelosuppression is self

I-131 Treatment of Graves' Disease in an Unsuspected First Trimester Pregnancy; the Potential for Adverse Effects on the Fetus and a Review of the Current Guidelines for Pregnancy Screening

Directory of Open Access Journals (Sweden)

Phuong Tran

2010-01-01

Full Text Available Graves' disease is a thyroid-specific autoimmune disorder in which the body makes antibodies to the thyroid-stimulating hormone receptor leading to hyperthyroidism. Therapeutic options for the treatment of Graves' disease include medication, radioactive iodine ablation, and surgery. Radioactive iodine is absolutely contraindicated in pregnancy as exposure to I-131 to the fetal thyroid can result in fetal hypothyroidism and cretinism. Here we describe a case of a female patient with recurrent Graves' disease, who inadvertently received I-131 therapy when she was estimated to be eight days pregnant. This was despite the obtaining of a negative history of pregnancy and a negative urine pregnancy test less than 24 hours prior to ablation. At birth, the infant was found to have neonatal Graves' disease. The neonatal Graves' disease resolved spontaneously. It was suspected that the fetal thyroid did not trap any I-131 as it does not concentrate iodine until 10 weeks of gestation.

I-131 Treatment of Graves' Disease in an Unsuspected First Trimester Pregnancy; the Potential for Adverse Effects on the Fetus and a Review of the Current Guidelines for Pregnancy Screening

Directory of Open Access Journals (Sweden)

Barrett Mark

2010-03-01

Full Text Available Graves' disease is a thyroid-specific autoimmune disorder in which the body makes antibodies to the thyroid-stimulating hormone receptor leading to hyperthyroidism. Therapeutic options for the treatment of Graves' disease include medication, radioactive iodine ablation, and surgery. Radioactive iodine is absolutely contraindicated in pregnancy as exposure to I-131 to the fetal thyroid can result in fetal hypothyroidism and cretinism. Here we describe a case of a female patient with recurrent Graves' disease, who inadvertently received I-131 therapy when she was estimated to be eight days pregnant. This was despite the obtaining of a negative history of pregnancy and a negative urine pregnancy test less than 24 hours prior to ablation. At birth, the infant was found to have neonatal Graves' disease. The neonatal Graves' disease resolved spontaneously. It was suspected that the fetal thyroid did not trap any I-131 as it does not concentrate iodine until 10 weeks of gestation.

Therapeutic applications of radioactive 131iodine: Procedures and incidents with capsules

International Nuclear Information System (INIS)

Al Aamri, Marwa; Ravichandran, Ramamoorthy; Binukumar, John Pichy; Al Balushi, Naima

2016-01-01

Treatments for thyrotoxicosis and carcinoma thyroid are carried out by oral administration of radioactive iodine ( 131 I) in the form of liquid or capsules. The liquid form of 131 I has higher risk factors such as vapourization, spillage and need for management of higher activity wastes. Use of 131 I in capsule form simplify procedures of handling compared to liquid form of 131 I. The guidelines of safe handling and quality assurance aspects for therapeutic use 131 I are well outlined by International Atomic Energy Agency (IAEA) reports. A few unusual incidents with I-131 capsules encountered in the past need to be highlighted from health physics point of view. In Royal Hospital, Oman, I-131 is imported in capsules, and the total activity handled/year steadily increased over 10 years. Discrete activities range from 185 MBq (5 mCi) up to 7.4 GBq (200 mCi). In four incidents deviations in standard operational procedures were recorded. Nature of incidents is described as follows: (1) After assay of activity, the capsule was directly put in the lead container with missing of inner cap. (2) Patient poured water in the Perspex tube, when the capsule was handed over to her, making an emergency situation. (3) In 3 high activity capsules (2 nos 2.96 GBq, 1 no. 4.26 GBq), observed sticky behavior in capsule holder on the 2 nd day post receipt, which were in order on the 1 st day. (4) A capsule could not be swallowed by a patient, which was taken back from the mouth. Monitoring of patient later did not show residual ingested activity. The report documents some of the unusual incidents for information to other centers engaged in such radioactive administrations

Facts and fallacies about radioactive iodine therapy for Graves' disease

International Nuclear Information System (INIS)

Miller, J.L.

1982-01-01

The therapeutic options available in the hyerthyroidism of Graves' disease are two basic treatments. Firstly antithyroid drugs and secondly one can 'ablate' the thyroid gland by means of thyroidectomy or radioactive iodine ( 131 I). At present 131 I is the current treatment of chioce for Graves' disease. In a follow-up study of 21 714 patients who were treated with 131 I and observed for a period of 8 years, there was no increase in the incidence of thyriod carcinoma. A possible explanation for this is that the dose of 131 I used destroys the ability of the thyroid cells to replicate and thus transmit genetically damaged material

Contribution of radio-iodine 131 in the treatment of Grave's Basedow disease in the department of nuclear medicine of Ibn Sina Hospital in Rabat; Apport de l'iode 131 dans le traitement de la maladie de Basedow dans le service de medecine nucleaire de l'hopital Ibn Sina de Rabat

Energy Technology Data Exchange (ETDEWEB)

Mbodj, M.; Amjad, I. [Faculte de Medecine de Dakar, Lab. de Biophysique et de Medecine Nucleaire, UCAD, Dakar (Senegal); Guerrouj, H.; Ben Rais, N.A. [Hopital Ibn Sina de Rabat, Service de Medecine Nucleaire, Rabat (Morocco)

2009-10-15

One hundred and twenty-nine Grave's Basedow diseases in any gender and variable age patients, coming from several cities of Morocco, were randomized in a study of radio-iodine treatment who took place at the nuclear medicine department of Ibn Sina Hospital (Rabat, Morocco) during the period (from January 2001 to December 2008). The radio-iodine treatment was a first, second or third option and radio-iodine activities delivered varied (from 222 to 555 MBq 6 to 15 mCi) according to the age, the thyroid volume, the degree of hyperthyroidism and socio-economical situation. The high amounts of {sup 131}I were reserved especially to the patients who live far and whose socio-economic level is low with an aim of quickly obtaining an easily controllable state of hypothyroidism by a substitute treatment. The results showed that: (1) 57.36% of patients reverted to euthyroidism (n = 74) with a patient having received two {sup 131}I cures. The second cure was justified by recurrence of hyperthyroidism after the first cure; (2) 34.88% passed in hypothyroidism (n = 45) with three patients having received two cures of {sup 131}I, the second cure was justified by recurrence of hyperthyroidism after the first cure in two patients and by the persistence of the hyperthyroidism after the first cure for the third patient. The average time of passage in hypothyroidism was 4.5 months; (3) 7.76% had remained in hyperthyroidism after the radioactive iodine treatment. Finally, 92.24% of our patients treated by radioactive iodine had passed in euthyroidism or hypothyroidism against 7.76% whose hyperthyroidism had persisted or occurred. (authors)

Radiochemical studies on the separation of iodine-131 and radioiodination of some organic compounds

International Nuclear Information System (INIS)

Mohamed, M.A.I.

2010-01-01

This thesis is constituted of three chapters:Chapter I: It deals with the theoretical consideration of the subject. The chapter deals with the importance of radioisotopes in medical applications, and the physical and biological properties of these isotopes. Also, this part deals with the chemical and physical properties of both tellurium and iodine and the methods of the production of radioiodine from tellurium targets especially dry distillation method and ion exchange method. It deals with general methods of labeling, chemistry of iodine especially the most frequently used in nuclear medicine, their methods of production and applications. It includes also the techniques used for the preparation of the radioiodinated compounds, especially the electrophilic technique or the oxidative radioiodination technique. In this technique, oxidizing agents are used to oxidize iodide ions to iodonium ions capable of electrophilic attack on the aryl group of the organic compound. This chapter deals also with the receptor tracers, their types and the effects that can occur due to the binding of these receptors to the cell membrane. Since these radiopharmaceuticals are used for diagnosis and therapeutic treatment of human diseases, quality control tests such as chemical purity, radionuclidic purity, radiochemical purity, sterility, apyrogenicity and biodistribution are performed to ensure the purity, the safety and efficiency of these products for the intended nuclear medicine application.Chapter II:It contains detailed information concerning the chemicals, reagents, the radionuclides, the equipment and the counting systems used in the study. It describes production technique of iodine-131 using dry distillation method. It describes also the electrophilic radioiodination for each of Y-indole and epidepride. Analysis of the labeled products was performed using two chromatographic techniques. The first technique is thin layer chromatography in which the compound was identified by

The evaluation of functioning thyroid nodules using sodium pertechnetate TC-99m scan in comparison with iodine-131

Directory of Open Access Journals (Sweden)

Saghari M

1993-04-01

Full Text Available Thyroid scintigraphy has been helpful in detecting and evaluation of thyroid nodules. Sodium pertechnetate Tc-99m is the most commonly used radionuclide for thyroid imaging because of its general availability, favorable dosimetric characteristics and low cost. But, there are reports of occasional disparity in isotope uptake in lesions compared with radioiodide. In order to determine percentage and clinical significance of this disparity, we screened 101 patients with solitary functioning nodules using sodium pertechnetate TC-99m in comparison with subsequent Iodine-131 scan in research institute for nuclear medicine. We conclude that sodium pertechnetate TC-99m is a reliable radiotracer for the detection and evaluation of thyroid nodules and there is no need for the subsequent Iodine-131 scan.

Risk factors of hepatic dysfunction in patients with Graves’ hyperthyroidism and the efficacy of 131iodine treatment

Science.gov (United States)

Wang, Renfei; Tan, Jian; Zhang, Guizhi; Zheng, Wei; Li, Chengxia

2017-01-01

Abstract Hepatic dysfunction is often observed in patients with Graves’ hyperthyroidism. The aims of this study were to investigate the risk factors for hepatic dysfunction and to analyze the efficacy of 131I (radioactive iodine-131) treatment. In total, 2385 patients with Graves’ hyperthyroidism (478 males, 1907 females; age 42.8 ± 13.5 years) were involved in our study. Of these, 1552 cases with hepatic dysfunction received 131I treatment. All clinical data were retrospectively reviewed to explore the risk factors associated with hepatic dysfunction using logistic regression analysis. Furthermore, we observed thyroid and liver function indices for the 1552 subjects at 3, 6 and 12 months after 131I treatment, in order to evaluate efficacy. Overall, 65% patients were affected by hepatic dysfunction. The most common abnormality was elevated alkaline phosphatase (ALP), of which the prevalence was 52.3%. The percentages of hepatocellular injury type, bile stasis, and mixed type were 45.8%, 32.4%, and 21.8%, respectively. Both univariate and multivariate analyses demonstrated that age, duration of Graves hyperthyroidism, free triiodothyronine (FT3)level, and thyrotrophin receptor antibody (TRAb) concentration were the most significant risk factors predicting hepatic dysfunction. Additionally, the patients with mild hepatic dysfunction, or hepatocellular injury type were more likely to attain normal liver function after 131I treatment. Furthermore, after 131I treatment, liver function was more likely to return to normal in the cured group of patients compared with the uncured group. Older patients and cases with a longer history of Graves’ hyperthyroidism, higher FT3 or TRAb concentration were more likely to be associated with hepatic dysfunction, and the prognosis of hepatic dysfunction was closely associated with the outcomes of Graves’ hyperthyroidism after 131I treatment. PMID:28151911

Clinical outcome during the peri-operative (thyroidectomy) period of severely hyperthyroid patients with normalized pre-operative free-T4 levels: Importance of I-131 therapy as a part of pre-operative preparation

International Nuclear Information System (INIS)

Siguan-Crisaldo, M.A.L.; Mercado-Asis, L.B.

2005-01-01

Thyroidectomy is performed for hyperthyroidism on patients who do not respond to or are not compliant with medical therapy and in patients with very large goiters causing compressive symptoms. All thyrotoxic patients undergoing thyroidectomy usually are first treated with anti-thyroid drugs to normalize free thyroid hormone levels and render them euthyroid before surgery in order to prevent complications particularly thyroid storm and circulatory collapse. In this case series, we describe the clinical outcome during the perioperative (thyroidectomy) period of three severely hyperthyroid patients, two females and one male, with ages ranging from 13 to 38 years. All patients had grade III goiter, and only one had exophthalmos. The mean duration of goiter was 3.6 years. All of them were given preoperative treatment consisting of propylthiouracil (PTU) at 450-600 mg/day; iodone, 3 tablets daily and propranolol at 30-120 mg/day for one month. All of them had normalized preoperative thyroid function tests. In addition to the preoperative medications mentioned above, all three patients received radioactive iodine therapy before surgery. The first two patients received relatively low doses of 8.0 and 7.5 mCi of I-131 respectively. Unfortunately the first patient had supraventricular tachycardia (SVT), post skin cutting and the other one went into thyroid storm. The third patient who received a cumulative dose of 23.5 mCi of I-131 before surgery had an uneventful postoperative course. It is concluded that normalization of thyroid hormone parameters, especially free T4 is not sufficient for an uneventful and uncomplicated peri-thyroidectomy period in severely hyperthyroid patients with large goiters. Effective radioactive iodine therapy might prove to be helpful in inducing thyroid tissue fibrosis, thus leading to true clinical euthyroidism and excellent clinical course postoperatively. (author)

Experimental results concerning the metabolism of ingested iodine-131 in adult sheep under lactation; Resultats experimentaux relatifs au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation

Energy Technology Data Exchange (ETDEWEB)

Daburon, F.; Capelle, A.; Tricaud, Y.; Nizza, P. [Commissariat a l' Energie Atomique, 92 - Fontenay-aux-Roses (France). Centre d' Etudes Nucleaires. Departement de la Protection Sanitaire, Laboratoire-etable de Radiobiologie Appliquee

1967-07-01

The authors give the results of a series of experiments on metabolism of ingested iodine-131 in adult sheep under lactation; the measurement were carried out over a number of years from 1961 to 1966. The work was concerned initially with the fixation of iodine 131 in the thyroid gland, with the calculation of radiation doses absorbed and with ways of showing up any possible radiation damage in the gland. The modes of absorption of iodine 131 and its elimination through milk, urine and the faeces were then considered. Finally, a last chapter is devoted to changes in the radioactivity of the blood and of the milk, to variations of the PBI level of the blood serum as to different methods for measuring this level. (authors) [French] Les auteurs rapportent les resultats d'une serie d'experimentations relatives au metabolisme de l'iode 131 ingere chez la brebis adulte en lactation, et qui se sont etalees sur plusieurs annees, de 1961 a 1966. Les etudes ont porte d'abord sur les aspects de la fixation de l'iode 131 dans la thyroide, avec le calcul des doses de rayonnements absorbees et les moyens de mettre en evidence les radiolesions eventuelles de la glande. Ensuite ont ete traitees les modalites de l'absorption de l'iode 131 et de son elimination par le lait, les urines et les feces. Enfin un dernier chapitre a ete consacre a l'evolution de la radioactivite du sang et du lait, aux variations ainsi qu'aux divers moyens d'evaluation du taux de PBI du serum sanguin. (auteurs)

Dosimetric comparison fixed-individualized activity in the treatment of serious disease with I -131; Comparacion dosimetrica actividad fija-actividad individualizada en el tratamiento de la enfermedad de graves con I-131

Energy Technology Data Exchange (ETDEWEB)

Melgar Perez, J.; Orellana Salas, A.; Santaella, Y.; Arrocha Acevedo, J. F.

2013-07-01

The iodine-131 therapy has become the treatment with radiopharmaceuticals more frequent in our country, as well as the largest source of exposure to ionizing radiation for members who surround the patient. The aim of this article is to analyse the recommendations of radiological protection which are delivered to the patient receiving radiation discharge, in terms of the duration of the same time, taking into account the radiopharmaceutical dose, the time of entry, the dose rate measured at one meter and the family environment among others. (Author)

Clinical factors affecting the outcome in postradioactive iodine (RAI) therapy patients - Philippine Heart Center experience

International Nuclear Information System (INIS)

Quinon, A.; Oabel, E.; Jimeno, C.

2007-01-01

Full text: Clinical factors such as patient's age, duration of the underlying autoimmune thyroid stimulus and anti-thyroid drug therapy may affect the outcome of patients who underwent RAI therapy. Objective: To evaluate the clinical factors affecting the outcome of RAI therapy. Methodology: Patients (n=41) with Graves' disease treated with anti-thyroid drugs were followed up after Radioactive Iodine therapy treatment. Thyroid scan, 2 and 24 hours radioactive iodine uptake were taken to compute for the therapy dose (120 uci) (computed thyroid weight in gms) (24-hour I 131 uptake). Patients were then divided into groups (Group 1= hypothyroid, Group 2= euthyroid, Group 3 hyperthyroid) based on their thyroid function results (FT3, FT4, TSH) after 2, 4, 6, 12 months post-therapy. Clinical and physiologic factors were then correlated with the outcome. Results: The population consisted of 41 patients (male=8, female=33) with an overall incidence of Group 1= 17%, Group 2= 54% and Group 3= 29% posttherapy. Factors such as age, with their means (Groups 134, 2= 39, 3=39 p= 0.42) and gland uptake (24-hour Groups 1= 53, 2= 61 358, p= 0.41) were not associated with the remission rate. Other factors that were related to the length of the disease such as duration of symptoms (Groups 121, 2=24, 3= 29 months p0.68), duration of medicine prior to RAI therapy (Group 1= 10, 2= 15, 3= 18 months p=0.306) and gland weight (Groups 1=40 2=42 3=46 grams p=0.78) tends to have a higher mean values in therapy failure patients. Conclusion: Clinical factors studied showed no significant differences among patients developing hypothyroid, euthyroid or hyperthyroid state. The data suggested that treatment failures in patients with Graves' disease could be improved by lessening the time interval between the diagnosis and radioactive iodine therapy. (author)

The absorption of iodine-131 on a ceramic matrix

International Nuclear Information System (INIS)

Han, H.S.; Park, U.J.; Dash, A.

2004-01-01

The retention of 131 I on ceramic rod coated with silver nitrate followed by coating with a polyurethane membrane to be applied in brachytherapy was studied. The concentration of silver nitrate (20 g/l), the volume of 131 I as a sodium iodide solution (100 μl), the pH of the reaction mixture (pH 9) etc., were optimized to get a maximum uptake on the ceramic rod. The concentration of coating solution (5%, polyurethane in tetrahydrofuran) was also optimized to obtain a minimum leaching of 131 I activity in normal saline solution. After coating with a polyurethane membrane, the 131 I absorbed on the ceramic rod exhibited low leachability (0.03%). This method can be applied for the preparation of 125 I interstitial sources to be used in eye and prostate cancer therapy. (author)

Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease

Science.gov (United States)

2013-01-01

Objective To describe the association of the rare and serious complication of liver toxicity in previously healthy Grave’s disease (GD) patients after the treatment with radioactive iodine 131I (RAI). Case presentation We report the clinical, laboratory and pathologic findings of 2 cases of severe liver toxicity associated with the treatment with RAI in previously healthy patients with GD. Clinical examination and laboratory investigations excluded viral hepatitis, autoimmune hepatitis, granulomatous disease, primary biliary disease, extrahepatic biliary obstruction, and heart failure. Case 1: A previously healthy 52-years old man reportedly having a typical GD but following RAI treatment, concomitantly developed severe liver toxicity that required 1 week of treatment in hospital. Case 2: A previously healthy 34-years old woman is reported as having a typical GD but developed jaundice following RAI treatment that required several weeks of in hospital treatment in the hepato-biliary department. In both cases, the liver dysfunction resolved after intensive treatment with hepato-protective agents. In this report the therapeutic considerations as well as the pathogenetic possibilities are reviewed. Conclusion To the best of our knowledge, this is the first description of the association observed, which is rare but may be severe and should be considered in any case of thyrotoxicosis where a liver dysfunction develops after the treatment with radioactive iodine 131I. PMID:23497434

Chemical treatment of wastewaters produced during separation of iodine 131

International Nuclear Information System (INIS)

Cohen, P.; Marcaillou, J.; Amavis, R.

1959-01-01

The authors report the development and assessment of a chemical treatment of radioactive wastewaters by co-precipitation. This treatment is aimed at replacing a treatment based on the use of calcium phosphate which proved to be insufficient for wastewaters resulting from the production of iodine 131. After a presentation of the characteristics of the effluents to be processed, the authors report co-precipitation tests performed on effluents before release in the storage vessel (by using barium hydroxide, lead acetate or lead sulfate) and on effluents diluted on the storage vessel. They show that a co-precipitation method based on the use of lead sulfate in alkaline medium gives the best results

Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience

International Nuclear Information System (INIS)

Verburg, Frederik A.; Haenscheid, Heribert; Biko, Johannes; Hategan, Maria C.; Lassmann, Michael; Kreissl, Michael C.; Reiners, Christoph; Luster, Markus

2010-01-01

In patients with advanced differentiated thyroid carcinoma (DTC), therapy with the highest safe 131 I activity is desirable to maximize the tumour radiation dose yet avoid severe myelotoxicity. Recently, the European Association of Nuclear Medicine (EANM) published a standard operational procedure (SOP) for pre-therapeutic dosimetry in DTC patients incorporating a safety threshold of a 2 Gy absorbed dose to the blood as a surrogate for the red marrow. We sought to evaluate the safety and effectiveness in everyday tertiary referral centre practice of treating advanced DTC with high 131 I activities chosen primarily based on the results of dosimetry following this SOP. We retrospectively assessed toxicity as well as biochemical and scintigraphic response in our first ten patients receiving such therapy for advanced DTC. The 10 patients received a total of 13 dosimetrically guided treatments with a median administered activity of 14.0 GBq (range: 7.0-21.4 GBq) 131 I. After 6 of 13 treatments in 6 of 10 patients, short-term side effects of 131 I therapy, namely nausea, vomiting or sialadenitis, were observed. Leukocyte and platelet counts dropped significantly in the weeks after 131 I treatment, but returned to pre-treatment levels by 3 months post-therapy. Serum thyroglobulin levels decreased after 12 of 13 treatments (median reduction: 58%) in 9 of 10 patients. In our initial patient cohort, high-activity 131 I therapy for advanced DTC based on pre-therapeutic blood dosimetry following the EANM SOP was safe and well tolerated. Such treatment almost always produced a partial biochemical tumour response. (orig.)

A case of xerostomia caused by exposure to radioactive iodine

International Nuclear Information System (INIS)

Kusafuka, Yuji; Kamata, Takahiro; Nakanishi, Yoshitaka; Kurita, Hiroshi; Sakai, Hironori

2012-01-01

Oral radioiodine ( 131 I) therapy is known to be an effective treatment for differentiated thyroid carcinoma, but it can cause salivary gland impairment. We report a case of xerostomia caused by oral radioiodine therapy for thyroid cancer. A 47-year-old woman consulted our hospital because of tongue pain accompanied by xerostomia. The patient had a history of receiving radioiodine therapy for metastatic thyroid carcinoma 3 times (total 9,990 MBq). Clinical examination demonstrated oral dryness and reduced salivary gland function. On the gum test, the salivary flow was 2 ml in 6 minutes. It was hard to continue chewing for more than 6 minutes because of irritation. A computed tomographic scan showed atrophic changes of both parotid glands. On radioiodine whole-body imaging, uptake of radioiodine was evident in both the parotid and submandibular glands. Based on these findings, xerostomia caused by salivary gland injury due to radioiodine therapy was clinically diagnosed. The salivary gland injury was irreversible, and the patient received symptomatic therapy and pilocarpine hydrochoride. Early intervention to avoid salivary gland injury is important in patients who receive radioactive iodine therapy. (author)

Dosimetric comparison fixed-individualized activity in the treatment of serious disease with I -131

International Nuclear Information System (INIS)

Melgar Perez, J.; Orellana Salas, A.; Santaella, Y.; Arrocha Acevedo, J. F.

2013-01-01

The iodine-131 therapy has become the treatment with radiopharmaceuticals more frequent in our country, as well as the largest source of exposure to ionizing radiation for members who surround the patient. The aim of this article is to analyse the recommendations of radiological protection which are delivered to the patient receiving radiation discharge, in terms of the duration of the same time, taking into account the radiopharmaceutical dose, the time of entry, the dose rate measured at one meter and the family environment among others. (Author)

Iodine 131 therapy patients: radiation dose to staff

International Nuclear Information System (INIS)

Castronovo, F.P. Jr.; Beh, R.A.; Veilleux, N.M.

1986-01-01

Metastasis to the skeletal system from follicular thyroid carcinoma may be treated with an oral dose of 131 I-NaI. Radiation exposures to hospital personnel attending these patients were calculated as a function of administered dose, distance from the patient and time after administration. Routine or emergency patient handling tasks would not exceed occupational radiation protection guidelines for up to 30 min immediately after administration. The emergency handling of several patients presents the potential for exceeding these guidelines. (author)

Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis

Energy Technology Data Exchange (ETDEWEB)

Khelds, A O; Ozols, V K; Shtelmane, I A

1986-03-01

A total of 1587 patients with thyrotoxicosis (1387 women and 266 men) were examined over time after /sup 131/I therapy. The radioactive drug was given once to 808 patients, two times to 337 patients, 3 times to 198 and 4 times to 82 patients. 669 patients received 74-185 MBq of /sup 131/I. 649 patients 222-370 MBq, 128 patients 407-555 MBq and 94 patients 592-740 MBq. The other 47 patients received /sup 131/I of higher activity. Posttherapeutic hypothyrosis was revealed in 5.4% of the cases. In half of the patients hypothyrosis developed after a single administration of /sup 131/I. In all the patients with posttherapeutic hypothyrosis, i.v. administration of thyroliberin resulted in a significant rise of the thyrotropin level indicating to great importance of this test. A follow up of such patients is necessary as hypothyrosis can develop at different time after treatment of thyrotoxicosis patients with /sup 131/I.

Clinical Significance of Diffuse Intrathoracic Uptake on Post-Therapy I-131 Scans in Thyroid Cancer Patients

International Nuclear Information System (INIS)

Choi, Hyun Su; Kim, Sung Hoon; Park, Sonya Youngju; Park, Hye Lim; Seo, Ye Young; Choi, Woo Hee

2014-01-01

The purpose of this study was to identify the frequency and possible cause of diffuse intrathoracic uptake on post-therapy I-131 scans in thyroid cancer patients. We retrospectively reviewed 781 post-therapy scans of 755 thyroid cancer patients who underwent total thyroidectomy and radioactive iodine therapy between January and December 2010. Diffuse intrathoracic uptake on post-therapy scans was examined, and clinical patient characteristics including sex, age, regimen for thyroid-stimulating hormone (TSH) stimulation (thyroid hormone withdrawal or recombinant human TSH injection), TSH, thyroglobulin (Tg) and anti-thyroglobulin antibody (anti-Tg Ab) levels, therapeutic dose of radioactive iodine therapy and prior history of radioactive iodine therapy were recorded.Scan findings were correlated with chest CT, chest radiographs, laboratory tests and/or clinical status. Diffuse intrathoracic uptake without evidence of pathologic condition was categorized as indeterminate. The association between clinical characteristics and intrathoracic uptake were analyzed for negative intrathoracic uptake and indeterminate uptake groups. Diffuse intrathoracic uptake on post-therapy scans was demonstrated in 39 out of 755 (5.2 %) patients, among which 3 were confirmed as lung metastasis. The 14 patients that showed high Tg or anti-Tg Ab levels were considered to be at risk of having undetected micrometastasis on other imaging modalities. The remaining 22 were indeterminate (2.9 %). Upon comparison of negative intrathoracic uptake and indeterminate uptake groups, TSH stimulation by thyroid hormone withdrawal was shown to be significantly correlated with diffuse intrathoracic uptake (p <0.05). The frequency of diffuse intrathoracic uptake on post-therapy scans was 5.2 % and could be seen in thyroid cancer patients with underlying lung metastasis as well as those without definite pathologic condition. In the latter, there was a higher frequency for diffusely increased intrathoracic

External dose measurements for patients receiving therapeutic I-131 for thyroid cancer

International Nuclear Information System (INIS)

Molfetas, M.; Kottou, S.

2002-01-01

Iodine-131 is a well established and effective treatment, supplementing surgery, in differentiated thyroid carcinoma. Iodine-131 except from its β-emission, that generates a cell-killing effect in a small area, has also a γ-emission irradiating distant tissues and even people who are close enough with the treated patient. The International Commission on Radiation Protection, ICRP has estimated the probability of a radiation-induced fatal cancer for the whole population at 5.0 % per sievert for low doses and at low dose rates and at 1.3 % for serious genetic diseases. For elderly people the probability seems to be 3 to 10 times lower, whereas for children up to the age of 10 years, 2-3 times higher. These findings led the ICRP to recommend new dose limits, lower than the previous ones. The European Union has endorsed the ICRP recommendations and the Council issued two directives, with which the Greek legislation complied recently. The current annual public dose limit is 1 mSv, while in the new Greek legislation the concept of dose constrains (0.5 m Sv in Greece) has also been proposed as a goal to reach whenever possible

Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium)

International Nuclear Information System (INIS)

Monsieurs, M.; Thierens, H.; Dierckx, R.A.; Casier, K.; Simons, M.; Baere, E. de; Ridder, L. de; Saedeleer, C. de; Winter, H. de; Lippens, M.; Imschoot, S. van; Wulfrank, D.

1998-01-01

In view of the EURATOM 96/29 regulations, a prospective multicentre study was performed to evaluate the present guidelines given to relatives of patients treated with iodine-131 for both thyroid carcinoma and thyrotoxicosis, based on the real-life radiation burden. This study comprised 166 measurements carried out on a group of 94 relatives of 65 patients. All relatives wore a thermoluminescent dosemeter (TLD) on the wrist for 7 days. Sixty-one relatives agreed to wear another TLD for an additional 7 days. TLD were placed on nine patients' bedside tables. The eight participating centres were arbitrarily divided into three groups according to the period of time they advised their patients to sleep separately. Groups I, II and III respectively advised their patients to sleep separately for 0, 7-10 and 14-21 days. The median dose received by in-living relatives of thyroid carcinoma patients during the 14 days following hospital discharge was 281 μSv (doses to infinity not calculated); the median dose to infinity received by in-living relatives of ambulatory treated thyrotoxicosis patients was 596 μSv, as compared with 802 μSv for in-living relatives of hospitalised thyrotoxicosis patients. In general the children of patients received a significantly (P 131 I, while still following the ALARA principle. (orig.)

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.

Science.gov (United States)

George, Sally L; Falzone, Nadia; Chittenden, Sarah; Kirk, Stephanie J; Lancaster, Donna; Vaidya, Sucheta J; Mandeville, Henry; Saran, Frank; Pearson, Andrew D J; Du, Yong; Meller, Simon T; Denis-Bacelar, Ana M; Flux, Glenn D

2016-05-01

Iodine-131-labelled meta-iodobenzylguanidine (I-mIBG) therapy is an established treatment modality for relapsed/refractory neuroblastoma, most frequently administered according to fixed or weight-based criteria. We evaluate response and toxicity following a dosimetry-based, individualized approach. A review of 44 treatments in 25 patients treated with I-mIBG therapy was performed. Patients received I-mIBG therapy following relapse (n=9), in refractory disease (n=12), or with surgically unresectable disease despite conventional treatment (n=4). Treatment schedule (including mIBG dose and number of administrations) was individualized according to the clinical status of the patient and dosimetry data from either a tracer study or previous administrations. Three-dimensional tumour dosimetry was also performed for eight patients. The mean administered activity was 11089±7222 MBq and the mean whole-body dose for a single administration was 1.79±0.57 Gy. Tumour-absorbed doses varied considerably (3.70±3.37 mGy/MBq). CTCAE grade 3/4 neutropenia was documented following 82% treatments and grade 3/4 thrombocytopenia following 71% treatments. Further acute toxicity was found in 49% of patients. All acute toxicities resolved with appropriate therapy. The overall response rate was 58% (complete or partial response), with a further 29% of patients having stable disease. A highly personalized approach combining patient-specific dosimetry and clinical judgement enables delivery of high activities that can be tolerated by patients, particularly with stem cell support. We report excellent response rates and acceptable toxicity following individualized I-mIBG therapy.

Role of post-therapy 131Iodine SPECT-CT in risk stratification and management of patients with differentiated thyroid cancer

International Nuclear Information System (INIS)

Agarwal, K.; Bhattacharya, A.; Harishankar, C.N.B.; Manohar, K.; Mittal, B.R.

2010-01-01

Full text: To determine whether post therapy 131 I SPECT/CT changed the American Thyroid Association risk of recurrence classification and further management of the patients with differentiated thyroid carcinoma. Materials and Methods: In this prospective study, 33 consecutive patients with thyroid carcinoma (28 papillary, 4 follicular, 1 Hurthle cell) were included. Planar imaging and SPECT/CT were performed 4-7 days after the therapeutic administration of 1,221-5,180 MBq (33-140 mCi) of 131 I. SPECT/CT of the neck and upper chest were obtained for all subjects. Additional SPECT/CT scans of the abdomen or pelvis were acquired if planar imaging showed any abnormal focus of uptake. Planar and SPECT/CT images were interpreted independently, and sites of uptake were categorized as residual thyroid uptake, level VI cervical lymph node uptake, level II-V cervical lymph nodal uptake or distant metastasis. An experienced nuclear medicine physician determined if the imaging findings changed the patient's risk category and further management. Results: In 4 of 33 post surgical patients, SPECT/CT findings changed the initial ATA risk of recurrence classification. In 3 of these 4 patients, WB planar imaging showed distant metastases (1 in lung, 1 in spleen, 1 in left humerus), SPECT/CT confirming these to physiological uptake in breast and intestine and skin contamination respectively. This altered the risk of recurrence from high to intermediate category. In 1 of these 4 patients, WB planar imaging was suggestive of cervical lymph nodal metastasis, but SPECT/CT localized the abnormal focus of uptake to residual thyroid tissue, altering the risk of recurrence from intermediate to low. SPECT/CT changed the further post ablation management in 13 out of 33 patients. In 4/13 patients SPECT/CT detected cervical lymph nodes metastases, in 1/13 patient supraclavicular lymph node metastasis was detected, in 7/13 patients distant metastases was confirmed as physiological uptake or

Prediction of thyroidal 131I effective half-life in patients with Graves' disease.

Science.gov (United States)

Zhang, Ruiguo; Zhang, Guizhi; Wang, Renfei; Tan, Jian; He, Yajing; Meng, Zhaowei

2017-10-06

Calculation of effective thyroidal half-life (Teff) of iodine-131( 131 I) is cumbersome and tedious. The aim of this study was to investigate factors that could be used to predict Teff and to develop a Teff prediction model in Graves' disease patients. A total of 256 patients with GD were involved in this study. We investigated the influences of age, gender, disease duration, thyroid weight, antithyroid drugs, antithyroid drugs discontinuation period (ADP), thyroid function indexes, thyroid autoantibodies, thyroid-stimulating hormone receptor antibody (TRAb) level and radioactive iodine uptake (RAIU) values before 131 I therapy on Teff, applying univariate and multivariate analyses. Teff correlated negatively with thyroid peroxidase antibody, TRAb and thyroid weight, as well as positively with 24-hour, 48-hour, and 72-hour RAIU. Additionally, a longer ADP (especially≥ 14d) or without antithyroid drugs before 131 I therapy led to a longer Teff. Stepwise multiple linear regression analysis showed that 24-hour and 72-hour RAIU were statistically significant predictors of Teff ( P Graves' disease, with high prediction accuracy.

Salivary gland dysfunction following radioactive iodine therapy

International Nuclear Information System (INIS)

Wiesenfeld, D.; Webster, G.; Cameron, F.; Ferguson, M.M.; MacFadyen, E.E.; MacFarlane, T.W.

1983-01-01

Radioactive iodine is used extensively for the treatment of thyrotoxicosis and thyroid carcinoma. Iodine is actively taken up by the salivary glands and, following its use, salivary dysfunction may result as a consequence of radiation damage. The literature is reviewed and a case is reported in which a patient presented with a significant increase in caries rate attributed to salivary dysfunction following radioactive iodine therapy for a thyroid carcinoma

Status of thyroidal radioiodine (I-131) uptake and urinary iodine in Bangladesh population: A re-look following implementation of universal iodination of salt

International Nuclear Information System (INIS)

Alam, F.; Sultana Haque, F.; Karim, M.A.; Faruque, O.; Ali, L.; Azad Khan, A.K.

2007-01-01

Iodide plays a central role in thyroid physiology and in the production of thyroid hormones, which are essential for normal vertebrate growth and development. Radioiodine uptake test is one of the oldest radionuclide investigations for evaluation of thyroid function. On the other hand useful information about the nutritional status of a population can be obtained by measuring the prevalence of deficiency in a population. The main aim of this study was to find out the present status of urinary iodine and thyroid uptake status of people living in and around Dhaka City (Bangladesh). The present study was carried out over a period of three years from 1999 to 2002 involving 300 subjects inclusive of 216 females and 84 males. Efforts were made to randomly include people from a broad spectrum of social and economic strata, starting from people belonging to the lowest to the highest income groups; as well as people representing the urban, rural and suburban populations. Urinary iodine levels and 24 hour percentage radioiodine uptake by the thyroid were estimated in all subjects included in this study. Subsequently patients were grouped into four categories based on the values of their percentage 24-hour radioiodine uptake; e.g., Group-A (N-99) with lowest uptake (0-5%), Group-B (N=100) with uptake ranging between 5-10%, Group-C (N=73) with uptake ranging between 10-30% and Group D (N=28) with uptake above 30%. The median 24 hours RAIU values in groups A, B, C and D were 3, 7, 23 and 34% respectively. The corresponding mean urinary iodine levels in the four groups were 43.31, 33.95, 12.97 and 9.35μgm/dl respectively. The results have shown that 1.04, 3.48, 16.72 and 78.74% people studied had levels of urinary iodine indicating severe, moderate, mild or no iodine deficiency respectively as per the WHO Criteria (Severe: <2 μgm /dl, Moderate: 2-4.9 μgm /dl, mild: 5.0-9.9μgm /dl, normal: ≥ 10 μgm /dl). It may be noted that the normal values of Thyroidal I-131 uptake were

A Study on Labelling of Linolenic Acid as A Model of Isolated Benalu Teh for Cancer Diagnosis with Iodine-131

International Nuclear Information System (INIS)

Isti Daruwati; Eva Maria Widyasari; Nanny Kartini Oekar

2009-01-01

A study on active fraction of benalu teh has been carried out at Center for Application of Isotope and Radiation Technology - BATAN. This benalu teh active fraction has inhibition capability about 99% to the cancer cell. The isolated fraction is octadeca-8,10,12-triyonic acid compound which have long chain unsaturated fatty acid compound with three triple bonds. The Benalu teh active fraction has similar structure with linolenic acid which is a long chain unsaturated fatty acid with three triple bonds. Based on this similarity, the study of labelling of linolenic acid with iodine-131 has been conducted. The research was focused on optimum conditions for labelling of linolenic acid using Iodine-131 radionuclide. Labelling with iodine-131 was conducted using KIO 3 as an oxidizing agent, which can additionated linolenic acid and sodium metabisulfite for ending the reaction. Labelling efficiency determination was conducted using paper chromatography technique. The result showed that the optimum condition achieved by using KIO 3 as an oxidizing agent that gave radiochemical purity of 99,44% in virgin coconut oil, and labelling efficiency of about 69,9%. The labelled compound has high radiochemical purity i.e 96,85% in chloroform and 98,33% virgin coconut oil that was stable until 10 days in refrigerator. (author)

The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation

International Nuclear Information System (INIS)

Watanabe, Ken; Uchiyama, Mayuki; Fukuda, Kunihiko

2017-01-01

This article examines the outcome of radioactive iodine ablation therapy for thyroid cancer in nigh-risk patients and investigates background factors influencing ablation failure. We included 91 patients in this retrospective analysis and evaluated the ablation success rate. Successful ablation was defined as the absence of visible iodine-131 (I-131) accumulation in the thyroid bed after whole-body scans and thyroglobulin levels <2 ng/ml in a TSH-stimulated state after ablation. We extracted data on patients' age, sex, I-131 dose, pathology, resection stump findings, tumor T category and thyroglobulin levels, which could affect ablation outcome. Successful ablation was achieved in only 14 patients (15.4%). Pre-ablation serum thyroglobulin levels were significantly higher in the ablation failure group than in the success group (P < 0.001), while no significant differences were found for other factors between the groups. Furthermore, thyroglobulin levels >10 ng/ml were significantly related to ablation failure after multivariate analysis (odds ratio 27.2; 95% confidence interval 2.469-299.7; P = 0.007). The ablation success rate was very low because of high thyroglobulin levels, even with high-dose I-131. High-risk patients, especially those with high thyroglobulin levels (>10 ng/ml), are unlikely to reach levels low enough to meet successful ablation criteria. (author)

Thyroid dose from 131 iodine of the population in Poland following the Chernobyl accident

International Nuclear Information System (INIS)

Krzesniak, J.W.

1987-11-01

The following studies were carried out in the period from 28 April to 20 June 1986 in the Central Laboratory of radiological Protection (C.L.O.R.) in Poland: atmosphere monitoring in the period from 28 April to 22 May evaluating 131 I environmental concentration with the percentage of iodine in elementary, aerosol and organic compound form; determination of thyroid dose in 1049 persons from mine regions in Poland [fr

Diet low in iodine as well as goitrogens (LILGD) enhanced radioiodine (I-131) uptake in treatment of differentiated thyroid cancer

International Nuclear Information System (INIS)

Aaro, Erik; Gebre-Medhin, Mehari; Lindahl, Sten-AAke

2005-01-01

Full text: Low iodine diet (LID) is accepted as an adjuvant to post-thyroidectomy radioiodine therapy of differentiated thyroid cancer since it is held to enhance radioiodine uptake in thyroid remnants and thyroid cancer tissue. However, in the few clinical investigations performed only an indirect and weak evidence of a positive effect of the LID has been demonstrated. Also we had discouraging experience in the application of a strict LID using the same design as in the present study. We therefore decided to investigate the effect of a diet low in iodine as well as in goitrogens (LILGD). Methods: Six patients with differentiated thyroid cancer entered the study and they were their own control. After thyroid hormone withdrawal (TSH > 30 m U/L) and on regular diet a diagnostic whole body scan was performed 24 h after administration of 50 MBq (1,4 mCi) 123 I. The day following diagnostic scan the patients were put on LILGD for 4 days prior and two days after radioiodine therapy. In LILGD beverages, fruits and vegetables containing flavonoids, glucosinolates, cyanides and thiocyanates were avoided and spices and smoking prohibited. Therapeutic radioiodine was administered one week after diagnostic procedures and in the morning after over-night fasting with an activity range of 3,7-5,4 GBq (100 -150 mCi) 131 I. A 24-h therapeutic whole body scan and calculations of percentage uptake U(24) were performed. Diagnostic (basal) D U(24)% and subsequent therapeutic T U(24)% uptake were compared and expressed as therapeutic/diagnostic uptake ratios T/D U(24). Results: A significant increase in therapeutic versus diagnostic uptake T/D U(24) was observed (mean 2,53, median 2,30, range 1,40 - 4,46, p 131 I uptake in radio-ablation of normal and thyroid cancer tissue. (author)

18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans

International Nuclear Information System (INIS)

Ma, C.; Wu, Z.; Wang, H.; Wang, X.; Shao, M.; Zhao, L.; Jiawei, X.

2015-01-01

Aim of the present study was to investigate the usefulness of 18 F-FDG SPECT/CT in differentiated thyroid cancer (DTC) with elevated serum thyroglobulin (Tg) but negative iodine-131 scan. This retrospective review of patients with DTC recurrence who had 18 F-FDG SPECT/CT and 18 F-FDG PET/CT for elevated serum Tg but negative iodine-131 scan (March 2007-October 2012). After total thyroidectomy followed by radioiodine ablation, 86 consecutive patients with elevated Tg levels underwent 18 F-FDG SPECT/CT or 18 F-FDG PET/CT. Of these, 45 patients had 18 F-FDG SPECT/CT, the other 41 patients had 18 F-FDG PET/CT 3-4 weeks after thyroid hormone withdrawal. The results of 18 F-FDG PET/CT and SPECT/CT were correlated with patient follow-up information, which included the results from subsequent imaging modalities such as neck ultrasound, MRI and CT, Tg levels, and histologic examination of surgical specimens. The diagnostic accuracy of the two imaging modalities was evaluated. In 18 F-FDG SPECT/CT scans, 24 (24/45) patients had positive findings, 22 true positive in 24 patients, false positive in 2 patients, true-negative and false-negative in 6, 15 patients, respectively. The overall sensitivity, specificity, and accuracy of 18F-FDG SPECT/CT were 59.5%, 75% and 62.2%, respectively. Twenty six patients had positive findings on 18 F-FDG PET/CT scans, 23 true positive in 26 (26/41) patients, false positive in 3 patients, true-negative and false-negative in 9, 6 patients, respectively. The overall sensitivity, specificity, and accuracy of 18F-FDG PET/CT were 79.3%, 81.8% and 78.1%, respectively. Clinical management changed for 13 (29%) of 45 patients by 18 F-FDG SPECT/CT, 14 (34%) of 41 patients by 18F-FDG PET/CT including surgery, radiation therapy, or multi kinase inhibitor. Based on the retrospective analysis of 86 patients, 18F-FDG SPECT/CT has lower sensitivity in the diagnosis of DTC recurrence with elevated Tg and negative iodine-131scan to 18F-FDG PET/CT. The clinical

Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma; Obstrucao de vias lacrimais associada ao tratamento radioiodoterapico de carcinoma de tireoide

Energy Technology Data Exchange (ETDEWEB)

Fonseca, Fabricio Lopes da; Lunardelli, Patricia; Matayoshi, Suzana, E-mail: suzana.matayoshi@gmail.com [Setor de Plastica Ocular, Divisao de Clinica Oftalmologica, Universidade de Sao Paulo (HC/FM/USP), Sao Paulo (SP) (Brazil)

2012-03-15

Purpose: To report the finding of nasolacrimal drainage system obstruction associated with radio iodine therapy and to review clinical data and the surgical treatment outcome of this rare complication. Methods: We retrospectively analyzed ophthalmological data of patients with history of thyroid carcinoma that underwent radioactive iodine I-131 therapy and were referred to lacrimal surgery. Results: 17 patients with thyroid cancer treated with thyroidectomy and radioactive iodine I-131 therapy presented symptomatic nasolacrimal duct obstruction after 13.2 months following cancer treatment. 11 patients presented bilateral epiphora, 8 had lacrimal sac mucocele. Age range was 30 to 80 years, 10 patients had less than or equal to 49 years. The mean cumulative dose of radioiodine was 571mCi (range: 200-1200 mCi). Nasal obstruction symptoms and increased salivary glands were also present in 53% of patients. All subjects underwent dacryocystorhinostomy. Dilation of the lacrimal sac and increased intraoperative bleeding was also observed in 3 younger patients. Complete epiphora and dacryocystitis resolution after surgery occurred in 82.4%, and partial in 17.6% (3 patients that still presented unilateral relapse after correction of bilateral obstruction). Mean follow-up was 6 months (range: 2-24 months). Conclusions: Cumulative high dose of radioiodine, nasal and salivary gland dysfunction are associated with lacrimal drainage obstruction. We observed a great percentage of younger patients presenting dacryocystitis when compared to the idiopathic dacryostenosis. Radioactive iodine uptake by nasolacrimal duct mucosa with subsequent inflammation, edema and fibrosis seems to have a relationship to lacrimal duct obstruction. The knowledge of this complication is important for the study and proper management of these patients (author)

Production of fusion radionuclides: Molybdenum-99/ Iodine - 131 and Xenon-133; Produccion de los radionucleidos de fision: Molibdeno-99, Yodo-131 y Xenon-133

Energy Technology Data Exchange (ETDEWEB)

Barrachina, M; Carrillo, D

1982-07-01

This report presents a new radiochemical method for industrial production of the radionuclides: molybdenum-99, iodine-131 and xenon-133. The above mentioned method based on the alkaline metathesis reaction of irradiated uranium (IV) fluoride, presents the best characteristics for the proposed objective. The study deals with the analysis of that reaction and the separation and purification processes. (Author) 71 refs.

47 CFR 25.131 - Filing requirements for receive-only earth stations.

Science.gov (United States)

2010-10-01

... 47 Telecommunication 2 2010-10-01 2010-10-01 false Filing requirements for receive-only earth stations. 25.131 Section 25.131 Telecommunication FEDERAL COMMUNICATIONS COMMISSION (CONTINUED) COMMON CARRIER SERVICES SATELLITE COMMUNICATIONS Applications and Licenses Earth Stations § 25.131 Filing...

[Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131].

Science.gov (United States)

Hermida, J S; Jarry, G; Tcheng, E; Moullart, V; Arlot, S; Rey, J L; Schvartz, C

2004-03-01

Amioradone-induced hyperthyroidism is a common complication of amiodarone therapy. Although definitive interruption of amiodarone is recommended because of the risks of aggravation of the arrhythmias, some patients may require the reintroduction of amiodarone several months after normalisation of thyroid function. The authors undertook a retrospective study of the effects of preventive treatment of recurrences of amiodarone-induced hyperthyroidism with I131. The indication of amiodarone therapy was recurrent, symptomatic, paroxysmal atrial fibrillation in 13 cases and ventricular tachycardia in 5 cases (M = 14, average age 64 +/- 13 years). The underlying cardiac disease was dilated cardiomyopathy (N = 5), ischaemic heart disease (N = 3), hypertensive heart disease (N = 2), arrhythmogenic right ventricular dysplasia (N = 2) or valvular heart disease (N = 2). Two patients had idiopathic atrial fibrillation. An average dose of 576 +/- 184 MBq of I131 was administered 34 +/- 37 months after an episode of amiodarone-induced hyperthyroidism. Amiodarone was reintroduced in 16 of the 18 patients after a treatment-free period of 98 +/- 262 days. Transient post-radioiodine hyperthyroidism was observed in 3 cases (17%). Sixteen patients (89%) developed hypothyroidism requiring replacement therapy with L-thyroxine. There were no recurrences of amiodarone-induced hyperthyroidism. After 24 +/- 17 months follow-up, the arrhythmias were controlled in 13 of the 16 patients (81%) who underwent the whole treatment sequence. The authors conclude that preventive treatment with I131 is an effective alternative to prevent recurrence of amiodarone-induced hyperthyroidism in patients requiring reintroduction of amiodarone to control their arrhythmias.

Cost-utility analysis of antithyroid drug therapy versus 131I therapy for Graves' disease

International Nuclear Information System (INIS)

Hayashi, Katsumi; Abe, Katsumi; Sakata, Ikuko; Sakaguchi, Chiharu; Yamamoto, Kentaro; Kosuda, Shigeru

2005-01-01

There is no comparative cost-utility study between 131 I therapy and antithyroid drugs (ATD) therapy for Graves' disease, though 131 I therapy has higher remission rate and less side effects. The objective of the study was to analyze the cost-utility of ATD therapy versus 131 I therapy by calculating life-long medical costs and utility, based on the responses of Graves' disease patients to questionnaires. To determine the expected cost and expected utility, a decision tree analysis was designed on the basis of the 2 competing strategies of ATD therapy versus 131 I therapy. A simulation of 1,000 female patients weighing≥50 kg who assumed to experience the onset of Graves' disease at the age of 30, to first complain of thyrotoxic symptoms and moderate goiter 2-3 mo. previously, and to undergo a 40-years-long cohort study, was created for each strategy using a decision tree and baselines of other relevant variables. The variables and costs were based on the literature and hospital bills. The maximum and minimum values of utility were defined as 1.0 and 0.0, respectively. Future costs and utilities were discounted 5%. The medical costs and utilities were 85,739-88,650 yen/patient/40 years and 16.47-16.56/patient/40 years, respectively, for the ATD therapy strategy, and 81,842 yen/patient/40 years and 17.41/patient/40 years, respectively, for the 131 I therapy strategy. These results quantitatively demonstrated that the 131 I therapy strategy was superior to the ATD therapy strategy in terms of both cost and utility. 131 I therapy should be used more widely in Japan because of its greater utility and lower cost. (author)

Comparison of four different protocols of I-131 therapy for toxic single thyroid nodule

International Nuclear Information System (INIS)

Zakavi, S.R.; Mousavi, Z.

2007-01-01

Full text: Aim: Radio-iodine therapy is the preferred method of treatment of toxic thyroid nodule, however there is no consensus on the dose of I-131 administered. The aim of this study was to compare 4 different dose protocols for treatment of these patients. Methods and patients: All patients with hyperthyroidism and single hot thyroid nodule were referred for I-131 therapy after thyroid physical examination, ultrasonography and measurements of 24 hours thyroid iodine uptake. They were randomly entered in one of 4 groups: fixed low dose (FLD), fixed high dose (FHD), calculated low dose (CLD) and calculated high dose (CHD). In fixed dose protocol, 13mCi of I-131 was administered for patients in FLD group and 22.5mCi was administered for patients in FHD group. Quimby formula was used for calculation of radio-iodine dose in calculated groups with 90-100uCi and 180-200uCi per gram of thyroid weight in CLD and CHD groups respectively. Patients were followed up for a mean of 2, 5, 10 , 22 and 50 months later and physical exam and measurements of thyroid values were done in each follow up. Results: One hundred and sixteen patients were studied. One 72 year old patient was decreased 2 months after treatment due to coronary artery disease and 18 other patients did not complete follow up. From 97 patients who completed follow- up 8 patients were male and 89 patients were female. Mean age of patients were 43.3 years (SD=13.4) and mean thyroid nodule weight was 51 grams (SD=19.2).Mean 24 hours thyroid uptake was 48.07% (SD=14.07). Follow up was done up to 85 months with a median follow up of 14 months. Twenty two patients were in CHD group, 23 patients in CLD, 25 patients in FLD and 27 patients in FHD group. No significant difference was noted in 4 groups regarding age, sex, thyroid uptake and thyroid weight. The mean administered dose was 10.5mCi (SD=3.2) and 18.7mCi (SD=5.3) in CLD and CHD groups respectively (P<0.001). In CHD group, hyperthyroidism was decreased from 33

Iodine-131 in sewage sludge from a small water pollution control plant serving a thyroid cancer treatment facility.

Science.gov (United States)

Rose, Paula S; Swanson, R Lawrence

2013-08-01

Iodine-131 (half-life = 8.04 d) is the most widely used radionuclide in medicine for therapeutic purposes. It is excreted by patients and is discharged directly to sewer systems. Despite considerable dilution in waste water and the relatively short half-life of I, it is readily measured in sewage. This work presents I concentrations in sewage sludge from three water pollution control plants (WPCPs) on Long Island, NY. Iodine-131 concentrations ranged from 0.027 ± 0.002 to 148 ± 4 Bq g dry weight. The highest concentrations were measured in the Stony Brook WPCP, a relatively small plant (average flow = 6.8 × 10 L d) serving a regional thyroid cancer treatment facility in Stony Brook, NY. Preliminary radiation dose calculations suggested further evaluation of dose to treatment plant workers in the Stony Brook WPCP based on the recommendations of the Interagency Steering Committee on Radiation Standards.

Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma

International Nuclear Information System (INIS)

Nakajo, M.; Shimabukuro, K.; Miyaji, N.; Shimada, J.; Shirono, K.; Sakata, H.; Yoshimura, H.; Yonekura, R.; Shinohara, S.

1985-01-01

Iodine-131 MIBG, a radiolabeled adrenergic neuron-blocking agent, decreased rapidly from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma when compared with eight controls. However, there was no significant difference in the rate of [ 131 I]MIBG decrease in these organs between controls and patients in the intervals subsequent to 4 hr. These findings suggest that adrenergic neuronal uptake of [ 131 I]MIBG in these organs is smaller in the patients than in the controls. Measurements of time-activity relationships of radioiodinated MIBG may be useful for assessment of adrenergic function of these organs and thus of generalized disorders of adrenergic innervation

Radiation Dose to Family Member of Hospitalized Patient Receiving I-131 Therapy for Thyroid Cancer: Case Study

International Nuclear Information System (INIS)

Tuntawiroon, M; Chaudakshetrin, P; Sritongkul N; Thongprapal, T

2009-07-01

Full text: During high-dose I-131 therapy, hospitalized patient who is unable to walk to the bathroom is at risk of radiation burden to comforter from excreted urine. Foley catheter is usually placed in the patient before I-131 administration. The urine was collected and housed in lead shielding, emptied every 4 to 6 hours on the first day, and every 8 to 10 hours on subsequent days. After specific instructions with regard to radiation safety, family member designed as the caregiver of patient was provided an electronic personal dosimeter to directly measure radiation dose for three days in isolated hospitalization and two more weeks at home. The caregiver recorded time spent in contact with the patient and activities performed during these times. Total accumulative dose for 16 days was 650 μSv of which 44% (288 μSv) was from the first 24 hours and more than 70% (462 μSv) during the first 72 hours, and about 25% (162 μSv) from emptying urine bags. Most of the dose received (488 μSv) was from attending time spent in the vicinity of the patients. However, this was not exceeding the constraints of 1 mSv/y and well below the limit of 5 mSv in any one year for exposed caregiver and comforter

Radioiodine 131I metabolism in human

International Nuclear Information System (INIS)

Mori, Toru

1976-01-01

Metabolic fate of orally administered 131 I in human was studied. Chronological observations of whole body radioactivity distribution and thyroid 131 I uptake curve revealed that 131 I metabolism was greatly affected by the amount of dietary iodine intake. Under the high iodine intake exceeding 1 mg per day, uptake curve showed biphasic descending type, that is, rapid accumulation during 3 to 6 hours and rapid fall up to 48 hours and gradual decrease afterwards. While, ascending type, monophasic and maximal at 24 hours, was found universary under low iodine intake less than 500 μg per day. Thyroid function should not be affected by the amount of iodine intake, and we analysed 131 I metabolism using a new four compartments which included intrathyroidal inorganic iodine pool. The results, especially hormone production rate, were found quite useful even under high iodine intake. Thyroidal organic iodine contents were calculated as approximately 2.5 mg and this value was much less than previously reported values from other countries. Administered radioiodine were mixed up with stable body iodine and reached equilibration by around 10 days. From seroimmunological, histological (microscopic and electron microscopic) studies, and irradiation studies to the cultured human thyroid cells, we concluded that this unexpected phenomenon was derived from chromosomal damage which induced gradual decrease in cell population because of inability to reproduce. Carcinogenic and genetic effects were not serious, and only three leukemic patients were reported in this country and 484 normal babies were born from 7,500 treated parents. Thus, therapeutic dose of 131 I was proved rather safe, and even when exposed to radioiodine, administration of perchlorate or thiocyanate, excessive iodine and TSH seemed effective to avoid radiation injuries. (auth.)

Activity concentrations of iodine-131 and radiocesium in milk

International Nuclear Information System (INIS)

Rabitsch, H.; Kahr, G.; Oswald, K.

1991-12-01

We have measured the activity concentrations of iodine-131 and radiocesium in pasteurized fresh milk following the Chernobyl accident. Average monthly concentrations of radiocesium are given until December 1991. Samples originated from the local dairy (Milchhof Graz, Austria) and the measured activities in milk represent a large part of the total intake in the population of Graz. Observed activities are also compared with the activity levels obtained after the earlier nuclear contaminations. From the data of our measurements for radiocesium we have estimated the internal effective dose equivalent due to the intake of contaminated milk during the first year after the fallout. Results indicate that the averaged consumer rates for milk, usually used for predictions of dose, were too high. We have also observed great differences in the activity levels of raw milk and the activities in milk consumed by the population. (authors)

[Proposals for the revision of radiation protection measures for doses up to 222 MBq iodine-131 for whole body scintiscan for the detection of metastatic lesions].

Science.gov (United States)

Karaveli, Maria; Hatzigiannaki, Anastasia; Dedousi, Eleni

2006-01-01

The goal of this study was to estimate the necessary period of time, required for radiation protection instructions to be followed by patients with differentiated thyroid carcinoma (DTC) after total thyroidectomy who are given iodine-131 ((131)I) for a whole body scintiscan (WBS) in relation to the instructions of the European Commission and the ICRP. In order to estimate and evaluate the dose received by the family members and the general public, we have studied 30 patients and were given a dose of 92-222 MBq of (131)I for a diagnostic WBS. The patients studied were four men with mean age+/-standard deviation (M+/-SD)=55+/-6 y and 26 women with: M+/-SD=47+/-14 y. Dose rate measurements were carried out at the Nuclear Medicine Department of the AHEPA University Hospital; 1 h after the patients had received the (131)I dose and 48 h later when they returned to the hospital for the WBS. The calculated doses received by the in-living relatives of the patients and by the general public, assuming that radiation protection measures were applied for 2d, ranged between 76-640 microSv and 22-171 microSv respectively. In conclusion, the results of this study, compared to the dose constraints suggested by the European Commission, indicate that the duration of radiation protection guidelines for patients receiving (131)I for diagnostic purposes could be reduced to only two days without any potential risk to family members or to members of the public. The case of children of the immediate family environment, aged less than 3 y, was not investigated in this study.

Colon transit scintiraphy in health and constipation using oral iodine-131-cellulose

International Nuclear Information System (INIS)

McLean, R.G.; Smart, R.C.; Gaston-Parry, D.; Barbagallo, S.; Baker, J.; Lyons, N.R.; Bruck, C.E.; King, D.W.; Lubowski, D.Z.; Talley, N.A.

1990-01-01

The purpose of the study was to assess if a new scintigraphic method for noninvasive assessment of colonic transit could differentiate between subjects with normal bowel transit and those with constipation. Eleven normal subjects and 29 constipated patients were given 4 MBq iodine-131-cellulose ( 131 I-cellulose) orally and sequential abdominal scans were performed at 6, 24, 48, 72, and 96 hr from which total and segmental percent retentions were calculated. There were clear differences between the normal subjects and the constipated patients for the total percent retention at all time intervals, on a segmental basis in the right colon at 24 hr, and in all segments at 48 and 72 hr. Three-day urinary excretion of radioiodine was minimal; 2.4% +/- 1.2% (mean +/- s.d.) in constipated patients and 3.1% +/- 0.8% in normals, with approximately 75% occurring in the first day. The use of oral radiotracers in the investigation of constipation appears promising

Follow-up and evaluation of the pregnancy outcome in women of reproductive age with Graves’ disease after 131Iodine treatment

International Nuclear Information System (INIS)

Zhang, Li-Hua; Li, Jing-Yan; Tian, Qi; Liu, Shuang; Zhang, Hong; Liu, Sheng; Liang, Jiu-Gen; Lu, Xian-Ping; Jiang, Ning-Yi

2016-01-01

The aims of the present study were to analyze the outcomes of pregnancy, after 131 I treatment, in patients of reproductive age with Graves’ hyperthyroidism and to investigate the effects, if any, of the 131 I treatment on the mothers and newborns. From 2009 to 2014, 257 pregnant female patients with Graves’ hyperthyroidism in the outpatients at the Department of Nuclear Medicine and 166 healthy pregnant women from the Department of Obstetrics at Sun Yat-Sen Memorial Hospital were included in our study. They were divided into a 131 I therapy group (n = 130) and an anti-thyroid drug (ATD) group (n = 127) according to their therapy before conception. The neonatal gender, rate of preterm birth, body weight ratio and occurrence of low birth weight [except for higher rates of abortion (odds ratio; OR = 2.023) and cesarean delivery (OR = 1.552) in patients with Graves’ hyperthyroidism] showed no statistically significant differences from those of the healthy group (P > 0.05). The level of intrauterine growth restriction did not differ between the Graves’ hyperthyroidism group and the healthy group (8 vs 2, 3.0% vs 1.2%). The outcomes of pregnancy among the 131 I therapy group, ATD group and healthy group also showed no significant differences. Of the patients treated with 131 I, no significant differences were observed in the outcomes of their pregnancies, whether they received propylthiouracil (PTU), levothyroxine or no additional drug treatment during pregnancy. Women with hyperthyroidism who were treated with 131 I therapy could have normal delivery if they ceased 131 I treatment for at least six months prior to conception and if their thyroid function was reasonably controlled and maintained using the medication: anti-thyroid drug and levothyroxine before and during pregnancy.

Assessing Selenium, Manganese, and Iodine Status in Pediatric Patients Receiving Parenteral Nutrition.

Science.gov (United States)

Johnsen, Jacob Clarke; Reese, Susan Anne; Mackay, Mark; Anderson, Collin R; Jackson, Daniel; Paul, Irasema Libertad

2017-08-01

Pediatric patients who are receiving parenteral nutrition (PN) unsupplemented with trace minerals can become deficient. Due to shortages in trace mineral products and the 2004 American Society for Parenteral and Enteral Nutrition report stating that individualized trace element supplementation may be warranted, a review was conducted concerning the trace minerals selenium (Se), manganese (Mn), and iodine (I). A retrospective review of pediatric patients receiving PN that contained Se and Mn was conducted to determine if a difference existed between them and patients receiving PN without Se and Mn. Statistical analysis was done to assess a difference between trace mineral levels and the time to deficiency between supplemented and unsupplemented patients. Unsupplemented I patients had urine I levels assessed to determine deficiencies in patients receiving PN. Plasma Se levels were measured at a mean of 20 days for supplemented patients (n = 131) and 19 days for nonsupplemented patients (n = 57) with no difference between groups ( P = .2973). Plasma Mn levels were measured at a mean of 28 days, showing no statistical difference ( P = .721). Of the 177 nonsupplemented I patients, 74% demonstrated I deficiencies without supplementation. Time to the development of a Se, Mn, or I deficiency is important to guide supplementation of exclusive PN in children when trace mineral products are short in supply. Our retrospective experience supports assessment of the trace minerals Se at 21 days and Mn at 30 days. It also suggests that some pediatric patients receiving PN are deficient in I.

Testicular effects of 131radioiodine therapy for hyperthyroidism

International Nuclear Information System (INIS)

Ceccarelli, Claudia; Canale, Domenico; Carolina, Caglieresi; Moschini, Cecilia; Grasso, Lucia; Pinchera, Aldo; Vitti, Paolo

2005-01-01

Full text: Little data is available on possible untoward effects of 131 I therapy for hyperthyroidism on gonad male function. FSH, LH, Total Testosterone(T), Inhibin B and spermiogram were evaluated in 15 hyperthyroid males (mean age 38.5+/-6.7 years, m +/- SD) before, and at day 45, month 3, 6 and 12 after 131 I therapy. Mean basal FSH was 5.6 +/- 3.8 mU/ml. After 131 I, FSH remained unchanged in 13 patients. In two, one of whom with basal FSH in the upper normal limits (16.4 mU/ml), a mild increase was observed after therapy. Basal LH and T were in normal range and did not vary significantly after 131 I, but T/LH ratio significantly decreased at month 3 and 6 (basal: 1.34 +/- 0.6; month 3: 0.85 +/- 0.3, p=0.02, month 6: 0.8 +/- 0.1, p= 0.06). Basal Inhibin B values did not vary significantly after 131 I. Basal mean sperm concentration did not differ from that found in a control group of 20 normal men (51.0 +/- 6.9 x 106 E/ml, vs. 57.6 +/- 7.5 x 106 E/ml) and did not vary significantly after 131 I therapy. Sperm progressive motility (SPM) was 39.1+/-4.7 % in hyperthyroid patients and 54.4 +/- 1.8 % in the controls (p=0.02). Ten patients (67%) were asthenospermic (SPM 131 I treatment of hyperthyroidism may account for a marginal and transient damage of Leydig cells, as highlighted by T/LH ratio. The lower SPM and increased theratospermia observed in patients before treatment could be due to hyperthyroidism per se, as suggested by the normalization of SPM in 5/10 patients after therapy. (author)

Radio-iodine therapy and Helicobacter pylori infection

International Nuclear Information System (INIS)

Gholamrezanezhad, A.; Mirpour, S.; Saghari, M.; Abdollahzadeh, J.; Pourmoslemi, A.; Yarmand, S.

2008-01-01

Helicobacter pylori is the most important cause of gastritis and related morbidities. Following consumption, radioactive iodine accumulates considerably in the stomach. On the basis of this observation, we decided to determine whether the high radiation induced by radio-iodine in the stomach is effective in the eradication of this infection. All consecutive patients with differentiated thyroid carcinoma, who were referred for radio-iodine therapy [dose 117.1±24.4 mCi (4.3±0.9 GBq), range 100-200 mCi (3.7-7.4 GBq)], were enrolled. To detect H. pylori infection, the urease breath test (UBT) was performed 1-2 h before radio-iodine consumption and the test was repeated 2 months later. Of 88 patients, 71 had pre-treatment positive UBT. Of these, 23 patients had negative post-treatment result, which means a significant reduction (26.1%, 95% confidence interval (CI) 16.8-35.5%) in the number of positive UBT results in our treated population (32.4% of UBT-positive cases became UBT-negative). Considering the high prevalence of reinfection in developing countries, the therapeutic benefit would have been more considerable if the second UBT had been done with a lag time of less than 2 months. Although radio-iodine therapy is not a logical method for the treatment of patients suffering from H. pylori, our finding provides indirect evidence about the radiosensitivity of bacteria, the future clinical applications of which need to be further evaluated. Also this finding can be useful for the food industry, where radiation is used widely to sterilize food. Regarding the possibility of H. pylori suppression, we recommend not using UBT for screening for the infection for at least within 2 months following radio-iodine therapy. (author)

Radioiodine (I-131) therapy in thyroid cancer differentiated type (abstract)

International Nuclear Information System (INIS)

Khan, M.S.

1999-01-01

Carcinoma thyroid is not an uncommon malignancy in Pakistan because of its location in iodine deficient terrain. Painless palpable (solitary) thyroid nodule is the common presentation in majority (>90%) of the patients and > 25% cold nodules in females turned malignant on biopsy whereas in males >75% of cold nodules turned malignant on historical examination. The disease is more common in females as compared to males (3:1) and in females pure papillary carcinoma is more common whereas in males mostly follicular or mixed tumors are seen. Radical surgery (thyroidectomy) is not a routine surgical treatment in our country. In teaching hospitals the routine surgical procedure is lobectomy and Isthmectomy, whereas in DHQ Hospitals less surgical procedures, e.g. tumorectomy or partial labectomy etc. are done. Therefore, in view of limited/partial surgical ablation, I-131 ablation is mandatory for better and longer survival. We have treated 118 patients of thyroid carcinoma (Differential type) at our centre (AEMC) with therapeutic dose of Radioactive iodine (I-131) during the last 13 years with encouraging results (Disease free survival). (author)

An estimation of Iodine 131 intakes for occupational workers of nuclear medicine group at the Instituto Nacional de Cancerologia, Bogota, Colombia

International Nuclear Information System (INIS)

Nino, Nelcy Yasmin; Lagares, Luis Carlos; Veloza, Luz Stella; Martinez, Maria Cristina; Reyes, Amelia de los

2008-01-01

Full text: In nuclear medicine, unsealed radioactive substances are administered to patients for diagnosis, treatment or research. The manipulation of these radionuclides, particularly those volatile, like iodine 131 (I-131), generates a risk of internal contamination by ingestion and inhalation. The inhaled radioactive particles are retained in the lungs or uptake by the thyroid tissue and could produce health effects. The IAEA provides regulatory practices in handling radioactive material to reduce internal contamination in the staff, based on the radiation protection principle to achieve occupational doses as low as reasonably achievable (ALARA). A quality assurance program in radioprotection should include the monitoring of occupational intakes. This paper describes a pilot study which determined quantitative methods to monitoring the nuclear medicine staff. The estimates of intakes and doses of I-131 were derived from the review and interpretation of urine monitoring data, using a Ludlum model 203 Shielded Well Scintillator (2 inches diameter x 1.8 inches thick), with a ratemeter model 2200. This study included workers occupationally exposed to I-131: physicians, technicians, radio pharmacists and physicists. The initial tests of the activity levels of I-131 in urine showed an average MPBB (Maximum Permissible Body Burden) of 0.035%, i.e. 0.025 μCi. Comparing with the maximum value of whole body 0.7μCi, the percentages of I-131 MPBB indicate the presence of small activities of I-131 in the urine, suggesting low-level chronic exposures from occupational workers in Nuclear Medicine. The higher values are the medical personnel who perform treatments for thyroid disorders. Conclusion: To do statistically significant the sampling and to protect individuals in each area it should be considered the daily urinary excretion, which is due to implement a protocol for regular assessment of the levels of incorporation of iodine 131 for jobs and activities, personnel in

Using medically-derived iodine-131 to track sewage effluent in the Laurentian Great Lakes.

Science.gov (United States)

Montenero, Michael P; Dilbone, Elizabeth K; Waples, James T

2017-10-15

Tracking sewage wastewater in a large lake is difficult. Concentrations of pharmaceuticals that can be used as indicator compounds are quickly diluted and not easy to measure. In this study, we examined the potential of using medically-derived iodine-131 ( 131 I, t ½  = 8.02 d) as a tracer for Milwaukee sewage effluent in Lake Michigan. 131 I activities in sewage effluent from two Milwaukee wastewater treatment plants (WWTPs) were measured in conjunction with 131 I activities in water, sediment and biota in the Milwaukee Outer Harbor and Lake Michigan. 131 I discharge rates from both WWTPS ranged from 34 ± 15 to 1807 ± 24 MBq d -1 , with average and median 131 I discharges of 278 and 129 MBq d -1 . A budget of 131 I in the Milwaukee Outer Harbor - based on measured sediment and water column inventories - showed that ∼11% of the 131 I discharged to the harbor was scavenged to bottom sediments, ∼19% decayed in the harbor water column, and ∼70% was flushed out of the harbor to Lake Michigan. From this budget, we derived a harbor flushing rate of 3.1 days. In Lake Michigan, 131 I activity was found in Cladophora algae (undetected to 91 ± 2 Bq kg -1 ) along ∼40 km of shoreline. Benthic trawl samples showed 131 I activity up to 8 km from shore. Calculated 131 I length scales were 30 km alongshore and 3.4 km offshore and corresponded to sewage effluent dispersion rates of ∼2.6 km d -1 and ∼0.3 km d -1 in along- and offshore directions. Using 131 I as a tracer of sewage effluent from other coastal municipalities to the Laurentian Great Lakes appears feasible, particularly for larger (>10 5 ) population centers. Copyright © 2017 Elsevier Ltd. All rights reserved.

Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

Energy Technology Data Exchange (ETDEWEB)

NONE

1996-03-01

This publication is part of practical radiation safety manual series for different fields of application aimed primarily at persons handling radiation sources on a daily routine basis, which could at same time be used by the competent authorities, supporting their efforts in the radiation protection training of workers or medical assistance personnel or helping on-site management to set up local radiation protection rules. It is dedicated to therapeutic uses of Iodine-131: its application and procedures guides.

Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

International Nuclear Information System (INIS)

1996-01-01

This publication is part of practical radiation safety manual series for different fields of application aimed primarily at persons handling radiation sources on a daily routine basis, which could at same time be used by the competent authorities, supporting their efforts in the radiation protection training of workers or medical assistance personnel or helping on-site management to set up local radiation protection rules. It is dedicated to therapeutic uses of Iodine-131: its application and procedures guides

Evaluation of a potential parathyroid dysfunction under treatment with radioactive iodine of benign thyroid diseases

International Nuclear Information System (INIS)

Schumacher, Serena Christine

2011-01-01

.54 %). The serum level of intact parathyroid hormone prior to radioactive iodine therapy was on average 48.99 ± 24.05 ng/l [n=105], on day 1 after 131 I administration it decreased to 34.09 ± 16.25 ng/l [n=100], on day 3 to 32.74 ± 14.11 ng/l [n=97], on day 5 to 37.02 ± 21.52 ng/l [n=54] and at the follow-up examination one month after the start of the therapy it was on average 44.62 ± 20.54 ng/l [n=91]. On average the patients received a mean activity of 1341.43 ± 459.16 MBq [n=105] and the thyroid dose was on average 422.53 ± 245.56 Gy [n=101]. The one-way analysis of variance of all data up to day 3 confirmed the decline in the serum level of parathyroid hormone (p<0.0001). The student t-test for paired samples resulted in a statistically significant decrease in the mean values of parathyroid hormone level before therapy with regard to the mean values on day 1 (p<0.0001) and on day 3 (p<0.0001). The two-way analysis of variance, however, did not show a significant difference in the decline of the parathyroid hormone level with regard to the course of the four subgroups (p=0.32). A correlation between the absolute or relative decline of the parathyroid hormone level and the thyroid dose could not be proved. The present thesis demonstrates for the first time that already within the first days of radioactive iodine therapy a decline in parathyroid hormone serum level occurs. Most likely this is a consequence of an acute parathyroid dysfunction caused by ionizing radiation. It is improbable that this is due to immobilisation during treatment with radioiactive iodine as immobilisation by bed rest only leads to a significant decrease in parathyroid hormone serum level at the earliest after 12 days. A temporary subclinically hyperthyroidism on treatment with 131 I could not be excluded entirely as being the reason for the change in parathyroid hormone levels, but further research made this appear unlikely. Due to the fact that all values were determined during the morning

Radioactive iodine therapy for patients with Graves' disease aged 18 or younger

International Nuclear Information System (INIS)

Ogawa, Takahiro; Goshi, Kazuto; Tajiri, Junichi

2008-01-01

There have been few reports concerning radioactive iodine therapy (RI therapy) for Graves' disease in children, even in the United States of America (USA), and there have been no reports of such treatment in Japan. We evaluated the short-term results of RI therapy for Graves' disease aged 18 or younger. A total of 36 patients (10 male and 26 female) with Graves' disease, aged 18 and younger (range, 13 to 18 years; mean age, 15.8±1.5 years), received RI therapy on an outpatient basis at our clinic between July 1999 and July 2005. The mean interval from initiation of an antithyroid drug (ATD) to RI therapy was 25.3±21.5 months (range, 1 to 78 months). Twenty patients received therapy once, 14 twice, and 2 three times. The mean initial dose of radioactive iodine was 7.8±2.9 mCi (range, 3.6 to 13.0 mCi) and the mean total dose was 12.3±7.7 mCi (range, 3.6 to 29.8 mCi). The mean estimated weight of the thyroid gland was 42.6±23.4 g (range, 15.5 to 99.4 g) before RI therapy and 7.1±3.0 g (range, 2.0 to 13.6 g) after RI therapy. The mean follow-up period after RI therapy was 41.1±18.0 months (range, 6 to 71 months). Currently, 15 patients (42%) have hypothyroidism, 8 (22%) have subclinical hypothyroidism, 5 (14%) have euthyroidism, and 8 (22%) have subclinical hyperthyroidism. Patients taking thyroid hormone were considered hypothyroid. Patients with subclinical hypothyroidism are currently being monitored without treatment. No patients with subclinical hyperthyroidism are taking an ATD or KI (potassium iodide). A total of 36 patients with Graves' disease, aged 18 and younger, received RI therapy, and the short-term outcome in these patients were favorable. However, prolonged follow-up observation is required to confirm long-term safety. (author)

Uncertainty of inhalation dose coefficients for representative physical and chemical forms of iodine-131

Science.gov (United States)

Harvey, Richard Paul, III

Releases of radioactive material have occurred at various Department of Energy (DOE) weapons facilities and facilities associated with the nuclear fuel cycle in the generation of electricity. Many different radionuclides have been released to the environment with resulting exposure of the population to these various sources of radioactivity. Radioiodine has been released from a number of these facilities and is a potential public health concern due to its physical and biological characteristics. Iodine exists as various isotopes, but our focus is on 131I due to its relatively long half-life, its prevalence in atmospheric releases and its contribution to offsite dose. The assumption of physical and chemical form is speculated to have a profound impact on the deposition of radioactive material within the respiratory tract. In the case of iodine, it has been shown that more than one type of physical and chemical form may be released to, or exist in, the environment; iodine can exist as a particle or as a gas. The gaseous species can be further segregated based on chemical form: elemental, inorganic, and organic iodides. Chemical compounds in each class are assumed to behave similarly with respect to biochemistry. Studies at Oak Ridge National Laboratories have demonstrated that 131I is released as a particulate, as well as in elemental, inorganic and organic chemical form. The internal dose estimate from 131I may be very different depending on the effect that chemical form has on fractional deposition, gas uptake, and clearance in the respiratory tract. There are many sources of uncertainty in the estimation of environmental dose including source term, airborne transport of radionuclides, and internal dosimetry. Knowledge of uncertainty in internal dosimetry is essential for estimating dose to members of the public and for determining total uncertainty in dose estimation. Important calculational steps in any lung model is regional estimation of deposition fractions

Therapy of benign thyroid diseases (hyperthyroidism, autonomic adenomas, euthyreotic struma)

International Nuclear Information System (INIS)

Glanzmann, C.; Horst, W.

1976-01-01

The study deals with methods of treatment of benign thyroid affections: diffuse hyperthyroidism, autonomous adenoma, euthyreotic struma. 70% of the patients examined require resective therapy for diffuse hyperthyroidism. In the majority of the cases radio-iodine resection is the method to be chosen. The risk of an eventual X-ray cancer is smaller than the operation mortality. As far as children and adolescents are concerned, 131-iodine therapy is generally not advisable because of the carcinogenic risk which might be heightened. The autonomous adenoma can be eliminated without any problems by using 131-iodine. In case of a large adenoma with considerable regressive changes operation should be preferred. The therapeutic measures in the case of a struma mainly depend on the question if there are any clinical symptoms or any signs indicating an increased risk of malignancy. In case of mechanical complaints caused by a struma nodosa without important regressive changes parenchyma can be reduced by administering 131-iodine once or several times. The reduction of the thyroid function to the middle or lower limit of the normal range in case of euthyreosis is carried out by 131-iodine administration. (GSE) [de

Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis

International Nuclear Information System (INIS)

Hawkins, P.N.; Pepys, M.B.; Aprile, C.; Capri, G.; Vigano, L.; Munzone, E.; Gianni, L.; Merlini, G.

1998-01-01

Radiolabelled serum amyloid P component (SAP) is a specific tracer for amyloid. Iodine-123 has ideal physical characteristics for scintigraphy but is expensive and not widely available. Here we report serial imaging and turnover studies in which we labelled SAP with iodine-131, a cheap alternative isotope which would be expected to yield poorer images but permit more prolonged turnover measurements. Imaging and plasma clearance and whole body retention (WBR) of tracer were studied for up to 7 days in ten patients with proven systemic AL amyloidosis and two patients in whom the diagnosis was suspected, after i.v. administration of about 37 MBq of 131 I-SAP. Normal blood pool images were obtained in the latter two subjects and amyloidosis was subsequently refuted histologically. WBR at 48 h was 65% of the injected dose (i.d.). Among the other ten patients, amyloid deposits were identified in the spleen in eight cases, liver in five and kidneys in four; other sites that gave positive results included bone, joints and soft tissues, and the myocardium in one case. Up to 95% of the tracer localised into amyloid within 6-h, and the values for WBR became progressively more discriminating during the study period, exceeding the normal reference value ( 131 I-SAP produced diagnostic scans in every patient in this series and, coupled with the detailed turnover information, is adequate for monitoring disease progress. (orig.)

Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine

International Nuclear Information System (INIS)

Hoefnagel, C.A.; Den Hartog Jager, F.C.; Van Gennip, A.H.; Marcuse, H.R.; Taal, B.G.

1986-01-01

Scintigraphy using I-131 meta-iodobenzylguanidine has been introduced as an effective method to detect pheochromocytomas and neuroblastomas, and the radiopharmaceutical also is applied in therapy of these tumors. The authors present a case of a metastatic gastric carcinoid tumor, another neural crest tumor, concentrating I-131 MIBG, which was documented by conventional scintigraphy and SPECT in correlation with CT scans and colloid scintigrams of the liver. Two therapeutic attempts in this patient, using I-131 MIBG, are described. The metabolic basis of this phenomenon is discussed, and the importance of I-131 MIBG imaging in the detection of neural crest tumors is underlined

Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975

International Nuclear Information System (INIS)

Holm, L.E.

1982-01-01

The incidence of hypothyroidism was analyzed in 4,553 hyperthyroid patients treated with I-131 between 1951 and 1975. The average annual rate of hypothyroidism during the first 7 yr after therapy increased continuously for each 5-yr period of treatment, from 3.6% for patients treated between 1951 and 1955 to 7.7% for patients treated during the period from 1971 though 1975 (p less than 0.001). The increase in the incidence of hypothyroidism was seen before the introduction of TSH assays and when allowance was made for thyroid gland size, the age of the patient, and the experience of the radiotherapist. The use of TSH assays has probably resulted in an earlier recognition of hypothyroidism, which may explain why the most marked rise in the incidence of hypothyroidism was observed after the introduction of TSH assays

Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975

International Nuclear Information System (INIS)

Holm, L.E.

1982-01-01

The incidence of hypothyroidism was analyzed in 4,553 hyperthyroid patients treated with I-131 between 1951 and 1975. The average annual rate of hypothyroidism during the first 7 yr after therapy increased continuously for each 5-yr period of treatment, from 3.6% for patients treated between 1951 and 1955 to 7.7% for patients treated during the period from 1971 through 1975 (p<0.001). The increase in the incidence of hypothyroidism was seen before the introduction of TSH assays and when allowance was made for thyroid gland size, the age of the patient, and the experience of the radiotherapist. The use of TSH assays has probably resulted in an earlier recognition of hypothyroidism, which may explain why the most marked rise in the incidence of hypothyroidism was observed after the introduction of TSH assays

Effect on thyroid function and serum PTH, BGP, CT of small dose of iodine 131 combined with Methimazole in patients with hyperthyroidism

Directory of Open Access Journals (Sweden)

Jia-Yin Qiu

2016-03-01

Full Text Available Objective: To observe the effect on thyroid function and serum PTH, BGP, CT of small dose of iodine 131 combined with Methimazole in patients with hyperthyroidism. Methods: A total of 104 patients with hyperthyroidism willing be incorporated into the study were randomly divided into the observation group (54 cases and the control group (50 cases. The control group was treated with Methimazole, and the observation group was given a small dose of iodine 131 the basised on the control group. For 2 months, to observe the changes of thyroid function (TT3, TT4, FT3, FT4 and TSH and bone metabolism related indexes (PTH, BGP and CT of the two groups. Results: (1 After treatment, TT3, FT3, TT4 and FT4 of the two groups decreased with before, and the observation group improved more significantly than the control group, with statistical difference; TSH of the two groups had no significant change. (2 After treatment, BGP and CT of the two groups decreased and PTH increased, the observation group improved more significantly than the control group, with statistical difference. Conclusion: small dose of iodine 131 combined with Methimazole can correct thyroid function and bone metabolism quickly in patients with hyperthyroidism.

Evaluation of 131I retention in several adsorbers

International Nuclear Information System (INIS)

Catanoso, Marcela F.; Osso Junior, Joao Alberto

2011-01-01

Several iodine radioisotopes are used in nuclear medicine for treatment and diagnostic purposes. The radioisotope 131 I is used both in diagnosis and therapy due to its physical characteristics of decay by β - and its γ-ray emissions suitable for diagnosis. It is routinely produced at IPEN through the irradiation of TeO 2 targets in the IEA-R1m nuclear reactor. After the irradiation, the 131 I is separated by dry distillation, where the targets are put in an oven, heated at 760 deg C for 2 hours and the 131 I, volatile, is carried by an O 2 gas stream. The aim of this work was to evaluate the retention and elution of 131 I samples produced at IPEN in several adsorbers as part of a project aiming the purification of these radioisotopes, allowing the labeling of biomolecules. Samples of 131 I were used for retention and elution studies with the following adsorbers: commercial cartridges, anionic resin columns and cationic resin column. The results showed that Ag cartridges and anionic resins Dowex 1X8, Dowex 3 and IRA 400 had a great iodine retention but no elution after using specific eluents. The QMA light, acid alumina, neutral alumina and cationic resin Dowex 50WX4 showed high retention and elution and QMA plus and cationic resin Dowex 50WX8 and Dowex 50WX12 had a good retention but lower elution. Regarding to the better retention and elution, Ag cartridges and resins showed a higher percentage of iodine retention but lower elution yield and QMA light, acid and neutral alumina cartridges showed better results. (author)

Separation of iodine-131 from water using isotopic exchange with iodine-starch compound

International Nuclear Information System (INIS)

Ignatov, V.P.; Kolomejtseva, I.V.

1990-01-01

Conditions of iodine isotopic exchange with iodine-starch compound (ISC) were studied with the aim of compound utilizatoin for radioactive iodine separation from solution. It is shown that in pH range from 2 to 7 the degree of iodine extraction and coefficient of its distribution practically do not depend on pH, at pH>7 ISC destruction (decolorizing) starts and iodine extraction decreases. Rapid method of iodine separation from solution is suggested. The method can be used in radiochemical techniques. The degree of extraction equals 80 %, a higher degree of extraction can not be achieved owing to ISC formation peculiarities

Toxicity of upfront {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

Energy Technology Data Exchange (ETDEWEB)

Bleeker, Gitta; Schoot, Reineke A.; Caron, Huib N.; Kraker, Jan de; Tytgat, Godelieve A. [Emma Children' s Hospital, Academic Medical Centre (AMC), Department of Paediatric Oncology, PO Box 22700, Amsterdam (Netherlands); Hoefnagel, Cees A. [National Cancer Institute (NKI-AvL), Department of Nuclear Medicine, Amsterdam (Netherlands); Eck, Berthe L. van [Academic Medical Centre (AMC), Department of Nuclear Medicine, Amsterdam (Netherlands)

2013-10-15

In the treatment of patients with high-risk neuroblastoma, different doses of {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) are administered at different time points during treatment. Toxicity, mainly haematological (thrombocytopenia), from {sup 131}I-MIBG therapy is known to occur in extensively chemotherapy pretreated neuroblastoma patients. Up to now, acute toxicity from {sup 131}I-MIBG as initial treatment has never been studied in a large cohort. The aim of this retrospective study was to document acute toxicity related to upfront {sup 131}I-MIBG. All neuroblastoma patients (stages 1-4 and 4S) treated upfront with {sup 131}I-MIBG at the Emma Children's Hospital, Academic Medical Centre (1992 - 2008) were included in this retrospective analysis. The acute toxicity (during therapy) and short-term toxicity (1st month following therapy) of the first two {sup 131}I-MIBG therapies were studied. Of 66 patients (34 boys, 32 girls; median age 2.2 years, range 0.1 - 9.4 years), 49 had stage 4 disease, 5 stage 4S, 6 stage 3, 1 stage 2 and 5 stage 1. The median first dose was 441 MBq/kg (range 157 - 804 MBq/kg). The median second dose was 328 MBq/kg (range 113 - 727 MBq/kg). The most frequently observed symptoms were nausea and vomiting (21 %, maximum grade II). The main toxicity was grade IV haematological, occurring only in stage 4 patients, after the first and second {sup 131}I-MIBG therapies: anaemia (5 % and 4 %, respectively), leucocytopenia (3 % and 4 %) and thrombocytopenia (2 % and 4 %). No stem cell rescue was needed. The main acute toxicity observed was haematological followed by nausea and vomiting. One patient developed posterior reversible encephalopathy syndrome during {sup 131}I-MIBG therapy, possibly related to {sup 131}I-MIBG. We consider {sup 131}I-MIBG therapy to be a safe treatment modality. (orig.)

Sodium Iodide-131 (Na131I) AS Gelatin Capsules At TNRC-In Libya

International Nuclear Information System (INIS)

Sherief, M. F.; Abudeeb, F. N.; Abudaia, J. A.; Elghanoudy, Y. A.

2004-01-01

In this contribution, the production of a capsulated Na 131 I radiopharmaceutical, for treatment of variety of hyperthyroidism diseases, at Tajoura Nuclear Research Center in Tripoli-Libya is described. The process requires the application of a very small volume of iodine-131 (not more than 25μ l in some cases) with radioactivities reaching some 37 GBq per capsule. The application of such volume is necessary to prevent damage to gelatin material. Loading a volume of 100 μ l of radioactive Na 131 I solution containing 37 GBq. radioactivity within a capsule filled with anhydrous sodium hydrogen phosphate as an adsorption material for Na 131 I solution brings such solution into a direct interaction with the gelatin material. This is assumed to have an inadequate effect in therapy. To overcome this problem, the work team has introduced some substantial alterations on the irradiation procedure and the process of the pre-irradiation treatment of the target. As a consequence, that has successfully culminated in production of Na 131 I capsules with proper perspective (e.g. radioactive yield of 74 GBq from 37 GBq previously and radioactive concentration of 37 GBq/ml). (Authors)

Thyroid-hormone concentrations after radioiodine therapy for hyperthyroidism

International Nuclear Information System (INIS)

Tamagna, E.I.; Levine, G.A.; Hershman, J.M.

1979-01-01

Fourteen hyperthyroid patients (11 men, three women), ages 28 to 66, were followed with serial measurements of serum thyroid hormone levels for 1 mo after therapy with I-131. Twelve patients had diffuse toxic goiters (25 to 70 g in size); two patients had multinodular glands (40 to 100 g). The patients were taking no antithyroid medications; ten patients were treated with propranolol. All patients received the equivalent of 5000 rad, except the two with multinodular glands, who received larger doses. There was no consistent pattern of serum T 4 and T 3 levels after the I-131 therapy. For the entire group, there was no significant increase of the mean serum hormone concentration. One group (three patients) had a mean T 4 increase of 28% and a T 3 increase of 91% above baseline at Days 10--11. Seven patients had minimal increases of hormone levels at Days 2--3, and a third group (four paients) had no increase of thyroid hormones after I-131 therapy. The patients with no rise in hormone concentrations had smaller goiters than the other groups. There was no correlation of the dose of radioactive iodine, or of the initial hormone concentration, with the rises or declines of T 4 and T 3 levels after I-131 therapy. Radioiodine therapy caused no significant increase of serum T 4 and T 3 concentrations in the majority of patients

Survival improvement in patients with disseminated medullary thyroid carcinoma treated with 131I-MIBG therapy

International Nuclear Information System (INIS)

Mihaljevic, I.; Topuzovi, N.; Snajder, D.

2015-01-01

Full text of publication follows. Introduction and aim: The aim of this paper is to present our experience of 131 I-MIBG therapy in the cases of aggressive form of medullary thyroid carcinoma (MTC) with local and distant metastases. MTC is an uncommon thyroid tumor, accounting from 3-5% of all thyroid malignancies, and arises from para-follicular C cells which produce calcitonin (CT). Prognosis of MTC is related to tumor extension at disease detection, but long-term survival in patients with disseminated MTC is still unsatisfactory. Methods: 4 female patients with metastatic MTC (63, 69 and 2 patients aged 73 years), which already underwent total thyroidectomy and selective neck dissection, received therapy with 100 mCi 131 I-MIBG in our Institute. Patients had widespread disease with neck recurrences (all 4 cases), liver and bone metastases (2 cases) and lung metastases (1 case). All those patients received the therapy twice, second one 3 months up to 1 year after the first cycle. After therapy, whole body scintigraphy was performed; tumor marker levels (CT, carcinoembryonic antigen - CEA, neuron specific enolase - NSE, chromogranin A - CgA and pro-gastrin releasing peptide - pro-GRP) were measured before and after therapy. Results: in one patient we observed a slight decrease in CT level after first MIBG therapy, in another one a slight decrease in CEA serum level, and no lung metastases were visible on whole body scan after second 131 I-MIBG therapy. In one of the two remaining cases there was a significant decrease in CT serum level only after neck dissection. In all cases the patients reported an improvement in subjective symptom reduction. Conclusion: 131 I-MIBG therapy could provide additional benefit to patients with MTC and could improve overall survival, but more patient should be treated in order to define the true potential of the therapy. The aim of this paper is to present our experience of 131 I-MIBG therapy in the cases of aggressive form of

Considerations of food hygiene in the case of mussels accidentally contaminated by iodine 131

International Nuclear Information System (INIS)

Battani, N.; Chambost, Marie-Daniel; Leandri, Marcel

1969-09-01

As the transfer to mankind of radioactive pollution by food chains is a matter of concern, the authors report the study of the use of mussels contaminated by iodine 131 in a food preparation in order to follow the evolution of this radionuclide. After their contamination in seawater, mussels are prepared either with or without their shell. Counting is performed after cooking. Results are discussed in terms of presence of the radionuclide in the different parts of the crude or cooked mussels (shell, body, liquid) [fr

Standard dose 131I therapy for toxic multinodular goiter in an endemic goiter region

International Nuclear Information System (INIS)

Goncalves, E.; Castro, J.A.S.; Gross, J.L.

1986-01-01

The effect of the standard 15 mCi dose of 131 I on the thyroid function of 25 patients from an endemic goiter region with toxic multinodular goiter of different sizes was determined. The patients were followed for 1 to 5 years and 7 months (mean: 2 years and 10 months). Eighteen patients were treated with the antithyroid drugs propylthiouracil or methimazole before 131 I and seven only received 131 I. All but three patients achieved euthyroidism after a single dose of 131 I. Two patients in the antithyroid treatment group became hypothyroid 2 months and 2 years after the isotope therapy, respectively. Pretreatment with antithyroid drugs did not significantly modify the effectiveness of 131 I treatment. This simplified dose regimen of 131 I was effective in the treatment of hyperthyroidism caused by multinodular goiter in an endemic region, and the efficacy was independent of the size of the goiter. (author)

Comparison of curative effect of 131I and antithyroid drugs in Graves' disease: a meta analysis.

Science.gov (United States)

Yuan, Ju; Lu, Xiuqing; Yue, Yan

2017-03-01

Radioactive 131I is currently reported to be a potential effective intervention for Graves' Disease treatment in China. Whether 131I treatment was associated with effective outcome or reduced risk of side effects, reccurence rate remained unknown. Eligible studies were selected from Chinese VIP, Wangfang, CNKI databases using the keywords "Iodine" and "Graves Disease". Finally, 13 clinical trials met the inclusion criterion and were included this meta-analysis. Our meta-analysis included 1355 patients diagnosed of Graves' Disease with regular anti-thyroid drugs oral administration and 1320 patients with 131I therapy. The results showed that there was significant symptom improvement with radioactive iodine intervention (Odd Ratio (OR)=4.50, 95% CI [3.55, 5.71], PGraves' Disease. Treatment with 131I was associated with better clinical outcome; it reduced side effects and reccurence rate but increased hypothyroidism in Graves' Disease.

Iodine-131 dose dependent gene expression in thyroid cancers and corresponding normal tissues following the Chernobyl accident.

Directory of Open Access Journals (Sweden)

Michael Abend

Full Text Available The strong and consistent relationship between irradiation at a young age and subsequent thyroid cancer provides an excellent model for studying radiation carcinogenesis in humans. We thus evaluated differential gene expression in thyroid tissue in relation to iodine-131 (I-131 doses received from the Chernobyl accident. Sixty three of 104 papillary thyroid cancers diagnosed between 1998 and 2008 in the Ukrainian-American cohort with individual I-131 thyroid dose estimates had paired RNA specimens from fresh frozen tumor (T and normal (N tissue provided by the Chernobyl Tissue Bank and satisfied quality control criteria. We first hybridized 32 randomly allocated RNA specimen pairs (T/N on 64 whole genome microarrays (Agilent, 4×44 K. Associations of differential gene expression (log(2(T/N with dose were assessed using Kruskall-Wallis and trend tests in linear mixed regression models. While none of the genes withstood correction for the false discovery rate, we selected 75 genes with a priori evidence or P kruskall/P trend <0.0005 for validation by qRT-PCR on the remaining 31 RNA specimen pairs (T/N. The qRT-PCR data were analyzed using linear mixed regression models that included radiation dose as a categorical or ordinal variable. Eleven of 75 qRT-PCR assayed genes (ACVR2A, AJAP1, CA12, CDK12, FAM38A, GALNT7, LMO3, MTA1, SLC19A1, SLC43A3, ZNF493 were confirmed to have a statistically significant differential dose-expression relationship. Our study is among the first to provide direct human data on long term differential gene expression in relation to individual I-131 doses and to identify a set of genes potentially important in radiation carcinogenesis.

Treatment with antithyroid drugs or iodine following radioiodine therapy for Graves' disease

International Nuclear Information System (INIS)

Mazeto, Glaucia; Leal, B.M.B.; Souza, L.S.; Griva, B.L.; Moriguchi, S.M.; Moreira, C.C.; Lemos, A.C.; Kiy, Y.

2005-01-01

Full text: The effect of radioiodine ( 131 I) therapy in Graves' disease is gradual and the patients continue to be hyperthyroid for much time after this therapy. In a retrospective study, we compared the evolution of 196 patients in this situation treated with some therapeutic regimens. They received propylthiouracil or methimazole (ATD), one of them and potassium iodide (KI), KI only, or no drugs after 131 I therapy. ATD was started usually one day and KI two months after the radioiodine. The groups had similar age, pretreatment serum T 4 concentrations and 131 I treatment dose. Cure of the hyperthyroidism occurred in 83,9%, 75,5%, 75,0% and 70,6% in no-drugs, KI, ATD and KI-ATD groups, respectively. Hyperthyroidism was longer in KI and KI-ATD groups. Definitive hypothyroidism occurred in 39,2%, 47,2%, 52,9% and 66,1% in KI-ATD, KI, ATD and no-drugs groups, respectively. This condition appeared more quickly in no-drugs and ATD groups. Conclusion: We conclude that KI and ATD groups had similar evolutions as to cure of hyperthyroidism and occurrence of hypothyroidism. (author)

A comparison of physical and cytogenetic estimates of radiation dose in patients treated with iodine-131 for thyroid carcinoma

International Nuclear Information System (INIS)

Lloyd, D.C.; Purrott, R.J.; Dolphin, G.W.; Horton, P.W.; Halnan, K.E.; Scott, J.S.; Mair, G.

1976-01-01

Physical and cytogenetic estimates of the whole-body radiation doses have been compared in 11 patients receiving large doses of iodine-131 for the treatment of thyroid carcinoma. The physical estimate was based on the measurement of thyroid uptake, of the plasma activity variation, and of urinary activity. The cytogenetic estimate was obtained from the analysis of chromosome aberrations in peripheral blood lymphocytes. Good agreement between the estimates was observed in patients whose thyroid glands had previously be ablated by radioiodine. In patients who had varying degrees of thyroid function, there were considerable differences between the estimates with the cytogenetic value always being higher. It is suggested that these differences might be due in part to non-uniform irradiation of lymphocytes by local sources of activity in the thyroid and in the liver. (author)

Contamination of pasture by iodine 131

International Nuclear Information System (INIS)

Angeletti, Livio

1980-08-01

The reassessment of the experimental data on the transfer of iodine to aerial parts of rye-gras leads to the following significant findings: 1 - Water content of herbage depending markedly on time and location, the contamination of the vegetals has to be expressed on a dry weight basis. 2 - The value of the geometrical mean of the deposition velocity of iodine vapour as derived from 19 experiments carried out over 4 years is 0.76 cm/s. This value agrees very well with the value of V(d)=0.80 obtained in the USA during experiments comparable as to the number of tests and their duration. Consequently we propose a value of V(d)=0.76 cm/s for the evaluation of pasture land contamination by iodine resulting from routine releases. For accidental releases, however, we propose a value of V(d)=2 cm/s, which was the upper limit in about 90% of our experimental results. 3 - The analysis of data on wet deposition of iodine on the aerial parts of rye-grass shows that the initial retention when expressed as percent of the total deposit decreases with aspersion intensities. If expressed as retention factor, the initial retention is constant, for all aspersion intensities. The average initial iodine retention being lower by a factor of 2.3 than water retention the value of the latter will therefore be the upper limit for this radionuclide [fr

Test of irradiation of tellurium oxide for obtaining iodine-131 by dry distillation

International Nuclear Information System (INIS)

Alanis M, J.

2003-07-01

With the purpose of optimizing to the maximum independently the work of the reactor of those mathematical calculations of irradiation that are already optimized, now it corresponds to carry out irradiation tests in the different positions with their respective neutron fluxes that it counts the reactor for samples irradiation. Then, it is necessary to carry out the irradiation of the tellurium dioxide through cycles, with the purpose of observing the activity that it goes accumulating in each cycle and this way to obtain an activity of the Iodine-131 obtained when finishing the last cycle. (Author)

Administration of additional inactive iodide during radioiodine therapy for Graves' disease. Who might benefit?

International Nuclear Information System (INIS)

Dietlein, M.; Moka, D.; Reinholz, U.; Schmidt, M.; Schomaecker, K.; Schicha, H.; Wellner, U.

2007-01-01

Aim: Graves' hyperthyroidism and antithyroid drugs empty the intrathyroid stores of hormones and iodine. The consequence is rapid 131 I turnover and impending failure of radioiodine therapy. Can administration of additional inactive iodide improve 131I kinetics? Patients, methods: Fifteen consecutive patients, in whom the 48 h post-therapeutically calculated thyroid dose was between 150 and 249 Gy due to an unexpectedly short half-life, received 3 x 200 μg inactive potassium-iodide ( 127 I) daily for 3 days (Group A), while 17 consecutive patients with a thyroid dose of = 250 Gy (Group B) served as the non-iodide group. 48 hours after 131 I administration (M1) and 4 or 5 days later (M2) the following parameters were compared: effective 131 I half-life, thyroid dose, total T3, total T4, 131 I-activity in the T3- and T4-RIAs. Results: In Group A, the effective 131 I half-life M1 before iodine (3.81 ± 0.93 days) was significantly (p 131 I half-life M2 (4.65 ± 0.79 days). Effective 131 I half-life M1 correlated with the benefit from inactive 127 I (r = -0.79): Administration of 127 I was beneficial in patients with an effective 131 I half-life M1 of 131 I activity of T3 and T4 showed lower specific 131 I activity after addition of inactive iodine compared with patients from the same group with a lower initial specific 131 I activity of T3 and T4 and compared with the patient group B who was given no additional inactive iodide. This correlation was mathematically described and reflected in the flatter gradient in Group A (y = 0.5195x + 0.8727 for 131 I T3 and y = 1.0827x - 0.4444 for 131 I T4) and steeper gradient for Group B (y = 0.6998x + 0.5417 for 131 I T3 and y = 1.3191x - 0.2901 for 131 I T4). Radioiodine therapy was successful in all 15 patients from Group A. Conclusion: The administration of 600 μg inactive iodide for three days during radioiodine therapy in patients with Graves' hyperthyroidism and an unexpectedly short half-life of <3 or 4 days was a safe

Tests of some methods to remove I-131 from contaminated tap water

International Nuclear Information System (INIS)

Tagami, Keiko; Uchida, Shigeo

2011-01-01

Following the Fukushima Daiichi Nuclear Power Plant accident, iodine-131 concentrations in tap water higher than 100 Bq L"-"1 were reported by several local governments in the Kanto Plain in March 2011. To remove iodine-131 from tap water, five methods were tested in this study, that is, (1) boiling, (2) adding charcoals from oak or bamboo, (3) activated charcoals, (4) water purifiers, and (5) reverse osmosis (RO) treatments. Boiling was shown to be not effective in removing iodine-131 from tap water; indeed even higher concentrations may result from the liquid-volume reduction accompanying this process. Adding charcoals and activated charcoal treatment could not remove iodine-131, because no reduction of iodine-131 was observed in tap water samples after these treatments. Only limited effect was found with water purifiers with first several portions; no effect was expected with further water treatment. On the other hand, the RO showed high iodine-131 removal percentage of more than 95%, although the method needs about 5-10 L water to obtain 1 L of RO treated water. (author)

Evaluation of {sup 131}I retention in several adsorbers

Energy Technology Data Exchange (ETDEWEB)

Catanoso, Marcela F.; Osso Junior, Joao Alberto, E-mail: marcela.forli@gmail.co, E-mail: jaosso@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil). Diretoria de Radiofarmacia

2011-07-01

Several iodine radioisotopes are used in nuclear medicine for treatment and diagnostic purposes. The radioisotope {sup 131}I is used both in diagnosis and therapy due to its physical characteristics of decay by {beta}{sup -} and its {gamma}-ray emissions suitable for diagnosis. It is routinely produced at IPEN through the irradiation of TeO{sub 2} targets in the IEA-R1m nuclear reactor. After the irradiation, the {sup 131}I is separated by dry distillation, where the targets are put in an oven, heated at 760 deg C for 2 hours and the {sup 131}I, volatile, is carried by an O{sub 2} gas stream. The aim of this work was to evaluate the retention and elution of {sup 131}I samples produced at IPEN in several adsorbers as part of a project aiming the purification of these radioisotopes, allowing the labeling of biomolecules. Samples of {sup 131}I were used for retention and elution studies with the following adsorbers: commercial cartridges, anionic resin columns and cationic resin column. The results showed that Ag cartridges and anionic resins Dowex 1X8, Dowex 3 and IRA 400 had a great iodine retention but no elution after using specific eluents. The QMA light, acid alumina, neutral alumina and cationic resin Dowex 50WX4 showed high retention and elution and QMA plus and cationic resin Dowex 50WX8 and Dowex 50WX12 had a good retention but lower elution. Regarding to the better retention and elution, Ag cartridges and resins showed a higher percentage of iodine retention but lower elution yield and QMA light, acid and neutral alumina cartridges showed better results. (author)

Radioimmunotherapy in refractory b-cell nonhodgkins lymphoma with I-131-labeled chimeric anti cd-20 c2b8 (I-131 rituximab): preliminary result

International Nuclear Information System (INIS)

Kang, Hye Jin; Park, Yeon Hee; Kim, Sung Eun and others

2005-01-01

Recently, the native chimeric human-mouse anti CD-20 antibody IDEC-C2B8 (Rituximab) has been widely applied in NHL. This ongoing phase study was to evaluate whether radioimmunotherapy (RIT) with I-131 rituximab is effective in refractory B-cell NHL. Inclusion criteria were as follows: B-cell NHL with relapsed or refractory to primary standard therapy, measurable disease, adequate hematologic, renal, and hepatic function, informed consent. The rituximab (Mabthera, Roach) was radiolabeled with iodine-131(I-131) using a modified chloramine T method with high radiochemical purity (95%) and preservation of immuno-reactivity. All patients received loading doses of unlabeled rituximab (median, 40 mg: range, 20∼70 mg) immediately prior to administration of therapeutic dose (51.4∼152.2 MBq/kg), and then underwent gamma camera scan. 11 patients were enrolled (4 low-grade B-cell NHL, 7 DLBCL, median age 63 years). Patients had received a median of three prior chemotherapy regimens. The objective response rate was 36.4% (1 CR, 3 PRs). These all responses were observed in low-grade B-cell NHL, except one with DLBCL. Adverse events were primarily hematologic toxicities; the incidence of grade 3/4 neutropenia, thrombocytopenia, and anemia was 27.3%, 45.5%, and 18.2%, respectively. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. RIT with I-131 rituximab seems to be effective tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLBCL are warranted

Radioimmunotherapy in refractory b-cell nonhodgkins lymphoma with I-131-labeled chimeric anti cd-20 c2b8 (I-131 rituximab): preliminary result

Energy Technology Data Exchange (ETDEWEB)

Kang, Hye Jin; Park, Yeon Hee; Kim, Sung Eun and others [Korea University Medical School, Seoul (Korea, Republic of)

2005-07-01

Recently, the native chimeric human-mouse anti CD-20 antibody IDEC-C2B8 (Rituximab) has been widely applied in NHL. This ongoing phase study was to evaluate whether radioimmunotherapy (RIT) with I-131 rituximab is effective in refractory B-cell NHL. Inclusion criteria were as follows: B-cell NHL with relapsed or refractory to primary standard therapy, measurable disease, adequate hematologic, renal, and hepatic function, informed consent. The rituximab (Mabthera, Roach) was radiolabeled with iodine-131(I-131) using a modified chloramine T method with high radiochemical purity (95%) and preservation of immuno-reactivity. All patients received loading doses of unlabeled rituximab (median, 40 mg: range, 20{approx}70 mg) immediately prior to administration of therapeutic dose (51.4{approx}152.2 MBq/kg), and then underwent gamma camera scan. 11 patients were enrolled (4 low-grade B-cell NHL, 7 DLBCL, median age 63 years). Patients had received a median of three prior chemotherapy regimens. The objective response rate was 36.4% (1 CR, 3 PRs). These all responses were observed in low-grade B-cell NHL, except one with DLBCL. Adverse events were primarily hematologic toxicities; the incidence of grade 3/4 neutropenia, thrombocytopenia, and anemia was 27.3%, 45.5%, and 18.2%, respectively. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. RIT with I-131 rituximab seems to be effective tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLBCL are warranted.

Recombinant human thyrotropin stimulation prior to 131I therapy in toxic multinodular goitre with low radioactive iodine uptake.

Science.gov (United States)

Azorín Belda, M J; Martínez Caballero, A; Figueroa Ardila, G C; Martínez Ramírez, M; Gómez Jaramillo, C A; Dolado Ardit, J I; Verdú Rico, J

Stimulation with recombinant human thyrotropin (rhTSH) increases thyroid radioiodine uptake, and is an aid to 131 I therapy in non-toxic multinodular goitre (MNG). However, there are not many studies using rhTSH prior to 131 I in toxic multinodular goitre to improve hyperthyroidism and compressive symptoms. A prospective study was conducted on patients with MNG and hyperthyroidism. Patients were recruited consecutively and divided into group I, stimulated with 0.3mg of rhTSH before radioiodine therapy, and a control group or group II, without stimulation. Thyroid function, radioiodine thyroid uptake, thyroid weight, and compressive symptoms were measured, and patients were followed-up for 9 months. Group I consisted of 16 patients (14 women), with a mean age 69.7 years, and group II with 16 patients (12 women), with a mean age 70.7 years. After stimulation with 0.3mg rhTSH in group I, 131 I uptake (RAIU) at 24h increased by 78.4%, and the estimated absorbed dose by 89.3%. In group II, the estimated absorbed dose was lower than group I after stimulation with rhTSH (29.8Gy vs. 56.4Gy; P=0.001). At 9 months of follow-up, hyperthyroidism was controlled in 87.5% of patients in group I, and 56.2% in group II (P=0.049). The mean reduction in thyroid weight was higher in group I than in group II (39.3% vs. 26.9%; P=0.017), with a tendency towards subjective improvement of compressive symptoms in group I, although non-significant. Only 2 patients described tachycardias after rhTSH administration, which were resolved with beta-blockers. Stimulation with 0.3mg of recombinant human thyrotropin prior to radioiodine therapy achieves a reduction in thyroid weight and functional improvement in patients with hyperthyroidism and multinodular goitre with low uptake, and with no need for hospital admission. Copyright © 2016 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

International Nuclear Information System (INIS)

Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

1999-01-01

In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow's milk are considerably less . Detailed

Comparison of fixed low dose versus high dose radioactive iodine for the treatment of hyperthyroidism: retrospective multifactorial analysis impacting the outcome of therapy

International Nuclear Information System (INIS)

Suresh Kumar, A.C.; Malhotra, G.; Basu, S.; Asopa, R.V.

2010-01-01

Full text: Radioactive iodine ( 131 I) as a fixed dose protocol is widely used for treatment of hyperthyroidism. However, there is no consensus on the best optimum dose for an individual patient. The objectives of this study were to observe the outcome of 131 I therapy in patients of primary hyperthyroidism in relation to fixed low dose versus high dose regimen, impact of antithyroid drugs and influence of thyroid gland size on therapy outcome. Materials and Methods: Study design: Retrospective analysis. Study group included 287 diagnosed patients of primary hyperthyroidism who had undergone 131 I therapy for the first time (68 M, 219 F; Mean age ± S.D.: 43.84 ± 12.53). All patients with low RAIU, thyrocardiac disease were excluded. Details of antithyroid (ATD) drug treatment were recorded. Analysis was done from 2002 till patients became euthyroid/hypothyroid or until January 2010. Each patient's response was evaluated initially at 6 weeks and thereafter every three months. Appropriate statistical tests were applied to compare treatment response between the groups. A P value<0.05 was considered significant. Results: Of 287 patients, 209 patients had been administered low dose (Mean ± S.D.: 4.68 ± 0.62 mCi) while 78 patients had received high dose (Mean ± S.D.: 9.15 ± 1.05 mCi) of radioiodine. 57.9% (121/ 209) patients in the low dose group responded as compared to 75.6% (59/78) in high dose group after a follow up of more than 36 months. Similarly, among patients with and without antithyroid drug treatment, grade II and above goiters the response rates were significantly higher for high dose group as compared to low dose group. Conclusion: We suggest that high dose radioiodine treatment with 8 to 10 mCi is effective in treating hyperthyroidism in patients with a better success rate than the low dose treatment with 3 to 5 mCi. This is also likely to be helpful in patients who have not received antithyroid drugs. It appears that clinically relevant

An estimation of the risk for the use of stable iodine in radiation protection in an iodine deficient population

International Nuclear Information System (INIS)

Gloebel, B.; Gloebel, H.; Muth, H.; Andres, C.

1982-01-01

The radiation risk of the thyroid is estimated by use of data from the literature and our investigations. Comparing these results with the statistical incidence of radiation evoked diseases the risk of a patient to develop thyroid carcinoma receiving 50 μCi 131 I for thyroid diagnostics is about tenfold compared to the spontaneous risk with a twofold risk to develop hypothyroidism. Using sup(99m)Tc or 123 I these risks are minimized to a small percentage. For technicians in the RIA lab or during labelling of proteins the thyroid's radiation risk can be diminished by ingestion of inactive iodine, however, this procedure includes new risks of iodine side-effects. Comparing the pharmacological risks of iodine intake and the radiation risk it seems to be useful to suggest iodine prophylaxis when the expected radiation dose exceeds 10 rad in the thyroid. (author)

Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism

International Nuclear Information System (INIS)

Robertson, J.S.; Gorman, C.A.

1976-01-01

Published estimates of radiation dose to the gonads from 131 I therapy of Graves' disease vary widely, largely because of differences in assumptions regarding the details of iodine kinetics. The calculations described in this paper show that hyperthyroid patients treated with 10 mCi of 131 I will usually receive a total radiation dose to the ovaries or testes of less than 3 rad. Several common roentgenographic diagnostic procedures may involve a greater radiation dose and a greater genetic hazard than does the usual 131 I treatment for hyperthyroidism. It is important to minimize total exposure to radiation, but it seems unreasonable to deny 131 I treatment for hyperthyroidism to young men and nonpregnant young women on the grounds of genetic hazard alone

Implementation of the protocol on treatment of outpatients and hospitalized patients with iodine 131r

International Nuclear Information System (INIS)

Mildred De Mendoza, L.

1996-01-01

In Nuclear medicine different working protocols are used which are adequate for the treatment of patients with radioactive materials and which at the same time prevent the contamination of the occupationally exposed workers In Guatemala (the implementation of these protocols aims at keeping a records all the personal and centers that make use of iodine 131, improving the quality of diagnostic information; utilizing the necessary amount of radionuclide activity so as to ensure a good diagnosis and effectively utilizing economic resources

Survey of iodine metabolism in man illustrated by an iodide load investigation

International Nuclear Information System (INIS)

Bassoee, C.-F.; Langaasdalen, H.

1977-12-01

The first part of this report deals with the human metabolism of iodine, its sources, serum iodine, uptake in the thyroid, hormonal thyroid secretion and iodine excretion. The thyroid hormones are discussed as is the regulating of the iodine metabolism. The second part consists of a study performed on six healthy persons over two days. These were given 5mg iodine in aqueous solution rally and series of blood tests taken. Two persons were also given 100mg and 200mg respectively per day for 3weeks. The results are tabulated and discussed. In the third and final section the radiation hygiene aspects are treated. The basis is the uptake of large amounts of I - 131 from radioactive fallout. Carcinogenesis and hypothyroidism following this are discussed and therapy and iodine prophylaxis are described. (JIW)

Value of 201Tl imaging in predicting therapeutic 131I uptake in patients with thyroglobulin-positive but 131I scan-negative differentiated thyroid carcinoma

International Nuclear Information System (INIS)

Conlu, R.A.O.; Obaldo, J.M.

2004-01-01

Background: Serum thyroglobulin assay and 131Iodine (1311) whole body scan are considered complementary in detecting malignant thyroid tissue or metastases. A large number of patients, however, are encountered presenting with scan-negative, thyroglobulin-positive differentiated thyroid carcinoma posing a dilemma in therapeutic management. One of the first alternative scanning agents to be employed is 201Thallium (201Tl). Recent studies have demonstrated its usefulness in identifying lesions that are not visualized with traditional 131I whole body scan. It is not clear, however, whether 201Tl scan helps in the decision-making for subsequent 131I therapy. This study was conducted to determine if 201Tl scan can predict therapeutic 131I uptake and to define the clinical role of 201Tl scanning in these patients. Methods and results: A total of 12 patients (20-63 y/o), 5 males and 7 females, underwent surgery for differentiated thyroid cancer and all had serum thyroglobulin values above 10 ng/ml and normal TPO autoantibodies. Pre-therapy 131I scan using 111 MBq (3mCi) of 131I were obtained. As required for inclusion, all patients had negative pre-therapy scan and negative TPO autoantibody results and underwent 20lTl scanning within 3 weeks. All patients were given 131I therapy (3.7-5.5 GBq or 100-150 mCi) between one to two months after 201Tl scanning. Within a week after therapy, all patients underwent whole body 1311 scanning. 201Tl imaging demonstrated thyroid remnants in 9 out of 12 patients having positive 201Tl scan but negative pre-therapy 1311 scan. However, only 2 of the positive 201Tl scans showed 131I uptake post-therapy (positive predictive value of 20%). None of the subjects presented with a negative 201Tl scan and a positive post-therapy 131I scan. Conclusion: Our study suggests that evidence of remnants or metastases on 201Tl scanning may be an inappropriate basis for the decision to proceed with 131I therapy. The role of 20lTl imaging in this subset of

A model for determination of human foetus irradiation during intrauterine development when the mother incorporates iodine 131

International Nuclear Information System (INIS)

Vasilev, V.; Doncheva, B.

1989-01-01

A model is presented for irradiation calculation of human foetus during weeks 8-15 of the intrauterine development, when the mother chronically incorporates iodine 131. This period is critical for the nervous system of the foetus. Compared to some other author's models, the method proposed eliminates some uncertainties and takes into account the changes in the activity of mother's thyroid in time. The model is built on the base of data from 131 I-kinetics of pregnant women and experimental mice. A formula is proposed for total foetus irradiation calculation including: the internal γ and β irradiation; the external γ and β irradiation from the mother as a whole; and the external γ irradiation from the mother's thyroid

131I therapy of Graves' disease using lithium

International Nuclear Information System (INIS)

Sato, Kenshi

1983-01-01

Lithium is known to cause goiter and hypothyroidism. In the mechanism of goitrogenesis, there is general agreement that lithium inhibits the release of the thyroid hormones from the thyroid gland without significantly impairing other thyroid functions. The present study was undertaken, therefore, to investigate the usefulness of lithium in the radioiodine treatment of Graves' disease. Nine patients with Graves' disease who were all, except one, previously treated with antithyroid drugs were studied. 600 mg of lithium carbonate were administered daily to investigate the effects on thyroidal 131 I uptake, disappearance rate of 131 I from the prelabeled thyroid and the serum concentrations of thyroid hormones. Lithium showed no significant effect on the thyroidal 131 I uptake when the 24 hour thyroidal 131 I uptakes were determined both before and during lithium treatment in the five cases. On the other hand, lithium clearly prolonged the mean value of effective half-lives of 131 I to approximately 8 days vs. 5.1 days before lithium treatment (p 4 and T 3 levels significantly decreased during lithium treatment, from 21.3 to 12.4μg/dl (n=9, p 131 I for the Graves' disease can be reduced by using lithium, the radiation exposure to the total body is decreased. Moreover, it is possible to perform the 131 I therapy while improving the thyrotoxicosis with lithium. Finally, it is concluded that lithium is a very useful drug to be combined with the 131 I therapy of Graves' disease. (author)

Incidence of symptomatic salivary disease in patients with differentiated thyroid cancer treated with radioactive iodine

International Nuclear Information System (INIS)

Goni E, Ignacio; Selt A, Guillermo Vander; Ruiz A, Catalina; Leon R, Augusto; Solar G, Antonieta; Orellana B, Catalina

2015-01-01

Background: The radioactive iodine therapy for differentiated thyroid cancer can produce severe and frequent salivary symptoms, during the treatment or later. Aim: To analyze the incidence, severity and characteristics of the salivary signs and symptoms in these patients. Patients and Method: Retrospective and descriptive anal isis of 106 patients with confirmed diagnosis of differentiated thyroid cancer, treated with surgery and radioactive iodine, that completed a telephonic survey for the evaluation of salivary symptoms. Results: 26 (24.52%) patients presented with salivary symptoms or signs after the radioactive iodine therapy (mean 5 months). The average doses of I 131 was 128,5 mCi. Xerostomy, pain, xeroftalmy, inflammation, sialoadenitis and dysgeusia, were the most frequent clinical symptoms. Conclusions: After radioactive iodine therapy the salivary symptoms and signs incidence is high. We conclude that the indication for this treatment must be selective, but in accordance with the oncological risk of each patient

The early changes of thyroid hormone concentrations after 131I therapy for graves' hyperthyroidism - the role of pretreatment with methimazole

International Nuclear Information System (INIS)

Pirnat, E.; Fidler, V.; Zaletel, K.; Gaberscek, S.; Hojker, S.

2002-01-01

Full text: 131 I therapy may cause exacerbation of hyperthyroidism due to leakage of previously formed thyroid hormones from damaged thyroid cells in Graves' patients. To avoid this complication pretreatment with antithyroid drugs is recommended. Otherwise, the use of antithyroid drugs prior to 131 I therapy may diminish the success of 131 I therapy and should therefore be discontinued. The aim of our prospective clinical study was to compare early changes of thyroid hormone concentrations after 131 I therapy in Graves' patients, pretreated or not pretreated with methimazole. 92 consecutive Graves' patients, 84 females and 8 males, aged 17 to 80 were treated with 555 MBq of 131 I. Absorbed dose of 131 I was calculated. In the first group of 22 patients treatment with methimazole (20 mg/day) was discontinued 7 days before 131 I therapy, the second group of 33 patients received methimazole until the day of 131 I therapy and the third group of 37 patients was not pretreated with methimazole before 131 I therapy. 7 and 2 days before 131 I therapy and 2, 5, 12 and 30 days after serum free T 4 (fT 4 ) and free T 3 (fT 3 ) concentrations were measured. In the first group a significant increase of fT 4 and fT 3 was observed 7 days after discontinuation of methimazole (fT 4 14.60 ± 4.10 vs. 18.25 ± 7.16; fT 3 5.45 ± 1.44 vs. 7.79 ± 5.27 pmol/l), while gradual decrease of fT 4 and fT 3 was observed after 131 I therapy. In the second group a significant increase of fT 4 and fT 3 after 131 I therapy peaking on day 5 was observed (fT 4 20.91 ± 13.70 vs. 27.85 ± 18.17; fT 3 7.81 ± 5.21 vs. 9.42 ± 6.21 pmol/l). In the third group significant decrease of fT 4 and fT 3 concentrations was observed after 131 I therapy (fT 4 36.12 ± 18.55 vs. on day 12th 27.49 ± 15.20; fT 3 12.66 ± 7.04 vs. on day 12th 8.31 ± 4.92 pmol/l). No correlation between absorbed dose of 131 I and changes of fT 4 and fT 3 concentrations was observed. Therefore, our results indicate that not 131 I

Estimation of the activity and doses to personnel which intake Iodine 131 by coffee consumption in a cabinet of Nuclear Medicine

International Nuclear Information System (INIS)

Ruiz C, M.A.; Alfaro L, M.; Salinas, J.A.; Molina, G.

2003-01-01

Soon after an incident in a cabinet of nuclear medicine, its were carried out in the National Institute of Nuclear Research of Mexico (ININ), a series of bio essays measurements by whole-body counting to six people attributed to this cabinet. Of six people, five are classified as Occupational Exposed Personnel (POE), and the other one that works as secretary, according to the General Regulation of Radiological Safety, is classified as public member. Six people that were involved in this incident, the one which presumably it took place among November 15 and 18, 2002 and that it consisted on the effusion of a vial containing an unknown quantity of Iodine-131 to a coffeepot, they ingested coffee in diverse quantities. The Iodine-131 is used in nuclear medicine, so much for the illnesses diagnostic like in the treatment of thyroid cancer and of hyperthyroidism. (Author)

Metabolic therapy of thyroid by {sup 131}I and radiation protection; Therapie metabolique thyroidienne par {sup 131}I et radioprotection

Energy Technology Data Exchange (ETDEWEB)

Mathieu, I.; Caussin, J.; Smeesters, P.; Wambersie, A.; Beckers, C. [Centre de Medecine Nucleaire, Universite Catholique de Louvain, B-1200 Brussels (Belgium)

1997-12-31

The recommendations of International Commission on Radiological Protection (ICRP 60) to be applied in the European Union from the year 2000 imply a limit of the annual dose of 1 mSv for public as well as the compliance with the dose constraints. In order to verify the possibility of observing these new standards without losing the very favourable cost-profit of the {sup 131}I therapy in thyroiditis, 73 members of patient families treated by radioiodine were surveyed by direct dosimetry. A number of 22 patients afflicted with thyroid cancer received doses of 3700 to 7400 MBq and 18 hyperthyroid patients received 200 to 600 MBq. Dosemeters mounted around the neck were carried for 2-3 weeks by 35 spouses and 38 children 4 months to 25 years old. The residual thyroid radioactivity and the T{sub 1/2} of {sup 131}I were measured by gamma chambers in every patients. In the group of patients with thyroid cancers the effective T{sub 1/2} is 2.2 days. The doses measured in families are lower than 1 mSv in any spouses and lower than 0.3 mSv in all the children except one. In hyperthyroid patients the effective T{sub 1/2} is 6.2 days. The average dose received is 1.04 mSv (0.05-5.2) for spouses and 0.13 mSv (0.04-3.1) for children. These direct dosimetry data are reliable and allow to propose reasonable and efficient restrictions which will not compromise neither the efficiency of treatment or the environment safety

Treatments with radioactive iodine, 131 I. How, when and where?

International Nuclear Information System (INIS)

Ruiz J, A.; Gonzalez T, O.

2006-01-01

A great variety of approaches exists in the application of the treatments with radioactive materials, as the 131 I, but it is necessary to standardize them for the patient's benefit, because their doctor doesn't always know the principle that it bases this therapy, called metabolic therapy or radioiodine therapy (RYT). In this work the experience that was acquired by more of 50 years of RYT management in the Thyroid and Nuclear Medicine Clinic in patients with thyroid pathologies is informed, so that their management fulfills its function and it was carried out inside the corresponding juridical frame and the physicochemical and endocrinological principles that should take implicit. (Author)

Age dependency in the absorption of radioactive Iodine (131I) in the thyroid and total body of newborn, pubertal and adult fischer 344 rats

International Nuclear Information System (INIS)

Nitta, Yumiko; Endo, Satoru; Fujimoto, Nariaki; Kamiya, Kenji; Ohtaki, Megu; Hayakawa, Norihiko; Takada, Jun; Hoshi, Masaharu

1998-01-01

In this study, activities of 131 I in the thyroid, total body and blood were measured for rats of three different ages to estimate the movement of 131 I in the body, the absorbed doses were calculated in the thyroid and total body under the exposed condition of iodine deficiency and sufficiency, and the standard curves for the determination of absorbed doses in the thyroid and total body were obtained for rats of newborn, pubertal and adult. Authors used female rats of Fisher 344 strain in this experiment and set up twelve experimental group of different ages (1, 4 and 9 weeks old), and divided each age group into one standard diet (SD) group and three iodine deficient diet (IDD) groups. Rats were intravenously injected once with 131 I in 0.9% saline with the activity of 0.38, 1.03 and 9.42 kBq per g weight. In the thyroid and total body, the absorbed dose values increased in an injected activity-dependent manner, and those of 1-week-old rats were significantly higher than those of 4- and 9-weeks old rats. The absorbed dose values in IDD-treated groups were higher than those in the SD-treated groups. The speed of 131 I accumulation into the thyroid and that of 131 I excretion from the body was slow in 1-week-old groups. The data also showed that most of injected 131 I distributed in the thyroid and blood in 4- and 9-week-old groups but not in the 1-week-old group, indicating that 131 I is pooled in certain tissues or organs except the thyroid in rats of the 1-week-old group at which the development of the thyroid has not been completed. Standard curves were obtained for the estimation of absorbed doses in the thyroid and total body on the bases of injected activity of 131 I for each age group of rats. These standard curves are to be used in the carcinogenesis experiment which compare the effectiveness of internal with external irradiation under the condition of iodine deficiency or sufficiency in the rats of different ages. (K.H.)

Radiation exposure by radio-iodine release of the planned nuclear power plant Wyhl. Expert's opinion on thyroid exposure due to radioactive I-131

Energy Technology Data Exchange (ETDEWEB)

Bleck-Neuhaus, J

1981-01-01

The radioecology of iodine-131 in the off-air of a nuclear power plant is subject to investigation of the critical exposure pathway air - pasture ground - cow - milk. According to the findings on the factors influencing the radiation exposure of man presented in scientific publication we have to deviate today from static equilibrium models. Such models can no longer satisfy at the present state of the art. The viewing of the short-term time behaviour of the radioecological parameter that is imperative with iodine-131 shows that the conventional calculation, chiefly with mean values of many years, does not satisfy the requirements to replace the calculation of the radiation exposure at the most unfavourable points of exposure demanded by the Radiation Protection Ordinance. This report proves that in a number of possible events under normal operating conditions the radiation exposure is far more important and the limiting dose rates are unmistakably exceeded. If favourable conditions coincide it can in fact be expected that the radiation exposure by radio iodine remains below the limiting close rate.

Chemisorption of organic iodine compounds forming from fission isotopes of radioactive iodine

International Nuclear Information System (INIS)

Tot, G.; Galina, F.; Zel'd, E.

1977-01-01

Studied is ethyl iodine adsorption, labelled by iodine 131, on palladium black and on aluminium oxide activized by palladium. The desorption of adsorbed iodine in the temperature range of 20-600 deg C by the mass spectroscopy and thermal gravimetric methods was investigated. At the ethyl iodine and palladium interaction the bond between carbon and iodine in the ethyl iodine molecule breaks down and extracting iodine reacts with palladium, forming a stable compound at high temperatures. Desorption of adsorbed iodine is insignificant up to the temperatures of 250-300 deg C. Thus, sorbents, containing palladium, may be successfully applied for iodine absorption from the organic iodine compounds. These compounds spontaneously appear from the iodine fragment ratio isotopes during their interaction with some environmental organic impurities

Age-dependent exposure to radioactive iodine (131I) in the thyroid and total body of newborn, pubertal and adult fischer 344 rats

International Nuclear Information System (INIS)

Nitta, Yumiko; Fujimoto, Nariaki; Kamiya, Kenji; Hoshi, Masaharu; Endo, Satoru

2001-01-01

Female rats of the Fischer 344 strain at ages of 1, 4 and 9 weeks were exposed to 131 I intraperitoneally with activities of 0.38, 1.03 and 3.42 kBq per gram of body weight under the condition of iodine deficiency. The absorbed doses in the thyroid increased linearly depending on the injected activities. Irradiation at 1 week old caused heavier exposure than those at 4 and 9 weeks old by 7.5 and 7.7 times, respectively; however, damage of the thyroid tissue was more obvious in the 4-week-old groups than in the 1-week-old groups. The absorbed doses in the total body were proportional to the square root of the injected activities. The one-week-old groups were exposed more heavily than the 4- and 9-week-old groups by 3.6 and 4.7 times, respectively, shown by the slow excretion of 131 I with the values of effective half-life of 131 I activity (T eff ). An IDD-treatment was not so effective to enhance the 131 I absorption in the total body, as in the thyroid. No matter how the iodine concentration in the blood changed, the 1-week-old groups could not react to normalize the level. We drew standard curves, which enabled us to estimate the absorbed doses in the thyroid and the total body in the case of the injected activities of 131 I for the newborn, pubertal and adult rats. (author)

Diffuse Non-toxic Goitre Therapy with Iodine Alone or with Combination of Iodine and Levothyroxine

Directory of Open Access Journals (Sweden)

N Galkina

2008-12-01

Full Text Available Aim: to assess the efficacy and tolerability of low-dose iodine therapy compared with the combination of iodine and levothyroxine in endemic goitre patients. Methods: 12-month prospective study was performed, in which 81 patients were randomized on two groups: Group 1 (n = 40 - KI (200 micrograms/day and Group 2 (n = 41 - KI (100 mcg/day + L-T4 (1.0 mcg/kg. Thyroid volume, TSH and Anti-TPO-Ab levels were evaluated at baseline, at 8 month of the treatment and at 12 month (4 month after the cessation of the therapy. Results: the significant decreasing of thyroid volumes was found in group 1 at 8 month compared with baseline (20.5 ml at baseline and 16,4 ml at 8 month р < 0.001. After the therapy cessation the further benefit of a sustained effect was demonstrated (16.4 ml at 8 month and 16.1 ml at 12 month, р = 0.31. Iodine-induced hypo- and hyperthyroidism were not observed. High Anti-TPO-Ab level was found in one of 31 patients (3%. In group 2 significant difference between thyroid volumes was found at 8 month compared with baseline (20,5 ml at baseline and 16.2 ml at 8 month р < 0.001. The sustained effect was revealed at least 4 month after the therapy cessation (16.2 ml at 8 month and 16.1 ml at 12 month, р = 0.77. One man had iodine-induced subclinical hyperthyroidism. Anti-TPO-Ab was not detected in this group. No significant difference between thyroid volume decreasing, TSH and Anti-TPO-Ab levels in two comparable groups was observed. Conclusion: KI alone (200 mcg/day or the combination of L-T4 (1.0 mcg/kg and KI (100 mcg/day are equally effective and tolerable for endemic goitre therapy.

Radioiodine therapy in non toxic multi nodular goitre, preliminary results

International Nuclear Information System (INIS)

Chiti, A.; Travaini, L.L.; Tadayyon, S.; Vannucchi, G.; Fugazzola, L.; Beck-Peccoz, P.

2002-01-01

Aim: Aim of our study was to assess the efficacy of 131 I therapy in patients (pts) affected by non toxic multinodular goitre (NTMG). NTMG is a thyroid disease with a high prevalence, especially in low-iodine intake regions. Treatment of NTMG often requires surgery. However, thyroidectomy may be risky in some patients and radioiodine therapy could be an alternative treatment to reduce thyroid volume. We also evaluated if lithium administration can improve the efficacy of radioiodine treatment in this pts. Material and Methods: We enrolled 39 pts (8 males, 31 females; mean age 59 y, range 40-79 y) affected by NTMG. Mean thyroid volume (TV) at ultrasound was of 46.8 ml (range 18.5-87.3). Pts were randomised in 2 groups. Group 1: iodine therapy + lithium therapy 900 mg/die for 6 days; Group 2: iodine therapy alone. We also define 3 clusters of pts by TV. A:15-30 ml; B:31-40 ml; C: > 40 ml. The 131 I activity (MBq) was calculated as follows: [4.44 (MBq) x 100/24 hours uptake (%)] x TV. All patients are evaluated for thyroid function and TV at 3, 6, 12, 18 and 24 months after treatment, since we postulate that major reduction in thyroid volume will occur 1 year after 131 I therapy. Results: Up to now 16 pts were treated with 131 I (mean activity: 512 MBq) and no side effects from 131 I and lithium therapy were reported. Four out of 5 pts evaluated at 3 months (2 of group 1 and 3 of group 2) had a reduction in TV (mean value: 8.8 ml). Five out of 10 pts had sub-clinical hyperthyroidism at 1 week, likely as a consequence of thyroid tissue destruction. Conclusion: Our preliminary results suggest the safety and effectiveness of 131 I treatment in NTMG. We expect to clarify the role of lithium administration in improving 131 I efficacy. This therapy could have a future role in patients with NTMG that can't be submitted to surgery

Radioactive iodine ablation of Grave disease; Traitement ablatif par iode

Energy Technology Data Exchange (ETDEWEB)

Taieb, D.; Tessonnier, L.; Nwatsock, F.J.; Mundler, O. [Service central de biophysique et de medecine nucleaire, centre hospitalo-universitaire de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, (France)

2009-05-15

The isotopic destruction by iodine of the thyroid body is an alternative to the surgery in the radical treatment of the Basedow disease, particularly for recurrent forms. Several strategies are possible in the use of iodine 131. between 2004 and 2008, 240 patients with a Basedow disease were treated in our service by an ablative activity of iodine 131 (555 MBq on average). the results are rather reproducible, that is to say a quasi constant hypothyroidism in the first three months. It appears important to underline that the ambulatory management of induced hypothyroidism is often unappropriated with too progressive introductions of LT4, leaving the patient in deep hypothyroidism during several weeks. The recurrences at short and middle term are very rare ( under 4%). A case of severe exophthalmos was observed. The other patients did not progressed with corticosteroids. The evolution of anti receptors autoantibodies of the TSH have been studying. to conclude, this kind of strategy is very efficient and reproducible, but needs an appropriate management of post therapy hypothyroidism, source of discomfort and potential morbidity. (N.C.)

Cytogenetic in thyroid carcinoma and therapy with 131{sup I}; Citogenetica en cancer de tiroides y terapia con 131''I

Energy Technology Data Exchange (ETDEWEB)

Popova, L.; Hadjidekova, V.; Christova, R.; Agova, S.; Grudeva, V.; Hadjieva, T.; Dominguez, I.

2007-07-01

In order to assess the genotoxic risk of the therapy with radioiodine-131(''131I), the production of micronuclei (MN) and chromosome aberrations (CA) were analyzed in the peripheral blood lymphocytes of group of 26 patients undergoing therapy with this radionuclide for differentiated thyroid carcinoma (DTC). Blood samples were taken immediately before ''131 I administration and 1 month later. The patients underwent radioiodine ablation (RIA) or radioiodine therapy (RIT) after radical thyroidectomy. The amount of orally administered ''131I activity varied from 3330 to 4030 MBq according to the king of therapy (RIA or RIT). results show that after radioiodine therapy there is a significant increase in the frequency of MN and CA. The mean frequencies of MN {+-} Sd before and after the therapy were 10.72 % {+-} 5.84 % and 25.28 %{+-} 12.6% respectively. For CA, the mean frequencies obtained were 1.16% {+-} 0.36% before and 2.3% {+-} 0.87% after the therapy. These findings indicate a genotoxic activity of ''131I therapy estimated after a period of one month. (Author) 38 refs.

Image findings of a false positive radioactive iodine-131 uptake mimicking metastasis in pulmonary aspergillosis identified on single photon emission computed tomography-computed tomography

Directory of Open Access Journals (Sweden)

Kamaleshwaran Koramadai Karuppusamy

2015-01-01

Full Text Available High doses of iodine-131 are commonly used in patients with differentiated thyroid cancer after total or subtotal thyroidectomy, in order to ablate the remaining cancer or normal thyroid tissue. Multiple different false-positive scans can occur in the absence of residual thyroid tissue or metastases. The authors present a case of abnormal uptake of radioactive iodine in the aspergilloma, potentially masquerading as pulmonary metastases.

Estimation of iodine in soils by neutron activation analysis

International Nuclear Information System (INIS)

Krishnamoorthy, K.R.; Iyer, R.K.

1982-01-01

This paper reports the determination of the iodine content of soils by neutron activation analysis. The irradiated sample is fused with alkali in presence of 131 I tracer. From the aqueous extract, iodine activity is extracted into carbon tetrachloride and stripped back to aqueous phase with a high selectivity for iodine. 131 I tracer is used to measure chemical yield. Iodine contents in the range 1 to 20 ppm. have been determined by this technique. (author)

I-131 therapy for thyroid diseases: Doses, new regulations and patient advice

International Nuclear Information System (INIS)

Amaral, H.; Michaud, P.

2001-01-01

I-131 therapy has been widely used in the past 50 years. Its main applications are hyperthyroidism and functioning thyroid cancer. The indications, doses, regulations, precautions and guidelines differ in various centers. The following are recommended: 1. I-131 should be indicated in agreement of the endocrinologist and the nuclear physician with the patient consent; 2. Pre-treatment I-131 thyroid uptake must be performed; 3. The only contraindication for treatment is pregnancy, in children it might be used with caution; 4. For thyrotoxicosis both a calculated or an ablative dose (555 MBq) criteria are acceptable In this case secondary hypothyroidism must be considered an objective rather than a complication; 5. In uninodular toxic goiter a 1110 MBq dose is recommended; 6. Iodine free diet is indicated only for cancer patients; 7. Propylthiouracil (PTU) must be discontinued 5 days before treatment, it should be reinitiated 5 days later; 8. Prophylactic use of corticoid in Graves' disease still require more clinical data to support its use; 9. In treatment failure, wait six months for a new dose; 10. In intrathyroid cancer disease an ablative dose of 3700 MBq should be administered 4 weeks post-thyroidectomy or with a TSH level above 30 μUI/mL; 11. A whole body scan should be done one week later; 12. Follow-up whole body scan should be used only if there is clinical suspicion of metastasis. Thyroid hormone replacement must be discontinued for 30 days or with TSH value above 30 I/mL. For follow-up scan 185 MBq of I-131 are recommended to ovoid thyroid tissue stunning; 13. For metastases, 5700 to 7400 MBq dose is recommended if there are cervical lymphatic nodes or distant metastases. We recommended to adopt the criteria proposed by the United States Nuclear Regulatory Commission (NRC) published as 10 CFR 35.75 and the Regulatory Guide 8.39 for patients release after I-131 administration. (author)

A cause of false positive of the whole body scanning with iodine 131: obstructive hydronephrosis; Une cause de faux-positif du balayage corps entier a l'iode 131: l'hydronephrose obstructive

Energy Technology Data Exchange (ETDEWEB)

Sellem, A.; Elbez, I.; Rejeb, O.; Elkadri, N.; Hammami, H. [Service de medecine nucleaire, hopital Militaire, Tunis, (Tunisia)

2009-05-15

The objective is to report the case of a differentiated carcinoma of the thyroid with a false positive aspect to the whole-body scanning with iodine 131 in relation with an accumulation of the tracer at the level of an obstructive appearance hydronephrosis. (N.C.)

Evaluation of irradiation in patient's environment receiving 131I therapy

International Nuclear Information System (INIS)

Husar, J.; Fueriova, A.; Borovicova, F.

1998-01-01

This article describes measurements made in the bed station of Clinic of Nuclear Medicine in St. Elizabeth Oncological Institute in Bratislava. There are treated thyroid cancer and thyrotoxicosis with the use of 131 I. The aim of the measurements was to determine the possibility of the ambulation treatment of thyrotoxicosis or the possibility of shortening of the patient;s stay in the bed station that the effective dose would not be exceeded suggestions according to the publication of EURATOM. The measurements were made also with thyroid cancer patients but owing to clinical reasons the ambulation treating in this case is not permissible. Therefore this article does not describe the results of these measurements.The effective dose rates were measured in 0.25 m; 0.5 m; 1 m and 2 m distances from the patient's thyroid so the effective dose in the patient's surroundings could be determined. To the present time the results of effective dose rates measurements for 17 patients were evaluated by described way. The age of the patients was from 41 to 82 years, the administered quantity of 131 I was from 259 to 481 MBq, in fractions 37 MBq, 74 MBq, or 111 MBq. The calculated effective half-life of 131 I excretion from the patients body is crucial for the length of patient's necessary staying in the bed station, were from 4.2 days to 8 days. This great extend of values is given by by the different clinical parameters of the treated patients. After the analyse of them can be said that the effective half-life increases, when the patient is elder, has greater mass of thyroid and the accumulation is higher. At the present time authors don't suggest using the ambulation treatment of thyrotoxicosis by 131 I. For discharging the patient from the hospital authors suggest to think criteria according to the model of behaviour D with the effective dose limit 0.5 mSv. For the households with children up to 2 years and/or pregnant women according to the model B with effective dose limit 0

Thyroid uptake of I-131 during anti-thyroid drug treatment

International Nuclear Information System (INIS)

Hoque, M.; Alam, F.; Haque, F.S.; Karim, M.A.; Fariduddin, M.

2004-01-01

Hyperthyroidism is a global ailment and its treatment is very promising either by ant-thyroid drug or by radioiodine. Iodine-131 uptake test is very important for evaluation of hyperthyroid in respect to its therapy and to exclude thyroiditis. This study was performed to observe the thyroid uptake pattern during intake of anti-thyroid medicine and workout the possibility to start I-131 therapy just after withdraw of antithyroid drug without waiting few days. In this study total 252 patient's I-131 uptake test is performed. Among the patient 135 (53.57%) were female, 117 (64.43%) were male. All this patients were hyperthyroid both clinically and biochemically. Thyroid uptake was taken to all patients at 24 hours after oral administration of 5 to 10 micro-curie of I -131. Uptake was taken by an uptake system and recorded as percentage uptake. These patients are grouped into three categories. Group-A-newly diagnosed cases, who have not taken antithyroid drug or I-131 therapy, there were 82 patients in this group, and their mean uptake was 37.12 ±18.5%. Group B - this group of patients were studied during intake of antithyroid medicine, there were 130 patients in this group and their mean uptake was 34.34±16.0%. Group-B patients were further divided in two sub-groups, patients having antithyroid drug for 1 to 3 weeks (group-B 1), group B1 have mean uptake 37±21% and those were taking antithyroid for 3 weeks to 2 years (group-B2), group B2 have uptake 34.34±20%. Group C- these patients are taken from those patients who had withdrawn antithyroid drug for 3 days to 3 months, there were 40 such patients. Group C further divided into two sub-group, group-C1 (stopped for 3-10 days) and group C2 (stopped for 11 days to 3 months). Group C1 had mean uptake 38±16% and group C2 had mean uptake 35±19%. From this study it is observed that Iodine-131 uptake percentage of untreated hyperthyroid; during antithyroid drug treatment and after withdraw of antithyroid drug almost

Behavior of medically-derived 131I in the tidal Potomac River

International Nuclear Information System (INIS)

Rose, Paula S.; Smith, Joseph P.; Cochran, J. Kirk; Aller, Robert C.; Swanson, R. Lawrence

2013-01-01

Iodine-131 (t 1/2 = 8.04 d) is administered to patients for treatment of thyroid disorders, excreted by patients and discharged to surface waters via sewage effluent. Radionuclides generally behave like their stable analogs; therefore, medically-derived 131 I is useful as a transport-reaction tracer of anthropogenic inputs and the aquatic biogeochemistry of iodine. Iodine-131 was measured in Potomac River water and sediments in the vicinity of the Blue Plains Water Pollution Control Plant (WPCP), Washington, DC, USA. Concentrations measured in sewage effluent from Blue Plains WPCP and in the Potomac River suggest a relatively continuous source of this radionuclide. The range of 131 I concentrations detected in surface water was 0.076 ± 0.006 to 6.07 ± 0.07 Bq L −1 . Iodine-131 concentrations in sediments ranged from 1.3 ± 0.8 to 117 ± 2 Bq kg −1 dry weight. Partitioning in the sewage effluent from Blue Plains and in surface waters indicated that 131 I is associated with colloidal and particulate organic material. The behavior of medically-derived 131 I in the Potomac River is consistent with the nutrient-like behavior of natural iodine in aquatic environments. After discharge to the river via sewage effluent, it is incorporated into biogenic particulate material and deposited in sediments. Solid phase sediment profiles of 131 I indicated rapid mixing or sedimentation of particulate debris and diagenetic remineralization and recycling on short time scales. - Highlights: ► Medically-derived 131 I was measured in sewage effluent, river water, and sediments. ► Sediment 210 Pb and 7 Be profiles help characterize the sedimentary environment. ► 131 I flux to sediments in study area is ∼ 1% of that discharged in sewage effluent. ► 131 I distributions constrain reaction-transport processes to weekly time scales. ► Collectively these data are used to better understand iodine biogeochemistry

Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

Energy Technology Data Exchange (ETDEWEB)

Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

1999-07-01

In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow

Complications of high dose iodine therapy in the case of reactor accidents

International Nuclear Information System (INIS)

Joseph, K.; Hoeffken, H.

1996-01-01

In the case of a reactor accident pharmacological doses of iodine should be applied in order to reduce iodine 131 thyroid uptake. The risks may twofold: Iodine goiter only in a minority of predisposed persons or iodine induced hyperthyroidism in people with autonomously functioning thyroid tissue (AFTT). The risk of iodine induced hyperthyroidism in patients with AFTT increases with the amount of AFTT and depends on the amount of administered iodine, too. Small doses of iodine up to 100μg/day do not induce hyperthyroidism in these patients. But the optimisation of the daily iodine supply with 200μg/day is already sufficient to induce latent hyperthyroidism in 14% and clinically manifest hyperthyroidism in 4% of the patients with AFTT. The amount and the activity of autonomous thyroid tissue can be estimated by the determination of the Tc-99m-pertechnetate uptake during TSH-suppression (TcTUsupp), because TCTUsupp and the volume of autonomous thyroid tissue (Va) correlate linearly. All patients with got hyperthyroid had a TcTUsupp higher than 3,3%. From that the ''critical'' volume of autonomous thyroid tissue can be calculated to be between 8 and 12 ml, which equals a solitaire nodule with about 2.8 cm diameter. On the other hand an enhanced risk of hyperthyroidism can be excluded with a high probability in those patients whose TcTUsupp is less than 2%. (author). 32 refs

Complications of high dose iodine therapy in the case of reactor accidents

Energy Technology Data Exchange (ETDEWEB)

Joseph, K; Hoeffken, H [Phillips Univ., Marburg (Germany). Dept. of Nuclear Medicine

1996-08-01

In the case of a reactor accident pharmacological doses of iodine should be applied in order to reduce iodine 131 thyroid uptake. The risks may twofold: Iodine goiter only in a minority of predisposed persons or iodine induced hyperthyroidism in people with autonomously functioning thyroid tissue (AFTT). The risk of iodine induced hyperthyroidism in patients with AFTT increases with the amount of AFTT and depends on the amount of administered iodine, too. Small doses of iodine up to 100{mu}g/day do not induce hyperthyroidism in these patients. But the optimisation of the daily iodine supply with 200{mu}g/day is already sufficient to induce latent hyperthyroidism in 14% and clinically manifest hyperthyroidism in 4% of the patients with AFTT. The amount and the activity of autonomous thyroid tissue can be estimated by the determination of the Tc-99m-pertechnetate uptake during TSH-suppression (TcTUsupp), because TCTUsupp and the volume of autonomous thyroid tissue (Va) correlate linearly. All patients with got hyperthyroid had a TcTUsupp higher than 3,3%. From that the ``critical`` volume of autonomous thyroid tissue can be calculated to be between 8 and 12 ml, which equals a solitaire nodule with about 2.8 cm diameter. On the other hand an enhanced risk of hyperthyroidism can be excluded with a high probability in those patients whose TcTUsupp is less than 2%. (author). 32 refs.

Iodine-131 imaging using 284 keV photons with a small animal CZT-SPECT system dedicated to low-medium-energy photon detection.

Science.gov (United States)

Kojima, Akihiro; Gotoh, Kumiko; Shimamoto, Masako; Hasegawa, Koki; Okada, Seiji

2016-02-01

Iodine-131 is widely used for radionuclide therapy because of its β-particle and for diagnostic imaging employing its principal gamma ray. Since that principal gamma ray has the relatively high energy of 364 keV, small animal single-photon emission computed tomography (SPECT) imaging systems may be required to possess the ability to image such higher energy photons. The aim of this study was to investigate the possibility of imaging I-131 using its 284 keV photons instead of its 364 keV photons in a small animal SPECT imaging system dedicated to the detection of low-medium-energy photons (below 300 keV). The imaging system used was a commercially available preclinical SPECT instrument with CZT detectors that was equipped with multi-pinhole collimators and was accompanied by a CT imager. An energy window for I-131 imaging was set to a photopeak of 284 keV with a low abundance compared with 364 keV photons. Small line sources and two mice, one of each of two types, that were injected with NaI-131 were scanned. Although higher counts occurred at the peripheral region of the reconstructed images due to the collimator penetration by the 364 keV photons, the shape of the small line sources could be well visualized. The measured spatial resolution was relatively poor (~1.9 mm for full width at half maximum and ~3.9 mm for full width at tenth maximum). However, a good linear correlation between SPECT values and the level of I-131 radioactivity was observed. Furthermore, the uptake of NaI-131 to the thyroid gland for the two mice was clearly identified in the 3D-SPECT image fused with the X-ray CT image. We conclude that the use of an energy window set on the photopeak of 284 keV and the multi-pinhole collimator may permit I-131 imaging for a preclinical CZT-SPECT system that does not have the ability to acquire images using the 364 keV photons.

Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine

International Nuclear Information System (INIS)

Raymond, J.P.; Izembart, M.; Marliac, V.; Dagousset, F.; Merceron, R.E.; Vulpillat, M.; Vallee, G.

1989-01-01

We studied ovarian function retrospectively in 66 women who had regular menstrual cycles before undergoing complete thyroidectomy for differentiated thyroid cancer and subsequent thyroid remnant ablation with 131 I. Eighteen women developed temporary amenorrhea accompanied by increased serum gonadotropin concentrations during the first year after 131 I therapy. No correlation was found between the radioactive iodine dose absorbed, thyroid uptake before treatment, oral contraceptive use, or thyroid autoimmunity. Only age was a determining factor, with the older women being the most affected. We conclude that radioiodine ablation therapy is followed by transient ovarian failure, especially in older women

Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine

Energy Technology Data Exchange (ETDEWEB)

Raymond, J.P.; Izembart, M.; Marliac, V.; Dagousset, F.; Merceron, R.E.; Vulpillat, M.; Vallee, G.

1989-07-01

We studied ovarian function retrospectively in 66 women who had regular menstrual cycles before undergoing complete thyroidectomy for differentiated thyroid cancer and subsequent thyroid remnant ablation with /sup 131/I. Eighteen women developed temporary amenorrhea accompanied by increased serum gonadotropin concentrations during the first year after /sup 131/I therapy. No correlation was found between the radioactive iodine dose absorbed, thyroid uptake before treatment, oral contraceptive use, or thyroid autoimmunity. Only age was a determining factor, with the older women being the most affected. We conclude that radioiodine ablation therapy is followed by transient ovarian failure, especially in older women.

Behavior of Na131I and meta(131I) iodobenzylguanidine (MIBG) in municipal sewerage.

Science.gov (United States)

Fenner, F D; Martin, J E

1997-08-01

Behavior of 131I activity in primary sludge at the Ann Arbor, Michigan, Municipal Waste Water Treatment Plant was studied in relation to known radioiodine therapy events at the University of Michigan Hospital complex. The principal compounds administered are Na131I, which has widespread use, and meta (131I) iodobenzylguanidine (MIBG), which is a compound unique to the University of Michigan, although labeled antibodies and other forms are also used in therapy and research. The objectives of the study were to determine the environmental fate of such discharges and to determine radiation exposures to workers and the public when sludges are incinerated. Approximately 17% of the MIBG activity administered in a therapy was found in the primary sludge, whereas only 1.1% of the Na131I was in sludge. When land applied, the short half life of 131I in the sludge presents few radiological health concerns; however, incineration, which is done in winter months, is assumed to release organically bound 131I to the atmosphere. Radiation doses due to incineration of sludge containing measured concentrations were calculated for a maximally exposed worker to be 1.7 microSv (0.17 mrem) of which 0.48 microSv (0.048 mrem) was due to a 2-d upset condition. For a more typically exposed worker, and a member of the public, the committed effective dose equivalents were 1.2 microSv (0.12 mrem) and 0.06 microSv (0.006 mrem), respectively, for a 22-wk incineration period with release of all radioiodine in the sludge. Transport time to the treatment plant for radioiodine was found to be much longer than that of normal sewage, possibly due to organic material in sewer lines that absorb iodine. The residence time of radioiodine in the sewer also appears to be longer than expected; whether other radioactive materials are held up the same way is not known but chemical form is surely a factor.

Administration of additional inactive iodide during radioiodine therapy for Graves' disease. Who might benefit?

Energy Technology Data Exchange (ETDEWEB)

Dietlein, M.; Moka, D.; Reinholz, U.; Schmidt, M.; Schomaecker, K.; Schicha, H.; Wellner, U. [Koeln Univ. (Germany). Dept. of Nuclear Medicine

2007-07-01

Aim: Graves' hyperthyroidism and antithyroid drugs empty the intrathyroid stores of hormones and iodine. The consequence is rapid {sup 131}I turnover and impending failure of radioiodine therapy. Can administration of additional inactive iodide improve 131I kinetics? Patients, methods: Fifteen consecutive patients, in whom the 48 h post-therapeutically calculated thyroid dose was between 150 and 249 Gy due to an unexpectedly short half-life, received 3 x 200 {mu}g inactive potassium-iodide ({sup 127}I) daily for 3 days (Group A), while 17 consecutive patients with a thyroid dose of = 250 Gy (Group B) served as the non-iodide group. 48 hours after {sup 131}I administration (M1) and 4 or 5 days later (M2) the following parameters were compared: effective {sup 131}I half-life, thyroid dose, total T3, total T4, {sup 131}I-activity in the T3- and T4-RIAs. Results: In Group A, the effective {sup 131}I half-life M1 before iodine (3.81 {+-} 0.93 days) was significantly (p <0.01) shorter than the effective {sup 131}I half-life M2 (4.65 {+-} 0.79 days). Effective {sup 131}I half-life M1 correlated with the benefit from inactive {sup 127}I (r = -0.79): Administration of {sup 127}I was beneficial in patients with an effective {sup 131}I half-life M1 of <3 or 4 days. Patients from Group A with high initial specific {sup 131}I activity of T3 and T4 showed lower specific {sup 131}I activity after addition of inactive iodine compared with patients from the same group with a lower initial specific {sup 131}I activity of T3 and T4 and compared with the patient group B who was given no additional inactive iodide. This correlation was mathematically described and reflected in the flatter gradient in Group A (y = 0.5195x + 0.8727 for {sup 131}I T3 and y = 1.0827x - 0.4444 for {sup 131}I T4) and steeper gradient for Group B (y = 0.6998x + 0.5417 for {sup 131}I T3 and y = 1.3191x - 0.2901 for {sup 131}I T4). Radioiodine therapy was successful in all 15 patients from Group A

Chemical treatment of wastewaters produced during separation of iodine 131; Traitement chimique des eaux residuaires provenant de la preparation d'iode-131

Energy Technology Data Exchange (ETDEWEB)

Cohen, P.; Marcaillou, J.; Amavis, R.

1959-06-22

The authors report the development and assessment of a chemical treatment of radioactive wastewaters by co-precipitation. This treatment is aimed at replacing a treatment based on the use of calcium phosphate which proved to be insufficient for wastewaters resulting from the production of iodine 131. After a presentation of the characteristics of the effluents to be processed, the authors report co-precipitation tests performed on effluents before release in the storage vessel (by using barium hydroxide, lead acetate or lead sulfate) and on effluents diluted on the storage vessel. They show that a co-precipitation method based on the use of lead sulfate in alkaline medium gives the best results.

IODINE CONTENT OF ENTERAL AND PARENTERAL NUTRITION SOLUTIONS.

Science.gov (United States)

Willard, Devina L; Young, Lorraine S; He, Xuemei; Braverman, Lewis E; Pearce, Elizabeth N

2017-07-01

Iodine is essential for thyroid hormone synthesis, and iodine deficiency may result in thyroid disorders including goiter and hypothyroidism. Patients on long-term enteral nutrition (EN) or parenteral nutrition (PN) may be at risk for micronutrient deficiencies. The recommended daily allowance for iodine intake is 150 μg for nonpregnant adults. However, there is no current consensus among scientific societies regarding the quantity of iodine to be added in adult EN and PN formulations. The objective of this study was to determine the iodine content of U.S. adult enteral and parenteral nutrition solutions. This study also aimed to determine whether adult patients in the United States who are receiving long-term artificial nutrition may be at risk for iodine deficiency. Ten enteral nutrition solutions and 4 parenteral nutrition solutions were evaluated. The iodine contents of these solutions were measured spectrophotometrically and compared to the labeled contents. Measured and labeled EN iodine contents were similar (range 131-176 μg/L and 106-160 μg/L, respectively). In contrast, PN formulas were found to contain small, unlabeled amounts of iodine, averaging 27 μg/L. Typical fluid requirements are 30 to 40 mL/kg/day for adults receiving either total EN (TEN) or total PN (TPN). Adults on long-term TEN likely consume enough servings to meet their daily iodine requirements. However, patients on long-term TPN would require on average 5.6 L PN/day to meet the recommended daily allowance of iodine. This volume of PN is far in excess of typical consumption. Thus, U.S. patients requiring long-term TPN may be at risk for iodine deficiency. EN = enteral nutrition; PN = parenteral nutrition; TEN = total enteral nutrition; TPN = total parenteral nutrition; UIC = urinary iodine concentration.

The Relative Frequency of Persistent Hyperthyroidism After I131Therapy

International Nuclear Information System (INIS)

Al-EID, M.A.

1998-01-01

517 patients with different types of hyperthyroidism who had treated by I 131 therapy were studied. The study demonstrated that diffuse toxic goiter was the most common type of hyperthyroidism. The relative frequency of persistent hyperthyroidism in all types after the first dose of I 131 utilizing our empirical regimen in estimation of therapy doses was low (9.5%). While high frequency of persistent hyperthyroidism among diffuse toxic goiter patients (14%), probably was due to many factors discussed in this paper. Some of these factors are impossible to be estimated precisely and therefore, can not be avoided. But careful dose estimation for each case with diffuse toxic goiter may reduce the rate of retreatment by I 131 . Antithyroid medication prior to I 131 therapy might be another factor resulted in increasing of retreatment of retreatment rate diffuse toxic goiter cases. Longer time interval (more than 5 days) of ceasing antithyroid medication prior therapy is suggested to avoid the effects of these drugs. Patients with other types of hyperthyroidism were not frequently required more than one dose and the frequency of persistent hyperthyroidism was almost negligible

Iodine intake in Ireland

International Nuclear Information System (INIS)

Smith, P.P.A.; Hetherton, A.M.; O'Carroll, D.; Smith, D.F.; O'Halloran, M.J.; O'Donovan, D.K.

1988-01-01

A study of urinary iodine excretion and thyroid gland uptake of radioactive iodine 131 I was undertaken in the Dublin area with a view to providing data on the current iodine status in Ireland. A mean urinary iodine excretion of 118±82μg/gram creatinine (Median 96) obtained from 821 subjects attending general hospital outpatient clinics in the Dublin area in 1987, while excluding severe iodine deficiency in this particular cohort, obscured the fact that 250 (30%) had iodine excretion values ≤70 μ/g creatinine, a value approximating to the minimum daily iodine requirement. The results provide sufficient evidence of sporadic iodine deficiency to justify a more widespread study of the iodine status of the Irish population with a view to making recommendations on the possible need for iodine prophylaxis

Dosimetry prior to I-131-therapy of benign thyroid disease

International Nuclear Information System (INIS)

Haenscheid, Heribert; Lassmann, Michael; Reiners, Christoph

2011-01-01

The activity to be administered in I-131 therapy of benign thyroid disease is determined by the radiation absorbed dose necessary to cure the disease, the target mass, and the residence time of the I-131 in the target volume. Data from 73 patients with complete sets of uptake measurements 2, 6, 24, 48, and 96 (n = 53) or 120 (n = 20) hours after oral administration of 1 MBq I-131 were used to deduce residence times from subsets of 3, 2, or only 1 measurement for each individual. The values were compared to those obtained with the reference method, i.e. a fit of an uptake function based on a 2-compartment model to all 5 measurements, to quantify the errors introduced by the less demanding assessments. Deviations are less than 10% if the 2- compartment uptake function is fitted to only 3 values measured after 6, 24, and 96-120 h. Use of 2, 24, and 96-120 h data results in errors > 20% in individual patients. The effective half-lives as determined from 2 measurements after 24 and 96-120 h correlate well with those deduced from the reference method with larger deviations in individuals with slow iodine kinetics and late maximal uptake. Residence times determined from the 24 h uptake, assuming linear increase during the first day, and the effective half-life limited to maximum 8 days underestimate the actual values systematically in patients with long and short half-lives. These errors can be eliminated by a modification of the calculation method resulting in deviations less than 14% in all but one individual for this procedure. The accuracy of methods based on only one retention value increases with the time of measurement after the administration of I-131. While systematic errors up to a factor of two occur if the 24 h uptake is used for the estimate, deviations are less than 18% for measurements after 120 h. The results suggest that only one late uptake assessment warrants residence time estimates with an acceptable error. Given the high inherent uncertainties in the

Clinical Investigation and Treatment of Thyroid Disease with Radioactive Iodine (131I)

International Nuclear Information System (INIS)

Lee, Mun Ho; Koh, Chang Soon; Ro, Heung Kyu; Koo, In Seu; Suh, Whan Jo; Lee, Kyung Ja; Lee, Hong Kyu; Lee, Chung Sang

1970-01-01

A summary of the clinical data of the 131 I-thyroid function tests and the therapeutic results of 131 I among the 2,658 patients of various thyroid diseases treated over the past 10 years from May 1960 to Oct. 1969 at the Radioisotope Clinic and Laboratory, SNUH were presented and discussed. 1) The patients examined consisted of 929 cases (34.9%) of diffuse toxic goiter, 762 cases (28.7%) of diffuse nontoxic goiter, 699 cases (26.3%) of nodular nontoxic goiter, 58 cases (2.2%) of nodular toxic goiter and 210 cases (7.9%) of hypothyroidism. 2) There were 300 (11.4%) male and 2358 (88.6%) female, showing a ratio of 1 : 8. 3) The majority of patients (79.1%) were in the 3rd-5th decade of their lives. 3) The normal ranges, diagnostic values of 131 I uptake test, 48 hrs serum activity, BMR and main subjective symptoms of various thyroid diseases were discussed. 5) In the 579 patients among 867 cases with hyperthyroidism treated with 131 I, 47.8% were confirmed to be cured completely after single therapeutic doses. 6) The complications of 131 I therapy were discussed and myxedema had developed in 6.75% of our patients. 7) The results of 131 I thyroid function tests were analysed among the 160 cases of thyroid diseases which were confirmed the diagnosis with histopathological measures.

Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study

Energy Technology Data Exchange (ETDEWEB)

Brinks, Peter; Van Gils, Koen; Dickerscheid, Dennis B.M.; Habraken, Jan B.A. [Department of Medical Physics, St. Antonius Hospital, Nieuwegein (Netherlands); Kranenborg, Ellen; Lavalaye, Jules [Department of Nuclear Medicine, St. Antonius Hospital, Nieuwegein (Netherlands)

2017-06-15

Radionuclide therapy using I-131 is commonly used for the treatment of benign thyroid diseases. The therapeutic dose to be administered is calculated based on the type of disease, the volume of the thyroid, and the measured uptake percentage. This methodology assumes a similar biological half-life of iodine, whereas in reality a large variation in biological half-life is observed. More knowledge about the actual biological half-life of iodine for individual patients will improve the quantification of the delivered radiation dose during radioiodine therapy and could aid the evaluation of the success of the therapy. In this feasibility study we used a novel measurement device [Collar Therapy Indicator (CoTI)] to measure the uptake curve of patients undergoing I-131 radioiodine therapy. The CoTI device is a light-weight wearable device that contains two independent gamma radiation detectors that are placed in a collar. By comparing results of thyroid uptake measurements with results obtained with a gamma camera, the precision of the system is demonstrated. Additionally, for three patients the uptake curve is measured during 48 h of admission in the hospital. The presented results demonstrate the feasibility of the new measurement device to measure the uptake curve during radioiodine therapy. (orig.)

Iodine capsules in thyroid therapy: An individually controlled study of I-131 uptake kinetics as compared to liquid administration

International Nuclear Information System (INIS)

von Schulthess, G.K.; Seelentag, W.W.; Pfeiffer, G.; Blauenstein, P.; Bekier, A.

1984-01-01

The aim of this study was to determine the additional radiation dose sustained by parts of the patients gastric mucosa when given I-131 therapy in capsular rather than liquid form, and thus to establish the safety of this procedure. 16 patients with benign thyroid disease were studied by measuring serum radioactivity at 0, 5, 10, 20, 40, and 80 min. after administration of the capsule (120-200 MBq I131). These serum uptake values were compared to the uptake after administration of a liquid diagnostic dose of I-131 (2 MBq). From the resulting uptake curves the delay due to capsular dissolution was determined. The average dissolution time was found to be 12 min. with a large standard deviation of 7 min. Also, a theoretical curve was computed to indicate the dose rate as a function of the distance from the surface of the capsule. Based on this information the maximum dose to the gastric mucosa is of the order of 250 cGy for a therapeutic activity of 185 MBq, which is the maximum dose which may be given as single application to outpatients in Switzerland. By having the patient swallow some liquid during the first ten minutes, the capsule can be made to move around, and hence, the local radiation dose can be reduced substantially. The authors conclude, that I-131 in capsular form is a safe galenic form for therapeutic use in patients with thyroid disease. When large doses are given, administration of the dose in several capsules may be advisable

Radiation exposure to nuclear medicine technologists from administering I-131 therapy dosages

International Nuclear Information System (INIS)

Chaudakshetrin, P.; Pusuwan, P.; Sritongkul, N.; Tuntawiroon, M.

2007-01-01

Full text: Therapeutic doses of I-131 for treatment of thyroid cancer are administered orally in liquid or capsule form. During the last few years, a total number of patients loaded in our isolation ward increased from 4 to 10 patients per week. When considering radiation safety precautions for attending technologists, it is preferable to use the dose in capsules. The purpose of this study is to compare radiation exposure to nuclear medicine technologists from administering I-131 therapy dosages in capsules and in liquid form in a closed system. Materials and Methods: Three year radiation exposure to technologists during I-131 administration was analyzed. From January 2004 to June 2005 dose administration was in liquid form (n=263) and from July 2005 to February 2007 in capsules (n=541). Radiation dose assessment was performed with an electronic personal dosimeter (PDM 112). The dose rate in μSv and time spent per patient were recorded. Results: Dose received per patient when I-131 was given in a liquid was 3.50 ± 1.67 μSv and 1.17 ± 0.66 μSv when given in capsules. Compared with the use of a liquid, capsules significantly reduced radiation dose to technologists by 66% (P < 0.001). These doses received depended not only on the administered activity but also on the time, distance and shielding. Time spent per patient, including a brief visit before the time of dosing to explain the procedure and answer questions was reduced slightly from 4.4 ± 2.2 to 3.7 ± 1.8 minutes (P < 0.01). These correspond to a reduction in a yearly dose to 1 technologist by 40%, from 0.63 mSv to 0.38 mSv from dosing to 175 and 325 patients respectively. Conclusions: The measured doses clearly showed that handling of I-131 therapy dosages either in a liquid form or capsules are not the major contributors to the technologist's radiation exposure in routine clinical practice. However, one has to be cautious and follow good work practice to avoid risk of radiation exposure and radioiodine

The optimization of treatment with radioactive iodine (131I) of the hypersecretive ''hot'' tumors of the thyroid

International Nuclear Information System (INIS)

Gorowski, T.; Zgliczynski, S.

1987-01-01

The studies have been carried out in 50 patients with hyperthyroidism associated with the presence of ''hot'' thyroid tumor. The effectiveness of treatment with a standard dose of radioactive iodine, a dose which after 48 hours following the administration caused an appearance of 5.55 MBq (150 μCi) of 131 I in 1 cubic centimeter of the tumor, has been determined. In each case the condition of the patient was evaluated several times before and after the treatment, basing on clinical examination, scintigraphy of the thyroid, the determinations of T 3 , T 4 and TSH concentrations and, when needed, also the determination of TSH after stimulation with TRH. The period of observation after the administration of the first therapeutic dose of radioactive iodine was between 2 and 19 years (mean 6.5 years). The results obtained indicated that in 40 among 50 patients (80%) hyperthyroidism disappeared after administration of a single dose of radioactive iodine calculated as specified above. In two of these patients (4%) hypothyroidism resulted. In the remaining 10 patients (20%) the treatment with radioactive iodine had to be repeated. This resulted in disappearance of hyperthyroidism also in these 10 patients, bringing the total amount of cured patients to 50 (100%), and increasing the amount of patients with hypothyroidism to barely 3 cases (6%). 23 refs., 2 tabs. (author)

Inquiry about 131 Iodine use in Brazil

International Nuclear Information System (INIS)

Albino, Claudio Cordeiro; Takahashi, Mirian Hideko; Senhorini Junior, Sidney; Graf, Hans

2001-01-01

Radioactive iodine is an effective and widely accepted therapy for Graves disease (G D) and differentiated thyroid carcinoma (DTC), but there still are some controversies about the criteria for its use. To establish the present tendency for radioiodine indication, we have sent questionnaires for members of The Brazilian Society of Endocrinology and Latin American Thyroid Society, with 3 index cases: G D, toxic nodular goiter (TNG) and DTC. For each case, questions were proposed about diagnostic procedures and therapy with some clinical variants, which could modify the therapeutic choice. From the almost 2000 questionnaires sent only 82 replies (3.4%) were analyzed. Most of respondents defined themselves as general endocrinologists (85%), working in South and Southeast regions of Brazil (80%), with more than 20 years of professional activity and working mainly at University Hospitals (40%). In case index 1 (G D), 95% of the respondents used arrays of T 3, T 4 and TSH for the diagnosis and 25% added TRAb and thyroid scan. Antithyroid drugs (ATD) were the first choice for 72%, followed by radioiodine and surgery (26% and 1.3% respectively). None of clinical variants such as severe exophthalmos, older age or goiter size modified the therapy. In case 2 (TNG), radioiodine was the first therapy for 84% of professionals and the presence of compressive symptoms was the only variant that changed this tendency, when surgery was the main option. In case 3 (DTC), almost all indicated total thyroidectomy. Radioiodine for thyroid remnants was proposed by 45% of respondents, independent of residual uptake, while the remaining did so depending of different values of uptake, giving 30 to 100 mCI. These data show that radioiodine use is increasing for hyperthyroidism, but still less than observed in other countries and that we do not have uniformity for treatment of DTC. (author)

Effect of a Low Iodine Diet vs. Restricted Iodine Diet on Postsurgical Preparation for Radioiodine Ablation Therapy in Thyroid Carcinoma Patients.

Science.gov (United States)

Lim, Chi Young; Kim, Jung-Yeon; Yoon, Mi-Jin; Chang, Hang Seok; Park, Cheong Soo; Chung, Woong Youn

2015-07-01

The radioiodine ablation therapy is required for patients who underwent a total thyroidectomy. Through a comparative review of a low iodine diet (LID) and a restricted iodine diet (RID), the study aims to suggest guidelines that are suitable for the conditions of Korea. The study was conducted with 101 patients. With 24-hour urine samples from the patients after a 2-week restricted diet and after a 4-week restricted diet, the amount of iodine in the urine was estimated. The consumed radioiodine amounts for 2 hours and 24 hours were calculated. This study was conducted with 47 LID patients and 54 RID patients. The amounts of iodine in urine, the 2-week case and 4-week case for each group showed no significant differences. The amounts of iodine in urine between the two groups were both included in the range of the criteria for radioiodine ablation therapy. Also, 2 hours and 24 hours radioiodine consumption measured after 4-week restrictive diet did not show statistical differences between two groups. A 2-week RID can be considered as a type of radioiodine ablation therapy after patients undergo a total thyroidectomy.

Biological dosimetry of patients with differenced carcinoma of thyroid treated with Iodine-131

International Nuclear Information System (INIS)

Vallerga, M. B.; Rojo, A.M.; Taja, M.R.; Deluca, G.; Di Giorgio, M.; Fadel, A.; Cabrejas, M.; Valdivieso, C.

2006-01-01

The administration of I-131 to patient with Differentiated Thyroid Carcinoma (CaDiT) it is used inside the therapeutic outline as later step to the thyroidectomy. However, the good activity to give is of difficult determination due to factors such as, the variability in the capacity of tumoral reception of the I-131, distribution of the pharmaceutical, physiologic status, other associate pathologies, grade of advance of the illness, and previous treatments. Additionally, the activity to administer is dependent of the dose of tolerance in the healthy tissues; superior dose to 2 Gy in bone marrow, its could drive to myelotoxicity. At the moment, the form more extended of administration it is the empiric prescription that considers clinical parameters and of laboratory for their determination. Presently work, the protocol of applied treatment incorporates the evaluation for internal dosimetry and biological dosimetry to estimate absorbed dose in bone marrow. The biological estimate of the dose of these patients is based on the quantification of chromosomal aberrations whose frequency is referred to a curve-dose response in which the lymphocytes is irradiated in vitro with I-131, allowing to determine the in vivo dose to the patient's circulating lymphocytes. The objective of the present work is to determine the applicability of different cytogenetic essays in the estimate of the absorbed dose to the whole body or specific organs. Three patients were evaluated with CaDiT. Their treatment protocol consisted on a tracer administration of radioactive iodine of 74 - 111 MBq (2 - 3 mCi) and a therapy 7,4 - 11,1 GBq (200 - 300 mCi). Previous to the tracer administration and 8 days post-therapeutic administration took samples of veined blood that were evaluated by biological dosimetry by means of the application of the techniques: conventional cytogenetic Micronucleus and FISH (Hybridization in situ by Fluorescence). Starting from the frequencies of observed chromosomal

Long-term follow-up study of I-131 therapy for Graves' disease

International Nuclear Information System (INIS)

Kusakabe, Kiyoko; Nakano, Keiko; Maki, Masako

1990-01-01

We have studied the follow-up of thyroid function in the patients with late-onset hypothyroidism and euthyroidism after I-131 therapy of hyperthyroidism. Thirty three patients who did not need the thyroid treatment until ten years after I-131 therapy were classified as euthyroid group. And eleven patients who needed the thyroid supplement of thyroid hormone for late-onset hypothyroidism were classified as hypothyroid group. Patients in both groups who required only a single dose of I-131 for successful treatment of hyperthyroidism had similar age, gland size, 24 hour I-131 uptake, pretreatment serum T 3 uptake level and T 4 concentration, and I-131 treatment dose. Subclinical hypothyroidism occurred in 28.6% of euthyroid group and 66.7% of hypothyroid group four months after I-131 therapy. The levels of T 3 were recovered to higher than normal range at 6 months in euthyroid group, while the levels of T 3 were kept within the normal range in the seventy percent of hypothyroid group. Patients who were still lower in the level of T 3 uptake than normal range at 6 months had a higher incidence of late-onset hypothyroidism. Our observation showed no significant difference in the course of follow-up studies after I-131 therapy between the patients with late-onset hypothyroidism and euthyroidism. (author)

Thyrotoxicosis. Results and risks of current therapy

Energy Technology Data Exchange (ETDEWEB)

de los Santos, E.T.; Mazzaferri, E.L. (Ohio State Univ. College of Medicine, Columbus (USA))

1990-04-01

Effective therapy for thyrotoxicosis hinges on prompt recognition of the syndrome. When the diagnosis is suspected clinically but is not certain, the free thyroxine index is the most cost-effective test to order initially. The thyroidal radioactive iodine ({sup 123}I) uptake is measured to differentiate Graves' disease from thyroiditis and other forms of thyrotoxicosis. Definitive therapy includes antithyroid drugs, iodine 131, and surgery. Patient preference has a large role in the final therapeutic choice. 20 references.

Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered

International Nuclear Information System (INIS)

Velkeniers, B.; Vanhaelst, L.; Cytryn, R.; Jonckheer, M.H.

1988-01-01

To assess the value of antithyroid drugs as an adjunct to radioactive iodine for the treatment of hyperthyroidism the incidence of relapse or hypothyroidism after a mean follow-up of 51/2 years (range 2-7 years) was reviewed retrospectively for 206 patients, some treated with and others without antithyroid drugs after radioiodine therapy. Allocation to treatment group had been random, and both groups were similar in all respects except for the adjunctive treatment with antithyroid drugs. All doses of 131 I had been calculated by one physician. Compared with those who received 131 I alone, those starting on antithyroid drugs within 8 days after 131 I had a lower incidence of hypothyroidism but a higher incidence of early post-treatment recurrence or persistence of hyperthyroidism, and considerably lower incidence of remission. (author)

Comparison of computational models for estimation of whole body and organ radiation dose in rainbow trout from uptake of iodine-131 - Comparison of rainbow trout phantoms for estimation of whole body and organ radiation dose rates from uptake of iodine-131 in freshwater systems

Energy Technology Data Exchange (ETDEWEB)

Martinez, Nicole E. [Department of Environmental and Engineering Sciences, Clemson University, Clemson, South Carolina, 29634 (United States); Johnson, Thomas E.; Ruedig, Elizabeth; Pinder, John E. III [Department of Environmental and Radiological Health Sciences, Colorado State University, 1681 Campus Delivery, Fort Collins, Colorado, 80523 (United States)

2014-07-01

Internal radiation dose rates to biota are typically calculated utilizing dose conversion factors (DCF), which are values for absorbed dose rate per activity concentration (i.e. mGy d{sup -1} per Bq g{sup -1}). The current methodology employed by both the ICRP and within the ERICA Integrated Approach for calculating dose conversion coefficients is to use Monte Carlo modeling of a homogeneously distributed radionuclide within an ellipsoidal phantom chosen to represent a particular organism. It has been shown that for whole-body DCF, homogenous distribution is a reasonable assumption for electrons, and is associated with an uncertainty of less than 30% for photons. However, if a radionuclide has a specific tissue tropism (e.g. iodine-131 in thyroid) a much higher dose will be received by the organ or tissue than by the whole body. Internal organs are modeled generically as spheres within the ellipsoid phantom, due to the complex and variable nature of organ structure and arrangement within different types of organisms. Ratios of whole-body to organ mass offer conservative conversions of whole-body to organ specific DCF (Gomez-Ros et al 2008), but may considerably overestimate the organ dose; more accurate estimates can be made based on specific absorbed fractions and activity concentrations. Establishment of appropriate screening levels in the regulatory paradigm requires incorporation of sufficient knowledge of dose effects; the ICRP currently lists no derived consideration reference levels for organs, meaning that specific risks associated with organ dose rates are unavailable (ICRP 108). Model comparison and refinement is important in the process of determining both dose rates and dose effects, and here we develop and compare three models for rainbow trout (Oncorhynchus mykiss): the simple geometry described above, a more specific geometry employing anatomically relevant organ size and location, and voxel reconstruction of internal anatomy obtained from CT imaging

Radioiodine treatment of hyperthyroidism in patients with low thyroid iodine uptake

International Nuclear Information System (INIS)

Ruchala, M.; Sowinski, J.; Dolata, M.; Skiba, A.; Gembicki, M.; Junik, R.

2005-01-01

The aim of the study was to analyze the effectiveness of radioactive 131I in hyperthyroid patients with confirmed lowered iodine uptake as compared to patients with an uptake of over 30%. We retrospectively analyzed 53 consecutive patients aged from 29 to 84 (mean age 60 years) suffering from hyperthyroidism caused by Graves disease or toxic nodular goitre. The patients were divided into 2 sub-groups: the 1 st with a maximum iodine uptake of 18.7 ± 3.2% (range, 11 - 23%) - 24 patients; the 2 nd with a maximum iodine uptake of 27.1 ± 2.1% (range, 24 - 30%) - 29 patients. The control group consisted of 50 patients treated with 131I with an iodine uptake of over 30%. Each patient was evaluated before, and 6 months after, treatment for fT3, fT4 and TSH with ECLIA; TRAb with RIA; ultrasound with a 7.5 MHz linear probe. The volume of the thyroid gland was determined using the Gutekunst method. All these factors underwent statistical analysis and were considered along with the results of clinical examinations. Clinical remission of hyperthyroidism was evident in 79.3% of both sub-groups, in total (83.3% and 75.3%, respectively). TSH was normalized in 62.3% of these patients (54.2% and 69.0%, respectively). The mean range of TSH levels increased from 0.081 mU/ml to 4.0 mU/ml after therapy; that is, from 0.087 mU/ml to 4.97 mU/ml in the 1 st sub-group and from 0.076 mU/ml to 3.3 mU/ml in the 2 nd sub-group. The volume of the thyroid gland was uniformly significantly lower, with a mean range of 40.5 ml before treatment and 21.7 ml afterwards.The results seen in both sub-groups were similar; only age and dose of radioiodine were slightly higher in the 1 st , while mean uptake was higher in the 2 nd . By comparison of these results to those of the control patients, we observed that the values of TSH, as well as thyroid volume and evidence of clinical remission, reflected those found in the control group.The mean dose of 131I was lower in the control group, that is 11.3 m

Normalization of thyroid blood flow in Graves' hyperthyroidism following radioactive iodine therapy

Energy Technology Data Exchange (ETDEWEB)

Chang, D.C.S.; Woodcock, J.P.; Shedden, E.J.; Lazarus, J.H.; Wheeler, M.H.; McGregor, A.M. (University Hospital of Wales, Cardiff (UK). Medical Physics Dept.)

1990-05-01

In a group of 12 patients with Graves' hyperthyroidism, administration of 514 {plus minus} 43 (mean {plus minus} SD) MBq iodine-131 was associated with a fall of superior thyroid artery (STA) blood flow in two at 6 months and in eight at 11 months. The reduction in time-averaged velocity at 11 months correlated with the reduction in FT4 and in FT3 at this time. In four patients who had persistent elevated STA blood flow, two were still hyperthyroid. The diameter of the STA was unchanged at 6 months and only half the patients had reduction of their STA size at 11 months after radioiodine (RAI) therapy. These data indicate that normalization of STA blood flow precedes normalization of STA size in patients treated with RAI. Further work is required to determine whether STA blood flow measurements are of predictive value in treatment outcome. (author).

New bisphosphonate labeled with Iodine-131 for the palliative therapy for bone metastases pain

International Nuclear Information System (INIS)

Prats Capote, Anaís; Perera Pintado, Alejandro; León, Mariela; Hernández González, Ignacio; Leyva Montaña, René; Mocelo Castell, Raúl; O'Reilly, Beatriz; Calderón, Osmar; Griffith Pérez, Yoel; García Batle, Marisé; Rodríguez Tanty, Chryslaine

2016-01-01

The aim of this work was to obtain new bisphosphonate marked with 131I suitable for palliative treatment of bone metastases pain characteristics. Materials and Methods: It started with aromatic amino acids and the synthesis consisted of three stages: 1) Protection of amino groups by acetylation; 2) phosphonation protected amino acids with a mixture of phosphorous acid and phosphorus pentachloride; 3) Lack of protection of the amino groups by basic hydrolysis. The compounds obtained were characterized by IR, 1H NMR, RMN13-C mass. Los spectrometry bisphosphonic acids obtained were labeled with 131I using chloramine T and iodogen as oxidants. Stability of labeled compounds in aqueous solution was studied serum. 3 mg of 2-amino-3- (4-hydroxyphenyl) -1-hydroxypropyl-1,1-bisphosphonic acid labeled of 131I were administered to male wistar rats (170-190 g) through a lateral tail vein. The scintigraphic study was conducted at 2, 6 and 12 hours. Results: The yield of the reactions of the amino group protection four compounds ranged from 75 to 80%, while the phosphonation was between 50 and 60%. The radiochemical purity of 2-amino-3- (4-hydroxyphenyl) -1-hydroxypropyl-1,1- bisphosphonic acid labeled with 131I was (91.5 ± 1.4)% and its stability was satisfactory for 72h. Scintigraphic images suggest excretion by the kidneys of the compound and from 12 h post-administration begin to visualize bone structures of the animal, suggesting that the compound exhibits affinity for these tissues. Conclusions: A novel synthesis method with modifications that yielded the sodium salts of bisphosphonic acids starting from the respective aromatic amino acids was developed. 2-amino-3- (4-hydroxyphenyl) -1-hydroxypropyl-1,1-bisphosphonic acid 131I labeled was stable up to 72h and showed affinity for bone tissue. (author)

Three cases of respiratory failure after I-131 radioiodine therapy

International Nuclear Information System (INIS)

Watanabe, Ken; Uchiyama, Masayuki; Fukuda, Kunihiko

2016-01-01

We report three cases of respiratory failure after I-131 radioiodine therapy. All cases involved relapsed cervical lesions, and two showed edema of the larynx. Emergency tracheostomy was performed to treat the respiratory failure in one case while the others were treated conservatively. All patients showed improvements without after-effects. Patients who undergo I-131 radioiodine therapy, especially those with cervical lesions, should be carefully monitored for this rare complication after treatment. (author)

Comparative study of thyroid fixation of different iodine compounds; Etude comparative de la fixation thyroidienne de differents composes iodes

Energy Technology Data Exchange (ETDEWEB)

Rinaldi, R; Coeur, A; Raynfeld, Ch [Commissariat a l' Energie Atomique, Grenoble (France).Centre d' Etudes Nucleaires

1961-07-01

The aim of this work is to study the thyroid fixation of various iodine compounds in mineral or organic form. The animals (rats) are given therapeutic doses of the derivative orally with the object of saturating the thyroid, and then receive a determined dose of radio-iodine 131 by intra-peritoneal injection; any fixation of this latter is then measured under anaesthetic by means of a scintillation counter. Whatever form of iodine derivative was used whether in ionic (potassium iodide type) or organic form (iodo-tannic syrup) or in the form of elementary iodine (iodinated water), thyroid saturation was always obtained, as shown by practically zero fixation of the 4 {mu}curies of iodine 131 administered by intra-peritoneal injection. (author) [French] Notre travail a pour but l'etude de la fixation thyroidienne de differents composes iodes sous forme minerale ou organique. Les animaux (rats), apres absorption orale de doses therapeutiques de derives destines a saturer leur thyroide recoivent par voie intra-peritoneale une dose determinee de radio-iode {sup 131}I, la fixation eventuelle de ce dernier est ensuite mesuree sous anesthesie en utilisant un compteur a scintillation. Quelle que soit la forme utilisee, c'est-a-dire derive iode sous forme ionique (type iodure de potassium) ou sous forme organique (sirop iodotanique) ou encore sous forme d'iode metalloidique (eau iodee), nous avons obtenu chaque fois une saturation thyroidienne mise en evidence par une fixation pratiquement nulle des 4 {mu}curies de l'iode 131 injectes par voie intraperitoneale. (auteur)

Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with {sup 131}I-MIP-1095

Energy Technology Data Exchange (ETDEWEB)

Afshar-Oromieh, Ali; Haberkorn, Uwe [Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg (Germany); German Cancer Research Center, Clinical Cooperation Unit Nuclear Medicine, Heidelberg (Germany); Zechmann, Christian; Mier, Walter; Spohn, Fabian; Debus, Nils; Kratochwil, Clemens [Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg (Germany); Armor, Thomas [Progenics Pharmaceuticals, Inc., New York, NY (United States); Holland-Letz, Tim [German Cancer Research Center, Department of Biostatistics, Heidelberg (Germany); Babich, John [Weill Cornell Medicine, Division of Radiopharmaceutical Sciences, Department of Radiology, New York, NY (United States); Weill Cornell Medicine, Citigroup Biomedical Imaging Center, New York, NY (United States); Weill Cornell Medicine, Meyer Cancer Center, New York, NY (United States)

2017-06-15

Prostate-specific membrane antigen (PSMA)-targeting radioligand therapy (RLT) was introduced in 2011. The first report described the antitumor and side effects of a single dose. The aim of this analysis was to evaluate toxicity and antitumor activity after single and repetitive therapies. Thirty-four men with metastatic castration-resistant prostate cancer received PSMA-RLT with {sup 131}I-MIP-1095. Twenty-three patients received a second, and three patients a third dose, timed at PSA progression after an initial response to the preceding therapy. The applied doses were separated in three groups: <3.5, 3.5-5.0 and >5.0 GBq. Antitumor and side-effects were analyzed by blood samples and other clinical data. Follow-up was conducted for up to 5 years. The best therapeutic effect was achieved by the first therapy. A PSA decline of ≥50% was achieved in 70.6% of the patients. The second and third therapies were significantly less effective. There was neither an association between the applied activity and PSA response or the time-to-progression. Hematologic toxicities were less prevalent but presented in a higher percentage of patients with increasing number of therapies. After hematologic toxicities, xerostomia was the second most frequent side effect and presented more often and with higher intensity after the second or third therapy. The first dose of RLT with {sup 131}I-MIP-1095 presented with low side effects and could significantly reduce the tumor burden in a majority of patients. The second and third therapies were less effective and presented with more frequent and more intense side effects, especially hematologic toxicities and xerostomia. (orig.)

Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer- APPENDICES Appendices-Volume 1A

International Nuclear Information System (INIS)

Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

1999-01-01

This report consists of all the appendices for the report described below: In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values as appendices. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest

Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer- APPENDICES Appendices-Volume 1A

Energy Technology Data Exchange (ETDEWEB)

Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

1999-07-01

This report consists of all the appendices for the report described below: In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values as appendices. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from

Results of 131I-therapy of autonomous adenomas of the thyroid

International Nuclear Information System (INIS)

Swoboda, G.

1978-01-01

185 adenoma patients were re-examined after 131 I therapy. The examinations comprised an anamnesis, physical examinations, and scintiscanning. Further, the volume of the former adenoma was determined by planimetry and its weight calculated. For a diagnosis of the thyroid function, T 4 and T 3 levels were determined, the T 3 /T 4 ratio was calculated, a T 3 -in-vitro test was carried out, and the fT 4 index was calculated. TRH functional tests were carried out including radioimmunological TSH determination. Therapeutic success was judged on the basis of hot node disappearance in the scintigraphic picture and TSH level normalisation after TRH administration. Retrospective calculations were carried out in order to determine the dose received by the adenoma if its weight had been determined by planimetry. The problem of how to remove the surplus thyroid hormone formed before therapy could be solved by this functional diagnosis. Further, the author studied the correlation between the disappearance of the autonomous adenoma from the scintigraphic picture on the one hand and the restitution of the normal thyroid shape and a measurable TSH increase on the other. Special attention was paid to a relative or absolute shortage of thyroid hormone and to changes in the T 4 /T 3 ratio. Finally, the thyroid function after 131 I therapy was compared with that of normal subjects and struma patients. (orig./MG) [de

Evaluation of a potential parathyroid dysfunction under treatment with radioactive iodine of benign thyroid diseases; Pruefung einer potentiellen strahleninduzierten Nebenschilddruesenfunktionsstoerung waehrend einer Radioiodtherapie benigner Schilddruesenerkrankung

Energy Technology Data Exchange (ETDEWEB)

Schumacher, Serena Christine

2011-09-28

/l or 27.54 %). The serum level of intact parathyroid hormone prior to radioactive iodine therapy was on average 48.99 ± 24.05 ng/l [n=105], on day 1 after {sup 131}I administration it decreased to 34.09 ± 16.25 ng/l [n=100], on day 3 to 32.74 ± 14.11 ng/l [n=97], on day 5 to 37.02 ± 21.52 ng/l [n=54] and at the follow-up examination one month after the start of the therapy it was on average 44.62 ± 20.54 ng/l [n=91]. On average the patients received a mean activity of 1341.43 ± 459.16 MBq [n=105] and the thyroid dose was on average 422.53 ± 245.56 Gy [n=101]. The one-way analysis of variance of all data up to day 3 confirmed the decline in the serum level of parathyroid hormone (p<0.0001). The student t-test for paired samples resulted in a statistically significant decrease in the mean values of parathyroid hormone level before therapy with regard to the mean values on day 1 (p<0.0001) and on day 3 (p<0.0001). The two-way analysis of variance, however, did not show a significant difference in the decline of the parathyroid hormone level with regard to the course of the four subgroups (p=0.32). A correlation between the absolute or relative decline of the parathyroid hormone level and the thyroid dose could not be proved. The present thesis demonstrates for the first time that already within the first days of radioactive iodine therapy a decline in parathyroid hormone serum level occurs. Most likely this is a consequence of an acute parathyroid dysfunction caused by ionizing radiation. It is improbable that this is due to immobilisation during treatment with radioiactive iodine as immobilisation by bed rest only leads to a significant decrease in parathyroid hormone serum level at the earliest after 12 days. A temporary subclinically hyperthyroidism on treatment with {sup 131}I could not be excluded entirely as being the reason for the change in parathyroid hormone levels, but further research made this appear unlikely. Due to the fact that all values were